(the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence
CUMULATIVE SUPPLEMENT 10 OCTOBER 2021 APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 41st EDITION Department of Health and Human Services Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy 2021 Prepared By Food and Drug Administration Office of Medical Products and Tobacco Center for Drug Evaluation and Research Office of Generic Drugs Office of Generic Drug Policy APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 41th EDITION Cumulative Supplement 10 October 2021 CONTENTS PAGE Contents 1.0 INTRODUCTION.............................................................................................................................. v 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT........................................................................vi 1.2 CUMULATIVE SUPPLEMENT CONTENT ......................................................................................vi 1.3 APPLICANT NAME CHANGES......................................................................................................vii 1.4 LEVOTHYROXINE SODIUM ......................................................................................................... viii 1.5 AVAILABILITY OF THE EDITION.................................................................................................... x 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST................................ x 1.7 CUMULATIVE SUPPLEMENT LEGEND.........................................................................................xi DRUG PRODUCT LISTS Prescription Drug Product List ................................................................................ 1-1 OTC Drug Product List ........................................................................................................... 2-1 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ............................................................... 3-1 Orphan Product Designations and Approvals List ...................................................... 4-1 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ............................................................................ 5-1 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Patent and Exclusivity Lists ............................................................................................. A-1 B. Patent and Exclusivity Terms ............................................................................ B-1 iv APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 41st EDITION CUMULATIVE SUPPLEMENT 10 OCTOBER 2021 1.0 INTRODUCTION This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations (the List, commonly known as the Orange Book). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons. The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists. Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.) v Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2., How To Use The Drug Product Lists, describes the layout and usage of the List. 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item. New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item. The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms. 1.2 CUMULATIVE SUPPLEMENT CONTENT Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks. The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December). Currently, the monthly PDF CS includes: · Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication. vi · All product changes received and processed as of the date of publication. o Refer to CS Section 1.7 Cumulative Supplement Legend for types of changes · New Drug Application (NDA) approvals appear in the CS month they were approved. · Patent information, also updated daily in the EOB, is current to the date of publication. · Exclusivity information is updated monthly and is current as of the date of publication. Every effort is made to ensure the Cumulative Supplement is accurate. Applicant holders are requested to inform the FDA Division of Orange Book Publication and Regulatory Assessment (DOBPRA) of any changes or corrections. The DOBPRA can be contacted by email at orangebook@fda.hhs.gov. 1.3 APPLICANT NAME CHANGES It is not practical to identify in the Cumulative Supplement each product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement. It is also not practical to identify each, and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name. FORMER APPLICANT NAME (FORMER ABBREVIATED NAME) AUROBINDO PHARMA LTD (AUROBINDO PHARMA LTD) AKORN INC (AKORN) AKORN INC (AKORN INC) NEW APPLICANT NAME (NEW ABBREVIATED NAME) EUGIA PHARMA SPECIALITIES LTD (EUGIA PHARMA) AKORN OPERATING CO LLC (AKORN) AKORN OPERATING CO LLC (AKORN) vii JIANGSU HENGRUI MEDICINE CO LTD (JIANGSU HENGRUI MED) JIANGSU HENGRUI PHARMACEUTICALS CO LTD (JIANGSU PHARMS) ORCHID HEALTHCARE (ORCHID HLTHCARE) ORBION PHARMACEUTICALS PRIVATE LTD (ORBION PHARMS) PADDOCK LABORATORIES LLC (PADDOCK LABS LLC) PADAGIS US LLC (PADAGIS US) PADDOCK LABORATORIES LLC (PADDOCK LLC) PADAGIS US LLC (PADAGIS US) PAR PHARMACEUTICAL INC (PAR PHARM) STRIDES PHARMA GLOBAL PTE LTD (STRIDES PHARMA) PERRIGO CO OF TENESSEE INC (PERRIGO CO) PADAGIS US LLC (PADAGIS US) PERRIGO CO TENNESSEE INC (PERRIGO CO TENNESSEE) PADAGIS US LLC (PADAGIS US) PERRIGO NEW YORK INC (PERRIGO NEW YORK) PADAGIS US LLC (PADAGIS US) PERRIGO PHARMA INTERNATIONAL DAC (PERRIGO PHARMA INTL) PADAGIS US LLC (PADAGIS US) PERRIGO UK FINCO LTD PARTNERSHIP (PERRIGO UK FINCO) PADAGIS ISRAEL PHARMACEUTICALS LTD (PADAGIS ISRAEL) PERRIGO ISRAEL PHARMACEUTICALS PADAGIS ISRAEL PHARMACEUTICALS LTD LTD (PERRIGO ISRAEL) (PADAGIS ISRAEL) WEST-WARD PHARMACEUTICALS INTERNATIONAL LTD (WEST-WARD PHARMS INT) HIKMA PHARMACEUTICALS USA INC (HIKMA PHARMS) 1.4 LEVOTHYROXINE SODIUM1 Because there are multiple reference listed drugs for levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character therapeutic equivalence codes may be potentially confusing and inadequate for these drug products. Looking at the Orange Book listing alone for a product identified as a reference listed drug or reference standard, it may be difficult to determine to 1 In previous editions of the Orange Book, FDA provided a chart outlining therapeutic equivalence codes for all .025 mg levothyroxine sodium drug products in the Active Section of the Orange Book. FDA has decided, for ease of review, to revise the chart to identify the NDAs for the reference listed drugs for each therapeutic equivalence code (i.e., AB1, AB2, AB3, and AB4), and their corresponding reference standards, which are identified in 0.2 and 0.3 mg strengths. viii which therapeutic equivalence code the reference listed drugs and/or reference standard designation corresponds. For example, Unithroid 0.3 mg strength has been assigned the therapeutic equivalence codes AB1, AB2, and AB3 and it is identified as the reference listed drug and reference standard, but it is unclear that the reference listed drug and reference standard designations are associated with the AB1 therapeutic equivalence code. Accordingly, FDA provides the following chart, which identifies (1) a reference listed drug for each therapeutic equivalence code in the Orange Book and (2) and the reference standard products in the Active Section of the Orange Book.2 · Therapeutic equivalence has been established between products that have the same AB+number therapeutic equivalence code (i.e. AB1, AB2, AB3 or AB4). · More than one therapeutic equivalence code may apply to some products. One common therapeutic equivalence code indicates therapeutic equivalence between products. For example, Unithroid has been assigned therapeutic equivalence codes AB1, AB2, and AB3 therefore Unithroid tablets are considered therapeutically equivalent to other levothyroxine sodium products of the same strength with these therapeutic equivalence codes. TE Code AB1 Proprietary Name UNITHROID Applicant Strength Appl RLD RS No STEVENS J 0.3MG N021210 RLD RS AB2 SYNTHROID ABBVIE 0.3MG N021402 RLD RS AB3 LEVOXYL KING PHARMS 0.2MG N021301 RLD RS ALVOGEN AB4 THYRO-TABS GROUP HOLDINGS 4 0.3MG N021116 RLD - LLC AB4 LEVOTHYROXINE SODIUM3 MYLAN 0.3MG A076187 - RS 2 Please consult the Active Section of the Orange Book for information on other strengths. 3 Lloyd's Thyro-Tabs tablets (NDA 021116) (previously known as Levothroid) previously was listed in the Discontinued Drug Product List section of the Orange Book. It is the RLD for therapeutic equivalents identified with the AB4 code. During this time, Mylan's levothyroxine product (ANDA 076187) was selected as the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. It remains the reference standard for ANDA applicants to use to establish bioequivalence to Thyro-Tabs. If an ANDA that uses Mylan's levothyroxine product as its reference standard is approved, the ANDA will receive an AB4 rating. The ANDA applicant also may obtain an AB rating for its product to the other reference listed drugs (i.e., Unithroid, Synthroid, and Levoxyl) by submitting supplements that demonstrate that the generic product is bioequivalent to these other reference listed drugs and satisfies all other therapeutic equivalence criteria with respect to these reference listed drugs. See Letter from Janet Woodcock, M.D., Director, Center for Drug Evaluation and Research, FDA to Teri Nataline, Principal Consultant, Lachman Consultant Services, Inc., Docket No. FDA-2015-P-0403 (May 27, 2016). ix 1.5 AVAILABILITY OF THE EDITION Since 1997, the Electronic Orange Book Query (EOBQ) http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product. Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement. The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: http://bookstore.gpo.gov; toll free 866-512-1800. There are historical lists of Orange Book cumulative supplement product monthly changes at http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly. Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket *95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, https://www.fda.gov/about-fda/reports-manuals-forms/forms. The current listing of the Orphan Product Designations and Approvals is available at https://www.fda.gov/industry/developing-products-rarediseases-conditions/designating-orphan-product-drugs-and-biologicalproducts. 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST DESCRIPTION OF REPORT This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those x now regarded as medical devices, biologics or foods. The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count. DEFINITIONS Drug Product For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name. New Molecular Entity A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination. REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER CATEGORIES COUNTED DRUG PRODUCTS LISTED SINGLE SOURCE MULTISOURCE THERAPEUTICALLY EQUIVALENT NOT THERAPEUTICALLY EQUIVALENT EXCEPTIONS 4 NEW MOLECULAR ENTITIES APPROVED NUMBER OF APPLICANTS DEC 2020 20478 2659 (13.0%) 17819 (87.0%) 17746 (86.7%) 73 (0.4%) 54 (0.3%) 22 1185 MAR 2021 20726 2671 (12.9%) 18055 (87.1%) 17990 (86.8%) 65 (0.3%) 54 (0.3%) 29 1184 JUN 2021 20916 2675 (12.8%) 18241 (87.2%) 18175 (86.9%) 66 (0.3%) 54 (0.3%) 33 1182 SEP 2021 20919 2659 (12.7%) 18260 (87.3%) 18114 (86.6%) 146 (0.7%) 54 (0.3%) 18 1167 DEC 2021 1.7 CUMULATIVE SUPPLEMENT LEGEND 4 Amino acid containing products of varying composition (see Introduction, page xx of the List). xi The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists). The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, Reference Standard symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred. New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>. Changes to currently listed products will list two records. The deleted product record will be proceeded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change. The change code and description: NEWA New drug product approval NFTG New first-time generic approval CAHN5 Applicant holder firm name has changed CAIN Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name. CDFR Change. Dosage Form; Route of Administration CFTG Change. A TE Code is added when a first time generic for an innovator is approved. CMFD Change. The product is moved from the Discontinued Section due to a change in marketing status. CMKT Change. RX to OTC marketing status switch. CMS1 Change. Miscellaneous addition to list. CMS2 Change. Miscellaneous deletion from list. CPOT Change. Potency amount/unit. CRLD Change. Reference Listed Drug CHRS Change. Reference Standard CTEC Change. Therapeutic Equivalence Code. CTNA Change. Trade Name. DISC Discontinued. The Rx or OTC listed product is not being marketed and will appear in the discontinued section in the next edition. 5 The Cumulative Supplement (CS) currently displays a condensed 20 character collapsed applicant holder firm name and the Electronic Orange Book (EOB) query may display up to a 250-character full applicant holder firm name. An applicant holder firm name change usually changes both the collapsed name and long name. On occasion, only the long name is changed resulting in the CS displaying only the collapsed name for the >D> and >A> action. The new firm long name will display in the EOB query. xii PRESCRIPTION DRUG PRODUCT LIST - 41ST EDITION RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -1 ABIRATERONE ACETATE TABLET;ORAL ABIRATERONE ACETATE AB AMNEAL PHARMS AB QILU 500MG 500MG ACARBOSE TABLET;ORAL ACARBOSE AB EMCURE PHARMS LTD AB AB @ HANGZHOU ZHONGMEI @ @ 25MG 50MG 100MG 25MG 50MG 100MG ACETAMINOPHEN POWDER;INTRAVENOUS ACETAMINOPHEN + @ MYLAN LABS LTD SOLUTION;INTRAVENOUS ACETAMINOPHEN +! B BRAUN MEDICAL INC +! AP BAXTER HLTHCARE CORP 1GM/VIAL 500MG/50ML (10MG/ML) 1GM/100ML (10MG/ML) 1GM/100ML (10MG/ML) ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE CAPSULE;ORAL CODEINE, ASPIRIN, APAP FORMULA NO. 2 + @ SCHERER LABS 150MG;180MG;15MG CODEINE, ASPIRIN, APAP FORMULA NO. 3 + @ SCHERER LABS 150MG;180MG;30MG ACETAMINOPHEN; BUTALBITAL TABLET;ORAL BUTALBITAL AND ACETAMINOPHEN AA ALVOGEN AA + @ WATSON LABS PHRENILIN 300MG;50MG 325MG;50MG 325MG;50MG + @ VALEANT 325MG;50MG AA AA AA AA AA AA AA >A> AA >D> AA ACETAMINOPHEN; BUTALBITAL; CAFFEINE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE + @ GILBERT LABS 325MG;50MG;40MG HAVIX 300MG;50MG;40MG 325MG;50MG;40MG SENORES PHARMS 300MG;50MG;40MG 325MG;50MG;40MG XSPIRE PHARMA 300MG;50MG;40MG TABLET;ORAL BUTALBITAL, ACETAMINOPHEN AND CAFFEINE + ACTAVIS LABS UT INC 325MG;50MG;40MG ALVOGEN 325MG;50MG;40MG @ GRANULES 325MG;50MG;40MG ! STRIDES PHARMA 325MG;50MG;40MG ! VINTAGE PHARMS 325MG;50MG;40MG ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE CAPSULE;ORAL BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE AB NOSTRUM LABS INC 325MG;50MG;40MG;30MG A 208327 002 Dec 23, 2020 Apr NEWA A 212462 002 Jun 25, 2021 Jun NEWA A 202271 001 Feb 07, 2012 A 202271 002 Feb 07, 2012 A 202271 003 Feb 07, 2012 A 213821 001 Aug 18, 2020 A 213821 002 Aug 18, 2020 A 213821 003 Aug 18, 2020 Apr CMFD Apr CMFD Apr CMFD Aug DISC Aug DISC Aug DISC N 206610 001 Jan 15, 2021 Jan NEWA N 204957 001 Feb 18, 2021 N 204957 002 Feb 18, 2021 A 214331 001 Sep 17, 2021 Feb NEWA Feb NEWA Sep NEWA A 085640 001 A 085639 001 Aug CRLD Aug CRLD A 207635 001 Jun 05, 2017 A 205120 001 Oct 30, 2015 A 087550 001 Oct 19, 1984 Jun CAHN Jun CAHN Aug CRLD A 087811 001 Jun 19, 1985 Aug CRLD A 088825 A 214087 A 214087 A 214087 A 214087 A 206615 001 Dec 05, 1984 001 Aug 13, 2021 002 Aug 13, 2021 001 Aug 13, 2021 002 Aug 13, 2021 001 Aug 04, 2017 Aug CRLD Aug NEWA Aug NEWA Aug CAHN Aug CAHN Feb CAHN A 088616 A 204984 A 040864 A 040511 A 040511 001 Nov 09, 1984 001 Jan 10, 2017 001 Dec 01, 2008 001 Aug 27, 2003 001 Aug 27, 2003 Aug CRLD Jun CAHN Apr CAHN Oct CAHN Oct CAHN A 075929 001 Apr 22, 2002 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -2 ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE CAPSULE;ORAL TREZIX XSPIRE PHARMA 320.5MG;30MG;16MG AA AA AA >A> >A> >A> >D> >D> >D> AA ACETAMINOPHEN; CODEINE PHOSPHATE SOLUTION;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE + @ ACTAVIS MID ATLANTIC 120MG/5ML;12MG/5ML TYLENOL W/ CODEINE + @ ORTHO MCNEIL PHARM 120MG/5ML;12MG/5ML TABLET;ORAL ACETAMINOPHEN AND CODEINE PHOSPHATE NOSTRUM LABS INC 300MG;15MG 300MG;30MG +! 300MG;60MG + @ PUREPAC PHARM 300MG;30MG + @ SANDOZ 300MG;15MG + @ 300MG;30MG @ STRIDES PHARMA 300MG;15MG @ 300MG;30MG @ 300MG;60MG @ VINTAGE 300MG;15MG @ 300MG;15MG @ 300MG;30MG @ 300MG;30MG @ 300MG;60MG @ 300MG;60MG 300MG;60MG TYLENOL W/ CODEINE NO. 2 + @ JANSSEN PHARMS 300MG;15MG TYLENOL W/ CODEINE NO. 3 + @ JANSSEN PHARMS 300MG;30MG TYLENOL W/ CODEINE NO. 4 + @ JANSSEN PHARMS 300MG;60MG AA AA AA >A> AA >A> AA >D> AA >D> AA ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET;ORAL ANEXSIA 5/325 ! SPECGX LLC ANEXSIA 7.5/325 325MG;5MG ! SPECGX LLC 325MG;7.5MG HYDROCODONE BITARTRATE AND ACETAMINOPHEN @ ALVOGEN @ @ @ @ @ @ ! SPECGX LLC STRIDES PHARMA VINTAGE PHARMS NORCO 300MG;5MG 300MG;7.5MG 300MG;10MG 325MG;2.5MG 325MG;5MG 325MG;7.5MG 325MG;10MG 325MG;10MG 325MG;5MG 325MG;7.5MG 325MG;5MG 325MG;7.5MG @ APIL @ @ @ @ 325MG;2.5MG 325MG;5MG 325MG;5MG 325MG;7.5MG 325MG;10MG ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE SOLUTION;ORAL OXYCODONE AND ACETAMINOPHEN AA ! ABHAI LLC 325MG/5ML;5MG/5ML AA NOSTRUM LABS INC 325MG/5ML;5MG/5ML TABLET;ORAL OXYCODONE 5/APAP 500 + @ BRISTOL MYERS SQUIBB 500MG;5MG A 204785 001 Nov 26, 2014 Jul CAHN A 085861 001 A 085057 001 Aug CRLD Aug CRLD A 088629 A 088629 A 088629 A 086681 A 087433 A 085917 A 089990 A 089805 A 089828 A 089990 A 089990 A 089805 A 089805 A 089828 A 089828 A 089828 002 Mar 06, 1985 003 Mar 06, 1985 001 Mar 06, 1985 001 001 001 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 001 Sep 30, 1988 Aug CMS1 Aug CMS1 Aug CRLD Aug CRLD Aug CRLD Aug CRLD Oct CAHN Oct CAHN Oct CAHN Oct CAHN Apr DISC Oct CAHN Apr DISC Oct CAHN Apr DISC Apr CAHN A 085055 002 Aug CRLD A 085055 003 Aug CRLD A 085055 004 Aug CRLD A 040409 001 Oct 20, 2000 Apr CHRS A 040405 001 Sep 08, 2000 Apr CHRS A 208540 A 208540 A 208540 A 209958 A 209958 A 209958 A 209958 A 040400 A 040655 A 040656 A 040655 A 040656 001 Nov 08, 2018 002 Nov 08, 2018 003 Nov 08, 2018 001 Oct 24, 2018 002 Oct 24, 2018 003 Oct 24, 2018 004 Oct 24, 2018 001 Jul 26, 2000 001 Jan 19, 2006 001 Jan 19, 2006 001 Jan 19, 2006 001 Jan 19, 2006 Aug CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN Apr CHRS Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 040148 A 040099 A 040148 A 040148 A 040148 004 Jul 07, 2014 001 Jun 25, 1997 005 Jul 07, 2014 003 Sep 12, 2000 001 Feb 14, 1997 Apr DISC Apr DISC Apr DISC Apr DISC Apr DISC A 211499 001 Dec 31, 2018 Aug CTEC A 201448 001 Aug 26, 2021 Aug NEWA A 085911 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -3 TABLET;ORAL OXYCODONE AND ACETAMINOPHEN AA CHARTWELL 325MG;5MG AA 325MG;7.5MG AA 325MG;10MG PERCOCET + @ VINTAGE PHARMS LLC 325MG;5MG ROXICET + @ HIKMA PHARMS 325MG;5MG @ 325MG;5MG ACETAZOLAMIDE CAPSULE, EXTENDED RELEASE;ORAL ACETAZOLAMIDE AB ACCORD HLTHCARE AB ! INDICUS PHARMA 500MG 500MG TABLET;ORAL ACETAZOLAMIDE AB APPCO AB AB RUBICON AB 125MG 250MG 125MG 250MG ACETIC ACID, GLACIAL; ALUMINUM ACETATE SOLUTION/DROPS;OTIC DOMEBORO + @ BAYER PHARMS 2%;0.79% ACETYLCYSTEINE INJECTABLE;INTRAVENOUS ACETYLCYSTEINE AP EXELA PHARMA 6GM/30ML (200MG/ML) ACITRETIN CAPSULE;ORAL ACITRETIN AB ! SIGMAPHARM LABS LLC SORIATANE + @ STIEFEL LABS INC + @ 25MG 10MG 25MG ACLIDINIUM BROMIDE POWDER, METERED;INHALATION TUDORZA PRESSAIR +! ASTRAZENECA 0.4MG/INH ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE POWDER, METERED;INHALATION DUAKLIR PRESSAIR +! ASTRAZENECA 0.4MG/INH;0.012MG/INH + 0.4MG/INH;0.012MG/INH 0.4MG/INH;0.012MG/INH AB >D> >A> AB AB ACYCLOVIR OINTMENT;TOPICAL ACYCLOVIR @ ANDA REPOSITORY MACLEODS PHARMS LTD SUSPENSION;ORAL ACYCLOVIR @ VISTAPHARM @ 5% 5% 200MG/5ML 200MG/5ML 200MG/5ML 200MG/5ML ACYCLOVIR SODIUM INJECTABLE;INJECTION ACYCLOVIR SODIUM AP NAMIGEN LLC AP ZYDUS PHARMS AP ! EQ 50MG BASE/ML EQ 50MG BASE/ML EQ 50MG BASE/ML A 207834 001 Aug 15, 2019 A 207834 002 Aug 15, 2019 A 207834 003 Aug 15, 2019 Jan CAHN Jan CAHN Jan CAHN A 085106 002 Aug CRLD A 087003 001 A 087003 001 Aug CRLD Jan DISC A 207659 001 Oct 18, 2018 Apr CMFD A 090779 001 Jul 14, 2011 Jun CAHN A 211372 001 Feb 22, 2021 A 211372 002 Feb 22, 2021 A 215101 001 Aug 19, 2021 A 215101 002 Aug 19, 2021 Feb NEWA Feb NEWA Aug NEWA Aug NEWA A 084476 001 Aug CRLD A 204797 001 Apr 15, 2021 Apr NEWA A 204633 004 May 22, 2015 Sep CHRS N 019821 001 Oct 28, 1996 Sep DISC N 019821 002 Oct 28, 1996 Sep DISC N 202450 001 Jul 23, 2012 Feb CAHN N 210595 001 Mar 29, 2019 N 210595 001 Mar 29, 2019 N 210595 001 Mar 29, 2019 Jun CHRS Jun CRLD Feb CAHN A 206437 001 Jul 31, 2017 Jun DISC A 212444 001 May 19, 2021 May NEWA A 213951 A 213951 A 213951 A 213951 001 Jan 11, 2021 001 Jan 11, 2021 001 Jan 11, 2021 001 Jan 11, 2021 Oct CMFD Oct CMFD Jul DISC Jan NEWA A 207919 001 Jun 17, 2020 A 206535 001 Aug 31, 2018 A 206535 001 Aug 31, 2018 Jun CAHN Jan CHRS Jan CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -4 ADAPALENE GEL;TOPICAL ADAPALENE @ TOLMAR 0.3% >D> >A> AB >D> >A> AB ADAPALENE; BENZOYL PEROXIDE GEL;TOPICAL ADAPALENE AND BENZOYL PEROXIDE @ TARO @ TOLMAR EPIDUO FORTE 0.3%;2.5% 0.3%;2.5% 0.1%;2.5% +! GALDERMA LABS +! +! 0.3%;2.5% 0.3%;2.5% 0.3%;2.5% ADENOSINE SOLUTION;INTRAVENOUS ADENOSINE AP EMCURE PHARMS LTD AP 60MG/20ML (3MG/ML) 90MG/30ML (3MG/ML) AIR POLYMER-TYPE A FOAM;INTRAUTERINE EXEM FOAM KIT +! GISKIT 10ML ALBENDAZOLE TABLET;ORAL ALBENDAZOLE AB DR REDDYS @ LUPIN LTD AB MSN 200MG 200MG 200MG ALBUTEROL SULFATE AEROSOL, METERED;INHALATION ALBUTEROL SULFATE @ PADAGIS US EQ 0.09MG BASE/INH AB1 SANDOZ INC EQ 0.09MG BASE/INH SOLUTION;INHALATION ALBUTEROL SULFATE @ LUOXIN AUROVITAS EQ 0.021% BASE @ EQ 0.042% BASE AN EQ 0.083% BASE TABLET;ORAL ALBUTEROL SULFATE AB AIZANT EQ 2MG BASE AB EQ 4MG BASE AB APPCO EQ 2MG BASE AB EQ 4MG BASE @ EYWA EQ 2MG BASE @ EQ 4MG BASE TABLET, EXTENDED RELEASE;ORAL ALBUTEROL SULFATE @ MYLAN EQ 4MG BASE @ EQ 8MG BASE VOSPIRE ER DAVA PHARMS INC EQ 4MG BASE ALBUTEROL SULFATE; IPRATROPIUM BROMIDE SOLUTION;INHALATION ALBUTEROL SULFATE AND IPRATROPIUM BROMIDE @ AUROBINDO PHARMA LTD EQ 0.083% BASE;0.017% @ LUOXIN AUROVITAS EQ 0.083% BASE;0.017% AN ! NEPHRON EQ 0.083% BASE;0.017% A 200298 001 Jun 14, 2012 Sep DISC A 209148 001 Oct 17, 2018 A 209148 001 Oct 17, 2018 A 206164 001 May 23, 2018 Oct CMFD Oct CMFD Sep DISC N 207917 001 Jul 15, 2015 N 207917 001 Jul 15, 2015 N 207917 001 Jul 15, 2015 Oct CTEC Oct CTEC Feb CTEC A 202313 001 Sep 15, 2014 Feb CMFD A 202313 002 Sep 15, 2014 Feb CMFD N 212279 001 Nov 07, 2019 Aug CAHN A 211034 001 Jan 26, 2021 A 211636 001 Jun 10, 2020 A 213435 001 Jan 21, 2021 Jan NEWA Jan DISC Jan NEWA A 203760 001 Feb 24, 2020 Jul CAHN A 207085 001 Jun 01, 2021 May NEWA A 211888 001 Apr 20, 2020 A 211888 002 Apr 20, 2020 A 206224 001 Oct 17, 2017 Aug CAHN Aug CAHN Aug CAHN A 210948 A 210948 A 210948 A 210948 A 213524 A 213524 001 Mar 15, 2019 002 Mar 15, 2019 001 Mar 15, 2019 002 Mar 15, 2019 001 Oct 08, 2020 002 Oct 08, 2020 Feb CMFD Feb CMFD Sep CAHN Sep CAHN Apr DISC Apr DISC A 078092 002 Jan 29, 2007 Sep DISC A 078092 001 Jan 29, 2007 Sep DISC A 076130 002 Sep 26, 2002 Sep CTEC A 206532 001 Jul 08, 2020 A 206532 001 Jul 08, 2020 A 076749 001 Dec 31, 2007 Jan DISC Aug CAHN Sep CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -5 >D> AB >A> >D> AB >A> >D> AB >A> >D> AB >A> >D> AB >A> >A> >A> >A> >A> >D> >D> >D> >D> ALENDRONATE SODIUM TABLET;ORAL ALENDRONATE SODIUM IMPAX LABS INC @ @ @ @ @ @ JUBILANT CADISTA @ @ @ @ PICKET PHARMS @ @ @ @ US ANTIBIOTICS @ @ @ @ @ @ @ EQ 5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 10MG BASE EQ 35MG BASE EQ 35MG BASE EQ 40MG BASE EQ 40MG BASE EQ 70MG BASE EQ 70MG BASE EQ 5MG BASE EQ 10MG BASE EQ 35MG BASE EQ 70MG BASE EQ 5MG BASE EQ 10MG BASE EQ 35MG BASE EQ 70MG BASE EQ 5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 10MG BASE EQ 35MG BASE EQ 35MG BASE EQ 70MG BASE EQ 70MG BASE ALENDRONATE SODIUM; CHOLECALCIFEROL TABLET;ORAL FOSAMAX PLUS D + ORGANON +! EQ 70MG BASE;2,800 IU EQ 70MG BASE;5,600 IU ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE TABLET;ORAL TEKTURNA HCT + @ NODEN PHARMA + @ EQ 150MG BASE;12.5MG EQ 150MG BASE;25MG ALLOPURINOL TABLET;ORAL ALLOPURINOL AB CHARTWELL AB 100MG 300MG AB AB AB AB >A> AB >A> AB >A> AB >A> AB >D> AB >D> AB >D> AB >D> AB ALPRAZOLAM TABLET;ORAL ALPRAZOLAM @ MYLAN @ @ @ NOVITIUM PHARMA STRIDES PHARMA VINTAGE PHARMS 0.25MG 0.5MG 1MG 2MG 0.25MG 0.5MG 1MG 2MG 0.25MG 0.5MG 1MG 2MG 0.25MG 0.5MG 1MG 2MG A 075710 A 075710 A 075710 A 075710 A 075710 A 075710 A 075710 A 075710 A 075710 A 075710 A 090557 A 090557 A 090557 A 090557 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 A 079049 001 Feb 06, 2008 001 Feb 06, 2008 002 Feb 06, 2008 002 Feb 06, 2008 003 Feb 06, 2008 003 Feb 06, 2008 004 Feb 06, 2008 004 Feb 06, 2008 005 Feb 06, 2008 005 Feb 06, 2008 001 Feb 18, 2010 002 Feb 18, 2010 003 Feb 18, 2010 004 Feb 18, 2010 003 Aug 04, 2008 004 Aug 04, 2008 001 Aug 04, 2008 002 Aug 04, 2008 003 Aug 04, 2008 003 Aug 04, 2008 004 Aug 04, 2008 004 Aug 04, 2008 001 Aug 04, 2008 001 Aug 04, 2008 002 Aug 04, 2008 002 Aug 04, 2008 Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Jun DISC Jun DISC Jun DISC Jun DISC Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN May CAHN Oct CAHN May CAHN Oct CAHN May CAHN Oct CAHN May CAHN N 021762 001 Apr 07, 2005 Jun CAHN N 021762 002 Apr 26, 2007 Jun CAHN N 022107 001 Jan 18, 2008 May DISC N 022107 002 Jan 18, 2008 May DISC A 077353 001 Sep 08, 2005 Jun CAHN A 077353 002 Sep 08, 2005 Jun CAHN A 074215 A 074215 A 074215 A 074215 A 074174 A 074174 A 074174 A 074174 A 090248 A 090248 A 090248 A 090248 A 090248 A 090248 A 090248 A 090248 001 Jan 27, 1994 002 Jan 27, 1994 003 Jan 27, 1994 004 Jan 27, 1994 001 Oct 19, 1993 002 Oct 19, 1993 003 Oct 19, 1993 004 Oct 19, 1993 001 Sep 17, 2010 002 Sep 17, 2010 003 Sep 17, 2010 004 Sep 17, 2010 001 Sep 17, 2010 002 Sep 17, 2010 003 Sep 17, 2010 004 Sep 17, 2010 Jun DISC Jun DISC Jun DISC Jun DISC Apr CMFD Apr CMFD Apr CMFD Apr CMFD Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -6 ALPROSTADIL INJECTABLE;INJECTION CAVERJECT + @ PFIZER AP + AP +! AP +! CAVERJECT IMPULSE PFIZER PROSTIN VR PEDIATRIC AP +! PFIZER 0.005MG/VIAL 0.01MG/VIAL 0.02MG/VIAL 0.04MG/VIAL 0.01MG/VIAL 0.02MG/VIAL 0.5MG/ML AMANTADINE HYDROCHLORIDE CAPSULE;ORAL AMANTADINE HYDROCHLORIDE BX STRIDES PHARMA 100MG SYRUP;ORAL AMANTADINE HYDROCHLORIDE AA INVATECH 50MG/5ML AA NOVELGENIX THERAPS 50MG/5ML @ WOCKHARDT BIO AG 50MG/5ML TABLET;ORAL AMANTADINE HYDROCHLORIDE @ INVAGEN PHARMS BX STRIDES PHARMA 100MG 100MG TABLET, EXTENDED RELEASE;ORAL OSMOLEX ER + ADAMAS PHARMA + @ + + @ +! + ADAMAS PHARMS + @ + +! EQ 129MG BASE EQ 161MG BASE EQ 193MG BASE EQ 258MG BASE EQ 258MG BASE EQ 129MG BASE EQ 161MG BASE EQ 193MG BASE EQ 258MG BASE AMILORIDE HYDROCHLORIDE TABLET;ORAL AMILORIDE HYDROCHLORIDE AB USPHARMA WINDLAS 5MG AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL AMILORIDE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ CHARTWELL RX EQ 5MG ANHYDROUS;50MG AMINOCAPROIC ACID SOLUTION;ORAL AMICAR AA +! AKORN AA +! AMINOCAPROIC ACID AA AIRIS PHARMA PVT LTD AA AMNEAL AA AA BELCHER AA LEADING PHARMA LLC AA AA TULEX PHARMS INC AA AA VISTAPHARM AA SYRUP;ORAL AMINOCAPROIC ACID AA LEADING PHARMA LLC TABLET;ORAL AMINOCAPROIC ACID AB EDENBRIDGE PHARMS AB LEADING PHARMA LLC 0.25GM/ML 1.25GM/5ML 0.25GM/ML 0.25GM/ML 1.25GM/5ML 0.25GM/ML 0.25GM/ML 1.25GM/5ML 0.25GM/ML 1.25GM/5ML 0.25GM/ML 1.25GM/5ML 1.25GM/5ML 500MG 500MG N 020379 N 020379 N 020379 N 020379 003 Jun 27, 1996 001 Jul 06, 1995 002 Jul 06, 1995 004 May 19, 1997 Jan CAHN Jan CAHN Jan CAHN Jan CAHN N 021212 001 Jun 11, 2002 Jan CAHN N 021212 002 Jun 11, 2002 Jan CAHN N 018484 001 Jan CAHN A 209047 001 Jun 07, 2017 Sep CTEC A 214178 001 Aug 20, 2021 A 214178 001 Aug 20, 2021 A 075060 001 Dec 24, 1998 Aug NEWA Sep CAHN Jan DISC A 207571 001 Jan 31, 2017 Jan DISC A 209035 001 Jun 09, 2017 Sep CTEC N 209410 N 209410 N 209410 N 209410 N 209410 N 209410 N 209410 N 209410 N 209410 001 Feb 16, 2018 004 Apr 22, 2020 002 Feb 16, 2018 003 Feb 16, 2018 003 Feb 16, 2018 001 Feb 16, 2018 004 Apr 22, 2020 002 Feb 16, 2018 003 Feb 16, 2018 Jan CAHN Jan CAHN Jan CAHN May DISC Jan CAHN Jan CAHN Jan CAHN Jan CAHN Jan CAHN A 204180 001 Aug 07, 2015 Sep CAHN A 073357 001 Nov 27, 1991 Aug CAHN N 015230 002 N 015230 002 Feb CPOT Feb CDFR A 213825 A 212780 A 212780 A 213825 A 214140 A 214140 A 212494 A 212494 A 212814 A 212814 001 Apr 08, 2021 001 Aug 23, 2019 001 Aug 23, 2019 001 Apr 08, 2021 001 Jan 26, 2021 001 Jan 26, 2021 001 Aug 11, 2020 001 Aug 11, 2020 001 Feb 26, 2020 001 Feb 26, 2020 Apr NEWA Feb CPOT Feb CDFR Jul CAHN Feb CPOT Feb CDFR Feb CPOT Feb CDFR Feb CPOT Feb CDFR A 214140 001 Jan 26, 2021 Jan NEWA A 212110 001 Jun 14, 2021 Jun NEWA A 213928 001 Feb 12, 2021 Feb NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -7 TABLET;ORAL AMINOCAPROIC ACID AB 1GM AMINOPHYLLINE INJECTABLE;INJECTION AMINOPHYLLIN + @ GD SEARLE LLC + @ 25MG/ML 25MG/ML AP AP >D> AP >A> AB AB AMIODARONE HYDROCHLORIDE INJECTABLE;INJECTION AMIODARONE HYDROCHLORIDE ACELLA HOSPIRA INC @ 50MG/ML 50MG/ML 50MG/ML 50MG/ML TABLET;ORAL AMIODARONE HYDROCHLORIDE RUBICON 100MG 400MG >D> >A> AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AMITRIPTYLINE HYDROCHLORIDE CONCENTRATE;ORAL ENDEP @ ROCHE + @ 40MG/ML 40MG/ML TABLET;ORAL AMITRIPTYLINE HYDROCHLORIDE MANKIND PHARMA @ MYLAN @ @ @ @ @ + SANDOZ + + + + UNICHEM 10MG 25MG 50MG 75MG 100MG 150MG 10MG 25MG 50MG 75MG 100MG 150MG 10MG 50MG 75MG 100MG 150MG 10MG 25MG 50MG 75MG 100MG 150MG >A> AB >A> AB >A> AB >D> AB >D> AB >D> AB AMLODIPINE BESYLATE TABLET;ORAL AMLODIPINE BESYLATE CHARTWELL RX @ WOCKHARDT @ @ YILING EQ 2.5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 2.5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 2.5MG BASE EQ 5MG BASE EQ 10MG BASE >D> AB >A> >D> AB AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM TABLET;ORAL AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM MYLAN @ EQ 2.5MG BASE;EQ 10MG BASE EQ 2.5MG BASE;EQ 10MG BASE EQ 2.5MG BASE;EQ 20MG BASE A 213928 002 Feb 12, 2021 Feb NEWA A 087243 001 May 24, 1982 Aug CRLD A 087621 001 May 24, 1982 Aug CRLD A 077610 001 Oct 30, 2008 A 077834 001 Oct 30, 2008 A 203885 001 Nov 25, 2013 A 203885 001 Nov 25, 2013 Aug CAHN Aug CAHN Oct DISC Oct DISC A 078578 002 Feb 26, 2021 Feb NEWA A 078578 003 Feb 26, 2021 Feb NEWA A 085749 001 A 085749 001 Oct CRLD Oct CRLD A 213999 001 Feb 19, 2021 A 213999 002 Feb 19, 2021 A 213999 003 Feb 19, 2021 A 213999 004 Feb 19, 2021 A 213999 005 Feb 19, 2021 A 213999 006 Feb 19, 2021 A 086009 002 A 086009 003 A 086009 001 A 086009 004 A 086009 005 A 086009 006 A 085968 004 A 085968 001 A 085968 006 A 085968 003 A 085968 005 A 214548 001 May 19, 2021 A 214548 002 May 19, 2021 A 214548 003 May 19, 2021 A 214548 004 May 19, 2021 A 214548 005 May 19, 2021 A 214548 006 May 19, 2021 Feb NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA Jun DISC Jun DISC Jun DISC Jun DISC Jun DISC Jun DISC Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD May NEWA May NEWA May NEWA May NEWA May NEWA May NEWA A 076692 001 Jul 20, 2007 A 076692 002 Jul 20, 2007 A 076692 003 Jul 20, 2007 A 078500 001 Sep 06, 2007 A 078500 002 Sep 06, 2007 A 078500 003 Sep 06, 2007 A 076692 001 Jul 20, 2007 A 076692 002 Jul 20, 2007 A 076692 003 Jul 20, 2007 Oct CAHN Oct CAHN Oct CAHN Jan DISC Jan DISC Jan DISC Oct CAHN Oct CAHN Oct CAHN A 200465 001 Nov 29, 2013 A 200465 001 Nov 29, 2013 A 200465 002 Nov 29, 2013 Oct DISC Oct DISC Oct DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -8 >A> >D> AB >A> >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB TABLET;ORAL AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM @ EQ 2.5MG BASE;EQ 20MG BASE EQ 2.5MG BASE;EQ 40MG BASE @ EQ 2.5MG BASE;EQ 40MG BASE EQ 5MG BASE;EQ 10MG BASE EQ 5MG BASE;EQ 10MG BASE EQ 5MG BASE;EQ 20MG BASE EQ 5MG BASE;EQ 20MG BASE EQ 5MG BASE;EQ 40MG BASE EQ 5MG BASE;EQ 40MG BASE EQ 5MG BASE;EQ 80MG BASE EQ 5MG BASE;EQ 80MG BASE EQ 10MG BASE;EQ 10MG BASE EQ 10MG BASE;EQ 10MG BASE EQ 10MG BASE;EQ 20MG BASE EQ 10MG BASE;EQ 20MG BASE EQ 10MG BASE;EQ 40MG BASE EQ 10MG BASE;EQ 40MG BASE EQ 10MG BASE;EQ 80MG BASE EQ 10MG BASE;EQ 80MG BASE A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 A 200465 002 Nov 29, 2013 003 Nov 29, 2013 003 Nov 29, 2013 004 Nov 29, 2013 004 Nov 29, 2013 005 Nov 29, 2013 005 Nov 29, 2013 006 Nov 29, 2013 006 Nov 29, 2013 007 Nov 29, 2013 007 Nov 29, 2013 008 Nov 29, 2013 008 Nov 29, 2013 009 Nov 29, 2013 009 Nov 29, 2013 010 Nov 29, 2013 010 Nov 29, 2013 011 Nov 29, 2013 011 Nov 29, 2013 Oct DISC Oct DISC Oct DISC Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN AMLODIPINE BESYLATE; CELECOXIB TABLET;ORAL CONSENSI >D> + @ COEPTIS EQ 2.5MG BASE;200MG + @ EQ 2.5MG BASE;200MG >D> + @ EQ 5MG BASE;200MG + @ EQ 5MG BASE;200MG >D> + @ EQ 10MG BASE;200MG + @ EQ 10MG BASE;200MG >A> + @ PURPLE BIOTECH EQ 2.5MG BASE;200MG >A> + @ EQ 5MG BASE;200MG >A> + @ EQ 10MG BASE;200MG N 210045 N 210045 N 210045 N 210045 N 210045 N 210045 N 210045 N 210045 N 210045 001 May 31, 2018 001 May 31, 2018 002 May 31, 2018 002 May 31, 2018 003 May 31, 2018 003 May 31, 2018 001 May 31, 2018 002 May 31, 2018 003 May 31, 2018 Oct CAHN Sep DISC Oct CAHN Sep DISC Oct CAHN Sep DISC Oct CAHN Oct CAHN Oct CAHN AMLODIPINE BESYLATE; OLMESARTAN MEDOXOMIL TABLET;ORAL AMLODIPINE AND OLMESARTAN MEDOXOMIL @ JUBILANT GENERICS EQ 5MG BASE;20MG @ EQ 5MG BASE;40MG @ EQ 10MG BASE;20MG @ EQ 10MG BASE;40MG A 207450 A 207450 A 207450 A 207450 001 May 15, 2017 002 May 15, 2017 003 May 15, 2017 004 May 15, 2017 Jun DISC Jun DISC Jun DISC Jun DISC AMMONIA N-13 INJECTABLE;INTRAVENOUS AMMONIA N 13 AP METHODIST AP NUKEMED 3.75mCi-260mCi/ML A 215083 001 Jul 09, 2021 Jul NEWA 30mCi-300mCi/8ML (3.75-37.5mCi/ML) A 204455 001 Apr 23, 2015 Jan CAHN AMOXAPINE TABLET;ORAL AMOXAPINE >A> @ CHARTWELL RX >A> @ >A> @ >A> @ >D> @ UPSHER SMITH LABS >D> @ >D> @ >D> @ 25MG 50MG 100MG 150MG 25MG 50MG 100MG 150MG A 072943 A 072944 A 072878 A 072879 A 072943 A 072944 A 072878 A 072879 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 001 Jun 28, 1991 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN AMOXICILLIN CAPSULE;ORAL AMOXICILLIN AB CHARTWELL AB AMOXIL AB US ANTIBIOTICS AB FOR SUSPENSION;ORAL AMOXIL AB US ANTIBIOTICS AB 250MG 500MG 250MG 500MG 50MG/ML 125MG/5ML A 062058 001 A 062058 002 A 062216 001 A 062216 004 A 062226 005 A 062226 001 Jun CAHN Jun CAHN May CAHN May CAHN May CAHN May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -9 FOR SUSPENSION;ORAL AMOXIL + @ AB + @ LAROTID AB US ANTIBIOTICS AB TABLET;ORAL AMOXIL + @ US ANTIBIOTICS + @ TABLET, CHEWABLE;ORAL AMOXICILLIN BX HIKMA BX AMOXIL + @ US ANTIBIOTICS @ + @ @ 200MG/5ML 250MG/5ML 400MG/5ML 125MG/5ML 250MG/5ML 500MG 875MG 125MG 250MG 125MG 200MG 250MG 400MG N 050760 001 Apr 15, 1999 May CAHN A 062226 002 May CAHN N 050760 002 Apr 15, 1999 May CAHN A 062226 003 A 062226 004 May CAHN May CAHN N 050754 002 Jul 10, 1998 May CAHN N 050754 001 Jul 10, 1998 May CAHN A 205274 001 Jun 25, 2020 Sep CTEC A 205274 002 Jun 25, 2020 Sep CTEC N 050542 N 050761 N 050542 N 050761 002 001 Apr 15, 1999 001 002 Apr 15, 1999 May CAHN May CAHN May CAHN May CAHN AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE CAPSULE, TABLET, CAPSULE, DELAYED REL PELLETS;ORAL LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN (COPACKAGED) @ ANI PHARMS @ @ AB ! RISING AB ! AB ! AB SANDOZ INC AB AB PREVPAC (COPACKAGED) 500MG;500MG;30MG 500MG;500MG;30MG 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,30MG 500MG;500MG;30MG 500MG;500MG;30MG 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,30MG 500MG;500MG;30MG 500MG;500MG;30MG 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,30MG A 200218 A 200218 A 200218 A 206006 A 206006 A 206006 A 202588 A 202588 A 202588 + @ TAKEDA PHARMS USA + @ + @ 500MG;500MG;30MG 500MG;500MG;30MG 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,30MG N 050757 N 050757 N 050757 001 Aug 30, 2013 001 Aug 30, 2013 001 Aug 30, 2013 001 Oct 07, 2016 001 Oct 07, 2016 001 Oct 07, 2016 001 Mar 04, 2014 001 Mar 04, 2014 001 Mar 04, 2014 001 Dec 02, 1997 001 Dec 02, 1997 001 Dec 02, 1997 Jul CTNA Jul CPOT Jul CDFR Jul CTNA Jul CPOT Jul CDFR Jul CTNA Jul CPOT Jul CDFR Jul CTNA Jul CPOT Jul CDFR AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE CAPSULE, TABLET, CAPSULE, DELAYED RELEASE;ORAL OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN + @ CUMBERLAND PHARMS 500MG,N/A,N/A;N/A,500MG,N/A;N/A,N/ A,20MG N 050824 001 Feb 08, 2011 May DISC AMOXICILLIN; CLAVULANATE POTASSIUM FOR SUSPENSION;ORAL AMOXICILLIN AND CLAVULANATE POTASSIUM AB MICRO LABS LTD INDIA 200MG/5ML;EQ 28.5MG BASE/5ML AB 400MG/5ML;EQ 57MG BASE/5ML AUGMENTIN '125' AB + US ANTIBIOTICS AUGMENTIN '200' 125MG/5ML;EQ 31.25MG BASE/5ML + @ US ANTIBIOTICS 200MG/5ML;EQ 28.5MG BASE/5ML AUGMENTIN '250' AB +! US ANTIBIOTICS AUGMENTIN '400' 250MG/5ML;EQ 62.5MG BASE/5ML + @ US ANTIBIOTICS 400MG/5ML;EQ 57MG BASE/5ML AUGMENTIN ES-600 AB + US ANTIBIOTICS 600MG/5ML;EQ 42.9MG BASE/5ML TABLET;ORAL AUGMENTIN '250' + @ US ANTIBIOTICS AUGMENTIN '500' 250MG;EQ 125MG BASE + @ US ANTIBIOTICS 500MG;EQ 125MG BASE AUGMENTIN '875' AB + US ANTIBIOTICS 875MG;EQ 125MG BASE A 205187 001 May 21, 2021 May NEWA A 205187 002 May 21, 2021 May NEWA N 050575 001 Aug 06, 1984 May CAHN N 050725 001 May 31, 1996 May CAHN N 050575 002 Aug 06, 1984 May CAHN N 050725 002 May 31, 1996 May CAHN N 050755 001 Jun 22, 2001 May CAHN N 050564 001 Aug 06, 1984 May CAHN N 050564 002 Aug 06, 1984 May CAHN N 050720 001 Feb 13, 1996 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -10 TABLET, CHEWABLE;ORAL AUGMENTIN '125' + @ US ANTIBIOTICS AUGMENTIN '200' 125MG;EQ 31.25MG BASE + @ US ANTIBIOTICS AUGMENTIN '250' 200MG;EQ 28.5MG BASE + @ US ANTIBIOTICS AUGMENTIN '400' 250MG;EQ 62.5MG BASE + @ US ANTIBIOTICS 400MG;EQ 57MG BASE TABLET, EXTENDED RELEASE;ORAL AUGMENTIN XR + @ US ANTIBIOTICS 1GM;EQ 62.5MG BASE N 050597 001 Jul 22, 1985 May CAHN N 050726 001 May 31, 1996 May CAHN N 050597 002 Jul 22, 1985 May CAHN N 050726 002 May 31, 1996 May CAHN N 050785 001 Sep 25, 2002 May CAHN AMPHETAMINE SUSPENSION, EXTENDED RELEASE;ORAL ADZENYS ER + @ NEOS THERAPS INC EQ 1.25MG BASE/ML N 204325 001 Sep 15, 2017 Sep DISC AMPHETAMINE ASPARTATE ; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB RHODES PHARMS AB AB 2.5MG;2.5MG;2.5MG;2.5MG 3.75MG;3.75MG;3.75MG;3.75MG 5MG;5MG;5MG;5MG A 213111 003 Jan 13, 2021 A 213111 005 Jan 13, 2021 A 213111 006 Jan 13, 2021 Jan NEWA Jan NEWA Jan NEWA AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL DETROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB ASCENT PHARMS INC 1.25MG;1.25MG;1.25MG;1.25MG AB 2.5MG;2.5MG;2.5MG;2.5MG AB 3.75MG;3.75MG;3.75MG;3.75MG AB 5MG;5MG;5MG;5MG AB 6.25MG;6.25MG;6.25MG;6.25MG AB 7.5MG;7.5MG;7.5MG;7.5MG A 214959 A 214959 A 214959 A 214959 A 214959 A 214959 001 Sep 29, 2021 002 Sep 29, 2021 003 Sep 29, 2021 004 Sep 29, 2021 005 Sep 29, 2021 006 Sep 29, 2021 Sep NEWA Sep NEWA Sep NEWA Sep NEWA Sep NEWA Sep NEWA TABLET;ORAL DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE AB ASCENT PHARMS INC 1.25MG;1.25MG;1.25MG;1.25MG A 213709 001 Apr 22, 2021 Apr NEWA AB 1.875MG;1.875MG;1.875MG;1.875MG A 213709 002 Apr 22, 2021 Apr NEWA AB 2.5MG;2.5MG;2.5MG;2.5MG A 213709 003 Apr 22, 2021 Apr NEWA AB 3.125MG;3.125MG;3.125MG;3.125MG A 213709 004 Apr 22, 2021 Apr NEWA AB 3.75MG;3.75MG;3.75MG;3.75MG A 213709 005 Apr 22, 2021 Apr NEWA AB 5MG;5MG;5MG;5MG A 213709 006 Apr 22, 2021 Apr NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 213709 007 Apr 22, 2021 Apr NEWA AB LIBERTY PHARMA INC 1.25MG;1.25MG;1.25MG;1.25MG A 210293 001 Apr 03, 2020 Aug CAHN AB 1.875MG;1.875MG;1.875MG;1.875MG A 210293 002 Apr 03, 2020 Aug CAHN AB 2.5MG;2.5MG;2.5MG;2.5MG A 210293 003 Apr 03, 2020 Aug CAHN AB 3.75MG;3.75MG;3.75MG;3.75MG A 210293 004 Apr 03, 2020 Aug CAHN AB 5MG;5MG;5MG;5MG A 210293 005 Apr 03, 2020 Aug CAHN AB 7.5MG;7.5MG;7.5MG;7.5MG A 210293 006 Apr 03, 2020 Aug CAHN @ MYLAN 1.25MG;1.25MG;1.25MG;1.25MG A 206721 001 Nov 10, 2015 Aug CAHN @ 1.25MG;1.25MG;1.25MG;1.25MG A 206721 001 Nov 10, 2015 Aug DISC @ 1.875MG;1.875MG;1.875MG;1.875MG A 206721 002 Nov 10, 2015 Aug CAHN @ 1.875MG;1.875MG;1.875MG;1.875MG A 206721 002 Nov 10, 2015 Aug DISC @ 2.5MG;2.5MG;2.5MG;2.5MG A 206721 003 Nov 10, 2015 Aug CAHN @ 2.5MG;2.5MG;2.5MG;2.5MG A 206721 003 Nov 10, 2015 Aug DISC @ 3.125MG;3.125MG;3.125MG;3.125MG A 206721 004 Nov 10, 2015 Aug CAHN @ 3.125MG;3.125MG;3.125MG;3.125MG A 206721 004 Nov 10, 2015 Aug DISC @ 3.75MG;3.75MG;3.75MG;3.75MG A 206721 005 Nov 10, 2015 Aug CAHN @ 3.75MG;3.75MG;3.75MG;3.75MG A 206721 005 Nov 10, 2015 Aug DISC @ 5MG;5MG;5MG;5MG A 206721 006 Nov 10, 2015 Aug CAHN @ 5MG;5MG;5MG;5MG A 206721 006 Nov 10, 2015 Aug DISC @ 7.5MG;7.5MG;7.5MG;7.5MG A 206721 007 Nov 10, 2015 Aug CAHN @ 7.5MG;7.5MG;7.5MG;7.5MG A 206721 007 Nov 10, 2015 Aug DISC AB RHODES PHARMS 1.25MG;1.25MG;1.25MG;1.25MG A 213111 001 Jan 13, 2021 Jan NEWA AB 1.875MG;1.875MG;1.875MG;1.875MG A 213111 002 Jan 13, 2021 Jan NEWA AB 3.125MG;3.125MG;3.125MG;3.125MG A 213111 004 Jan 13, 2021 Jan NEWA AB 7.5MG;7.5MG;7.5MG;7.5MG A 213111 007 Jan 13, 2021 Jan NEWA AB USPHARMA WINDLAS 1.25MG;1.25MG;1.25MG;1.25MG A 210293 001 Apr 03, 2020 Sep CAHN AB 1.875MG;1.875MG;1.875MG;1.875MG A 210293 002 Apr 03, 2020 Sep CAHN AB 2.5MG;2.5MG;2.5MG;2.5MG A 210293 003 Apr 03, 2020 Sep CAHN AB 3.75MG;3.75MG;3.75MG;3.75MG A 210293 004 Apr 03, 2020 Sep CAHN AB 5MG;5MG;5MG;5MG A 210293 005 Apr 03, 2020 Sep CAHN AB 7.5MG;7.5MG;7.5MG;7.5MG A 210293 006 Apr 03, 2020 Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -11 AMPHETAMINE SULFATE TABLET;ORAL AMPHETAMINE SULFATE @ GLENMARK PHARMS LTD 5MG AA 5MG @ 10MG AA 10MG + @ LANNETT 5MG + @ 10MG @ MAYNE PHARMA 5MG @ 10MG @ NOVAST LABS 5MG @ 10MG AA RHODES PHARMS 5MG AA 10MG AA SENORES PHARMS 5MG AA 10MG AA SPECGX LLC 5MG AA 10MG AA SUN PHARM INDS INC 5MG AA 10MG TABLET, ORALLY DISINTEGRATING;ORAL EVEKEO ODT + @ ARBOR PHARMS LLC 2.5MG + 2.5MG +! 20MG A 212186 A 212186 A 212186 A 212186 A 083901 A 083901 A 213898 A 213898 A 213763 A 213763 A 213852 A 213852 A 212901 A 212901 A 213583 A 213583 A 214574 A 214574 001 Jan 27, 2021 001 Jan 27, 2021 002 Jan 27, 2021 002 Jan 27, 2021 001 Aug 31, 1984 002 Aug 31, 1984 001 Jul 14, 2020 002 Jul 14, 2020 001 Aug 24, 2020 002 Aug 24, 2020 001 Sep 07, 2021 002 Sep 07, 2021 001 May 22, 2020 002 May 22, 2020 001 Jan 22, 2021 002 Jan 22, 2021 001 Jan 27, 2021 002 Jan 27, 2021 Jun DISC Jan NEWA Jun DISC Jan NEWA Aug CRLD Aug CRLD Jan DISC Jan DISC Mar DISC Mar DISC Aug NEWA Aug NEWA Aug CAHN Aug CAHN Jan NEWA Jan NEWA Jan NEWA Jan NEWA N 209905 005 Apr 16, 2021 N 209905 005 Apr 16, 2021 N 209905 004 Jan 30, 2019 Jul DISC Apr NEWA Apr CHRS AMPICILLIN SODIUM INJECTABLE;INJECTION AMPICILLIN SODIUM @ HQ SPECLT PHARMA AP AP @ AP @ AP @ AP EQ 125MG BASE/VIAL EQ 250MG BASE/VIAL EQ 500MG BASE/VIAL EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL EQ 2GM BASE/VIAL EQ 10GM BASE/VIAL A 062772 A 062772 A 062772 A 062772 A 062772 A 062772 A 062772 A 062772 A 063142 005 Apr 15, 1993 006 Apr 15, 1993 007 Apr 15, 1993 008 Apr 15, 1993 001 Apr 15, 1993 002 Apr 15, 1993 003 Apr 15, 1993 004 Apr 15, 1993 001 Apr 15, 1993 Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN >A> AP >A> AP AP AP AP >D> AP >D> AP AMPICILLIN SODIUM; SULBACTAM SODIUM INJECTABLE;INJECTION AMPICILLIN AND SULBACTAM HIKMA PHARMS EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL HQ SPECLT PHARMA EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL EQ 10GM BASE/VIAL;EQ 5GM BASE/VIAL WEST-WARD PHARMS INT EQ 1GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 2GM BASE/VIAL;EQ 1GM BASE/VIAL A 065074 A 065074 A 065176 A 065176 A 065188 A 065074 A 065074 001 Mar 19, 2002 002 Mar 19, 2002 001 Nov 30, 2005 002 Nov 30, 2005 001 Nov 25, 2005 001 Mar 19, 2002 002 Mar 19, 2002 Oct CAHN Oct CAHN Mar CAHN Mar CAHN Mar CAHN Oct CAHN Oct CAHN ANAGRELIDE HYDROCHLORIDE CAPSULE;ORAL ANAGRELIDE HYDROCHLORIDE @ CHARTWELL RX EQ 0.5MG BASE @ EQ 1MG BASE A 076683 001 Apr 18, 2005 Aug CAHN A 076683 002 Apr 18, 2005 Aug CAHN ANASTROZOLE TABLET;ORAL ANASTROZOLE @ FRESENIUS KABI USA 1MG >A> @ PICKET PHARMS 1MG >D> @ US ANTIBIOTICS 1MG @ 1MG A 090088 A 090732 A 090732 A 090732 001 Jun 28, 2010 001 Jun 28, 2010 001 Jun 28, 2010 001 Jun 28, 2010 Aug DISC Oct CAHN Oct CAHN May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -12 ANIDULAFUNGIN POWDER;INTRAVENOUS ERAXIS +! VICURON HOLDINGS +! 50MG/VIAL 100MG/VIAL >D> AB >A> AB >D> AB >A> AB APIXABAN TABLET;ORAL APIXABAN BRECKENRIDGE @ @ 2.5MG 2.5MG 2.5MG 5MG 5MG 5MG APREMILAST TABLET;ORAL APREMILAST AB ALKEM LABS LTD AB AB AB AMNEAL AB AB @ UNICHEM AB @ AB @ AB AB ZYDUS PHARMS AB AB OTEZLA AB + AMGEN INC AB + AB +! 10MG 20MG 30MG 10MG 20MG 30MG 10MG 10MG 20MG 20MG 30MG 30MG 10MG 20MG 30MG 10MG 20MG 30MG AN AN AN >A> AN AN ARFORMOTEROL TARTRATE SOLUTION;INHALATION ARFORMOTEROL TARTRATE AXAR PHARMS INC CIPLA GLENMARK PHARMS LTD TEVA PHARMS USA BROVANA +! SUNOVION EQ 0.015MG BASE/2ML EQ 0.015MG BASE/2ML EQ 0.015MG BASE/2ML EQ 0.015MG BASE/2ML EQ 0.015MG BASE/2ML AP AP >D> >A> ARGATROBAN INJECTABLE;INJECTION ARGATROBAN CAPLIN +! HIKMA PHARM CO LTD 50MG/50ML (1MG/ML) 50MG/50ML (1MG/ML) INJECTABLE;INTRAVENOUS ARGATROBAN IN SODIUM CHLORIDE + @ EAGLE PHARMS 50MG/50ML (1MG/ML) SOLUTION;INTRAVENOUS ARGATROBAN IN SODIUM CHLORIDE +! ACCORD HLTHCARE 50MG/50ML (1MG/ML) AUROBINDO PHARMA LTD 50MG/50ML (1MG/ML) EUGIA PHARMA SPECLTS 50MG/50ML (1MG/ML) AP AP AP >A> AP ARSENIC TRIOXIDE INJECTABLE;INJECTION ARSENIC TRIOXIDE AMNEAL @ EUGIA PHARMA 1MG/ML 1MG/ML 1MG/ML 2MG/ML 2MG/ML N 021632 001 Feb 17, 2006 Jul CAHN N 021632 002 Nov 14, 2006 Jul CAHN A 209845 A 209845 A 209845 A 209845 A 209845 A 209845 001 Jul 26, 2021 001 Jul 26, 2021 001 Jul 26, 2021 002 Jul 26, 2021 002 Jul 26, 2021 002 Jul 26, 2021 Oct DISC Oct DISC Jul NEWA Oct DISC Oct DISC Jul NEWA A 211761 A 211761 A 211761 A 211782 A 211782 A 211782 A 211819 A 211819 A 211819 A 211819 A 211819 A 211819 A 211859 A 211859 A 211859 001 Sep 21, 2021 002 Sep 21, 2021 003 Sep 21, 2021 001 Jun 30, 2021 002 Jun 30, 2021 003 Jun 30, 2021 001 Feb 17, 2021 001 Feb 17, 2021 002 Feb 17, 2021 002 Feb 17, 2021 003 Feb 17, 2021 003 Feb 17, 2021 001 Sep 21, 2021 002 Sep 21, 2021 003 Sep 21, 2021 Sep NEWA Sep NEWA Sep NEWA Jun NEWA Jun NEWA Jun NEWA Aug DISC Feb NFTG Aug DISC Feb NFTG Aug DISC Feb NFTG Sep NEWA Sep NEWA Sep NEWA N 205437 001 Mar 21, 2014 N 205437 002 Mar 21, 2014 N 205437 003 Mar 21, 2014 Feb CFTG Feb CFTG Feb CFTG A 213762 A 207306 A 213132 A 200293 001 Jun 22, 2021 001 Jun 22, 2021 001 Jun 22, 2021 001 Nov 09, 2021 Jun NFTG Jun NFTG Jun NFTG Oct NEWA N 021912 001 Oct 06, 2006 Jun CFTG A 214235 001 Jan 21, 2021 Jan NFTG N 203049 002 Sep 30, 2016 Jan CFTG N 022434 001 Jun 29, 2011 May DISC N 212035 001 Jun 07, 2021 N 209552 001 Nov 27, 2018 N 209552 001 Nov 27, 2018 Jun NEWA Oct CAHN Oct CAHN A 210739 A 210739 A 210739 A 210739 A 214011 001 Jan 25, 2021 001 Jan 25, 2021 001 Jan 25, 2021 002 Aug 19, 2021 001 Oct 15, 2021 Aug CMFD May DISC Jan NEWA Aug NEWA Oct NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -13 >A> AP AP INJECTABLE;INJECTION ARSENIC TRIOXIDE GLAND PHARMA LTD @ INGENUS PHARMS LLC 2MG/ML 2MG/ML 2MG/ML A 215059 001 Oct 07, 2021 A 209315 002 Jan 14, 2021 A 209315 002 Jan 14, 2021 Oct NEWA Feb DISC Jan NEWA >A> ASCIMINIB HYDROCHLORIDE >A> TABLET;ORAL >A> SCEMBLIX >A> + NOVARTIS >A> +! EQ 20MG BASE EQ 40MG BASE N 215358 001 Oct 29, 2021 Oct NEWA N 215358 002 Oct 29, 2021 Oct NEWA ASCORBIC ACID; BIOTIN; CHOLECALCIFEROL; CYANOCOBALAMIN; DEXPANTHENOL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN; THIAMINE; TOCOPHEROL ACETATE; VITAMIN A; VITAMIN K INJECTABLE;INTRAVENOUS INFUVITE PEDIATRIC (PHARMACY BULK PACKAGE) +! SANDOZ CANADA INC 80MG/VIAL;0.02MG/VIAL;400 N 021265 IU/VIAL;0.001MG/VIAL;5MG/VIAL;0.14 MG/VIAL;17MG/VIAL;1MG/VIAL;1.4MG/V IAL;1.2MG/VIAL;7 IU/VIAL;2,300 IU/VIAL;0.2MG/VIAL 002 Jan 29, 2004 Feb CAIN ASENAPINE MALEATE TABLET;SUBLINGUAL ASENAPINE MALEATE AB ALEMBIC PHARMS LTD AB BRECKENRIDGE EQ 2.5MG BASE EQ 5MG BASE A 206098 003 Jul 19, 2021 Jul NEWA A 205960 003 Mar 08, 2021 Feb NEWA ASPIRIN; BUTALBITAL; CAFFEINE CAPSULE;ORAL BUTALBITAL, ASPIRIN AND CAFFEINE >A> LGM PHARMA 500MG;50MG;40MG A 205230 001 Oct 18, 2021 Oct NEWA ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE TABLET;ORAL NORGESIC + @ BAUSCH NORGESIC FORTE 385MG;30MG;25MG + @ BAUSCH 770MG;60MG;50MG N 013416 003 Oct 27, 1982 May CAHN N 013416 004 Oct 27, 1982 May CAHN ASPIRIN; CAFFEINE; PROPOXYPHENE HYDROCHLORIDE CAPSULE;ORAL PROPOXYPHENE COMPOUND 65 + @ SANDOZ 389MG;32.4MG;65MG A 080044 002 Sep 16, 1983 Aug CRLD ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE TABLET;ORAL CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE ! INGENUS PHARMS NJ @ SANDOZ 325MG;200MG;16MG 325MG;200MG;16MG 325MG;200MG;16MG A 040860 001 Jan 07, 2010 A 040860 001 Jan 07, 2010 A 040118 001 Apr 16, 1996 Jul CHRS Jul CTEC Jul DISC ASPIRIN; DIPYRIDAMOLE CAPSULE, EXTENDED RELEASE;ORAL ASPIRIN AND DIPYRIDAMOLE @ LANNETT CO INC AB MICRO LABS @ SUN PHARM 25MG;200MG 25MG;200MG 25MG;200MG A 204552 001 Mar 20, 2019 A 209929 001 Aug 11, 2021 A 208572 001 Aug 21, 2018 Apr DISC Jul NEWA Aug DISC ASPIRIN; HYDROCODONE BITARTRATE TABLET;ORAL >D> HYDROCODONE BITARTRATE AND ASPIRIN >D> LGM PHARMA >A> @ 500MG;5MG 500MG;5MG 500MG;5MG A 205479 001 May 28, 2021 A 205479 001 May 28, 2021 A 205479 001 May 28, 2021 Oct DISC Oct DISC May NEWA ASPIRIN; OXYCODONE HYDROCHLORIDE TABLET;ORAL OXYCODONE AND ASPIRIN @ MAYNE PHARMA INC 325MG;4.8355MG A 091670 001 Mar 16, 2011 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -14 ATAZANAVIR SULFATE CAPSULE;ORAL ATAZANAVIR SULFATE AB LAURUS AB AB EQ 150MG BASE EQ 200MG BASE EQ 300MG BASE ATENOLOL TABLET;ORAL ATENOLOL >D> @ DAVA PHARMS INC >D> @ >D> @ >A> @ STRIDES PHARMA >A> @ >A> @ 25MG 50MG 100MG 25MG 50MG 100MG >A> AB >A> AB ATENOLOL; CHLORTHALIDONE TABLET;ORAL ATENOLOL AND CHLORTHALIDONE NOVITIUM PHARMA 50MG;25MG 100MG;25MG ATOGEPANT TABLET;ORAL QULIPTA + ABBVIE INC + +! 10MG 30MG 60MG ATOMOXETINE HYDROCHLORIDE CAPSULE;ORAL ATOMOXETINE HYDROCHLORIDE AB HETERO LABS LTD V 10MG AB 18MG AB 25MG AB 40MG AB 60MG AB 80MG AB 100MG @ MYLAN 10MG AB 10MG @ 18MG AB 18MG @ 25MG AB 25MG @ 40MG AB 40MG @ 60MG AB 60MG @ 80MG AB 80MG @ 100MG AB 100MG AB AB AB AB AB AB AB AB >D> AB >A> AB >D> AB >A> AB ATORVASTATIN CALCIUM TABLET;ORAL ATORVASTATIN CALCIUM ALKEM LABS LTD AUGUST DR REDDYS LABS LTD @ @ EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 80MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 80MG BASE EQ 10MG BASE EQ 10MG BASE EQ 10MG BASE EQ 20MG BASE EQ 20MG BASE EQ 20MG BASE A 212579 001 Apr 30, 2021 A 212579 002 Apr 30, 2021 A 212579 003 Apr 30, 2021 Apr NEWA Apr NEWA Apr NEWA A 074099 A 073542 A 073543 A 074099 A 073542 A 073543 001 Apr 28, 1992 001 Dec 19, 1991 001 Dec 19, 1991 001 Apr 28, 1992 001 Dec 19, 1991 001 Dec 19, 1991 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 215560 001 Oct 25, 2021 Oct NEWA A 215560 002 Oct 25, 2021 Oct NEWA N 215206 001 Sep 28, 2021 N 215206 002 Sep 28, 2021 N 215206 003 Sep 28, 2021 Sep NEWA Sep NEWA Sep NEWA A 202682 A 202682 A 202682 A 202682 A 202682 A 202682 A 202682 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 A 079021 001 Mar 11, 2021 002 Mar 11, 2021 003 Mar 11, 2021 004 Mar 11, 2021 005 Mar 11, 2021 006 Mar 11, 2021 007 Mar 11, 2021 001 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 003 Feb 18, 2021 004 Feb 18, 2021 004 Feb 18, 2021 005 Feb 18, 2021 005 Feb 18, 2021 006 Feb 18, 2021 006 Feb 18, 2021 007 Feb 18, 2021 007 Feb 18, 2021 Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA Feb DISC Feb NEWA A 209288 A 209288 A 209288 A 209288 A 214969 A 214969 A 214969 A 214969 A 214659 A 214659 A 214659 A 214659 A 214659 A 214659 001 Dec 21, 2018 002 Dec 21, 2018 003 Dec 21, 2018 004 Dec 21, 2018 001 Sep 02, 2021 002 Sep 02, 2021 003 Sep 02, 2021 004 Sep 02, 2021 001 Jul 14, 2021 001 Jul 14, 2021 001 Jul 14, 2021 002 Jul 14, 2021 002 Jul 14, 2021 002 Jul 14, 2021 Jan CAHN Jan CAHN Jan CAHN Jan CAHN Aug NEWA Aug NEWA Aug NEWA Aug NEWA Oct DISC Oct DISC Jul NEWA Oct DISC Oct DISC Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -15 >D> AB >A> AB >D> AB >A> AB TABLET;ORAL ATORVASTATIN CALCIUM @ @ EQ 40MG BASE EQ 40MG BASE EQ 40MG BASE EQ 80MG BASE EQ 80MG BASE EQ 80MG BASE A 214659 A 214659 A 214659 A 214659 A 214659 A 214659 003 Jul 14, 2021 003 Jul 14, 2021 003 Jul 14, 2021 004 Jul 14, 2021 004 Jul 14, 2021 004 Jul 14, 2021 Oct DISC Oct DISC Jul NEWA Oct DISC Oct DISC Jul NEWA ATORVASTATIN CALCIUM; EZETIMIBE TABLET;ORAL EZETIMIBE AND ATORVASTATIN CALCIUM @ SCOV3 EQ 10MG BASE;10MG @ EQ 20MG BASE;10MG @ EQ 40MG BASE;10MG @ LIPTRUZET EQ 80MG BASE;10MG + @ ORGANON EQ 10MG BASE;10MG + @ EQ 20MG BASE;10MG + @ EQ 40MG BASE;10MG + @ EQ 80MG BASE;10MG A 206084 A 206084 A 206084 A 206084 001 Apr 26, 2017 002 Apr 26, 2017 003 Apr 26, 2017 004 Apr 26, 2017 Jul CAHN Jul CAHN Jul CAHN Jul CAHN N 200153 N 200153 N 200153 N 200153 001 May 03, 2013 002 May 03, 2013 003 May 03, 2013 004 May 03, 2013 Feb CAHN Feb CAHN Feb CAHN Feb CAHN >A> AB AB ATOVAQUONE SUSPENSION;ORAL ATOVAQUONE ABON PHARMS LLC BIONPHARMA INC 750MG/5ML 750MG/5ML A 214272 001 Oct 25, 2021 Oct NEWA A 212918 001 Mar 30, 2021 Mar NEWA ATROPINE SULFATE SOLUTION;INTRAVENOUS ATROPINE SULFATE AP ACCORD HLTHCARE 0.25MG/5ML (0.05MG/ML) A 212868 001 Jul 26, 2021 AP 0.5MG/5ML (0.1MG/ML) A 212868 002 Jul 26, 2021 AP 1MG/10ML (0.1MG/ML) A 212868 003 Jul 26, 2021 AP +! HOSPIRA 0.25MG/5ML (0.05MG/ML) N 021146 002 Jul 09, 2001 AP +! 0.5MG/5ML (0.1MG/ML) N 021146 004 Aug 17, 2017 AP +! 1MG/10ML (0.1MG/ML) N 021146 003 Jul 09, 2001 AP +! 1MG/10ML (0.1MG/ML) N 021146 005 Aug 17, 2017 AP INTL MEDICATION SYS 1MG/10ML (0.1MG/ML) A 212461 001 Oct 05, 2020 SOLUTION;INTRAVENOUS, INTRAMUSCULAR, SUBCUTANEOUS, INTRAOSSEOUS, ENDOTRACHEAL ATROPINE SULFATE AP ACCORD HLTHCARE 8MG/20ML (0.4MG/ML) A 213424 001 Mar 19, 2021 AP +! FRESENIUS KABI USA 8MG/20ML (0.4MG/ML) N 209260 001 Jan 26, 2018 Jul NFTG Jul NFTG Jul NEWA Jul CFTG Jul CFTG Jul CTEC Mar CTEC Mar CTEC Mar NFTG Mar CFTG ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE TABLET;ORAL DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE AA PHARMA LIFE 0.025MG;2.5MG AA WINDER LABS LLC 0.025MG;2.5MG A 207128 001 Oct 21, 2020 Sep CAHN A 211362 001 Jan 27, 2021 Jan NEWA ATROPINE SULFATE; EDROPHONIUM CHLORIDE INJECTABLE;INJECTION ENLON-PLUS + @ MYLAN 0.14MG/ML;10MG/ML N 019678 001 Nov 06, 1991 Jan CAHN >A> AVACOPAN >A> CAPSULE;ORAL >A> TAVNEOS >A> +! CHEMOCENTRYX 10MG N 214487 001 Oct 07, 2021 Oct NEWA AVAPRITINIB TABLET;ORAL AYVAKIT + BLUEPRINT MEDICINES + 25MG 50MG N 212608 004 Jun 16, 2021 Jun NEWA N 212608 005 Jun 16, 2021 Jun NEWA AVIBACTAM SODIUM; CEFTAZIDIME POWDER;INTRAVENOUS AVYCAZ +! ALLERGAN EQ 0.5GM BASE;2GM/VIAL N 206494 001 Feb 25, 2015 Jan CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -16 >A> AB >A> AB AZATHIOPRINE TABLET;ORAL AZATHIOPRINE AMNEAL 75MG 100MG A 074069 002 Nov 02, 2021 Oct NEWA A 074069 003 Nov 02, 2021 Oct NEWA >D> >D> AB >A> AB AB AB AB AB AB AB AB >D> AB >A> AB AB AB AB AB AB AB AB AB AB AB AZELASTINE HYDROCHLORIDE SPRAY, METERED;NASAL ASTELIN +! MYLAN SPCLT VIATRIS 0.137MG/SPRAY + @ 0.137MG/SPRAY +! 0.137MG/SPRAY +! MYLAN SPECIALITY LP ASTEPRO 0.137MG/SPRAY @ MYLAN SPECIALITY LP 0.137MG/SPRAY + @ 0.2055MG/SPRAY +! 0.2055MG/SPRAY AZELASTINE HYDROCHLORIDE AKORN 0.137MG/SPRAY 0.2055MG/SPRAY ALKEM LABS LTD 0.137MG/SPRAY AMNEAL 0.137MG/SPRAY 0.2055MG/SPRAY APOTEX INC 0.137MG/SPRAY ! 0.137MG/SPRAY 0.137MG/SPRAY 0.2055MG/SPRAY AUROBINDO PHARMA LTD 0.137MG/SPRAY 0.2055MG/SPRAY BRECKENRIDGE 0.137MG/SPRAY HIKMA PHARMS 0.137MG/SPRAY 0.2055MG/SPRAY SUN PHARM 0.137MG/SPRAY UPSHER SMITH LABS 0.137MG/SPRAY ZYDUS PHARMS 0.137MG/SPRAY N 020114 N 020114 N 020114 N 020114 001 Nov 01, 1996 001 Nov 01, 1996 001 Nov 01, 1996 001 Nov 01, 1996 Oct DISC Oct DISC Sep CAHN Aug CPOT N 022203 001 Oct 15, 2008 N 022203 002 Aug 31, 2009 N 022203 002 Aug 31, 2009 Aug CPOT Jul DISC Jul CPOT A 207610 A 210032 A 208156 A 204660 A 208199 A 077954 A 077954 A 077954 A 201846 A 212289 A 212775 A 090176 A 091444 A 207243 A 090423 A 202609 A 091409 001 May 17, 2019 001 Aug 23, 2019 001 Aug 18, 2017 001 Aug 28, 2017 001 Dec 15, 2017 001 Apr 30, 2009 001 Apr 30, 2009 001 Apr 30, 2009 001 Aug 31, 2012 001 May 08, 2020 001 Nov 12, 2020 001 Jul 28, 2015 001 Oct 24, 2014 001 Sep 22, 2017 001 May 23, 2012 001 Mar 17, 2017 001 Aug 14, 2017 Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Oct CHRS Oct CHRS Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT Aug CPOT AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE SPRAY, METERED;NASAL AZELASTINE HYDROCHLORIDE AND FLUTICASONE PROPIONATE AB APOTEX 0.137MG/SPRAY;0.05MG/SPRAY A 207712 001 Apr 28, 2017 AB PADAGIS ISRAEL 0.137MG/SPRAY;0.05MG/SPRAY A 208111 001 Feb 18, 2021 AB PERRIGO UK FINCO DYMISTA EQ 0.125MG BASE/SPRAY;0.05MG/SPRAY A 208111 001 Feb 18, 2021 AB +! MYLAN SPECIALITY LP 0.137MG/SPRAY;0.05MG/SPRAY N 202236 001 May 01, 2012 Aug CPOT Aug CPOT Feb NEWA Aug CPOT AZITHROMYCIN FOR SUSPENSION;ORAL AZITHROMYCIN AB TARO INJECTABLE;INJECTION AZITHROMYCIN @ MYLAN ASI TABLET;ORAL AZITHROMYCIN AB ALEMBIC PHARMS LTD AB YUNG SHIN PHARM AB EQ 200MG BASE/5ML EQ 500MG BASE/VIAL EQ 600MG BASE EQ 500MG BASE EQ 600MG BASE A 211521 001 Dec 11, 2019 Feb CMFD A 065506 001 Mar 24, 2009 Feb DISC A 211793 001 Jan 27, 2020 A 211318 001 Mar 17, 2021 A 211068 001 May 08, 2020 Jul CMFD Mar NEWA Feb CMFD >A> AP >A> AP AZTREONAM INJECTABLE;INJECTION AZTREONAM HOSPIRA INC 1GM/VIAL 2GM/VIAL A 206517 001 Nov 08, 2021 Oct NEWA A 206517 002 Nov 08, 2021 Oct NEWA BACITRACIN INJECTABLE;INJECTION BACITRACIN @ XELLIA PHARMS APS 50,000 UNITS/VIAL A 203177 001 Aug 25, 2014 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -17 BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE OINTMENT;TOPICAL CORTISPORIN + @ MONARCH PHARMS 400 UNITS/GM;1%;EQ 3.5MG BASE/GM;5,000 UNITS/GM N 050168 002 May 04, 1984 Jul DISC AP AP AP AP AP AP AP AP AP AB AB AB AB AB AB AB AB >D> AB >A> AB AB AB AB BACLOFEN INJECTABLE;INTRATHECAL BACLOFEN MAIA PHARMS INC GABLOFEN 0.05MG/ML 0.5MG/ML 2MG/ML +! PIRAMAL CRITICAL + +! + +! + 0.05MG/ML 0.05MG/ML 0.5MG/ML 0.5MG/ML 2MG/ML 2MG/ML TABLET;ORAL BACLOFEN AUROBINDO PHARMA LTD BEXIMCO PHARMS USA IMPAX INNOGENIX KARTHA @ @ @ LANNETT CO INC 10MG 20MG 10MG 20MG 5MG 10MG 20MG 5MG 5MG 5MG 5MG 10MG 10MG 20MG 20MG 5MG TABLET, ORALLY DISINTEGRATING;ORAL KEMSTRO + @ UCB INC + @ 10MG 20MG A 210777 001 Jan 15, 2021 A 210048 001 Sep 11, 2019 A 210048 002 Sep 11, 2019 Jan NEWA Aug CMFD Aug CMFD N 022462 N 022462 N 022462 N 022462 N 022462 N 022462 001 Nov 19, 2010 001 Nov 19, 2010 002 Nov 19, 2010 002 Nov 19, 2010 003 Nov 19, 2010 003 Nov 19, 2010 Mar CHRS Mar CRLD Mar CHRS Mar CRLD Mar CHRS Mar CRLD A 214099 A 214099 A 214114 A 214114 A 077971 A 077971 A 077971 A 212378 A 214374 A 214374 A 214374 A 214374 A 214374 A 214374 A 214374 A 077241 001 Jul 13, 2021 002 Jul 13, 2021 001 Jul 16, 2021 002 Jul 16, 2021 003 Jul 07, 2021 001 Oct 26, 2007 002 Oct 26, 2007 003 Apr 30, 2021 001 Mar 05, 2021 001 Mar 05, 2021 001 Mar 05, 2021 002 Mar 05, 2021 002 Mar 05, 2021 003 Mar 05, 2021 003 Mar 05, 2021 003 Sep 22, 2021 Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jun NEWA Jun CAHN Jun CAHN Apr NEWA Oct DISC Oct DISC Feb NEWA Sep DISC Feb NEWA Sep DISC Feb NEWA Sep NEWA N 021589 001 Oct 30, 2003 May CRLD N 021589 002 Oct 30, 2003 May CRLD BALOXAVIR MARBOXIL TABLET;ORAL XOFLUZA + GENENTECH INC 80MG N 210854 003 Mar 18, 2021 Mar NEWA BELUMOSUDIL MESYLATE TABLET;ORAL REZUROCK +! KADMON PHARMS LLC EQ 200MG BASE N 214783 001 Jul 16, 2021 Jul NEWA BELZUTIFAN TABLET;ORAL WELIREG +! MERCK SHARP DOHME 40MG N 215383 001 Aug 13, 2021 Aug NEWA BENAZEPRIL HYDROCHLORIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AB CADILA 5MG AB 10MG AB 20MG AB 40MG LOTENSIN AB + VALIDUS PHARMS AB + AB + AB +! 5MG 10MG 20MG 40MG A 078848 A 078848 A 078848 A 078848 001 May 23, 2008 002 May 23, 2008 003 May 23, 2008 004 May 23, 2008 Aug CAHN Aug CAHN Aug CAHN Aug CAHN N 019851 N 019851 N 019851 N 019851 001 Jun 25, 1991 002 Jun 25, 1991 003 Jun 25, 1991 004 Jun 25, 1991 Feb CAHN Feb CAHN Feb CAHN Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -18 BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE TABLET;ORAL BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ MYLAN @ @ @ SANDOZ LOTENSIN HCT 5MG;6.25MG 10MG;12.5MG 20MG;12.5MG 20MG;25MG 5MG;6.25MG + @ VALIDUS PHARMS AB + AB + AB +! 5MG;6.25MG 10MG;12.5MG 20MG;12.5MG 20MG;25MG BENOXINATE HYDROCHLORIDE; FLUORESCEIN SODIUM SOLUTION/DROPS;OPHTHALMIC FLUORESCEIN SODIUM AND BENOXINATE HYDROCHLORIDE +! BAUSCH LOMB IRELAND 0.4%;0.3% BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE GEL;TOPICAL CLINDAMYCIN PHOSPHATE AND BENZOYL PEROXIDE AB ENCUBE 5%;1.2% @ TOLMAR 5%;EQ 1% BASE @ 5%;1.2% DUAC AB + STIEFEL 5%;1.2% BENZOYL PEROXIDE; TRETINOIN CREAM;TOPICAL TWYNEO +! SOL-GEL TECHNOLOGIES 3%;0.1% BENZPHETAMINE HYDROCHLORIDE TABLET;ORAL BENZPHETAMINE HYDROCHLORIDE @ SCINOPHARM TAIWAN 50MG >A> AP BENZTROPINE MESYLATE INJECTABLE;INJECTION BENZTROPINE MESYLATE HIKMA 1MG/ML BEPOTASTINE BESILATE SOLUTION/DROPS;OPHTHALMIC BEPOTASTINE BESILATE AT APOTEX AT MYLAN BEPREVE 1.5% 1.5% AT +! BAUSCH AND LOMB INC 1.5% BETAMETHASONE ACETATE; BETAMETHASONE SODIUM PHOSPHATE INJECTABLE;INJECTION CELESTONE SOLUSPAN AB +! ORGANON 3MG/ML;EQ 3MG BASE/ML BETAMETHASONE DIPROPIONATE SPRAY;TOPICAL SERNIVO +! PRIMUS PHARMS EQ 0.05% BASE/SPRAY BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE LOTION;TOPICAL CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE AB ! TARO EQ 0.05% BASE;1% LOTRISONE + @ MERCK SHARP DOHME EQ 0.05% BASE;1% A 076688 A 076688 A 076688 A 076688 A 076631 001 Feb 11, 2004 002 Feb 11, 2004 003 Feb 11, 2004 004 Feb 11, 2004 001 Feb 11, 2004 Jul DISC Jul DISC Jul DISC Jul DISC Jul CTEC N 020033 N 020033 N 020033 N 020033 001 May 19, 1992 002 May 19, 1992 004 May 19, 1992 003 May 19, 1992 Feb CAHN Feb CAHN Feb CAHN Feb CAHN N 211039 001 Mar 09, 2020 May CAHN A 212433 001 Apr 28, 2021 A 204087 001 Jun 27, 2017 A 203688 001 Aug 25, 2016 Apr NEWA Sep DISC Sep DISC N 050741 001 Aug 26, 2002 Jan CHRS N 214902 001 Jul 26, 2021 Jul NEWA A 040578 001 Apr 17, 2006 Sep CAHN A 209442 001 Oct 14, 2021 Oct NEWA A 206066 001 Mar 05, 2019 May CMFD A 206220 001 Mar 18, 2019 May CMFD N 022288 001 Sep 08, 2009 May CTEC N 014602 001 Aug CAHN N 208079 001 Feb 05, 2016 Mar CAHN A 076493 001 Jul 28, 2004 Feb CHRS N 020010 001 Dec 08, 2000 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -19 BETAXOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC BETAXOLOL HYDROCHLORIDE AT ACELLA EQ 0.5% BASE A 078694 001 Nov 16, 2009 Aug CAHN BETHANECHOL CHLORIDE TABLET;ORAL BETHANECHOL CHLORIDE AA BIOPHARM AA AA AA @ WOCKHARDT @ URECHOLINE + @ ODYSSEY PHARMS + @ 5MG 10MG 25MG 50MG 5MG 50MG 10MG 25MG A 040728 A 040728 A 040728 A 040728 A 040532 A 040518 002 Oct 26, 2007 003 Oct 26, 2007 004 Oct 26, 2007 001 Oct 26, 2007 001 Sep 29, 2003 001 Sep 29, 2003 Sep CAHN Sep CAHN Sep CAHN Sep CAHN Jan DISC Jan DISC A 088440 001 May 29, 1984 Aug CRLD A 088441 001 May 29, 1984 Aug CRLD BEXAROTENE CAPSULE;ORAL BEXAROTENE AB TEVA PHARMS USA 75MG A 209931 001 Jan 14, 2021 Jan NEWA BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE TABLET;ORAL BIKTARVY >A> + GILEAD SCIENCES INC EQ 30MG BASE;120MG;EQ 15MG BASE N 210251 002 Oct 07, 2021 Oct NEWA BIMATOPROST SOLUTION/DROPS;OPHTHALMIC BIMATOPROST @ AKORN 0.03% AT ! ALEMBIC PHARMS LTD 0.03% AT LUPIN LTD 0.03% A 203299 001 Nov 08, 2018 A 210263 001 Apr 12, 2019 A 203991 001 Feb 20, 2015 Feb CAHN Jan CHRS Jan CHRS >A> AB >A> AB AB AB BISOPROLOL FUMARATE TABLET;ORAL BISOPROLOL FUMARATE NOVITIUM PHARMA UNICHEM ! 5MG 10MG 5MG 10MG A 215563 A 215563 A 078635 A 078635 001 Oct 29, 2021 002 Oct 29, 2021 001 Aug 18, 2009 002 Aug 18, 2009 Oct NEWA Oct NEWA Apr CAHN Apr CAHN >A> AB >A> AB >A> AB BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE TABLET;ORAL BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE NOVITIUM PHARMA 2.5MG;6.25MG 5MG;6.25MG 10MG;6.25MG A 215562 001 Nov 04, 2021 A 215562 002 Nov 04, 2021 A 215562 003 Nov 04, 2021 Oct NEWA Oct NEWA Oct NEWA BIVALIRUDIN INJECTABLE;INTRAVENOUS BIVALIRUDIN AP HAINAN POLY PHARM 250MG/VIAL A 213078 001 May 28, 2021 May NEWA >A> AP >A> AP >D> AP >D> AP BLEOMYCIN SULFATE INJECTABLE;INJECTION BLEOMYCIN SULFATE @ CIPLA HIKMA PHARMS WEST-WARD PHARMS INT EQ 15 UNITS BASE/VIAL EQ 15 UNITS BASE/VIAL EQ 30 UNITS BASE/VIAL EQ 15 UNITS BASE/VIAL EQ 30 UNITS BASE/VIAL A 209439 A 065042 A 065042 A 065042 A 065042 001 Mar 11, 2019 002 Oct 17, 2001 001 Oct 17, 2001 002 Oct 17, 2001 001 Oct 17, 2001 Aug DISC Oct CAHN Oct CAHN Oct CAHN Oct CAHN BORTEZOMIB INJECTABLE;INTRAVENOUS, SUBCUTANEOUS VELCADE +! TAKEDA PHARMS USA 3.5MG/VIAL N 021602 001 May 13, 2003 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -20 BOSENTAN TABLET;ORAL BOSENTAN @ ALEMBIC PHARMS LTD 62.5MG AB 62.5MG @ 125MG AB 125MG @ NATCO PHARMA LTD 62.5MG @ 125MG TRACLEER AB + ACTELION AB +! 62.5MG 125MG TABLET, FOR SUSPENSION;ORAL TRACLEER +! ACTELION 32MG BRIGATINIB TABLET;ORAL ALUNBRIG + TAKEDA PHARMS USA + +! 30MG 90MG 180MG BRIMONIDINE TARTRATE GEL;TOPICAL BRIMONIDINE TARTRATE AB PADAGIS ISRAEL MIRVASO AB +! GALDERMA LABS LP EQ 0.33% BASE EQ 0.33% BASE BRIMONIDINE TARTRATE; BRINZOLAMIDE SUSPENSION/DROPS;OPHTHALMIC SIMBRINZA +! ALCON LABS INC 0.2%;1% BRINCIDOFOVIR SUSPENSION;ORAL TEMBEXA +! CHIMERIX TABLET;ORAL TEMBEXA +! CHIMERIX 10MG/ML 100MG BRINZOLAMIDE SUSPENSION/DROPS;OPHTHALMIC BRINZOLAMIDE AB BAUSCH 1% BROMFENAC SODIUM SOLUTION/DROPS;OPHTHALMIC BROMFENAC SODIUM @ NOVITIUM PHARMA EQ 0.09% ACID BROMOCRIPTINE MESYLATE CAPSULE;ORAL PARLODEL AB + VALIDUS PHARMS TABLET;ORAL PARLODEL AB + VALIDUS PHARMS EQ 5MG BASE EQ 2.5MG BASE BUDESONIDE CAPSULE, DELAYED RELEASE;ORAL BUDESONIDE @ ALVOGEN 3MG AB AMNEAL PHARMS 3MG AB MAYNE PHARMA 3MG AB MYLAN 3MG AB RISING 3MG AB SCIECURE PHARMA INC 3MG A 211461 001 Jan 23, 2020 A 211461 001 Jan 23, 2020 A 211461 002 Jan 23, 2020 A 211461 002 Jan 23, 2020 A 206987 001 Apr 26, 2019 A 206987 002 Apr 26, 2019 Aug DISC May CMFD Aug DISC May CMFD Sep DISC Sep DISC N 021290 001 Nov 20, 2001 Feb CAHN N 021290 002 Nov 20, 2001 Feb CAHN N 209279 001 Sep 05, 2017 Feb CAHN N 208772 001 Apr 28, 2017 N 208772 002 Apr 28, 2017 N 208772 003 Oct 02, 2017 May CAHN May CAHN May CAHN A 209158 001 Sep 23, 2021 Sep NFTG N 204708 001 Aug 23, 2013 Sep CFTG N 204251 001 Apr 19, 2013 Sep CAHN N 214460 001 Jun 04, 2021 Jun NEWA N 214461 001 Jun 04, 2021 Jun NEWA A 204884 001 Aug 18, 2021 Aug NEWA A 201941 001 Feb 10, 2015 Sep CAHN N 017962 002 Mar 01, 1982 Feb CAHN N 017962 001 Feb CAHN A 206724 001 Nov 23, 2016 A 206200 001 Jul 31, 2017 A 206623 001 Apr 08, 2016 A 090410 001 May 16, 2011 A 207367 001 Apr 07, 2017 A 209041 001 Sep 28, 2017 Apr CDFR Apr CDFR Apr CDFR Apr CDFR Apr CDFR Apr CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -21 CAPSULE, DELAYED RELEASE;ORAL BUDESONIDE AB ZYDUS PHARMS 3MG SUSPENSION;INHALATION BUDESONIDE AN SUN PHARM 0.25MG/2ML AN 0.5MG/2ML AN 1MG/2ML A 206134 001 May 04, 2017 Apr CDFR A 211922 001 Apr 14, 2021 A 211922 002 Apr 14, 2021 A 211922 003 Apr 14, 2021 Apr NEWA Apr NEWA Apr NEWA BUMETANIDE TABLET;ORAL BUMETANIDE BX RISING BX BX 0.5MG 1MG 2MG A 212019 001 Dec 12, 2019 A 212019 002 Dec 12, 2019 A 212019 003 Dec 12, 2019 Sep CTEC Sep CTEC Sep CTEC BUPIVACAINE SOLUTION, EXTENDED RELEASE;INFILTRATION POSIMIR + @ DURECT +! 660MG/5ML (132MG/ML) 660MG/5ML (132MG/ML) N 204803 001 Feb 01, 2021 Mar DISC N 204803 001 Feb 01, 2021 Feb NEWA AP AP >D> AP >A> AP AP AP BUPIVACAINE HYDROCHLORIDE INJECTABLE;INJECTION BUPIVACAINE HYDROCHLORIDE HIKMA PHARMS 0.25% 0.5% HOSPIRA 0.25% @ 0.25% BUPIVACAINE HYDROCHLORIDE PRESERVATIVE FREE HIKMA PHARMS 0.25% 0.5% 0.75% A 205141 001 Feb 11, 2021 A 205141 002 Feb 11, 2021 A 070586 001 Mar 03, 1987 A 070586 001 Mar 03, 1987 Feb NEWA Feb NEWA Oct DISC Oct DISC A 204842 001 Feb 11, 2021 A 204842 002 Feb 11, 2021 A 204842 003 Feb 11, 2021 Feb NEWA Feb NEWA Feb NEWA BUPIVACAINE; MELOXICAM SOLUTION, EXTENDED RELEASE;PERIARTICULAR ZYNRELEF KIT +! HERON THERAPS INC +! +! +! 60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML 200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML) 300MG/10.5ML (29.25MG/ML);9MG/10.5ML 400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML) N 211988 001 May 12, 2021 N 211988 002 May 12, 2021 N 211988 003 May 12, 2021 N 211988 004 May 12, 2021 Jun NEWA Jun NEWA Jun NEWA Jun NEWA BUPRENORPHINE FILM, EXTENDED RELEASE;TRANSDERMAL BUPRENORPHINE AB AVEVA 5MCG/HR AB 7.5MCG/HR AB 10MCG/HR AB 15MCG/HR AB 20MCG/HR @ MYLAN TECH VIATRIS 5MCG/HR @ 5MCG/HR @ 7.5MCG/HR @ 7.5MCG/HR @ 10MCG/HR @ 10MCG/HR @ 15MCG/HR @ 15MCG/HR @ 20MCG/HR @ 20MCG/HR AB MYLAN TECHNOLOGIES 5MCG/HR AB 7.5MCG/HR AB 10MCG/HR AB 15MCG/HR AB 20MCG/HR AB WATSON LABS TEVA 7.5MCG/HR A 210272 A 210272 A 210272 A 210272 A 210272 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 210162 A 204937 001 Sep 23, 2021 002 Sep 23, 2021 003 Sep 23, 2021 004 Sep 23, 2021 005 Sep 23, 2021 001 May 03, 2021 001 May 03, 2021 002 May 03, 2021 002 May 03, 2021 003 May 03, 2021 003 May 03, 2021 004 May 03, 2021 004 May 03, 2021 005 May 03, 2021 005 May 03, 2021 001 May 03, 2021 002 May 03, 2021 003 May 03, 2021 004 May 03, 2021 005 May 03, 2021 005 Jun 29, 2021 Sep NEWA Sep NEWA Sep NEWA Sep NEWA Sep NEWA Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Apr NEWA Apr NEWA Apr NEWA Apr NEWA Apr NEWA Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -22 BUPRENORPHINE HYDROCHLORIDE FILM;BUCCAL BELBUCA AB + BDSI EQ 0.075MG BASE AB + EQ 0.15MG BASE AB + EQ 0.3MG BASE AB + EQ 0.45MG BASE AB + EQ 0.6MG BASE AB + EQ 0.75MG BASE AB +! EQ 0.9MG BASE BUPRENORPHINE HYDROCHLORIDE AB ALVOGEN AB AB AB AB AB AB AB AB AB AB AB AB AB EQ 0.075MG BASE EQ 0.075MG BASE EQ 0.15MG BASE EQ 0.15MG BASE EQ 0.3MG BASE EQ 0.3MG BASE EQ 0.45MG BASE EQ 0.45MG BASE EQ 0.6MG BASE EQ 0.6MG BASE EQ 0.75MG BASE EQ 0.75MG BASE EQ 0.9MG BASE EQ 0.9MG BASE BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE TABLET;SUBLINGUAL BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE AB ALKEM LABS LTD EQ 2MG BASE;EQ 0.5MG BASE AB EQ 8MG BASE;EQ 2MG BASE @ MAYNE PHARMA INC EQ 2MG BASE;EQ 0.5MG BASE @ EQ 8MG BASE;EQ 2MG BASE AB EQ 8MG BASE;EQ 2MG BASE @ EQ 8MG BASE;EQ 2MG BASE AB RHODES PHARMS EQ 2MG BASE;EQ 0.5MG BASE AB EQ 8MG BASE;EQ 2MG BASE BUPROPION HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL APLENZIN + BAUSCH 174MG + 348MG +! 522MG BUPROPION HYDROCHLORIDE TABLET;ORAL BUPROPION HYDROCHLORIDE @ MYLAN 75MG @ 100MG TABLET, EXTENDED RELEASE;ORAL BUPROPION HYDROCHLORIDE @ IMPAX LABS 150MG @ 200MG @ TORRENT 100MG @ 150MG @ 200MG FORFIVO XL +! ALMATICA WELLBUTRIN XL 450MG AB3 + BAUSCH 150MG AB3 +! 300MG BUSPIRONE HYDROCHLORIDE TABLET;ORAL BUSPIRONE HYDROCHLORIDE AB RUBICON 5MG AB 7.5MG AB 10MG AB 15MG AB 30MG N 207932 N 207932 N 207932 N 207932 N 207932 N 207932 N 207932 001 Oct 23, 2015 002 Oct 23, 2015 003 Oct 23, 2015 004 Oct 23, 2015 005 Oct 23, 2015 006 Oct 23, 2015 007 Oct 23, 2015 Jul CFTG Jul CFTG Jul CFTG Jul CFTG Jul CFTG Jul CFTG Jul CFTG A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 A 211594 001 Aug 03, 2021 001 Aug 03, 2021 002 Aug 03, 2021 002 Aug 03, 2021 003 Aug 03, 2021 003 Aug 03, 2021 004 Aug 03, 2021 004 Aug 03, 2021 005 Aug 03, 2021 005 Aug 03, 2021 006 Aug 03, 2021 006 Aug 03, 2021 007 Aug 03, 2021 007 Aug 03, 2021 Aug CAHN Jul NFTG Aug CAHN Jul NFTG Aug CAHN Jul NFTG Aug CAHN Jul NFTG Aug CAHN Jul NFTG Aug CAHN Jul NFTG Aug CAHN Jul NFTG A 214930 A 214930 A 206953 A 206953 A 206953 A 206953 A 205601 A 205601 001 Jun 15, 2021 002 Jun 15, 2021 001 Jul 17, 2020 002 Jul 17, 2020 002 Jul 17, 2020 002 Jul 17, 2020 001 Mar 30, 2020 002 Mar 30, 2020 Jun NEWA Jun NEWA Jan DISC Jul DISC May CMFD Jan DISC Jul CMFD Jul CMFD N 022108 001 Apr 23, 2008 N 022108 002 Apr 23, 2008 N 022108 003 Apr 23, 2008 Feb CAHN Feb CAHN Feb CAHN A 075491 001 Apr 17, 2000 Aug DISC A 075491 002 Apr 17, 2000 Aug DISC A 077415 A 076711 A 203969 A 203969 A 203969 001 Nov 26, 2008 001 Dec 03, 2004 001 Oct 31, 2014 002 Oct 31, 2014 003 Oct 31, 2014 Aug DISC Aug DISC Jan DISC Jan DISC Jan DISC N 022497 001 Nov 10, 2011 Sep CAHN N 021515 001 Aug 28, 2003 Feb CAHN N 021515 002 Aug 28, 2003 Feb CAHN A 075521 A 075521 A 075521 A 075521 A 075521 001 Apr 05, 2002 004 Mar 16, 2021 002 Apr 05, 2002 003 Apr 05, 2002 005 Mar 16, 2021 Feb CMFD Mar NEWA Feb CMFD Feb CMFD Mar NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -23 BUSULFAN INJECTABLE;INJECTION BUSULFAN AP AM REGENT 6MG/ML A 202259 001 Dec 22, 2015 Feb CAHN BUTABARBITAL SODIUM TABLET;ORAL BUTABARBITAL SODIUM + @ SANDOZ 15MG A 085938 001 Aug CRLD CABERGOLINE TABLET;ORAL DOSTINEX + @ PFIZER 0.5MG N 020664 001 Dec 23, 1996 Jan CAHN CABOTEGRAVIR SODIUM TABLET;ORAL VOCABRIA +! VIIV HLTHCARE EQ 30MG BASE N 212887 001 Jan 21, 2021 Jan NEWA CABOTEGRAVIR; RILPIVIRINE SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR CABENUVA KIT +! VIIV HLTHCARE +! 400MG/2ML (200MG/ML);600MG/2ML (300MG/ML) 600MG/3ML (200MG/ML);900MG/3ML (300MG/ML) N 212888 001 Jan 21, 2021 Jan NEWA N 212888 002 Jan 21, 2021 Jan NEWA CAFFEINE CITRATE SOLUTION;INTRAVENOUS CAFCIT AP +! HIKMA PHARMS SOLUTION;ORAL CAFCIT AA +! HIKMA PHARMS EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N 020793 001 Sep 21, 1999 Jul CAHN EQ 30MG BASE/3ML (EQ 10MG BASE/ML) N 020793 002 Apr 12, 2000 Jul CAHN CAFFEINE; ERGOTAMINE TARTRATE TABLET;ORAL CAFERGOT + @ SANDOZ 100MG;1MG @ 100MG;1MG ERGOTAMINE TARTRATE AND CAFFEINE ! MIKART 100MG;1MG 100MG;1MG A 084294 001 A 084294 001 Aug CRLD Jul DISC A 040590 001 Sep 16, 2005 Jul CHRS A 040590 001 Sep 16, 2005 Jul CTEC CALCITONIN SALMON INJECTABLE;INJECTION CALCITONIN-SALMON AP CUSTOPHARM INC MIACALCIN AP +! MYLAN IRELAND LTD 200 IU/ML 200 IU/ML A 212416 001 May 14, 2021 May NFTG N 017808 002 Mar 29, 1991 May CFTG >D> AB >A> AB CALCIUM ACETATE CAPSULE;ORAL CALCIUM ACETATE AMNEAL PHARMS @ TABLET;ORAL CALCIUM ACETATE ! CHARTWELL MOLECULAR 667MG 667MG 667MG A 201658 001 Oct 06, 2014 Oct DISC A 201658 001 Oct 06, 2014 Oct DISC A 202420 001 Feb 05, 2013 Apr CHRS CALCIUM CARBONATE; RISEDRONATE SODIUM TABLET;ORAL ACTONEL WITH CALCIUM (COPACKAGED) + @ WARNER CHILCOTT + @ EQ 500MG BASE;35MG EQ 500MG BASE,N/A;N/A,35MG N 021823 001 Aug 12, 2005 Jul CPOT N 021823 001 Aug 12, 2005 Jul CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -24 >A> >A> AP CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE INJECTABLE;INJECTION POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND LACTATED RINGER'S IN PLASTIC CONTAINER FRESENIUS KABI USA 20MG/100ML;5GM/100ML;179MG/100ML;6 A 211428 001 Nov 09, 2021 00MG/100ML;310MG/100ML Oct NFTG CALCIUM GLUCEPTATE INJECTABLE;INJECTION CALCIUM GLUCEPTATE + @ ABBOTT EQ 90MG CALCIUM/5ML A 080001 001 Aug CRLD CALCIUM GLUCONATE SOLUTION;INTRAVENOUS CALCIUM GLUCONATE IN SODIUM CHLORIDE +! FRESENIUS KABI USA +! +! HQ SPCLT PHARMA 1GM/50ML (20MG/ML) 2GM/100ML (20MG/ML) 1GM/100ML (10MG/ML) N 208418 004 Jun 17, 2021 N 208418 005 Jun 17, 2021 N 210906 003 Jun 04, 2021 Aug NEWA Aug NEWA Jun NEWA CAPREOMYCIN SULFATE INJECTABLE;INJECTION CAPASTAT SULFATE + @ AKORN EQ 1GM BASE/VIAL N 050095 001 Jun DISC CAPTOPRIL TABLET;ORAL CAPTOPRIL AB ANNORA PHARMA AB AB AB AB ! HIKMA INTL PHARMS @ MYLAN @ @ @ @ @ @ @ 12.5MG 25MG 50MG 100MG 100MG 12.5MG 12.5MG 25MG 25MG 50MG 50MG 100MG 100MG A 074737 A 074737 A 074737 A 074737 A 074505 A 074434 A 074434 A 074434 A 074434 A 074434 A 074434 A 074434 A 074434 001 Oct 28, 1998 002 Oct 28, 1998 003 Oct 28, 1998 004 Oct 28, 1998 004 Feb 13, 1996 001 Feb 13, 1996 001 Feb 13, 1996 002 Feb 13, 1996 002 Feb 13, 1996 003 Feb 13, 1996 003 Feb 13, 1996 004 Feb 13, 1996 004 Feb 13, 1996 Jul CMFD Jul CMFD Jul CMFD Jul CMFD Sep CHRS Sep CAHN Sep DISC Sep CAHN Sep DISC Sep CAHN Sep DISC Sep CAHN Sep DISC CAPTOPRIL; HYDROCHLOROTHIAZIDE TABLET;ORAL CAPTOPRIL AND HYDROCHLOROTHIAZIDE @ MYLAN @ @ @ @ @ @ @ 25MG;15MG 25MG;15MG 25MG;25MG 25MG;25MG 50MG;15MG 50MG;15MG 50MG;25MG 50MG;25MG A 074896 A 074896 A 074896 A 074896 A 074896 A 074896 A 074896 A 074896 001 Dec 29, 1997 001 Dec 29, 1997 002 Dec 29, 1997 002 Dec 29, 1997 004 Dec 29, 1997 004 Dec 29, 1997 003 Dec 29, 1997 003 Dec 29, 1997 Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC CARBAMAZEPINE TABLET;ORAL CARBAMAZEPINE AB VGYAAN 200MG TABLET, EXTENDED RELEASE;ORAL CARBAMAZEPINE AB ANBISON LAB AB AB AB CSPC OUYI AB AB 100MG 200MG 400MG 100MG 200MG 400MG A 214328 001 Aug 16, 2021 Aug NEWA A 212948 A 212948 A 212948 A 213311 A 213311 A 213311 001 Sep 30, 2021 002 Sep 30, 2021 003 Sep 30, 2021 001 Apr 13, 2021 002 Apr 13, 2021 003 Apr 13, 2021 Sep NEWA Sep NEWA Sep NEWA Apr NEWA Apr NEWA Apr NEWA CARBIDOPA; LEVODOPA TABLET;ORAL CARBIDOPA AND LEVODOPA AB SCIEGEN PHARMS INC AB AB 10MG;100MG 25MG;100MG 25MG;250MG A 214092 001 May 07, 2021 A 214092 002 May 07, 2021 A 214092 003 May 07, 2021 Apr NEWA Apr NEWA Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -25 TABLET;ORAL SINEMET AB + ORGANON 10MG;100MG AB + 25MG;100MG AB + 25MG;250MG TABLET, EXTENDED RELEASE;ORAL CARBIDOPA AND LEVODOPA AB SCIEGEN PHARMS INC 25MG;100MG AB 50MG;200MG SINEMET CR + @ ORGANON 25MG;100MG + @ 50MG;200MG TABLET, ORALLY DISINTEGRATING;ORAL CARBIDOPA AND LEVODOPA @ MYLAN 10MG;100MG @ 10MG;100MG @ 25MG;100MG @ 25MG;100MG @ 25MG;250MG @ 25MG;250MG ! SUN PHARM 25MG;250MG AB ! 25MG;250MG CARBOPLATIN INJECTABLE;INTRAVENOUS CARBOPLATIN AP ! HOSPIRA AP ! AP ! AP ! @ MEITHEAL @ @ @ AP PHARMACHEMIE BV AP AP AP 50MG/5ML (10MG/ML) 150MG/15ML (10MG/ML) 450MG/45ML (10MG/ML) 600MG/60ML (10MG/ML) 50MG/5ML (10MG/ML) 150MG/15ML (10MG/ML) 450MG/45ML (10MG/ML) 600MG/60ML (10MG/ML) 50MG/5ML (10MG/ML) 150MG/15ML (10MG/ML) 450MG/45ML (10MG/ML) 600MG/60ML (10MG/ML) CARBOPROST TROMETHAMINE INJECTABLE;INJECTION CARBOPROST TROMETHAMINE AP SUNNY EQ 0.25MG BASE/ML CARFILZOMIB POWDER;INTRAVENOUS CARFILZOMIB @ BRECKENRIDGE AP @ AP KYPROLIS + ONYX THERAP AP + 10MG/VIAL 10MG/VIAL 60MG/VIAL 60MG/VIAL 10MG/VIAL 10MG/VIAL >D> >A> AB >A> >A> AB CARGLUMIC ACID TABLET, FOR SUSPENSION;ORAL CARBAGLU +! RECORDATI RARE +! CARGLUMIC ACID 200MG 200MG NOVITIUM PHARMA 200MG AA >A> AA BX BX CARISOPRODOL TABLET;ORAL CARISOPRODOL MLV STRIDES PHARMA 350MG 350MG 250MG 350MG N 017555 001 N 017555 003 N 017555 002 Aug CAHN Aug CAHN Aug CAHN A 214091 001 Oct 05, 2021 Sep NEWA A 214091 002 Oct 05, 2021 Sep NEWA N 019856 002 Dec 24, 1992 Sep CAHN N 019856 001 May 30, 1991 Sep CAHN A 078893 A 078893 A 078893 A 078893 A 078893 A 078893 A 078690 A 078690 001 Sep 18, 2008 001 Sep 18, 2008 002 Sep 18, 2008 002 Sep 18, 2008 003 Sep 18, 2008 003 Sep 18, 2008 003 Jul 31, 2009 003 Jul 31, 2009 Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CTEC Aug CHRS A 076517 A 076517 A 076517 A 077059 A 077096 A 077096 A 077096 A 077096 A 077269 A 077269 A 077269 A 077269 001 Oct 14, 2004 002 Oct 14, 2004 003 Oct 14, 2004 001 Nov 23, 2004 001 Jun 14, 2005 002 Jun 14, 2005 003 Jun 14, 2005 004 Jun 03, 2013 001 Oct 14, 2004 002 Oct 14, 2004 003 Oct 14, 2004 004 Dec 28, 2007 Mar CHRS Mar CHRS Mar CHRS Mar CHRS Aug DISC Aug DISC Aug DISC Aug DISC Mar CHRS Mar CHRS Mar CHRS Mar CHRS A 213118 001 Mar 25, 2021 Mar NEWA A 209330 001 Jun 11, 2021 A 209330 001 Jun 11, 2021 A 209330 002 Jun 11, 2021 A 209330 002 Jun 11, 2021 Aug DISC Jun NFTG Aug DISC Jun NEWA N 202714 003 Jun 07, 2018 Aug CTEC N 202714 003 Jun 07, 2018 Jun CFTG N 022562 001 Mar 18, 2010 Oct CFTG N 022562 001 Mar 18, 2010 Oct CFTG A 213729 001 Oct 13, 2021 Oct NFTG A 040245 A 211789 A 205513 A 205513 001 Sep 08, 1997 001 Oct 20, 2021 001 Nov 12, 2015 002 Nov 12, 2015 Sep CAHN Oct NEWA Sep CTEC Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -26 CARMUSTINE INJECTABLE;INJECTION BICNU AP +! AVET LIFESCIENCES CARMUSTINE AP HONG KONG AP MEITHEAL 100MG/VIAL 100MG/VIAL 100MG/VIAL N 017422 001 Aug CAHN A 213460 001 Aug 02, 2021 Jul NEWA A 213460 001 Aug 02, 2021 Sep CAHN CARVEDILOL TABLET;ORAL CARVEDILOL @ ACI @ @ @ @ AXXELENT PHARMA @ @ @ COREG AB + WOODWARD AB + AB +! AB + 3.125MG 6.25MG 12.5MG 25MG 3.125MG 6.25MG 12.5MG 25MG 3.125MG 6.25MG 12.5MG 25MG A 078786 A 078786 A 078786 A 078786 A 078786 A 078786 A 078786 A 078786 001 Dec 22, 2009 002 Dec 22, 2009 003 Dec 22, 2009 004 Dec 22, 2009 001 Dec 22, 2009 002 Dec 22, 2009 003 Dec 22, 2009 004 Dec 22, 2009 Sep CAHN Sep CAHN Sep CAHN Sep CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN N 020297 N 020297 N 020297 N 020297 004 May 29, 1997 003 Sep 14, 1995 002 Sep 14, 1995 001 Sep 14, 1995 Jul CAHN Jul CAHN Jul CAHN Jul CAHN CARVEDILOL PHOSPHATE CAPSULE, EXTENDED RELEASE;ORAL COREG CR AB + WOODWARD 10MG AB + 20MG AB +! 40MG AB + 80MG N 022012 N 022012 N 022012 N 022012 001 Oct 20, 2006 002 Oct 20, 2006 003 Oct 20, 2006 004 Oct 20, 2006 Jul CAHN Jul CAHN Jul CAHN Jul CAHN CASIMERSEN SOLUTION;INTRAVENOUS AMONDYS 45 +! SAREPTA THERAPS INC 100MG/2ML (50MG/ML) N 213026 001 Feb 25, 2021 Feb NEWA CASPOFUNGIN ACETATE POWDER;INTRAVENOUS CASPOFUNGIN ACETATE AP UBI AP 50MG/VIAL 70MG/VIAL A 211263 001 Oct 01, 2021 Sep NEWA A 211263 002 Oct 01, 2021 Sep NEWA CEFAZOLIN SODIUM SOLUTION;INTRAVENOUS CEFAZOLIN IN PLASTIC CONTAINER +! BAXTER HLTHCARE CORP EQ 1GM BASE/50ML (EQ 20MG BASE/ML) +! EQ 2GM BASE/100ML (EQ 20MG BASE/ML) ! EQ 2GM BASE/100ML (EQ 20MG BASE/ML) N 207131 N 207131 N 207131 002 Feb 01, 2021 001 Aug 07, 2015 001 Aug 07, 2015 Mar NEWA Mar CRLD Mar CHRS CEFDINIR CAPSULE;ORAL CEFDINIR AB ALKEM LABS LTD FOR SUSPENSION;ORAL CEFDINIR AB ALKEM LABS LTD AB 300MG 125MG/5ML 250MG/5ML A 210220 001 Feb 19, 2021 Feb NEWA A 210534 001 Feb 19, 2021 Feb NEWA A 210534 002 Feb 19, 2021 Feb NEWA CEFEPIME HYDROCHLORIDE INJECTABLE;INJECTION CEFEPIME HYDROCHLORIDE @ ASTRAL @ EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL A 212721 001 Jul 21, 2020 Mar DISC A 212721 002 Jul 21, 2020 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -27 CEFIXIME FOR SUSPENSION;ORAL CEFIXIME AB ALKEM LABS LTD AB 100MG/5ML 200MG/5ML CEFOTAXIME SODIUM INJECTABLE;INJECTION CLAFORAN + @ VALIDUS PHARMS EQ 500MG BASE/VIAL + @ EQ 1GM BASE/VIAL + @ EQ 2GM BASE/VIAL + @ EQ 10GM BASE/VIAL CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER @ VALIDUS PHARMS EQ 20MG BASE/ML @ EQ 40MG BASE/ML CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER @ VALIDUS PHARMS @ EQ 20MG BASE/ML EQ 40MG BASE/ML >A> AP >A> AP >A> AP >D> AP >D> AP >D> AP CEFOXITIN SODIUM INJECTABLE;INJECTION CEFOXITIN HIKMA PHARMS WEST-WARD PHARMS INT EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL EQ 10GM BASE/VIAL EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL EQ 10GM BASE/VIAL CEFTAROLINE FOSAMIL POWDER;INTRAVENOUS CEFTAROLINE FOSAMIL AP APOTEX AP TEFLARO AP +! ALLERGAN AP + AP +! 400MG/VIAL 600MG/VIAL 400MG/VIAL 400MG/VIAL 600MG/VIAL CEFTAZIDIME SODIUM INJECTABLE;INJECTION FORTAZ IN PLASTIC CONTAINER @ TELIGENT + @ + @ EQ 10MG BASE/ML EQ 20MG BASE/ML EQ 40MG BASE/ML CEFUROXIME SODIUM INJECTABLE;INJECTION ZINACEF AP +! TELIGENT AP +! EQ 1.5GM BASE/VIAL EQ 7.5GM BASE/VIAL INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ZINACEF AB +! TELIGENT EQ 750MG BASE/VIAL CELECOXIB CAPSULE;ORAL CELEBREX AB + UPJOHN AB + AB + AB +! CELECOXIB @ ACIC PHARMS @ BX AMNEAL PHARMS BX BX BX @ JUBILANT GENERICS 50MG 100MG 200MG 400MG 200MG 400MG 50MG 100MG 200MG 400MG 50MG A 211775 001 Feb 19, 2021 Feb NEWA A 211775 002 Feb 19, 2021 Feb NEWA N 050547 001 N 050547 002 N 050547 003 N 050547 004 Dec 29, 1983 Feb CAHN Feb CAHN Feb CAHN Feb CAHN N 050596 002 May 20, 1985 Feb CAHN N 050596 004 May 20, 1985 Feb CAHN N 050596 001 May 20, 1985 Feb CAHN N 050596 003 May 20, 1985 Feb CAHN A 065051 001 Sep 11, 2000 A 065051 002 Sep 11, 2000 A 065050 001 Sep 11, 2000 A 065051 001 Sep 11, 2000 A 065051 002 Sep 11, 2000 A 065050 001 Sep 11, 2000 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 208075 001 Sep 21, 2021 Sep NFTG A 208075 002 Sep 21, 2021 Sep NFTG N 200327 001 Oct 29, 2010 N 200327 001 Oct 29, 2010 N 200327 002 Oct 29, 2010 Sep CHRS Sep CFTG Sep CFTG N 050634 001 Apr 28, 1989 N 050634 002 Apr 28, 1989 N 050634 003 Apr 28, 1989 Feb CAHN Feb CAHN Feb CAHN N 050558 003 Oct 19, 1983 Feb CAHN N 050558 004 Oct 23, 1986 Feb CAHN N 050558 002 Oct 19, 1983 Feb CAHN N 020998 004 Dec 15, 2006 N 020998 001 Dec 31, 1998 N 020998 002 Dec 31, 1998 N 020998 003 Aug 29, 2002 Apr CAHN Apr CAHN Apr CAHN Apr CAHN A 212925 001 Dec 09, 2020 A 212925 002 Dec 09, 2020 A 208833 001 May 31, 2018 A 208833 002 May 31, 2018 A 208833 003 May 31, 2018 A 208833 004 May 31, 2018 A 207061 001 Apr 04, 2017 Jun DISC Jun DISC Sep CTEC Sep CTEC Sep CTEC Sep CTEC Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -28 CAPSULE;ORAL CELECOXIB @ @ @ AB UNICHEM AB AB AB AB YILING AB AB AB SOLUTION;ORAL ELYXYB + @ BDSI 100MG 200MG 400MG 50MG 100MG 200MG 400MG 50MG 100MG 200MG 400MG 25MG/ML >A> CELECOXIB; TRAMADOL HYDROCHLORIDE >A> TABLET;ORAL >A> SEGLENTIS >A> +! ESTEVE 56MG;44MG CENOBAMATE TABLET;ORAL XCOPRI +! SK LIFE + 12.5MG 200MG CEPHALEXIN CAPSULE;ORAL CEPHALEXIN ! ALKEM LABS LTD AB ! AB YUNG SHIN PHARM @ AB @ KEFLEX + @ PRAGMA + @ + @ EQ 750MG BASE EQ 750MG BASE EQ 250MG BASE EQ 250MG BASE EQ 500MG BASE EQ 500MG BASE EQ 250MG BASE EQ 500MG BASE EQ 750MG BASE CETIRIZINE HYDROCHLORIDE SYRUP;ORAL CETIRIZINE HYDROCHLORIDE AA MICRO LABS 5MG/5ML AA ! PADAGIS US 5MG/5ML CHLORDIAZEPOXIDE HYDROCHLORIDE CAPSULE;ORAL CHLORDIAZEPOXIDE HYDROCHLORIDE @ CHARTWELL RX 5MG @ 10MG @ 25MG + @ UPSHER SMITH LABS 10MG LIBRIUM AB +! VALEANT PHARM INTL 25MG AB >A> AB AB AB >A> AB CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDE CAPSULE;ORAL CHLORDIAZEPOXIDE HYDROCHLORIDE AND CLIDINIUM BROMIDE ALKEM LABS LTD AMNEAL DR REDDYS PHARMA LIFE TEVA PHARMS USA 5MG;2.5MG 5MG;2.5MG 5MG;2.5MG 5MG;2.5MG 5MG;2.5MG A 207061 A 207061 A 207061 A 213301 A 213301 A 213301 A 213301 A 211412 A 211412 A 211412 A 211412 002 Apr 04, 2017 003 Apr 04, 2017 004 Apr 04, 2017 001 Jan 12, 2021 002 Jan 12, 2021 003 Jan 12, 2021 004 Jan 12, 2021 001 Mar 06, 2020 002 Mar 06, 2020 003 Mar 06, 2020 004 Mar 06, 2020 Jun DISC Jun DISC Jun DISC Jan NEWA Jan NEWA Jan NEWA Jan NEWA Jun CMFD Jun CMFD Jun CMFD Jun CMFD N 212157 001 May 05, 2020 Sep CAHN N 213426 001 Oct 15, 2021 Oct NEWA N 212839 001 Mar 10, 2020 Jul CHRS N 212839 006 Mar 10, 2020 Jul CHRS A 090836 004 Mar 29, 2013 A 090836 004 Mar 29, 2013 A 065152 001 Feb 24, 2005 A 065152 001 Feb 24, 2005 A 065152 002 Feb 24, 2005 A 065152 002 Feb 24, 2005 Sep CTEC Sep CHRS Aug CMFD Mar DISC Aug CMFD Mar DISC N 050405 002 N 050405 003 N 050405 005 May 12, 2006 May DISC May DISC Sep DISC A 090191 001 Nov 12, 2009 Aug CAHN A 078398 001 Jun 17, 2008 Jul CAHN A 084678 001 A 084041 001 A 084679 002 A 084920 001 A 085475 001 Apr CAHN Apr CAHN Apr CAHN Aug CRLD Aug CRLD A 214065 A 215555 A 214698 A 213530 A 211476 001 Apr 26, 2021 001 Oct 25, 2021 001 May 10, 2021 001 Oct 20, 2020 001 Nov 02, 2021 Apr NEWA Oct NEWA Apr NEWA Sep CAHN Oct NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -29 CHLORHEXIDINE GLUCONATE SOLUTION;DENTAL CHLORHEXIDINE GLUCONATE AT BAJAJ 0.12% >D> AP >A> >D> AP >A> CHLOROPROCAINE HYDROCHLORIDE INJECTABLE;INJECTION CHLOROPROCAINE HYDROCHLORIDE HOSPIRA 2% @ 2% 3% @ 3% CHLOROQUINE PHOSPHATE TABLET;ORAL CHLOROQUINE PHOSPHATE AA SUVEN PHARMS 500MG BX BX BX BX BX AB AB AB AB AB AB AB AB AB AB >A> AB >A> AB >A> AB >A> AB >A> AB AB AB AB AB AB CHLORPROMAZINE HYDROCHLORIDE TABLET;ORAL CHLORPROMAZINE HYDROCHLORIDE AMNEAL PHARMS CO GLENMARK PHARMS LTD LANNETT CO INC @ MAYNE PHARMA @ @ @ @ TEVA PHARMS + UPSHER SMITH LABS +! + +! + 10MG 25MG 50MG 100MG 200MG 10MG 25MG 50MG 100MG 200MG 10MG 25MG 50MG 100MG 200MG 10MG 25MG 50MG 100MG 200MG 10MG 25MG 50MG 100MG 200MG 10MG 25MG 50MG 100MG 200MG CHLORPROPAMIDE TABLET;ORAL CHLORPROPAMIDE @ RISING @ 100MG 250MG CHLORTHALIDONE TABLET;ORAL CHLORTHALIDONE AB + MYLAN AB +! AB NOVAST LABS AB BX UMEDICA LABS PVT LTD BX THALITONE + CASPER PHARMA LLC BX +! 25MG 50MG 25MG 50MG 25MG 50MG 15MG 25MG A 075561 001 Nov 14, 2000 Feb CMFD A 087447 A 087447 A 087446 A 087446 001 Apr 16, 1982 001 Apr 16, 1982 001 Apr 16, 1982 001 Apr 16, 1982 Oct DISC Oct DISC Oct DISC Oct DISC A 214756 001 Sep 03, 2021 Aug NEWA A 209755 A 209755 A 209755 A 209755 A 209755 A 212144 A 212144 A 212144 A 212144 A 212144 A 212996 A 212996 A 212996 A 212996 A 212996 A 213590 A 213590 A 213590 A 213590 A 213590 A 215659 A 215659 A 215659 A 215659 A 215659 A 083386 A 084112 A 084113 A 084114 A 084115 001 Sep 10, 2018 002 Sep 10, 2018 003 Sep 10, 2018 004 Sep 10, 2018 005 Sep 10, 2018 001 Mar 23, 2021 002 Mar 23, 2021 003 Mar 23, 2021 004 Mar 23, 2021 005 Mar 23, 2021 001 Jan 22, 2021 002 Jan 22, 2021 003 Jan 22, 2021 004 Jan 22, 2021 005 Jan 22, 2021 001 Aug 31, 2020 002 Aug 31, 2020 003 Aug 31, 2020 004 Aug 31, 2020 005 Aug 31, 2020 001 Oct 25, 2021 002 Oct 25, 2021 003 Oct 25, 2021 004 Oct 25, 2021 005 Oct 25, 2021 001 001 001 001 001 Sep CTEC Sep CTEC Sep CTEC Sep CTEC Sep CTEC Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Jan NEWA Jan NEWA Jan NEWA Jan NEWA Jan NEWA Mar DISC Mar DISC Mar DISC Mar DISC Mar DISC Oct NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD A 088725 001 Aug 31, 1984 Jan CAHN A 088726 001 Aug 31, 1984 Jan CAHN A 086831 A 086831 A 206904 A 206904 A 207222 A 207222 002 001 001 Mar 30, 2017 002 Mar 30, 2017 001 May 24, 2018 002 May 24, 2018 Aug CRLD Aug CRLD Sep CAHN Sep CAHN Sep CTEC Sep CTEC N 019574 001 Dec 20, 1988 May CMFD N 019574 002 Feb 12, 1992 May CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -30 CHLORZOXAZONE TABLET;ORAL CHLORZOXAZONE AA HAVIX AA ! MIKART AB PAR PHARM INC AA SENORES PHARMS 250MG 250MG 375MG 250MG >A> AB >A> AB AB AB >A> AB >A> AB CHOLESTYRAMINE POWDER;ORAL CHOLESTYRAMINE ALKEM LABS LTD TAGI CHOLESTYRAMINE LIGHT ALKEM LABS LTD LOCHOLEST LIGHT @ CHARTWELL RX @ EQ 4GM RESIN/PACKET EQ 4GM RESIN/SCOOPFUL EQ 4GM RESIN/PACKET EQ 4GM RESIN/SCOOPFUL EQ 4GM RESIN/PACKET EQ 4GM RESIN/SCOOPFUL EQ 4GM RESIN/PACKET EQ 4GM RESIN/SCOOPFUL CHOLINE FENOFIBRATE CAPSULE, DELAYED RELEASE;ORAL FENOFIBRIC ACID AB ADAPTIS AB EQ 45MG FENOFIBRIC ACID EQ 135MG FENOFIBRIC ACID CICLESONIDE SPRAY, METERED;NASAL OMNARIS +! COVIS 0.05MG/SPRAY CICLOPIROX GEL;TOPICAL CICLOPIROX AB +! ALVOGEN SOLUTION;TOPICAL CICLOPIROX @ AKORN AT RISING 0.77% 8% 8% CILOSTAZOL TABLET;ORAL CILOSTAZOL @ EPIC PHARMA LLC @ NOSTRUM LABS INC AB @ AB 50MG 50MG 50MG 100MG 100MG CIMETIDINE TABLET;ORAL CIMETIDINE @ NOVITIUM PHARMA @ @ TAGAMET >D> @ GLAXOSMITHKLINE >A> + @ >D> @ >A> + @ >D> @ >A> + @ >D> @ >A> + @ 300MG 400MG 800MG 200MG 200MG 300MG 300MG 400MG 400MG 800MG 800MG A 215158 A 207483 A 212743 A 215158 001 Jul 29, 2021 001 Jun 24, 2016 002 Apr 29, 2021 001 Jul 29, 2021 Jul NEWA Jul CTEC Apr NEWA Aug CAHN A 211856 A 211856 A 209597 A 209597 001 Oct 19, 2021 002 Oct 19, 2021 001 Mar 09, 2021 002 Mar 09, 2021 Oct NEWA Oct NEWA Feb NEWA Feb NEWA A 211799 001 Oct 19, 2021 Oct NEWA A 211799 002 Oct 19, 2021 Oct NEWA A 074562 001 Aug 15, 1996 Apr CAHN A 074562 002 Aug 15, 1996 Apr CAHN A 211626 001 Jul 18, 2019 Aug CAHN A 211626 002 Jul 18, 2019 Aug CAHN N 022004 001 Oct 20, 2006 May CPOT N 020519 001 Jul 21, 1997 Jun CAHN A 078975 001 Feb 17, 2010 Apr DISC A 078124 001 Sep 18, 2007 May CAHN A 077022 A 077708 A 077708 A 077708 A 077708 002 Mar 11, 2005 001 Sep 28, 2009 001 Sep 28, 2009 002 Sep 28, 2009 002 Sep 28, 2009 Jan CMS1 Mar DISC Jan CAHN Mar DISC Jan CAHN A 074340 001 Jun 23, 1995 A 074340 002 Jun 23, 1995 A 074339 001 Jun 23, 1995 Feb CAHN Feb CAHN Feb CAHN N 017920 N 017920 N 017920 N 017920 N 017920 N 017920 N 017920 N 017920 002 002 003 003 004 Dec 14, 1983 004 Dec 14, 1983 005 Apr 30, 1986 005 Apr 30, 1986 Oct CRLD Oct CRLD Oct CRLD Oct CRLD Oct CRLD Oct CRLD Oct CRLD Oct CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -31 CINACALCET HYDROCHLORIDE TABLET;ORAL CINACALCET HYDROCHLORIDE @ MYLAN @ @ @ @ @ EQ 30MG BASE EQ 30MG BASE EQ 60MG BASE EQ 60MG BASE EQ 90MG BASE EQ 90MG BASE >D> AP >A> >D> AP >A> CIPROFLOXACIN INJECTABLE;INJECTION CIPROFLOXACIN HOSPIRA @ @ 200MG/20ML (10MG/ML) 200MG/20ML (10MG/ML) 400MG/40ML (10MG/ML) 400MG/40ML (10MG/ML) INJECTABLE, SUSPENSION;OTIC OTIPRIO +! ALK ABELLO 6% (60MG/ML) CIPROFLOXACIN HYDROCHLORIDE TABLET;ORAL CIPROFLOXACIN HYDROCHLORIDE >A> @ AMNEAL >A> @ >A> @ >A> @ >D> @ ANI PHARMS >D> @ >D> @ >D> @ EQ 100MG BASE EQ 250MG BASE EQ 500MG BASE EQ 750MG BASE EQ 100MG BASE EQ 250MG BASE EQ 500MG BASE EQ 750MG BASE CISATRACURIUM BESYLATE INJECTABLE;INJECTION CISATRACURIUM BESYLATE @ SAGENT PHARMS INC @ ZYDUS PHARMS EQ 2MG BASE/ML EQ 2MG BASE/ML CITRIC ACID; UREA C-13 FOR SOLUTION, TABLET, FOR SOLUTION;ORAL IDKIT:HP +! EXALENZ BIOSCIENCE 4GM;75MG CLARITHROMYCIN TABLET;ORAL CLARITHROMYCIN @ WOCKHARDT @ 250MG 500MG CLASCOTERONE CREAM;TOPICAL WINLEVI + @ CASSIOPEA SPA 1% +! SUN PHARM 1% + @ 1% CLINDAMYCIN HYDROCHLORIDE CAPSULE;ORAL CLEOCIN HYDROCHLORIDE AB + PFIZER AB + AB +! EQ 75MG BASE EQ 150MG BASE EQ 300MG BASE CLINDAMYCIN PALMITATE HYDROCHLORIDE FOR SOLUTION;ORAL CLEOCIN AA ! PFIZER EQ 75MG BASE/5ML A 203422 A 203422 A 203422 A 203422 A 203422 A 203422 001 Oct 16, 2018 001 Oct 16, 2018 002 Oct 16, 2018 002 Oct 16, 2018 003 Oct 16, 2018 003 Oct 16, 2018 Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC A 077245 A 077245 A 077245 A 077245 001 Aug 28, 2006 001 Aug 28, 2006 002 Aug 28, 2006 002 Aug 28, 2006 Oct DISC Oct DISC Oct DISC Oct DISC N 207986 001 Dec 10, 2015 Jun CAHN A 075939 A 075939 A 075939 A 075939 A 075939 A 075939 A 075939 A 075939 001 Mar 03, 2005 002 Jun 09, 2004 003 Jun 09, 2004 004 Jun 09, 2004 001 Mar 03, 2005 002 Jun 09, 2004 003 Jun 09, 2004 004 Jun 09, 2004 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 201851 001 Nov 06, 2020 Jul DISC A 213527 001 Aug 31, 2020 Feb DISC N 021314 001 Dec 17, 2002 Jul CPOT A 065266 001 May 31, 2006 Jan DISC A 065266 002 May 31, 2006 Jan DISC N 213433 001 Aug 26, 2020 N 213433 001 Aug 26, 2020 N 213433 001 Aug 26, 2020 Mar DISC Sep CMFD Sep CAHN N 050162 001 N 050162 002 N 050162 003 Apr 14, 1988 Feb CAHN Feb CAHN Feb CAHN A 062644 001 Apr 07, 1986 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -32 CLINDAMYCIN PHOSPHATE AEROSOL, FOAM;TOPICAL CLINDAMYCIN PHOSPHATE AT GLENMARK PHARMS LTD 1% CREAM;VAGINAL CLEOCIN @ PFIZER AB +! EQ 2% BASE EQ 2% BASE GEL;TOPICAL CLEOCIN T AB1 +! PFIZER AB +! CLINDAGEL EQ 1% BASE EQ 1% BASE AB2 +! BAUSCH CLINDAMYCIN PHOSPHATE EQ 1% BASE AB1 ENCUBE EQ 1% BASE AB EQ 1% BASE AB1 FOUGERA PHARMS EQ 1% BASE AB1 GLENMARK PHARMS LTD EQ 1% BASE AB EQ 1% BASE AB1 PADAGIS ISRAEL EQ 1% BASE AB PERRIGO UK FINCO EQ 1% BASE AB1 SOLARIS PHARMA CORP EQ 1% BASE AB2 EQ 1% BASE AB1 TARO PHARMS EQ 1% BASE INJECTABLE;INJECTION CLEOCIN PHOSPHATE AP PFIZER EQ 150MG BASE/ML AP +! EQ 150MG BASE/ML CLEOCIN PHOSPHATE IN DEXTROSE 5% IN PLASTIC CONTAINER + @ PFIZER + @ + @ CLINDAMYCIN PHOSPHATE EQ 6MG BASE/ML EQ 12MG BASE/ML EQ 18MG BASE/ML AP ALMAJECT @ AP @ MYLAN LABS LTD EQ 150MG BASE/ML EQ 150MG BASE/ML EQ 150MG BASE/ML EQ 150MG BASE/ML LOTION;TOPICAL CLEOCIN T AB +! PFIZER EQ 1% BASE CLINDAMYCIN PHOSPHATE AB TARO PHARMS EQ 1% BASE SOLUTION;TOPICAL CLEOCIN T + @ PFIZER EQ 1% BASE + @ PHARMACIA AND UPJOHN EQ 1% BASE SUPPOSITORY;VAGINAL CLEOCIN +! PFIZER 100MG SWAB;TOPICAL CLEOCIN + @ PFIZER AT +! EQ 1% BASE EQ 1% BASE CLINDAMYCIN PHOSPHATE; TRETINOIN GEL;TOPICAL ZIANA AB +! BAUSCH 1.2%;0.025% AB AB >D> >A> AB >A> AB CLOBAZAM SUSPENSION;ORAL CLOBAZAM ALKEM LABS LTD TARO TABLET;ORAL CLOBAZAM ALKEM LABS LTD BRECKENRIDGE 2.5MG/ML 2.5MG/ML 5MG 5MG 5MG A 210778 001 Sep 20, 2021 Sep NEWA N 050680 001 Aug 11, 1992 Feb CAHN N 050680 002 Mar 02, 1998 Feb CAHN N 050615 001 Jan 07, 1987 Aug CTEC N 050615 001 Jan 07, 1987 Feb CAHN N 050782 001 Nov 27, 2000 Aug CFTG A 212438 A 212438 A 064160 A 214251 A 214251 A 212104 A 212104 A 211872 A 212842 A 214052 001 Mar 11, 2021 001 Mar 11, 2021 001 Jan 28, 2000 001 Feb 10, 2021 001 Feb 10, 2021 001 Dec 31, 2020 001 Dec 31, 2020 001 Jul 29, 2020 001 Aug 13, 2021 001 Nov 10, 2020 Aug CTEC Mar NEWA Aug CTEC Aug CTEC Jan NEWA Aug CTEC Jan CAHN Aug CTEC Aug NFTG Aug CTEC A 062803 001 Oct 16, 1987 Feb CAHN N 050441 001 Feb CAHN N 050639 001 Aug 30, 1989 N 050639 002 Aug 30, 1989 N 050639 003 Apr 10, 1991 Feb CAHN Feb CAHN Feb CAHN A 062800 A 062801 A 062943 A 204748 001 Jul 24, 1987 001 Jul 24, 1987 001 Sep 29, 1988 001 Oct 10, 2017 Jul CAHN Jul CAHN Jul CAHN Jan DISC N 050600 001 May 31, 1989 Feb CAHN A 214526 001 Jun 28, 2021 Jun NEWA N 050537 001 N 050537 001 Feb CAHN Jan DISC N 050767 001 Aug 13, 1999 Feb CAHN N 050537 002 Feb 22, 1994 Mar DISC N 050537 002 Feb 22, 1994 Feb CAHN N 050802 001 Nov 07, 2006 May CAHN A 213039 001 May 06, 2021 Apr NEWA A 210978 001 Apr 15, 2019 Jul CMFD A 212714 003 Dec 21, 2020 A 212714 003 Dec 21, 2020 A 209308 003 Oct 19, 2021 Oct CTEC Oct CTEC Oct NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -33 TABLET;ORAL CLOBAZAM @ CELLTRION @ @ LANNETT CO INC @ AB MSN AB 10MG 20MG 10MG 20MG 10MG 20MG CLOBETASOL PROPIONATE CREAM;TOPICAL CLOBETASOL PROPIONATE AB1 >D> AB1 >A> AB1 GLASSHOUSE PHARMS PAI HOLDINGS PHARM @ IMPOYZ +! PRIMUS PHARMS OINTMENT;TOPICAL CLOBETASOL PROPIONATE @ TORRENT SHAMPOO;TOPICAL CLOBETASOL PROPIONATE AB AMNEAL AB TARO PHARMS SOLUTION;TOPICAL CLOBETASOL PROPIONATE AT PRINSTON INC SPRAY;TOPICAL CLOBETASOL PROPIONATE @ AKORN 0.05% 0.05% 0.05% 0.05% 0.025% 0.05% 0.05% 0.05% 0.05% 0.05% CLOFARABINE SOLUTION;INTRAVENOUS CLOFARABINE AP MEITHEAL @ NOVAST LABS 20MG/20ML (1MG/ML) 20MG/20ML (1MG/ML) CLOMIPRAMINE HYDROCHLORIDE CAPSULE;ORAL CLOMIPRAMINE HYDROCHLORIDE AB ALEMBIC PHARMS LTD 25MG AB 50MG AB 75MG AB VGYAAN 25MG AB 50MG AB 75MG CLONIDINE SYSTEM;TRANSDERMAL CATAPRES-TTS-1 AB + LAVIPHARM AB + TECHNOMED CATAPRES-TTS-2 AB + LAVIPHARM AB + TECHNOMED CATAPRES-TTS-3 AB +! LAVIPHARM AB +! TECHNOMED 0.1MG/24HR 0.1MG/24HR 0.2MG/24HR 0.2MG/24HR 0.3MG/24HR 0.3MG/24HR AP >D> AB >A> >D> AB CLONIDINE HYDROCHLORIDE INJECTABLE;INJECTION CLONIDINE HYDROCHLORIDE ! HIKMA FARMACEUTICA DURACLON + @ MYLAN INSTITUTIONAL TABLET;ORAL CATAPRES + BOEHRINGER INGELHEIM + @ + 5MG/10ML (0.5MG/ML) 5MG/10ML (0.5MG/ML) 0.1MG 0.1MG 0.2MG A 211959 A 211959 A 212092 A 212092 A 213404 A 213404 001 Dec 09, 2020 002 Dec 09, 2020 001 Oct 30, 2019 002 Oct 30, 2019 001 May 11, 2021 002 May 11, 2021 Jun DISC Jun DISC Mar DISC Mar DISC Apr NEWA Apr NEWA A 211207 001 Mar 26, 2021 A 211207 001 Mar 26, 2021 A 211207 001 Mar 26, 2021 A 211207 001 Mar 26, 2021 Mar NEWA Oct DISC Oct DISC Sep CAHN N 209483 001 Nov 28, 2017 Mar CAHN A 212926 001 Oct 25, 2019 Jan DISC A 214895 001 Jun 14, 2021 Jun NEWA A 214867 001 Mar 25, 2021 Mar NEWA A 213139 001 Feb 08, 2021 Jan NEWA A 207218 001 Apr 28, 2017 Apr DISC A 213461 001 Oct 23, 2020 Jan CAHN A 210270 001 Sep 14, 2018 Mar DISC A 211822 A 211822 A 211822 A 213221 A 213221 A 213221 001 Aug 04, 2021 002 Aug 04, 2021 003 Aug 04, 2021 001 Jun 22, 2020 002 Jun 22, 2020 003 Jun 22, 2020 Jul NEWA Jul NEWA Jul NEWA May CMFD May CMFD May CMFD N 018891 001 Oct 10, 1984 Jan CAHN N 018891 001 Oct 10, 1984 Jan CAHN N 018891 002 Oct 10, 1984 Jan CAHN N 018891 002 Oct 10, 1984 Jan CAHN N 018891 003 Oct 10, 1984 Jan CAHN N 018891 003 Oct 10, 1984 Jan CAHN A 200300 002 Jan 26, 2011 Mar CHRS N 020615 002 Apr 27, 1999 Mar DISC N 017407 001 N 017407 001 N 017407 002 Oct DISC Oct DISC Oct DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -34 >A> >D> AB >A> >D> AB >A> AB TABLET;ORAL CATAPRES + @ 0.2MG +! 0.3MG + @ 0.3MG CLONIDINE HYDROCHLORIDE UNICHEM 0.3MG ! 0.3MG N 017407 002 N 017407 003 N 017407 003 Oct DISC Oct DISC Oct DISC A 078895 003 Aug 26, 2009 Oct CHRS A 078895 003 Aug 26, 2009 Oct CHRS CLOPIDOGREL BISULFATE TABLET;ORAL CLOPIDOGREL BISULFATE AB POLYGEN PHARMS AB AB RISING EQ 75MG BASE EQ 300MG BASE EQ 75MG BASE A 213351 001 Jul 17, 2020 A 213351 002 Jul 17, 2020 A 204359 001 Feb 02, 2017 Feb CMFD Feb CMFD Sep CAHN CLORAZEPATE DIPOTASSIUM CAPSULE;ORAL TRANXENE + @ RECORDATI RARE 3.75MG + @ 7.5MG + @ 15MG TABLET;ORAL CLORAZEPATE DIPOTASSIUM AB AUROLIFE PHARMA LLC 3.75MG AB 7.5MG AB ! TRANXENE 15MG + @ RECORDATI RARE TRANXENE SD 3.75MG + @ RECORDATI RARE 11.25MG + @ 22.5MG N 017105 001 N 017105 002 N 017105 003 May CRLD May CRLD May CRLD A 071858 002 Jul 17, 1987 A 071858 003 Jul 17, 1987 A 071858 001 Jul 17, 1987 Jan CAHN Jan CAHN Jan CAHN N 017105 006 May CRLD N 017105 005 N 017105 004 May CRLD May CRLD CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE AA AKORN 10MG/5ML;5MG/5ML;6.25MG/5ML A 040674 001 Dec 23, 2014 Feb CAHN CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE AA +! ACTAVIS MID ATLANTIC 10MG/5ML;6.25MG/5ML A 088763 001 Oct 31, 1984 Aug CRLD COLCHICINE TABLET;ORAL COLCHICINE AB HETERO LABS LTD V AB PAR PHARM INC 0.6MG 0.6MG A 208993 001 Aug 13, 2021 Aug NEWA A 203976 001 Aug 12, 2021 Aug NEWA COLCHICINE; PROBENECID TABLET;ORAL COL-PROBENECID AB +! WATSON LABS 0.5MG;500MG A 084279 001 Aug CRLD >A> AB COLESEVELAM HYDROCHLORIDE FOR SUSPENSION;ORAL COLESEVELAM HYDROCHLORIDE GLENMARK PHARMS LTD 1.875GM/PACKET @ WATSON LABS INC 1.875GM/PACKET @ 3.75GM/PACKET TABLET;ORAL COLESEVELAM HYDROCHLORIDE BEIJING TIDE PHARM 625MG @ WATSON LABS INC 625MG A 202190 001 Jul 16, 2018 A 202178 001 Sep 01, 2020 A 202178 002 Sep 01, 2020 Feb CTEC Feb DISC Feb DISC A 206036 001 Oct 14, 2021 Oct NEWA A 200830 001 Sep 02, 2020 Feb DISC COLESTIPOL HYDROCHLORIDE GRANULE;ORAL COLESTID AB + PFIZER AB +! 5GM/SCOOPFUL 5GM/PACKET N 017563 003 Sep 22, 1995 Feb CAHN N 017563 004 Sep 22, 1995 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -35 GRANULE;ORAL FLAVORED COLESTID + PFIZER + TABLET;ORAL COLESTID AB +! PFIZER 5GM/PACKET 5GM/SCOOPFUL 1GM N 017563 001 N 017563 002 Feb CAHN Feb CAHN N 020222 001 Jul 19, 1994 Feb CAHN COLISTIMETHATE SODIUM INJECTABLE;INJECTION COLISTIMETHATE SODIUM AP EMCURE PHARMS LTD EQ 150MG BASE/VIAL A 202359 001 Sep 28, 2012 Sep CMFD CORTICOTROPIN INJECTABLE;INJECTION ACTHAR GEL @ MALLINCKRODT ARD +! 40 UNITS/ML 80 UNITS/ML N 008372 006 N 008372 008 Sep CTNA Sep CTNA CROTAMITON CREAM;TOPICAL EURAX + @ JOURNEY LOTION;TOPICAL EURAX AT +! JOURNEY 10% 10% N 006927 001 N 009112 003 Jan CAHN Jan CAHN CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE SOLUTION;INTRAVENOUS >D> MULTRYS >D> +! AM REGENT +! +! >D> +! +! +! +! +! >A> TRALEMENT (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML (1ML) EQ 0.06MG COPPER/ML;EQ 3MCG BASE/ML;EQ 6MCG BASE/ML;EQ 1MG BASE/ML N 209376 001 Jul 02, 2020 N 209376 001 Jul 02, 2020 N 209376 001 Jul 02, 2020 N 209376 002 Dec 02, 2020 N 209376 002 Dec 02, 2020 N 209376 002 Dec 02, 2020 N 209376 003 Jun 30, 2021 N 209376 003 Jun 30, 2021 Oct CTNA Aug CTNA Jan CPOT Oct CTNA Aug CTNA Jan NEWA Aug CTNA Jul NEWA >A> +! AM REGENT >A> +! (1ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML (5ML) EQ 0.3MG COPPER/ML;EQ 55MCG BASE/ML;EQ 60MCG BASE/ML;EQ 3MG BASE/ML N 209376 001 Jul 02, 2020 N 209376 002 Dec 02, 2020 Oct CTNA Oct CTNA CYANOCOBALAMIN INJECTABLE;INJECTION CYANOCOBALAMIN @ XIROMED AP VIBISONE AP +! FRESENIUS KABI USA 1MG/ML 1MG/ML 1MG/ML A 215046 001 Aug 20, 2021 Sep DISC A 215046 001 Aug 20, 2021 Aug NEWA A 080557 003 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -36 CYCLOBENZAPRINE HYDROCHLORIDE TABLET;ORAL CYCLOBENZAPRINE HYDROCHLORIDE @ MYLAN PHARMS INC 5MG @ 7.5MG @ 10MG CYCLOPENTOLATE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AKPENTOLATE AT AKORN 2% CYCLOGYL AT +! ALCON LABS INC AT +! AT +! AT ! 0.5% 1% 2% 2% CYCLOPHOSPHAMIDE SOLUTION;INTRAVENOUS CYCLOPHOSPHAMIDE >D> +! AUROMEDICS PHARMA 500MG/2.5ML (200MG/ML) +! 500MG/2.5ML (200MG/ML) >D> +! 1GM/5ML (200MG/ML) +! 1GM/5ML (200MG/ML) >A> +! EUGIA PHARMA SPECLTS 500MG/2.5ML (200MG/ML) >A> +! 1GM/5ML (200MG/ML) >A> AP >D> AP >A> >D> CYCLOSPORINE EMULSION;OPHTHALMIC VERKAZIA +! SANTEN INJECTABLE;INJECTION CYCLOSPORINE HIKMA PHARMS WEST-WARD PHARMS INT SOLUTION;OPHTHALMIC CEQUA +! SUN PHARM +! SUN PHARMA GLOBAL 0.1% 50MG/ML 50MG/ML 0.09% 0.09% CYPROHEPTADINE HYDROCHLORIDE SYRUP;ORAL CYPROHEPTADINE HYDROCHLORIDE + @ ACTAVIS MID ATLANTIC 2MG/5ML TABLET;ORAL CYPROHEPTADINE HYDROCHLORIDE AA +! HERITAGE PHARMA 4MG AA QUAGEN 4MG CYSTEAMINE BITARTRATE CAPSULE, DELAYED RELEASE;ORAL PROCYSBI + HORIZON EQ 25MG BASE +! EQ 75MG BASE CYTARABINE INJECTABLE;INJECTION CYTARABINE @ HONG KONG @ MEITHEAL @ MYLAN LABS LTD 20MG/ML 20MG/ML 20MG/ML DABIGATRAN ETEXILATE MESYLATE PELLET;ORAL PRADAXA + BOEHRINGER INGELHEIM EQ 20MG BASE/PACKET + EQ 30MG BASE/PACKET + EQ 40MG BASE/PACKET + EQ 50MG BASE/PACKET + EQ 110MG BASE/PACKET +! EQ 150MG BASE/PACKET A 073144 002 Feb 03, 2006 A 073144 003 Mar 25, 2013 A 073144 001 May 30, 1991 Aug DISC Aug DISC Aug DISC A 040165 001 Jan 13, 1997 Aug CMFD A 084109 001 A 084110 001 A 084108 001 A 084108 001 Aug CRLD Aug CRLD Aug CRLD Aug CTEC N 210735 N 210735 N 210735 N 210735 N 210735 N 210735 001 Aug 25, 2021 001 Aug 25, 2021 002 Aug 25, 2021 002 Aug 25, 2021 001 Aug 25, 2021 002 Aug 25, 2021 Oct CAHN Aug NEWA Oct CAHN Aug NEWA Oct CAHN Oct CAHN N 214965 001 Jun 23, 2021 Jun NEWA A 065004 001 Oct 29, 1999 Oct CAHN A 065004 001 Oct 29, 1999 Oct CAHN N 210913 001 Aug 14, 2018 Oct CAHN N 210913 001 Aug 14, 2018 Oct CAHN A 086833 001 Aug CRLD A 087056 001 Aug CRLD A 212491 001 Feb 24, 2021 Feb NEWA N 203389 001 Apr 30, 2013 May CAHN N 203389 002 Apr 30, 2013 May CAHN A 206189 001 Jun 26, 2020 A 206190 001 Nov 09, 2017 A 200914 001 Dec 13, 2011 Sep DISC Aug DISC May DISC N 214358 N 214358 N 214358 N 214358 N 214358 N 214358 001 Jun 21, 2021 002 Jun 21, 2021 003 Jun 21, 2021 004 Jun 21, 2021 005 Jun 21, 2021 006 Jun 21, 2021 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -37 PELLETS;ORAL PRADAXA + BOEHRINGER INGELHEIM + + + + +! EQ 20MG BASE/PACKET EQ 30MG BASE/PACKET EQ 40MG BASE/PACKET EQ 50MG BASE/PACKET EQ 110MG BASE/PACKET EQ 150MG BASE/PACKET DACTINOMYCIN INJECTABLE;INJECTION DACTINOMYCIN AP AUROMEDICS PHARMA AP EUGIA PHARMA @ HIKMA PHARMS AP MEITHEAL 0.5MG/VIAL 0.5MG/VIAL 0.5MG/VIAL 0.5MG/VIAL DAPSONE TABLET;ORAL DAPSONE AB ALVOGEN AB AB + JACOBUS AB +! 25MG 100MG 25MG 100MG >D> AP >A> AP AP >D> AP >A> AP AP >D> >A> AP AP AP DAPTOMYCIN POWDER;INTRAVENOUS DAPTOMYCIN HISUN PHARM HANGZHOU @ HONG KONG +! HOSPIRA INC @ +! MEITHEAL QILU POWDER;IV (INFUSION) DAPTOMYCIN @ DR REDDYS @ HONG KONG MEITHEAL 500MG/VIAL 500MG/VIAL 500MG/VIAL 500MG/VIAL 350MG/VIAL 500MG/VIAL 500MG/VIAL 500MG/VIAL 500MG/VIAL 500MG/VIAL 350MG/VIAL 350MG/VIAL 350MG/VIAL 350MG/VIAL 350MG/VIAL DARIFENACIN HYDROBROMIDE TABLET, EXTENDED RELEASE;ORAL DARIFENACIN HYDROBROMIDE @ JUBILANT GENERICS EQ 7.5MG BASE @ EQ 15MG BASE BX XIROMED EQ 7.5MG BASE BX EQ 15MG BASE DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR TABLET;ORAL VIEKIRA PAK (COPACKAGED) + @ ABBVIE INC +! EQ 250MG BASE;12.5MG, 75MG, 50MG EQ 250MG BASE;12.5MG, 75MG, 50MG DASABUVIR SODIUM; OMBITASVIR; PARITAPREVIR; RITONAVIR TABLET;ORAL VIEKIRA PAK (COPACKAGED) +! ABBVIE INC 250.0MG;12.5MG;75.0MG;EQ 250MG BASE,N/A,N/A,N/A; N/A,12.5MG,75MG,50MG N 214358 N 214358 N 214358 N 214358 N 214358 N 214358 001 Jun 21, 2021 002 Jun 21, 2021 003 Jun 21, 2021 004 Jun 21, 2021 005 Jun 21, 2021 006 Jun 21, 2021 Jul CDFR Jul CDFR Jul CDFR Jul CDFR Jul CDFR Jul CDFR A 203385 001 Nov 09, 2017 A 203385 001 Nov 09, 2017 A 090304 001 Mar 16, 2010 A 213463 001 Nov 13, 2020 Jan CAHN Aug CAHN Jul CAHN Feb CAHN A 205429 001 Jan 07, 2016 A 205429 002 Jan 07, 2016 A 086841 001 A 086842 001 Jun CAHN Jun CAHN Aug CRLD Aug CRLD A 212250 A 212250 A 212250 A 213623 N 210282 A 202857 A 202857 N 210282 A 213623 A 215316 001 Apr 21, 2021 001 Apr 21, 2021 001 Apr 21, 2021 001 Jun 29, 2021 001 Jun 21, 2021 001 Sep 12, 2014 001 Sep 12, 2014 002 Jun 21, 2021 001 Jun 29, 2021 001 Aug 24, 2021 Oct DISC Oct DISC Apr NEWA Jun NEWA Jun NEWA Oct DISC Oct DISC Jun NEWA Aug CAHN Aug NEWA A 211403 A 211403 A 211403 A 213786 A 213786 001 Aug 31, 2020 001 Aug 31, 2020 001 Aug 31, 2020 001 Jun 29, 2021 001 Jun 29, 2021 Oct CMFD Oct CMFD May DISC Jun NEWA Aug CAHN A 205550 A 205550 A 209571 A 209571 001 Oct 12, 2016 002 Oct 12, 2016 002 Oct 22, 2019 001 Oct 22, 2019 Jun DISC Jun DISC Sep CTEC Sep CTEC N 206619 001 Dec 19, 2014 Sep DISC N 206619 001 Dec 19, 2014 Aug CPOT N 206619 001 Dec 19, 2014 Aug CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -38 DASIGLUCAGON HYDROCHLORIDE SOLUTION;SUBCUTANEOUS ZEGALOGUE +! ZEALAND PHARMA EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) +! EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) ZEGALOGUE (AUTOINJECTOR) +! ZEALAND PHARMA +! EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) EQ 0.6MG BASE/0.6ML (EQ 0.6MG BASE/0.6ML) >A> AP >D> AP AP DAUNORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION CERUBIDINE ! HIKMA PHARMS EQ 20MG BASE/VIAL ! WEST-WARD PHARMS INT EQ 20MG BASE/VIAL DAUNORUBICIN HYDROCHLORIDE +! HIKMA PHARMS EQ 5MG BASE/ML DECITABINE INJECTABLE;INTRAVENOUS DECITABINE @ APOTEX @ CIPLA AP EUGIA PHARMA AP GLAND @ AP HONG KONG AP MEITHEAL AP QILU 50MG/VIAL 50MG/VIAL 50MG/VIAL 50MG/VIAL 50MG/VIAL 50MG/VIAL 50MG/VIAL 50MG/VIAL DEFERASIROX GRANULE;ORAL DEFERASIROX AB AMNEAL AB AB AB AUCTA AB AB AB MSN AB TABLET;ORAL DEFERASIROX AB ANNORA PHARMA AB AB AB CELLTRION AB AB 90MG 180MG 360MG 90MG 180MG 360MG 180MG 360MG 90MG 180MG 360MG 90MG 180MG 360MG DEFERIPRONE SOLUTION;ORAL FERRIPROX + @ CHIESI TABLET;ORAL DEFERIPRONE AB HIKMA PHARMS FERRIPROX AB +! CHIESI 80MG/ML 500MG 500MG DEOXYCHOLIC ACID SOLUTION;SUBCUTANEOUS DEOXYCHOLIC ACID AP SLAYBACK PHARMA LLC KYBELLA AP +! KYTHERA BIOPHARMS 20MG/2ML (10MG/ML) 20MG/2ML (10MG/ML) N 214231 001 Mar 22, 2021 May CAHN N 214231 001 Mar 22, 2021 Mar NEWA N 214231 002 Mar 22, 2021 May CAHN N 214231 002 Mar 22, 2021 Mar NEWA A 064103 001 Feb 03, 1995 Oct CAHN A 064103 001 Feb 03, 1995 Oct CAHN N 050731 001 Jan 30, 1998 Jul CAHN A 205539 A 208601 A 214569 A 205539 A 205539 A 212959 A 212959 A 212826 001 Nov 23, 2020 001 Nov 16, 2017 001 Sep 20, 2021 001 Nov 23, 2020 001 Nov 23, 2020 001 Jul 02, 2021 001 Jul 02, 2021 001 Apr 12, 2021 May DISC May DISC Sep NEWA Jul CMFD Jul CAHN Jun NEWA Sep CAHN Apr NEWA A 214194 A 214194 A 214194 A 214559 A 214559 A 214559 A 214650 A 214650 003 Aug 02, 2021 001 Feb 09, 2021 002 Feb 09, 2021 001 Mar 09, 2021 002 Mar 09, 2021 003 Mar 09, 2021 001 Mar 17, 2021 002 Mar 17, 2021 Jul NEWA Jan NEWA Jan NEWA Feb NEWA Feb NEWA Feb NEWA Mar NEWA Mar NEWA A 214341 A 214341 A 214341 A 212669 A 212669 A 212669 001 May 14, 2021 002 May 14, 2021 003 May 14, 2021 001 May 27, 2021 002 May 27, 2021 003 May 27, 2021 May NEWA May NEWA May NEWA May NEWA May NEWA May NEWA N 208030 002 Apr 20, 2018 Aug DISC A 213239 001 Mar 29, 2021 Mar NEWA N 021825 001 Oct 14, 2011 Mar CTEC A 212296 001 Apr 02, 2021 Mar NFTG N 206333 001 Apr 29, 2015 Mar CFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -39 DESIPRAMINE HYDROCHLORIDE TABLET;ORAL DESIPRAMINE HYDROCHLORIDE AB ALEMBIC PHARMS LTD 10MG AB 25MG AB 50MG AB 75MG AB 100MG AB 150MG NORPRAMIN AB + VALIDUS PHARMS AB + AB + AB + AB +! AB + 10MG 25MG 50MG 75MG 100MG 150MG DESLORATADINE TABLET;ORAL CLARINEX AB +! ORGANON 5MG DESLORATADINE @ SUN PHARM INDS 5MG DESLORATADINE; PSEUDOEPHEDRINE SULFATE TABLET, EXTENDED RELEASE;ORAL CLARINEX-D 12 HOUR +! ORGANON 2.5MG;120MG DESMOPRESSIN ACETATE SPRAY, METERED;NASAL NOCTIVA + @ ROIVANT + @ + @ SERENITY PHARMS LLC + @ 0.00083MG/SPRAY 0.00166MG/SPRAY 0.00083MG/SPRAY 0.00166MG/SPRAY DESONIDE GEL;TOPICAL DESONATE + @ LEO PHARMA AS DESONIDE ! CINTEX SVCS 0.05% 0.05% 0.05% DESOXIMETASONE CREAM;TOPICAL DESOXIMETASONE @ AKORN @ OINTMENT;TOPICAL DESOXIMETASONE AB ! GLENMARK GENERICS TOPICORT @ TARO PHARM INDS LTD 0.05% 0.25% 0.25% 0.25% AA BP BP BP BP >A> AB >A> AB >D> BP BP >A> AB DEXAMETHASONE ELIXIR;ORAL DEXAMETHASONE + WOCKHARDT BIO AG TABLET;ORAL DEXAMETHASONE ALVOGEN AMNEAL HIKMA ! HIKMA PHARMS 0.5MG/5ML 0.5MG 0.75MG 4MG 6MG 4MG 6MG 4MG 1MG 4MG A 209785 A 209785 A 209785 A 209785 A 209785 A 209785 001 Jul 07, 2021 002 Jul 07, 2021 003 Jul 07, 2021 004 Jul 07, 2021 005 Jul 07, 2021 006 Jul 07, 2021 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA N 014399 N 014399 N 014399 N 014399 N 014399 N 014399 007 Feb 11, 1982 001 003 004 005 006 Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN N 021165 001 Dec 21, 2001 Aug CAHN A 078359 001 Nov 16, 2010 Aug DISC N 021313 001 Feb 01, 2006 Jun CAHN N 201656 N 201656 N 201656 N 201656 001 Mar 03, 2017 002 Mar 03, 2017 001 Mar 03, 2017 002 Mar 03, 2017 Feb CAHN Feb CAHN Sep CAHN Sep CAHN N 021844 001 Oct 20, 2006 Mar DISC A 202470 001 May 11, 2020 Mar CHRS A 202470 001 May 11, 2020 Mar CTEC A 203787 001 Jan 06, 2017 Apr DISC A 203234 001 Jun 12, 2015 Apr DISC A 202838 001 Sep 20, 2013 Apr CHRS A 074286 001 Jun 07, 1996 Apr DISC A 088254 001 Jul 27, 1983 Aug CRLD A 088481 A 088481 A 088481 A 088481 A 215106 A 215106 A 084612 A 088306 A 084612 002 Apr 28, 1983 003 Apr 28, 1983 004 Apr 28, 1983 001 Nov 28, 1983 001 Oct 14, 2021 002 Oct 14, 2021 001 001 Sep 15, 1983 001 Jun CAHN Jun CAHN Jun CAHN Jun CAHN Oct CTEC Oct NEWA Oct CTEC Apr CHRS Oct CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -40 TABLET;ORAL DEXAMETHASONE >D> BP ! 6MG >A> AB ! 6MG A 088316 001 Sep 15, 1983 Oct CTEC A 088316 001 Sep 15, 1983 Oct CTEC DEXAMETHASONE SODIUM PHOSPHATE INJECTABLE;INJECTION DEXAMETHASONE SODIUM PHOSPHATE AP GLAND PHARMA LTD + @ LUITPOLD EQ 4MG PHOSPHATE/ML EQ 4MG PHOSPHATE/ML A 215654 001 Aug 04, 2021 Jul NEWA A 087440 001 Jul 21, 1982 Aug CRLD DEXAMETHASONE; TOBRAMYCIN SUSPENSION/DROPS;OPHTHALMIC TOBRAMYCIN AND DEXAMETHASONE AB AMNEAL 0.1%;0.3% A 212991 001 Jul 15, 2021 Jul NEWA DEXCHLORPHENIRAMINE MALEATE SYRUP;ORAL DEXCHLORPHENIRAMINE MALEATE AA +! WOCKHARDT BIO AG 2MG/5ML TABLET;ORAL POLARAMINE + @ SCHERING 2MG A 088251 001 Mar 23, 1984 Aug CRLD A 086835 001 Aug CRLD DEXMEDETOMIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEXMEDETOMIDINE HYDROCHLORIDE AP GLAND EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) AP HIKMA PHARMS EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) AP HONG KONG EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) AP PIRAMAL CRITICAL EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A 202126 001 Aug 20, 2015 May CAHN A 205046 001 Apr 26, 2017 Jul CAHN A 204843 001 Jan 18, 2019 Jun CMFD A 214794 001 Sep 03, 2021 Aug NEWA AB AB >A> AB >A> AB >A> AB >A> AB >A> AB >A> AB >A> AB >A> AB DEXMETHYLPHENIDATE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE @ MYLAN @ @ @ @ @ @ @ @ SUN PHARM INDS INC 5MG 10MG 15MG 20MG 25MG 25MG 30MG 30MG 35MG 35MG 40MG 5MG 10MG 15MG 20MG 25MG 30MG 35MG 40MG TABLET;ORAL DEXMETHYLPHENIDATE HYDROCHLORIDE @ BIONPHARMA INC @ 5MG 10MG A 204266 A 204266 A 204266 A 204266 A 204266 A 204266 A 202580 A 202580 A 204266 A 204266 A 204266 A 206734 A 206734 A 206734 A 206734 A 206734 A 206734 A 206734 A 206734 001 Aug 25, 2015 002 Aug 25, 2015 003 Aug 25, 2015 004 Dec 21, 2015 005 May 04, 2021 005 May 04, 2021 001 Aug 28, 2013 001 Aug 28, 2013 006 May 04, 2021 006 May 04, 2021 007 Aug 25, 2015 001 Nov 05, 2021 002 Nov 05, 2021 003 Nov 05, 2021 004 Nov 05, 2021 005 Nov 05, 2021 006 Nov 05, 2021 007 Nov 05, 2021 008 Nov 05, 2021 Jul DISC Jul DISC Jul DISC Jul DISC Jul DISC Apr NEWA Jul CAHN Jul DISC Jul DISC Apr NEWA Jul DISC Oct NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA A 209754 001 Mar 24, 2020 Sep CAHN A 209754 002 Mar 24, 2020 Sep CAHN DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE CAPSULE;ORAL AZSTARYS + COMMAVE THERAP + +! EQ 5.2MG BASE;EQ 26.1MG BASE EQ 7.8MG BASE;EQ 39.2MG BASE EQ 10.4MG BASE;EQ 52.3MG BASE N 212994 N 212994 N 212994 001 May 07, 2021 002 May 07, 2021 003 May 07, 2021 May NEWA May NEWA May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -41 DEXRAZOXANE HYDROCHLORIDE INJECTABLE;INJECTION DEXRAZOXANE HYDROCHLORIDE AP AUROMEDICS PHARMA EQ 250MG BASE/VIAL AP EQ 500MG BASE/VIAL AP ! EUGIA PHARMA EQ 250MG BASE/VIAL AP EQ 250MG BASE/VIAL AP ! EQ 500MG BASE/VIAL AP TOTECT EQ 500MG BASE/VIAL + @ CLINIGEN ZINECARD EQ 500MG BASE/VIAL + @ PFIZER EQ 250MG BASE/VIAL AP +! EQ 250MG BASE/VIAL + @ EQ 500MG BASE/VIAL AP +! EQ 500MG BASE/VIAL A 200752 A 200752 A 200752 A 200752 A 200752 A 200752 001 Oct 19, 2011 002 Oct 19, 2011 001 Oct 19, 2011 001 Oct 19, 2011 002 Oct 19, 2011 002 Oct 19, 2011 Jan CAHN Jan CAHN Aug CHRS Aug CAHN Aug CHRS Aug CAHN N 022025 001 Sep 06, 2007 Aug DISC N 020212 N 020212 N 020212 N 020212 001 May 26, 1995 001 May 26, 1995 002 May 26, 1995 002 May 26, 1995 Aug DISC Mar CAHN Aug DISC Mar CAHN DEXTROAMPHETAMINE SULFATE TABLET;ORAL DEXTROAMPHETAMINE SULFATE AA ARBOR PHARMS LLC 2.5MG AA 7.5MG AA 15MG AA 20MG AA 30MG AA WINDER LABS LLC 2.5MG AA 5MG AA 7.5MG AA 10MG AA 15MG AA 20MG AA DEXTROSTAT 30MG + @ SHIRE 5MG + @ 10MG A 090533 A 090533 A 090533 A 090533 A 090533 A 212160 A 212160 A 212160 A 212160 A 212160 A 212160 A 212160 001 Oct 25, 2011 003 Oct 25, 2011 005 Oct 25, 2011 006 Oct 25, 2011 007 Oct 25, 2011 001 Jun 07, 2021 002 Jun 07, 2021 003 Jun 07, 2021 004 Jun 07, 2021 005 Jun 07, 2021 006 Jun 07, 2021 007 Jun 07, 2021 May CTEC May CTEC May CTEC May CTEC May CTEC May NEWA May NEWA May NEWA May NEWA May NEWA May NEWA May NEWA A 084051 001 A 084051 002 Aug CRLD Aug CRLD DEXTROSE INJECTABLE;INJECTION DEXTROSE 50% AP + HOSPIRA AP INTL MEDICATION SYS 500MG/ML 500MG/ML N 019445 001 Jun 03, 1986 Mar CFTG A 203451 001 Mar 26, 2021 Mar CFTG DEXTROSE; POTASSIUM CHLORIDE INJECTABLE;INJECTION DEXTROSE 5% AND POTASSIUM CHLORIDE 0.075% @ FRESENIUS KABI USA 5GM/100ML;75MG/100ML DEXTROSE 5% AND POTASSIUM CHLORIDE 0.15% A 212346 @ FRESENIUS KABI USA 5GM/100ML;150MG/100ML A 212346 DEXTROSE 5% AND POTASSIUM CHLORIDE 0.224% IN PLASTIC CONTAINER + BAXTER HLTHCARE 5GM/100ML;224MG/100ML N 017634 001 Sep 10, 2020 002 Sep 10, 2020 003 Mar DISC Mar DISC Mar CTEC DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A 212348 001 Jul 30, 2021 5GM/100ML;149MG/100ML;225MG/100ML A 212348 001 Jul 30, 2021 POTASSIUM CHLORIDE 10MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% Sep DISC Jul NFTG @ FRESENIUS KABI USA 5GM/100ML;74.5MG/100ML;450MG/100ML A 213523 001 Mar 09, 2021 Sep DISC AP 5GM/100ML;74.5MG/100ML;450MG/100ML A 213523 001 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.225% IN PLASTIC CONTAINER @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;225MG/100ML A 212348 002 Jul 30, 2021 Sep DISC AP 5GM/100ML;149MG/100ML;225MG/100ML A 212348 002 Jul 30, 2021 Jul NFTG + ICU MEDICAL INC 5GM/100ML;149MG/100ML;225MG/100ML N 018365 001 Sep CTEC AP + 5GM/100ML;149MG/100ML;225MG/100ML N 018365 001 Jul CFTG POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;450MG/100ML A 213523 002 Mar 09, 2021 Sep DISC AP 5GM/100ML;149MG/100ML;450MG/100ML A 213523 002 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 20MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% @ FRESENIUS KABI USA 5GM/100ML;149MG/100ML;900MG/100ML A 213445 001 Mar 09, 2021 Sep DISC AP 5GM/100ML;149MG/100ML;900MG/100ML A 213445 001 Mar 09, 2021 Feb NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -42 INJECTABLE;INJECTION POTASSIUM CHLORIDE 30MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% @ FRESENIUS KABI USA 5GM/100ML;224MG/100ML;450MG/100ML A 213523 003 Mar 09, 2021 Sep DISC AP 5GM/100ML;224MG/100ML;450MG/100ML A 213523 003 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.45% @ FRESENIUS KABI USA 5GM/100ML;298MG/100ML;450MG/100ML A 213523 004 Mar 09, 2021 Sep DISC AP 5GM/100ML;298MG/100ML;450MG/100ML A 213523 004 Mar 09, 2021 Feb NEWA POTASSIUM CHLORIDE 40MEQ IN DEXTROSE 5% AND SODIUM CHLORIDE 0.9% @ FRESENIUS KABI USA 5GM/100ML;298MG/100ML;900MG/100ML A 213445 002 Mar 09, 2021 Sep DISC AP 5GM/100ML;298MG/100ML;900MG/100ML A 213445 002 Mar 09, 2021 Feb NFTG DEXTROSE; SODIUM CHLORIDE INJECTABLE;INJECTION DEXTROSE 2.5% AND SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 2.5GM/100ML;450MG/100ML A 211190 001 Dec 20, 2019 DEXTROSE 5% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 5GM/100ML;300MG/100ML @ 5GM/100ML;300MG/100ML AP +! ICU MEDICAL INC 5GM/100ML;300MG/100ML +! 5GM/100ML;300MG/100ML DEXTROSE 5% AND SODIUM CHLORIDE 0.45% A 211194 001 Aug 26, 2020 A 211194 001 Aug 26, 2020 N 017799 001 N 017799 001 AP FRESENIUS KABI USA 5GM/100ML;450MG/100ML @ 5GM/100ML;450MG/100ML DEXTROSE 5% AND SODIUM CHLORIDE 0.9% A 211276 001 Sep 15, 2020 A 211276 001 Sep 15, 2020 AP FRESENIUS KABI USA 5GM/100ML;900MG/100ML @ 5GM/100ML;900MG/100ML A 211211 001 Sep 14, 2020 A 211211 001 Sep 14, 2020 May CMFD May CMFD Feb DISC May CTEC Feb CTEC May CMFD Mar DISC May CMFD Mar DISC DIAZEPAM INJECTABLE;INJECTION DIAZEPAM AP ! BELOTECA INC 10MG/2ML (5MG/ML) A 210363 001 Mar 18, 2019 Aug CTEC >A> AB AB DICLOFENAC POTASSIUM CAPSULE;ORAL DICLOFENAC POTASSIUM AUROBINDO PHARMA LTD TABLET;ORAL CATAFLAM AMICI AB >A> AB AB DICLOFENAC POTASSIUM RICONPHARMA LLC RUBICON 25MG 25MG 25MG 50MG 50MG 25MG A 213875 001 Oct 19, 2021 Oct NEWA A 076561 002 Jul 21, 2021 A 076561 002 Jul 21, 2021 A 076561 001 Mar 18, 2004 Sep CTEC Jul NEWA May CTNA A 215585 001 Oct 08, 2021 Oct NEWA A 075229 002 Sep 16, 2021 Sep NEWA DICLOFENAC SODIUM GEL;TOPICAL DICLOFENAC SODIUM AB ! TARO 3% SOLARAZE + @ FOUGERA PHARMS 3% SOLUTION;TOPICAL DICLOFENAC SODIUM AT AKORN 1.5% @ RISING 1.5% SOLUTION/DROPS;OPHTHALMIC DICLOFENAC SODIUM AT ! BAUSCH AND LOMB VOLTAREN 0.1% + @ NOVARTIS 0.1% TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM @ MICRO LABS 50MG @ 75MG A 206298 001 Apr 28, 2016 Mar CHRS N 021005 001 Oct 16, 2000 Mar DISC A 206655 001 Jan 28, 2021 Jan NEWA A 206715 001 Aug 07, 2017 May CAHN A 078792 001 Dec 28, 2007 Aug CHRS N 020037 001 Mar 28, 1991 Aug DISC A 074986 001 Feb 26, 1999 Feb CAHN A 074986 002 Feb 26, 1999 Feb CAHN DICLOFENAC SODIUM; MISOPROSTOL TABLET, DELAYED RELEASE;ORAL DICLOFENAC SODIUM AND MISOPROSTOL AB MICRO LABS 50MG;0.2MG AB 75MG;0.2MG A 204355 001 Jul 15, 2021 Jul NEWA A 204355 002 Jul 15, 2021 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -43 DICLOXACILLIN SODIUM CAPSULE;ORAL DICLOXACILLIN SODIUM @ SANDOZ @ @ TEVA ! AB ! EQ 125MG BASE EQ 250MG BASE EQ 500MG BASE EQ 250MG BASE EQ 500MG BASE EQ 500MG BASE DICYCLOMINE HYDROCHLORIDE INJECTABLE;INJECTION DICYCLOMINE HYDROCHLORIDE AP GENE YORK PHARMS 10MG/ML AP PRAXGEN 10MG/ML SYRUP;ORAL DICYCLOMINE HYDROCHLORIDE AA NOVITIUM PHARMA 10MG/5ML TABLET;ORAL DICYCLOMINE HYDROCHLORIDE @ MYLAN 20MG DIDANOSINE CAPSULE, DELAYED REL PELLETS;ORAL DIDANOSINE @ AUROBINDO PHARMA @ @ @ 125MG 200MG 250MG 400MG DIFELIKEFALIN ACETATE SOLUTION;INTRAVENOUS KORSUVA +! CARA THERAP EQ 0.065MG BASE/1.3ML (EQ 0.05MG BASE/ML) DIFLORASONE DIACETATE CREAM;TOPICAL DIFLORASONE DIACETATE BX ! ANI PHARMS OINTMENT;TOPICAL DIFLORASONE DIACETATE @ AKORN 0.05% 0.05% DIFLUNISAL TABLET;ORAL DIFLUNISAL @ DASTECH INTL @ 250MG 500MG DIFLUPREDNATE EMULSION;OPHTHALMIC DIFLUPREDNATE AB CIPLA DUREZOL AB +! NOVARTIS 0.05% 0.05% DIGOXIN ELIXIR;ORAL DIGOXIN AA NOVITIUM PHARMA 0.05MG/ML DIHYDROERGOTAMINE MESYLATE INJECTABLE;INJECTION DIHYDROERGOTAMINE MESYLATE AP PROVEPHARM SAS 1MG/ML SPRAY, METERED;NASAL TRUDHESA +! IMPEL NEUROPHARMA 0.725MG/SPRAY A 061454 A 061454 A 061454 A 062286 A 062286 A 062286 002 001 003 001 Jun 03, 1982 002 Jun 03, 1982 002 Jun 03, 1982 Jan DISC Jan DISC Jan DISC Jan CTEC Jan CTEC Jan CHRS A 212058 001 Apr 26, 2019 Sep CAHN A 212058 001 Apr 26, 2019 Jun CAHN A 214721 001 Apr 23, 2021 Apr NEWA A 040317 001 Sep 07, 1999 Aug DISC A 090094 A 090094 A 090094 A 090094 001 Sep 24, 2008 002 Sep 24, 2008 003 Sep 24, 2008 004 Sep 24, 2008 Jan DISC Jan DISC Jan DISC Jan DISC N 214916 001 Aug 23, 2021 Aug NEWA A 076263 001 Dec 20, 2002 Apr CAHN A 206572 001 Jul 24, 2015 Apr DISC A 073562 001 Nov 27, 1992 Sep CAHN A 073563 001 Nov 27, 1992 Sep CAHN A 211776 001 Aug 09, 2021 Jul NFTG N 022212 001 Jun 23, 2008 Jul CFTG A 213000 001 Oct 04, 2019 Sep CAHN A 212046 001 Jan 07, 2020 Jan CAHN N 213436 001 Sep 02, 2021 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -44 DILTIAZEM HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL DILTIAZEM HYDROCHLORIDE AB1 AB1 AB1 AB1 AB1 AB1 ! GLENMARK PHARMS LTD MYLAN 60MG 90MG 120MG 60MG 90MG 120MG INJECTABLE;INJECTION DILTIAZEM HYDROCHLORIDE @ INTL MEDICATION 5MG/ML >A> SOLUTION;INTRAVENOUS >A> DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5% >A> +! EXELA PHARMA >A> +! 125MG/125ML (1MG/ML) 250MG/250ML (1MG/ML) TABLET;ORAL DILTIAZEM HYDROCHLORIDE @ MYLAN @ @ @ @ @ @ @ 30MG 30MG 60MG 60MG 90MG 90MG 120MG 120MG DIMENHYDRINATE INJECTABLE;INJECTION DIMENHYDRINATE + @ WATSON LABS TEVA TABLET;ORAL DIMENHYDRINATE + @ WATSON LABS 50MG/ML 50MG DIMETHYL FUMARATE CAPSULE, DELAYED RELEASE;ORAL DIMETHYL FUMARATE AB LUPIN AB AB PHARMATHEN AB @ ZYDUS PHARMS @ TECFIDERA 120MG 240MG 120MG 240MG 120MG 240MG AB + BIOGEN INC AB +! 120MG 240MG DINOPROSTONE GEL;ENDOCERVICAL PREPIDIL +! PFIZER >D> SUPPOSITORY;VAGINAL >D> PROSTIN E2 >D> +! PFIZER >A> + @ +! 0.5MG/3GM 20MG 20MG 20MG DIPHENHYDRAMINE HYDROCHLORIDE INJECTABLE;INJECTION DIPHENHYDRAMINE HYDROCHLORIDE AP +! WEST-WARD PHARMS INT 50MG/ML DIPYRIDAMOLE TABLET;ORAL DIPYRIDAMOLE AB OXFORD PHARMS AB AB 25MG 50MG 75MG A 212317 A 212317 A 212317 A 074910 A 074910 A 074910 001 Mar 22, 2021 002 Mar 22, 2021 003 Mar 22, 2021 001 May 02, 1997 002 May 02, 1997 003 May 02, 1997 Mar NEWA Mar NEWA Mar NEWA Mar CTEC Mar CTEC Mar CTEC A 075749 001 Nov 21, 2001 Jan DISC N 215252 001 Oct 28, 2021 Oct NEWA N 215252 002 Oct 28, 2021 Oct NEWA A 072838 A 072838 A 072838 A 072838 A 072838 A 072838 A 072838 A 072838 004 Nov 05, 1992 004 Nov 05, 1992 003 Nov 05, 1992 003 Nov 05, 1992 002 Nov 05, 1992 002 Nov 05, 1992 001 Nov 05, 1992 001 Nov 05, 1992 Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC A 080615 001 A 085166 001 Aug CRLD Aug CRLD A 210226 A 210226 A 210436 A 210436 A 210538 A 210538 001 Oct 05, 2020 002 Oct 05, 2020 001 Mar 26, 2021 002 Mar 26, 2021 001 Sep 24, 2020 002 Sep 24, 2020 Jul CAHN Jul CAHN Mar NEWA Mar NEWA Feb DISC Feb DISC N 204063 001 Mar 27, 2013 Apr CAHN N 204063 002 Mar 27, 2013 Apr CAHN N 019617 001 Dec 09, 1992 Jan CAHN N 017810 001 N 017810 001 N 017810 001 Oct DISC Oct DISC Jan CAHN A 080817 002 Aug CRLD A 040542 001 Apr 21, 2006 A 040542 002 Apr 21, 2006 A 040542 003 Apr 21, 2006 Jan CMFD Jan CMFD Jan CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -45 DIROXIMEL FUMARATE CAPSULE, DELAYED RELEASE;ORAL VUMERITY +! BIOGEN INC 231MG DISOPYRAMIDE PHOSPHATE CAPSULE;ORAL DISOPYRAMIDE PHOSPHATE @ MAYNE PHARMA @ EQ 100MG BASE EQ 150MG BASE DISULFIRAM TABLET;ORAL ANTABUSE + @ ODYSSEY PHARMS AB + + @ AB +! DISULFIRAM AB ! HIKMA PHARMS 250MG 250MG 500MG 500MG 500MG DIVALPROEX SODIUM CAPSULE, DELAYED REL PELLETS;ORAL DIVALPROEX SODIUM @ TEVA PHARMS USA EQ 125MG VALPROIC ACID TABLET, DELAYED RELEASE;ORAL DIVALPROEX SODIUM @ ANCHEN PHARMS EQ 500MG VALPROIC ACID TABLET, EXTENDED RELEASE;ORAL DIVALPROEX SODIUM @ AMTA EQ 250MG VALPROIC ACID AB EQ 250MG VALPROIC ACID @ EQ 500MG VALPROIC ACID AB EQ 500MG VALPROIC ACID DOCETAXEL INJECTABLE;INJECTION DOCETAXEL AP EUGIA PHARMA AP AP AP GLAND PHARMA LTD AP AP AP HIKMA AP AP HONG KONG AP AP @ INGENUS PHARMS LLC AP +! SHILPA AP + AP AP +! AP + AP AP +! AP + AP 20MG/2ML (10MG/ML) 80MG/8ML (10MG/ML) 160MG/16ML (10MG/ML) 20MG/2ML (10MG/ML) 80MG/8ML (10MG/ML) 160MG/16ML (10MG/ML) 20MG/ML (20MG/ML) 80MG/4ML (20MG/ML) 20MG/2ML (10MG/ML) 80MG/8ML (10MG/ML) 160MG/16ML (10MG/ML) 20MG/2ML (10MG/ML) 20MG/ML (20MG/ML) 20MG/ML (20MG/ML) 20MG/ML (20MG/ML) 80MG/4ML (20MG/ML) 80MG/4ML (20MG/ML) 80MG/4ML (20MG/ML) 160MG/8ML (20MG/ML) 160MG/8ML (20MG/ML) 160MG/8ML (20MG/ML) >A> AB >A> AB >A> AB DOFETILIDE CAPSULE;ORAL DOFETILIDE GRANULES @ NOVAST LABS @ @ @ RICONPHARMA LLC @ 0.125MG 0.25MG 0.5MG 0.125MG 0.25MG 0.5MG 0.125MG 0.25MG N 211855 001 Oct 29, 2019 Apr CAHN A 070173 001 May 31, 1985 Feb DISC A 070173 002 May 31, 1985 Feb DISC A 088482 A 088482 A 088483 A 088483 001 Dec 08, 1983 001 Dec 08, 1983 001 Dec 08, 1983 001 Dec 08, 1983 Sep DISC Aug CRLD Sep DISC Aug CRLD A 202652 002 Feb 05, 2014 Sep CHRS A 211505 001 Nov 17, 2020 May DISC A 078411 001 Nov 03, 2008 May DISC A 214462 A 214462 A 214462 A 214462 001 Mar 15, 2021 001 Mar 15, 2021 002 Mar 15, 2021 002 Mar 15, 2021 Sep DISC Mar NEWA Sep DISC Mar NEWA A 214575 A 214575 A 214575 A 213510 A 213510 A 213510 A 204490 A 204490 A 209634 A 209634 A 209634 A 207563 N 205934 N 205934 N 205934 N 205934 N 205934 N 205934 N 205934 N 205934 N 205934 001 Jun 25, 2021 002 Jun 25, 2021 003 Jun 25, 2021 001 Jul 01, 2021 002 Jul 01, 2021 003 Jul 01, 2021 001 Jan 14, 2021 002 Jan 14, 2021 001 Aug 24, 2018 002 Aug 24, 2018 003 Aug 24, 2018 001 Aug 31, 2017 001 Dec 22, 2015 001 Dec 22, 2015 001 Dec 22, 2015 002 Dec 22, 2015 002 Dec 22, 2015 002 Dec 22, 2015 003 Dec 22, 2015 003 Dec 22, 2015 003 Dec 22, 2015 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jan NEWA Jan NEWA Jun CMFD Jun CMFD Jun CMFD Apr DISC Apr CHRS Apr CRLD Jan CAHN Apr CHRS Apr CRLD Jan CAHN Apr CHRS Apr CRLD Jan CAHN A 212750 A 212750 A 212750 A 212410 A 212410 A 212410 A 212410 A 212410 001 Oct 14, 2021 002 Oct 14, 2021 003 Oct 14, 2021 001 Dec 27, 2019 002 Dec 27, 2019 003 Dec 27, 2019 001 Dec 27, 2019 002 Dec 27, 2019 Oct NEWA Oct NEWA Oct NEWA Sep CAHN Sep CAHN Sep CAHN Feb DISC Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -46 CAPSULE;ORAL DOFETILIDE @ 0.5MG DOLASETRON MESYLATE INJECTABLE;INJECTION ANZEMET + @ VALIDUS PHARMS + @ @ TABLET;ORAL ANZEMET + @ VALIDUS PHARMS + @ 12.5MG/0.625ML (20MG/ML) 100MG/5ML (20MG/ML) 500MG/25ML (20MG/ML) 50MG 100MG >D> AB >A> DONEPEZIL HYDROCHLORIDE TABLET;ORAL DONEPEZIL HYDROCHLORIDE MYLAN @ 23MG 23MG DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE SOLUTION/DROPS;OPHTHALMIC DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE AT ALEMBIC PHARMS LTD EQ 2% BASE;EQ 0.5% BASE AT FDC LTD EQ 2% BASE;EQ 0.5% BASE DOXAPRAM HYDROCHLORIDE INJECTABLE;INJECTION DOPRAM AP +! HIKMA PHARMS 20MG/ML DOXAZOSIN MESYLATE TABLET;ORAL DOXAZOSIN MESYLATE BX HERITAGE PHARMA BX BX BX @ MYLAN @ @ @ EQ 1MG BASE EQ 2MG BASE EQ 4MG BASE EQ 8MG BASE EQ 1MG BASE EQ 2MG BASE EQ 4MG BASE EQ 8MG BASE DOXEPIN HYDROCHLORIDE CAPSULE;ORAL DOXEPIN HYDROCHLORIDE AB ALEMBIC PHARMS LTD AB AB AB AB AB APPCO AB AB AB AB @ CHARTWELL RX @ @ @ @ AB LEADING PHARMA LLC AB AB AB AB AB @ UPSHER SMITH LABS @ @ @ EQ 10MG BASE EQ 25MG BASE EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE EQ 10MG BASE EQ 25MG BASE EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE EQ 10MG BASE EQ 25MG BASE EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE EQ 10MG BASE EQ 25MG BASE EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE EQ 150MG BASE EQ 10MG BASE EQ 10MG BASE EQ 25MG BASE EQ 25MG BASE A 212410 003 Dec 27, 2019 Feb DISC N 020624 002 Sep 11, 1997 N 020624 001 Sep 11, 1997 N 020624 003 Dec 11, 2001 Feb CAHN Feb CAHN Feb CAHN N 020623 001 Sep 11, 1997 Feb CAHN N 020623 002 Sep 11, 1997 Feb CAHN A 202656 001 Oct 22, 2015 Oct DISC A 202656 001 Oct 22, 2015 Oct DISC A 213099 001 May 04, 2021 Apr NEWA A 205295 001 Jun 13, 2019 Feb CMFD N 014879 001 Jul CAHN A 205210 A 205210 A 205210 A 205210 A 075509 A 075509 A 075509 A 075509 001 Feb 13, 2018 002 Feb 13, 2018 003 Feb 13, 2018 004 Feb 13, 2018 001 Oct 19, 2000 002 Oct 19, 2000 003 Oct 19, 2000 004 Oct 19, 2000 Sep CTEC Sep CTEC Sep CTEC Sep CTEC Jul DISC Jul DISC Jul DISC Jul DISC A 215076 A 215076 A 215076 A 215076 A 215076 A 214908 A 214908 A 214908 A 214908 A 214908 A 210268 A 210268 A 210268 A 210268 A 210268 A 211619 A 211619 A 211619 A 211619 A 211619 A 211618 A 210268 A 210268 A 210268 A 210268 001 Apr 21, 2021 002 Apr 21, 2021 003 Apr 21, 2021 004 Apr 21, 2021 005 Apr 21, 2021 001 Apr 01, 2021 002 Apr 01, 2021 003 Apr 01, 2021 004 Apr 01, 2021 005 Apr 01, 2021 001 Sep 04, 2020 002 Sep 04, 2020 003 Sep 04, 2020 004 Sep 04, 2020 005 Sep 04, 2020 001 Mar 09, 2021 002 Mar 09, 2021 003 Mar 09, 2021 004 Mar 09, 2021 005 Mar 09, 2021 001 Mar 01, 2021 001 Sep 04, 2020 001 Sep 04, 2020 002 Sep 04, 2020 002 Sep 04, 2020 Apr NEWA Apr NEWA Apr NEWA Apr NEWA Apr NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Aug CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN Feb NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA May CAHN Feb DISC May CAHN Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -47 CAPSULE;ORAL DOXEPIN HYDROCHLORIDE @ EQ 50MG BASE @ EQ 50MG BASE @ EQ 75MG BASE @ EQ 75MG BASE @ EQ 100MG BASE @ EQ 100MG BASE TABLET;ORAL DOXEPIN HYDROCHLORIDE AB RK PHARMA EQ 3MG BASE AB EQ 6MG BASE DOXERCALCIFEROL INJECTABLE;INJECTION DOXERCALCIFEROL @ SUN PHARM @ 2MCG/ML (2MCG/ML) 4MCG/2ML (2MCG/ML) >A> AP >D> AP >A> AB >A> AB DOXORUBICIN HYDROCHLORIDE INJECTABLE;INJECTION DOXORUBICIN HYDROCHLORIDE @ ALMAJECT HIKMA PHARMS WEST-WARD PHARMS INT 2MG/ML 200MG/100ML 200MG/100ML INJECTABLE, LIPOSOMAL;INJECTION DOXORUBICIN HYDROCHLORIDE AYANA PHARMA LTD 20MG/10ML (2MG/ML) 50MG/25ML (2MG/ML) DOXYCYCLINE CAPSULE;ORAL DOXYCYCLINE @ MYLAN AB @ AB @ AB MONODOX AB + CHARTWELL RX AB + AB + FOR SUSPENSION;ORAL DOXYCYCLINE AB CHARTWELL EQ 50MG BASE EQ 50MG BASE EQ 75MG BASE EQ 75MG BASE EQ 100MG BASE EQ 100MG BASE EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE EQ 25MG BASE/5ML DOXYCYCLINE HYCLATE CAPSULE;ORAL DOXYCYCLINE HYCLATE AB CHARTWELL EQ 50MG BASE AB EQ 100MG BASE @ NOSTRUM LABS INC EQ 50MG BASE @ EQ 100MG BASE CAPSULE, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE @ BAUSCH EQ 75MG BASE @ EQ 100MG BASE INJECTABLE;INJECTION DOXYCYCLINE HYCLATE AP WEST-WARD PHARMS INT EQ 100MG BASE/VIAL AP EQ 200MG BASE/VIAL SYSTEM, EXTENDED RELEASE;PERIODONTAL ATRIDOX + @ DEN-MAT 50MG TABLET;ORAL DOXYCYCLINE HYCLATE AB ALEMBIC PHARMS LTD EQ 50MG BASE @ AMICI EQ 100MG BASE AB CARIBE HOLDINGS EQ 50MG BASE AB CHARTWELL EQ 50MG BASE AB EQ 100MG BASE A 210268 A 210268 A 210268 A 210268 A 210268 A 210268 003 Sep 04, 2020 003 Sep 04, 2020 004 Sep 04, 2020 004 Sep 04, 2020 005 Sep 04, 2020 005 Sep 04, 2020 May CAHN Feb DISC May CAHN Feb DISC May CAHN Feb DISC A 202337 001 Jan 20, 2016 Jan CAHN A 202337 002 Jan 20, 2016 Jan CAHN A 203875 001 Nov 14, 2019 Aug DISC A 203875 002 Nov 14, 2019 Aug DISC A 065515 001 Nov 08, 2012 A 064097 001 Sep 13, 1994 A 064097 001 Sep 13, 1994 Jul CAHN Oct CAHN Oct CAHN A 207228 001 Oct 12, 2021 Oct NEWA A 207228 002 Oct 12, 2021 Oct NEWA A 208942 001 Jan 21, 2021 A 208942 001 Jan 21, 2021 A 208942 002 Jan 21, 2021 A 208942 002 Jan 21, 2021 A 208942 003 Jan 21, 2021 A 208942 003 Jan 21, 2021 Jan DISC Jan NEWA Jan DISC Jan NEWA Jan DISC Jan NEWA N 050641 002 Feb 10, 1992 N 050641 003 Oct 18, 2006 N 050641 001 Dec 29, 1989 Jun CMFD Jun CMFD Jun CMFD A 065454 001 Jul 16, 2008 Jun CAHN A 062500 001 Sep 11, 1984 A 062500 002 Sep 11, 1984 A 209393 001 Dec 10, 2020 A 209393 002 Dec 10, 2020 Jun CAHN Jun CAHN Jul DISC Jul DISC A 065281 001 Dec 21, 2005 May CAHN A 065281 002 Dec 21, 2005 May CAHN A 062992 001 Feb 16, 1989 May CMFD A 062992 002 Feb 16, 1989 May CMFD N 050751 001 Sep 03, 1998 Sep DISC A 210536 002 Sep 14, 2021 A 213475 001 Mar 10, 2021 A 062269 003 Oct 05, 1983 A 062505 002 Jul 27, 2021 A 062505 001 Sep 11, 1984 Sep NEWA Sep CAHN Jul CTEC Jul NEWA Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -48 TABLET;ORAL DOXYCYCLINE HYCLATE AB EQ 100MG BASE @ MYLAN EQ 100MG BASE @ ORYZA EQ 100MG BASE AB EQ 100MG BASE TABLET, DELAYED RELEASE;ORAL DOXYCYCLINE HYCLATE @ MYLAN EQ 50MG BASE @ EQ 50MG BASE @ EQ 75MG BASE @ EQ 80MG BASE @ EQ 100MG BASE @ EQ 200MG BASE A 062505 A 062432 A 213475 A 213475 001 Sep 11, 1984 001 Feb 15, 1983 001 Mar 10, 2021 001 Mar 10, 2021 Jun CAHN Jul DISC Apr DISC Feb NEWA A 090431 A 090431 A 090431 A 090431 A 090431 A 090431 003 May 23, 2016 003 May 23, 2016 001 Dec 28, 2010 004 Apr 29, 2016 002 Dec 28, 2010 005 May 19, 2016 Aug CAHN Jul DISC Aug CAHN Aug CAHN Aug CAHN Aug CAHN DROSPIRENONE; ESTETROL TABLET;ORAL NEXTSTELLIS +! MAYNE PHARMA 3MG;14.2MG N 214154 001 Apr 15, 2021 Apr NEWA DROSPIRENONE; ETHINYL ESTRADIOL TABLET;ORAL DROSPIRENONE AND ETHINYL ESTRADIOL AB HLTHCARE @ JUBILANT CADISTA KYRA 3MG;0.02MG 3MG;0.02MG @ SUN PHARM 3MG;0.02MG TABLET;ORAL-28 DROSPIRENONE AND ETHINYL ESTRADIOL @ JUBILANT CADISTA KEMEYA 3MG;0.03MG @ SUN PHARM 3MG;0.03MG A 203291 001 Jul 18, 2017 Jun CAHN A 209423 001 Dec 22, 2017 Jun DISC A 202318 001 Jul 23, 2019 Aug DISC A 210017 001 Sep 10, 2018 Jun DISC A 202138 001 Mar 13, 2019 Aug DISC DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM TABLET;ORAL BEYAZ AB +! BAYER HLTHCARE AB + 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG N 022532 001 Sep 24, 2010 3MG,N/A;0.02MG,N/A;0.451MG,0.451MG N 022532 001 Sep 24, 2010 Sep CHRS Sep CRLD DROXIDOPA CAPSULE;ORAL DROXIDOPA AB AJANTA PHARMA LTD AB AB AB ALKEM LABS LTD AB AB AB ANNORA AB AB AB AUROBINDO PHARMA LTD AB AB AB BIONPHARMA INC AB AB AB BLUEPHARMA AB AB AB HIKMA PHARMS AB AB AB LUPIN PHARMS AB AB AB MSN PHARMS INC AB AB AB MYLAN API AB AB 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG A 214391 A 214391 A 214391 A 213911 A 213911 A 213911 A 211726 A 211726 A 211726 A 214387 A 214387 A 214387 A 213033 A 213033 A 213033 A 214543 A 214543 A 214543 A 212835 A 212835 A 212835 A 211652 A 211652 A 211652 A 211741 A 211741 A 211741 A 213033 A 213033 A 213033 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 002 Aug 09, 2021 003 Aug 09, 2021 001 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Apr 28, 2021 002 Apr 28, 2021 003 Apr 28, 2021 001 May 05, 2021 002 May 05, 2021 003 May 05, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Apr 28, 2021 002 Apr 28, 2021 003 Apr 28, 2021 Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Jul NEWA Jul NEWA Feb NFTG Feb NFTG Feb NFTG Feb NFTG May CAHN May CAHN May CAHN Apr NEWA Apr NEWA Apr NEWA Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Apr NEWA Apr NEWA Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -49 AB AB AB >A> AB >A> AB >A> AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB CAPSULE;ORAL DROXIDOPA SCIEGEN PHARMS INC SLATE SUN PHARM TASMAN PHARMA @ TEVA PHARMS USA INC @ @ TRIS PHARMA INC ZYDUS PHARMS NORTHERA + LUNDBECK NA LTD + +! 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 100MG 200MG 200MG 300MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG 100MG 200MG 300MG DULOXETINE HYDROCHLORIDE CAPSULE, DELAYED REL PELLETS;ORAL DRIZALMA SPRINKLE + SUN PHARMA GLOBAL EQ 20MG BASE + EQ 30MG BASE + EQ 40MG BASE +! EQ 60MG BASE DULOXETINE HYDROCHLORIDE AB SUNSHINE AB AB EQ 20MG BASE EQ 30MG BASE EQ 60MG BASE DUTASTERIDE CAPSULE;ORAL AVODART AB +! WOODWARD DUTASTERIDE @ NOSTRUM LABS INC 0.5MG 0.5MG DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE CAPSULE;ORAL JALYN AB +! WOODWARD 0.5MG;0.4MG DYDROGESTERONE TABLET;ORAL GYNOREST + @ SOLVAY @ + @ @ 5MG 5MG 10MG 10MG ECHOTHIOPHATE IODIDE FOR SOLUTION;OPHTHALMIC PHOSPHOLINE IODIDE @ FERA PHARMS LLC @ +! @ 0.03% 0.06% 0.125% 0.25% A 214017 A 214017 A 214017 A 215265 A 215265 A 215265 A 214384 A 214384 A 214384 A 213661 A 213661 A 213661 A 213162 A 213162 A 213162 A 213162 A 213162 A 213162 A 214543 A 214543 A 214543 A 211818 A 211818 A 211818 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Nov 01, 2021 002 Nov 01, 2021 003 Nov 01, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 001 Feb 18, 2021 001 Feb 18, 2021 002 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 003 Feb 18, 2021 001 May 05, 2021 002 May 05, 2021 003 May 05, 2021 001 Feb 18, 2021 002 Feb 18, 2021 003 Feb 18, 2021 Feb NFTG Feb NFTG Feb NFTG Oct NEWA Oct NEWA Oct NEWA Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Aug DISC Feb NFTG Aug DISC Feb NFTG Aug DISC Feb NFTG Jun CAHN Jun CAHN Jun CAHN Feb NFTG Feb NFTG Feb NFTG N 203202 001 Feb 18, 2014 N 203202 002 Feb 18, 2014 N 203202 003 Feb 18, 2014 Feb CFTG Feb CFTG Feb CFTG N 212516 N 212516 N 212516 N 212516 001 Jul 19, 2019 002 Jul 19, 2019 003 Jul 19, 2019 004 Jul 19, 2019 Apr CDFR Apr CDFR Apr CDFR Apr CDFR A 212328 001 Feb 11, 2021 A 212328 002 Feb 11, 2021 A 212328 003 Feb 11, 2021 Feb NEWA Feb NEWA Feb NEWA N 021319 001 Nov 20, 2001 Jul CAHN A 204705 001 Nov 20, 2015 Apr CAHN N 022460 001 Jun 14, 2010 Jul CAHN N 017388 001 N 017388 001 N 017388 002 N 017388 002 Sep CRLD Jul CRLD Sep CRLD Jul CRLD N 011963 002 N 011963 004 N 011963 001 N 011963 003 Aug CAHN Aug CAHN Aug CAHN Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -50 ECONAZOLE NITRATE AEROSOL, FOAM;TOPICAL ECOZA +! RESILIA PHARMS 1% N 205175 001 Oct 24, 2013 Feb CAHN EDETATE CALCIUM DISODIUM INJECTABLE;INJECTION CALCIUM DISODIUM VERSENATE +! BAUSCH 200MG/ML TABLET;ORAL CALCIUM DISODIUM VERSENATE @ BAUSCH 500MG N 008922 001 N 008922 002 May CAHN May CAHN EFAVIRENZ TABLET;ORAL EFAVIRENZ AB STRIDES PHARMA 600MG A 078509 001 Jun 16, 2021 Jun NEWA EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EFAVIRENZ, EMTRICITABINE, AND TENOFOVIR DISOPROXIL FUMARATE AB MACLEODS PHARMS LTD 600MG;200MG;300MG A 204287 001 Sep 13, 2021 Sep NEWA EFAVIRENZ; LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EFAVIRENZ, LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE + @ AUROBINDO PHARMA LTD 600MG;300MG;300MG N 022343 001 Aug 15, 2018 Feb DISC EFINACONAZOLE SOLUTION;TOPICAL EFINACONAZOLE AB ACRUX DDS 10% @ AUROBINDO PHARMA LTD 10% AB 10% AB TEVA PHARMS USA 10% JUBLIA AB +! BAUSCH 10% A 211969 A 212066 A 212066 A 211827 001 Jun 21, 2021 001 Mar 29, 2021 001 Mar 29, 2021 001 Dec 16, 2020 Jun NEWA Sep DISC Mar NEWA Feb CTEC N 203567 001 Jun 06, 2014 Feb CTEC ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR TABLET;ORAL TRIKAFTA (COPACKAGED) + VERTEX PHARMS INC 50MG,37.5MG,25MG; 75MG +! 100MG,75MG,50MG; 150MG N 212273 002 Jun 08, 2021 Jun NEWA N 212273 001 Oct 21, 2019 Jun CPOT ELIGLUSTAT TARTRATE CAPSULE;ORAL CERDELGA AB +! GENZYME CORP ELIGLUSTAT TARTRATE AB AIZANT AB APPCO EQ 84MG BASE EQ 84MG BASE EQ 84MG BASE N 205494 001 Aug 19, 2014 Aug CFTG A 212463 001 Sep 08, 2021 Aug NFTG A 212463 001 Sep 08, 2021 Sep CAHN >A> AB AB AB AB AB AB AB AB AB AB AB EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE HETERO LABS LTD III 200MG;300MG EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE APOTEX CIPLA LAURUS LUPIN LTD MACLEODS PHARMS LTD MYLAN STRIDES PHARMA ZYDUS PHARMS 200MG;300MG 200MG;300MG 200MG;300MG 200MG;300MG 200MG;300MG 200MG;300MG 200MG;300MG 100MG;150MG 133MG;200MG 167MG;250MG A 201806 001 Oct 07, 2021 Oct NEWA A 208740 A 090958 A 212114 A 204131 A 203442 A 206436 A 091055 A 212689 A 212689 A 212689 001 Jun 16, 2021 001 Apr 02, 2021 001 Jul 26, 2019 001 Jun 04, 2021 001 May 15, 2020 001 Apr 09, 2018 001 Jan 13, 2021 002 Jul 01, 2021 003 Jul 01, 2021 004 Jul 01, 2021 Jun NEWA Mar NEWA Jan CMFD May NEWA Feb CMFD Feb CMFD Jan NEWA Jun NEWA Jun NEWA Jun NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -51 ENALAPRIL MALEATE SOLUTION;ORAL ENALAPRIL MALEATE AB BIONPHARMA INC EPANED AB +! AZURITY 1MG/ML 1MG/ML ENALAPRIL MALEATE; HYDROCHLOROTHIAZIDE TABLET;ORAL ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE @ MYLAN 5MG;12.5MG @ 10MG;25MG ENZALUTAMIDE CAPSULE;ORAL ENZALUTAMIDE AB ACTAVIS LABS FL INC XTANDI AB +! ASTELLAS 40MG 40MG EPHEDRINE HYDROCHLORIDE SOLUTION;INTRAVENOUS REZIPRES +! ETON + @ +! + @ +! +! SINTETICA SA +! +! 23.5MG/5ML (4.7MG/ML) 47MG/ML (47MG/ML) 47MG/ML (47MG/ML) 47MG/5ML (9.4MG/ML) 47MG/5ML (9.4MG/ML) 23.5MG/5ML (4.7MG/ML) 47MG/ML (47MG/ML) 47MG/5ML (9.4MG/ML) EPHEDRINE SULFATE SOLUTION;INTRAVENOUS AKOVAZ +! EXELA PHARMA 25MG/5ML (5MG/ML) EPINEPHRINE; LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE AND EPINEPHRINE AP B BRAUN MEDICAL INC 0.005MG/ML;1.5% AB AB >A> AB >A> AB AB AB EPLERENONE TABLET;ORAL EPLERENONE CHARTWELL RX @ PIRAMAL HLTHCARE UK @ WESTMINSTER PHARMS INSPRA + UPJOHN +! @ 25MG 50MG 25MG 50MG 25MG 50MG 25MG 50MG 100MG EPOPROSTENOL SODIUM INJECTABLE;INJECTION EPOPROSTENOL SODIUM AP2 SUN PHARM AP AP2 AP AP1 TEVA PHARMS USA AP1 FLOLAN AP1 +! GLAXOSMITHKLINE LLC AP1 +! VELETRI AP2 +! ACTELION AP2 +! EQ 0.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 1.5MG BASE/VIAL A 212408 001 Aug 10, 2021 Jul NFTG N 208686 001 Sep 20, 2016 Jul CFTG A 075624 001 Sep 18, 2001 Jul DISC A 075624 002 Sep 18, 2001 Jul DISC A 209614 001 May 14, 2021 May NFTG N 203415 001 Aug 31, 2012 May CFTG N 213536 N 213536 N 213536 N 213536 N 213536 N 213536 N 213536 N 213536 001 Jun 14, 2021 002 Jun 14, 2021 002 Jun 14, 2021 003 Jun 14, 2021 003 Jun 14, 2021 001 Jun 14, 2021 002 Jun 14, 2021 003 Jun 14, 2021 Jun CAHN Jun DISC Jun CAHN Jun DISC Jun CAHN Jun NEWA Jun NEWA Jun NEWA N 208289 002 Aug 02, 2021 Aug NEWA A 208475 001 Sep 08, 2021 Aug NEWA A 078482 A 078482 A 212765 A 212765 A 207842 A 207842 001 Jul 30, 2008 002 Jul 30, 2008 001 Aug 10, 2020 002 Aug 10, 2020 001 Oct 25, 2021 002 Oct 25, 2021 Apr CAHN Apr CAHN Feb DISC Feb DISC Oct CAHN Oct CAHN N 021437 001 Sep 27, 2002 N 021437 002 Sep 27, 2002 N 021437 003 Sep 27, 2002 Apr CAHN Apr CAHN Apr CAHN A 210473 A 210473 A 210473 A 210473 A 078396 A 078396 001 Jan 15, 2021 001 Jan 15, 2021 002 Jan 15, 2021 002 Jan 15, 2021 001 Apr 23, 2008 002 Apr 23, 2008 Feb CTEC Jan NFTG Feb CTEC Jan NFTG Feb CTEC Feb CTEC N 020444 001 Sep 20, 1995 Feb CTEC N 020444 002 Sep 20, 1995 Feb CTEC N 022260 002 Jun 28, 2012 Feb CAHN N 022260 001 Jun 27, 2008 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -52 INJECTABLE;INJECTION VELETRI AP2 +! ACTELION PHARMS LTD AP2 + AP + AP2 +! AP +! EQ 0.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 0.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EQ 1.5MG BASE/VIAL EPTIFIBATIDE INJECTABLE;INJECTION EPTIFIBATIDE AP ! MYLAN LABS LTD AP ! AP SHUANGCHENG INTEGRILIN + @ SCHERING + @ 2MG/ML 75MG/100ML 2MG/ML 2MG/ML 75MG/100ML ERGOCALCIFEROL CAPSULE;ORAL DRISDOL AA +! VALIDUS PHARMS 50,000 IU ERLOTINIB HYDROCHLORIDE TABLET;ORAL ERLOTINIB HYDROCHLORIDE AB ALEMBIC PHARMS LTD EQ 25MG BASE AB EQ 100MG BASE AB EQ 150MG BASE AB MSN EQ 25MG BASE AB EQ 100MG BASE AB EQ 150MG BASE ERTAPENEM SODIUM INJECTABLE;INTRAMUSCULAR, INTRAVENOUS ERTAPENEM SODIUM AP EUGIA PHARMA EQ 1GM BASE/VIAL AP GLAND PHARMA LTD EQ 1GM BASE/VIAL ERYTHROMYCIN SOLUTION;TOPICAL ERYTHRA-DERM AT SAPTALIS PHARMS 2% TABLET;ORAL ERYTHROMYCIN BX AMNEAL PHARMS CO 250MG BX 500MG AB CADILA PHARMS LTD 250MG AB 500MG AB ORANGE 250MG AB 500MG AB TEVA PHARMS USA INC 250MG AB 500MG TABLET, DELAYED RELEASE;ORAL ERYTHROMYCIN AB TORRENT 250MG AB 500MG ERYTHROMYCIN ETHYLSUCCINATE GRANULE;ORAL ERYTHROMYCIN ETHYLSUCCINATE @ PAR PHARM INC EQ 200MG BASE/5ML @ EQ 400MG BASE/5ML ESCITALOPRAM OXALATE SOLUTION;ORAL ESCITALOPRAM OXALATE @ ANTRIM PHARMS LLC EQ 5MG BASE/5ML N 022260 N 022260 N 022260 N 022260 N 022260 002 Jun 28, 2012 002 Jun 28, 2012 002 Jun 28, 2012 001 Jun 27, 2008 001 Jun 27, 2008 Feb CHRS Feb CTEC Jan CFTG Feb CTEC Jan CFTG A 203258 001 Jul 20, 2018 A 203258 002 Jul 20, 2018 A 213081 001 Sep 07, 2021 Apr CHRS Apr CHRS Aug NEWA N 020718 001 May 18, 1998 Apr DISC N 020718 002 May 18, 1998 Apr DISC N 003444 001 Feb CAHN A 214719 A 214719 A 214719 A 214366 A 214366 A 214366 001 Jul 08, 2021 002 Jul 08, 2021 003 Jul 08, 2021 001 May 10, 2021 002 May 10, 2021 003 May 10, 2021 Jul NEWA Jul NEWA Jul NEWA Apr NEWA Apr NEWA Apr NEWA A 209133 001 Jun 25, 2018 Aug CAHN A 212040 001 Mar 26, 2021 Mar NEWA A 062687 001 Feb 05, 1988 Apr CMFD A 209720 A 209720 A 213628 A 213628 A 213628 A 213628 A 214549 A 214549 001 Mar 09, 2018 002 Mar 09, 2018 001 Jun 28, 2021 002 Jun 28, 2021 001 Jun 28, 2021 002 Jun 28, 2021 001 Feb 11, 2021 002 Feb 11, 2021 Sep CTEC Sep CTEC Sep CAHN Sep CAHN Jun NEWA Jun NEWA Feb NEWA Feb NEWA A 211975 001 Jul 26, 2021 Jul NEWA A 211975 002 Jul 26, 2021 Jul NEWA A 211991 001 Oct 23, 2019 May DISC A 211991 002 Oct 23, 2019 May DISC A 203967 001 May 26, 2015 Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -53 ESLICARBAZEPINE ACETATE TABLET;ORAL APTIOM AB + SUNOVION PHARMS INC 200MG AB + 400MG AB + 600MG AB +! 800MG ESLICARBAZEPINE ACETATE AB DR REDDYS LABS LTD 200MG AB 400MG AB 600MG AB 800MG ESOMEPRAZOLE MAGNESIUM CAPSULE, DELAYED REL PELLETS;ORAL ESOMEPRAZOLE MAGNESIUM @ AMTA EQ 20MG BASE @ EQ 40MG BASE AB ETHYPHARM EQ 20MG BASE AB EQ 40MG BASE AB GRAVITI PHARMS EQ 20MG BASE AB EQ 40MG BASE AB INDCHEMIE HEALTH EQ 40MG BASE ESOMEPRAZOLE MAGNESIUM; NAPROXEN TABLET, DELAYED RELEASE;ORAL NAPROXEN AND ESOMEPRAZOLE MAGNESIUM AB MYLAN EQ 20MG BASE;375MG AB EQ 20MG BASE;500MG AB AB AB BX BX BX BX BX >D> AB >A> >D> AB >A> >D> AB >A> ESTRADIOL CREAM;VAGINAL ESTRACE +! ALLERGAN 0.01% ESTRADIOL ALVOGEN PRASCO LABS LLC 0.01% 0.01% FILM, EXTENDED RELEASE;TRANSDERMAL ALORA @ ALLERGAN @ @ @ 0.025MG/24HR 0.05MG/24HR 0.075MG/24HR 0.1MG/24HR INSERT, EXTENDED RELEASE;VAGINAL ESTRING +! PFIZER 0.0075MG/24HR SYSTEM;TRANSDERMAL ESTRADIOL AMNEAL 0.025MG/24HR 0.0375MG/24HR 0.05MG/24HR 0.075MG/24HR 0.1MG/24HR TABLET;ORAL ESTRACE + @ BRISTOL MYERS SQUIBB 1MG + @ 2MG ESTRADIOL MYLAN 0.5MG @ 0.5MG 1MG @ 1MG 2MG @ 2MG ESTRADIOL CYPIONATE INJECTABLE;INJECTION DEPO-ESTRADIOL @ PFIZER @ ! 1MG/ML 3MG/ML 5MG/ML N 022416 N 022416 N 022416 N 022416 001 Nov 08, 2013 002 Nov 08, 2013 003 Nov 08, 2013 004 Nov 08, 2013 Jun CFTG Jun CFTG Jun CFTG Jun CFTG A 211238 A 211238 A 211238 A 211238 001 Jun 29, 2021 002 Jun 29, 2021 003 Jun 29, 2021 004 Jun 29, 2021 Jun NFTG Jun NFTG Jun NFTG Jun NFTG A 213859 A 213859 A 090841 A 090841 A 213486 A 213486 A 210559 001 Nov 18, 2020 002 Nov 18, 2020 001 Mar 31, 2021 002 Mar 31, 2021 001 Mar 19, 2021 002 Mar 19, 2021 002 Feb 26, 2021 May DISC May DISC Mar NEWA Mar NEWA Mar NEWA Mar NEWA Feb NEWA A 204920 001 Jul 20, 2021 Jul NEWA A 204920 002 Jul 20, 2021 Jul NEWA A 086069 001 Jan 31, 1984 Aug CRLD A 209767 001 Mar 05, 2018 Aug CAHN A 212313 001 Jul 15, 2021 Jul NEWA N 020655 N 020655 N 020655 N 020655 004 Apr 05, 2002 001 Dec 20, 1996 002 Dec 20, 1996 003 Dec 20, 1996 Jul DISC Jul DISC Jul DISC Jul DISC N 020472 001 Apr 26, 1996 Jan CAHN A 211293 A 211293 A 211293 A 211293 A 211293 001 Feb 04, 2019 002 Feb 04, 2019 003 Feb 04, 2019 004 Feb 04, 2019 005 Feb 04, 2019 Sep CTEC Sep CTEC Sep CTEC Sep CTEC Sep CTEC A 084499 001 A 084500 001 Aug CRLD Aug CRLD A 040326 A 040326 A 040326 A 040326 A 040326 A 040326 001 Apr 21, 1999 001 Apr 21, 1999 002 Apr 21, 1999 002 Apr 21, 1999 003 Apr 21, 1999 003 Apr 21, 1999 Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC Oct DISC A 085470 001 A 085470 002 A 085470 003 Mar CAHN Mar CAHN Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -54 ESTRADIOL; NORETHINDRONE ACETATE TABLET;ORAL AMABELZ BX LUPIN LTD BX 0.5MG;0.1MG 1MG;0.5MG A 203339 001 Jun 20, 2016 Sep CTEC A 203339 002 Jun 20, 2016 Sep CTEC ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX TABLET;ORAL MYFEMBREE +! MYOVANT SCIENCES 1MG;0.5MG;40MG N 214846 001 May 26, 2021 May NEWA ESTROPIPATE TABLET;ORAL OGEN .625 + @ PFIZER @ OGEN 1.25 + @ PFIZER @ OGEN 2.5 + @ PFIZER @ OGEN 5 + PFIZER 0.75MG 0.75MG 1.5MG 1.5MG 3MG 3MG 6MG 6MG A 083220 001 A 083220 001 A 083220 002 A 083220 002 A 083220 003 A 083220 003 A 083220 004 A 083220 004 Aug CRLD Jan CAHN Aug CRLD Jan CAHN Aug CRLD Jan CAHN Aug CRLD Jan CAHN ESZOPICLONE TABLET;ORAL ESZOPICLONE @ NOSTRUM LABS INC 1MG @ 2MG @ 3MG A 203087 001 May 08, 2019 A 203087 002 May 08, 2019 A 203087 003 May 08, 2019 Jan CAHN Jan CAHN Jan CAHN ETHACRYNIC ACID TABLET;ORAL ETHACRYNIC ACID AB ALVOGEN 25MG A 205709 001 Jul 24, 2018 Jun CAHN ETHINYL ESTRADIOL; ETONOGESTREL RING;VAGINAL ETHINYL ESTRADIOL; ETONOGESTREL AB TEVA PHARMS USA INC 0.015MG/24HR;0.12MG/24HR A 204305 001 Jan 13, 2021 Jan NEWA ETHINYL ESTRADIOL; LEVONORGESTREL TABLET;ORAL SYLEVIA @ SUN PHARM 0.03MG;0.15MG A 202988 001 Feb 06, 2019 TABLET;ORAL-28 CERINTA @ SUN PHARM 0.02MG;0.1MG A 202817 001 Jan 07, 2019 LEVONORGESTREL AND ETHINYL ESTRADIOL BX LUPIN LTD BX 0.02MG;0.1MG A 091425 001 Jan 18, 2013 0.03MG,0.04MG,0.03MG;0.05MG,0.075M A 200248 001 Nov 19, 2015 G,0.125MG Aug DISC Aug DISC Sep CTEC Sep CTEC ETHINYL ESTRADIOL; NORELGESTROMIN FILM, EXTENDED RELEASE;TRANSDERMAL ETHINYL ESTRADIOL AND NORELGESTROMIN BX AMNEAL AB ONSURA 0.035MG/24HR;0.15MG/24HR 0.035MG/24HR;0.15MG/24HR AB TEVA PHARMS USA XULANE 0.035MG/24HR;0.15MG/24HR AB ! MYLAN TECHNOLOGIES 0.035MG/24HR;0.15MG/24HR A 213950 001 Feb 25, 2021 Sep CTEC A 213950 001 Feb 25, 2021 Feb NEWA A 213977 001 Aug 25, 2021 Aug NEWA A 200910 001 Apr 16, 2014 Feb CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -55 ETHINYL ESTRADIOL; NORETHINDRONE TABLET;ORAL-21 NORINYL 1+35 21-DAY @ ALLERGAN 0.035MG;1MG N 017565 001 TABLET;ORAL-28 CYCLAFEM 1/35 @ VINTAGE PHARMS LLC CYCLAFEM 7/7/7 0.035MG;1MG A 076337 001 Nov 12, 2010 @ VINTAGE PHARMS LLC NORINYL 1+35 28-DAY 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A 076338 001 Nov 16, 2010 MG,1MG @ ALLERGAN PIRMELLA 1/35 0.035MG;1MG N 017565 002 BX LUPIN LTD PIRMELLA 7/7/7 0.035MG;1MG A 201512 001 Apr 24, 2013 BX LUPIN LTD 0.035MG,0.035MG,0.035MG;0.5MG,0.75 A 201510 001 Apr 24, 2013 MG,1MG TABLET, CHEWABLE;ORAL NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE BX LUPIN LTD 0.035MG;0.4MG A 091332 001 Mar 23, 2016 Jul DISC Aug DISC Aug DISC Jul DISC Sep CTEC Sep CTEC Sep CTEC ETHINYL ESTRADIOL; NORETHINDRONE ACETATE CAPSULE;ORAL GEMMILY AB XIROMED 0.02MG;1MG A 213317 001 Nov 09, 2020 NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE AB AMNEAL PHARMS 0.02MG;1MG A 214292 001 Jul 20, 2021 TABLET;ORAL FEMHRT + @ APIL @ LOESTRIN 24 FE 0.0025MG;0.5MG 0.0025MG;0.5MG N 021065 001 Jan 14, 2005 N 021065 001 Jan 14, 2005 + @ TEVA BRANDED PHARM 0.02MG;1MG N 021871 001 Feb 17, 2006 TABLET;ORAL-21 GILDESS 1/20 @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 002 Jul 24, 2012 TABLET;ORAL-28 BLISOVI FE 1.5/30 BX LUPIN LTD CHABELINA FE 0.03MG;1.5MG A 201585 001 Nov 18, 2015 AB ! NOVAST LABS ESTROSTEP FE 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG A 202962 001 Apr 15, 2020 + @ APIL GILDESS FE 1/20 0.02MG,0.03MG,0.035MG;1MG,1MG,1MG N 020130 002 Oct 09, 1996 @ VINTAGE PHARMS LLC 0.02MG;1MG A 077077 001 May 20, 2005 Mar CAHN Jul NEWA Sep CRLD Sep DISC Sep DISC Jul DISC Sep CTEC Sep CHRS Sep DISC Jul DISC ETHINYL ESTRADIOL; NORGESTIMATE TABLET;ORAL-28 NORGESTIMATE AND ETHINYL ESTRADIOL >A> >A> >D> AB >D> AB @ MYLAN @ MYLAN LABS LTD 0.035MG,0.035MG,0.035MG;0.18MG,0.2 A 201897 001 Jan 27, 2016 15MG,0.25MG 0.035MG;0.25MG A 201896 001 Jan 27, 2016 0.035MG,0.035MG,0.035MG;0.18MG,0.2 A 201897 001 Jan 27, 2016 15MG,0.25MG 0.035MG;0.25MG A 201896 001 Jan 27, 2016 Oct CAHN Oct CAHN Oct CAHN Oct CAHN ETHOSUXIMIDE CAPSULE;ORAL ETHOSUXIMIDE BX HERITAGE PHARMS INC BX PURACAP PHARM LLC SYRUP;ORAL ZARONTIN AA +! PARKE-DAVIS 250MG 250MG 250MG/5ML A 200892 001 Sep 25, 2012 Sep CTEC A 210654 001 Mar 16, 2020 Sep CTEC A 080258 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -56 ETODOLAC TABLET;ORAL ETODOLAC AB BAYSHORE PHARMS LLC @ AB @ 400MG 400MG 500MG 500MG ETOMIDATE INJECTABLE;INJECTION ETOMIDATE AP CAPLIN @ 2MG/ML 2MG/ML ETRAVIRINE TABLET;ORAL ETRAVIRINE @ AMNEAL AB AB AB INTELENCE + JANSSEN R AND D AB + AB + AB +! 25MG 25MG 100MG 200MG 25MG 25MG 100MG 200MG AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB >A> AB >A> AB >A> AB >A> AB >D> >A> AB AB AB AB AB AB AB EVEROLIMUS TABLET;ORAL AFINITOR + NOVARTIS 10MG EVEROLIMUS BIOCON PHARMA @ @ @ @ BRECKENRIDGE MYLAN PAR PHARM ZORTRESS 2.5MG 2.5MG 2.5MG 5MG 5MG 5MG 7.5MG 7.5MG 7.5MG 10MG 10MG 10MG 0.25MG 0.5MG 0.75MG 2.5MG 5MG 7.5MG 10MG 10MG 0.25MG 0.5MG 0.75MG 1MG +! NOVARTIS 1MG +! 1MG TABLET, FOR SUSPENSION;ORAL AFINITOR DISPERZ + NOVARTIS PHARM 2MG + 3MG +! 5MG EVEROLIMUS MYLAN 2MG 3MG 5MG A 210704 A 210704 A 210704 A 210704 001 Dec 16, 2020 001 Dec 16, 2020 002 Dec 16, 2020 002 Dec 16, 2020 Aug CMFD Jul DISC Aug CMFD Jul DISC A 215028 001 Dec 18, 2020 Jul CMFD A 215028 001 Dec 18, 2020 Jun DISC A 214196 A 214196 A 214196 A 214196 001 Jun 14, 2021 001 Jun 14, 2021 002 Jun 14, 2021 003 Jun 14, 2021 Jul DISC Jun NFTG Jun NFTG Jun NFTG N 022187 N 022187 N 022187 N 022187 003 Mar 26, 2012 003 Mar 26, 2012 001 Jan 18, 2008 002 Dec 22, 2010 Jul CTEC Jun CFTG Jun CFTG Jun CFTG N 022334 002 Mar 30, 2009 Feb CTEC A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 214182 A 205432 A 205432 A 205432 A 205426 A 205426 A 205426 A 205426 A 212936 A 205775 A 205775 A 205775 A 205775 001 Feb 11, 2021 001 Feb 11, 2021 001 Feb 11, 2021 002 Feb 11, 2021 002 Feb 11, 2021 002 Feb 11, 2021 003 Feb 11, 2021 003 Feb 11, 2021 003 Feb 11, 2021 004 Feb 11, 2021 004 Feb 11, 2021 004 Feb 11, 2021 001 May 20, 2021 002 May 20, 2021 003 May 20, 2021 001 Mar 05, 2021 002 Mar 05, 2021 003 Mar 05, 2021 004 Mar 05, 2021 004 Jun 08, 2020 001 Oct 18, 2021 002 Oct 18, 2021 003 Oct 18, 2021 004 Oct 18, 2021 Aug CMFD Feb DISC Feb NEWA Aug CMFD Feb DISC Feb NEWA Aug CMFD Feb DISC Feb NEWA Aug CMFD Feb DISC Feb NEWA May NEWA May NEWA May NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA Aug CMFD Oct NEWA Oct NEWA Oct NEWA Oct NFTG N 021560 004 Aug 10, 2018 Oct CFTG N 021560 004 Aug 10, 2018 Oct CFTG N 203985 001 Aug 29, 2012 N 203985 002 Aug 29, 2012 N 203985 003 Aug 29, 2012 Aug CTEC Aug CTEC Aug CTEC A 210130 001 Apr 19, 2019 A 210130 002 Apr 19, 2019 A 210130 003 Apr 19, 2019 Aug CMFD Aug CMFD Aug CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -57 EXEMESTANE TABLET;ORAL AROMASIN AB +! PFIZER 25MG EXENATIDE SYNTHETIC FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS BYDUREON + @ ASTRAZENECA AB BYDUREON PEN 2MG/VIAL + @ ASTRAZENECA AB 2MG SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS BYDUREON BCISE +! ASTRAZENECA AB 2MG/0.85ML (2MG/0.85ML) EZETIMIBE TABLET;ORAL ZETIA AB +! ORGANON 10MG EZETIMIBE; ROSUVASTATIN CALCIUM TABLET;ORAL ROSZET + ALTHERA PHARMS 10MG;EQ 5MG BASE + 10MG;EQ 5MG BASE + 10MG;EQ 10MG BASE + 10MG;EQ 10MG BASE + 10MG;EQ 20MG BASE + 10MG;EQ 20MG BASE +! 10MG;EQ 40MG BASE +! 10MG;EQ 40MG BASE EZETIMIBE; SIMVASTATIN TABLET;ORAL EZETIMIBE AND SIMVASTATIN @ ANI PHARMS 10MG;10MG @ 10MG;20MG @ 10MG;40MG @ 10MG;80MG @ MYLAN 10MG;10MG @ 10MG;20MG @ 10MG;40MG @ 10MG;80MG VYTORIN AB + ORGANON AB + AB + AB +! 10MG;10MG 10MG;20MG 10MG;40MG 10MG;80MG AB AB >A> AB >A> AB >A> AB >A> AB >A> >A> >D> >D> FAMOTIDINE FOR SUSPENSION;ORAL FAMOTIDINE AKORN NOVITIUM PHARMA TABLET;ORAL FAMOTIDINE ANNORA PHARMA ASCENT PHARMS INC PEPCID + @ BAUSCH + @ + @ VALEANT PHARMS NORTH + @ 40MG/5ML 40MG/5ML 20MG 40MG 20MG 40MG 20MG 40MG 20MG 40MG N 020753 001 Oct 21, 1999 Mar CAHN N 022200 001 Jan 27, 2012 Feb DISC N 022200 002 Feb 28, 2014 Feb DISC N 209210 001 Oct 20, 2017 Aug CAIN N 021445 001 Oct 25, 2002 Feb CAHN N 213072 N 213072 N 213072 N 213072 N 213072 N 213072 N 213072 N 213072 001 Mar 23, 2021 001 Mar 23, 2021 002 Mar 23, 2021 002 Mar 23, 2021 003 Mar 23, 2021 003 Mar 23, 2021 004 Mar 23, 2021 004 Mar 23, 2021 Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA A 201890 A 201890 A 201890 A 201890 A 200082 A 200082 A 200082 A 200082 001 Apr 26, 2017 002 Apr 26, 2017 003 Apr 26, 2017 004 Apr 26, 2017 001 Dec 17, 2020 002 Dec 17, 2020 003 Dec 17, 2020 004 Dec 17, 2020 Jul DISC Jul DISC Jul DISC Jul DISC Jan DISC Jan DISC Jan DISC Jan DISC N 021687 N 021687 N 021687 N 021687 001 Jul 23, 2004 002 Jul 23, 2004 003 Jul 23, 2004 004 Jul 23, 2004 Feb CAHN Feb CAHN Feb CAHN Feb CAHN A 201995 001 May 30, 2014 Feb CAHN A 215043 001 Apr 20, 2021 Apr NEWA A 215767 A 215767 A 215689 A 215689 001 Nov 04, 2021 002 Nov 04, 2021 001 Oct 15, 2021 002 Oct 15, 2021 Oct NEWA Oct NEWA Oct NEWA Oct NEWA N 019462 N 019462 N 019462 N 019462 001 Oct 15, 1986 002 Oct 15, 1986 001 Oct 15, 1986 002 Oct 15, 1986 Oct CAHN Oct CAHN Oct CAHN Oct CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -58 AB AB >A> AB FAMOTIDINE; IBUPROFEN TABLET;ORAL DUEXIS +! HORIZON 26.6MG;800MG IBUPROFEN AND FAMOTIDINE ALKEM LABS LTD TEVA PHARMS USA 26.6MG;800MG 26.6MG;800MG FELBAMATE SUSPENSION;ORAL FELBAMATE AB NOVITIUM PHARMA 600MG/5ML FELODIPINE TABLET, EXTENDED RELEASE;ORAL FELODIPINE @ JUBILANT GENERICS 2.5MG @ 5MG @ 10MG FENOFIBRATE CAPSULE;ORAL FENOFIBRATE (MICRONIZED) AB AUROBINDO PHARMA LTD 67MG AB 134MG AB 200MG TABLET;ORAL FENOFIBRATE AB ADAPTIS 54MG AB 160MG AB AUSTARPHARMA 48MG AB 145MG FENOPROFEN CALCIUM CAPSULE;ORAL FENOPROFEN CALCIUM @ RISING @ EQ 200MG BASE EQ 300MG BASE >D> >D> AB >A> >D> >D> AB >A> >D> >D> AB >A> >D> >D> AB >A> >D> >D> AB >A> >D> >D> AB >A> >D> AB >A> AB FENTANYL FILM, EXTENDED RELEASE;TRANSDERMAL DURAGESIC-100 + JANSSEN PHARMS 100MCG/HR + @ 100MCG/HR DURAGESIC-12 + JANSSEN PHARMS + @ DURAGESIC-25 12.5MCG/HR 12.5MCG/HR +! JANSSEN PHARMS 25MCG/HR + @ 25MCG/HR DURAGESIC-37 + JANSSEN PHARMS + @ DURAGESIC-50 37.5MCG/HR 37.5MCG/HR + JANSSEN PHARMS 50MCG/HR + @ 50MCG/HR DURAGESIC-75 + JANSSEN PHARMS + @ FENTANYL-25 75MCG/HR 75MCG/HR SPECGX LLC 25MCG/HR ! 25MCG/HR FENTANYL CITRATE INJECTABLE;INJECTION FENTANYL CITRATE AP FRESENIUS KABI USA @ EQ 0.05MG BASE/ML EQ 0.05MG BASE/ML N 022519 001 Apr 23, 2011 Jul CFTG A 211890 001 Aug 03, 2021 Jul NFTG A 211278 001 Oct 29, 2021 Oct NEWA A 211333 001 May 31, 2019 Sep CAHN A 203983 001 Aug 19, 2016 A 203983 002 Aug 19, 2016 A 203983 003 Aug 19, 2016 Jun DISC Jun DISC Jun DISC A 212232 001 Sep 20, 2021 A 212232 002 Sep 20, 2021 A 212232 003 Sep 20, 2021 Sep NEWA Sep NEWA Sep NEWA A 210606 A 210606 A 208476 A 208476 001 Aug 17, 2018 002 Aug 17, 2018 001 Feb 10, 2021 002 Feb 10, 2021 Aug CAHN Aug CAHN Jan NEWA Jan NEWA A 072394 001 Oct 17, 1988 Jan CAHN A 072395 001 Oct 17, 1988 Jan CAHN N 019813 001 Aug 07, 1990 Oct DISC N 019813 001 Aug 07, 1990 Oct DISC N 019813 005 Feb 04, 2005 Oct DISC N 019813 005 Feb 04, 2005 Oct DISC N 019813 004 Aug 07, 1990 Oct DISC N 019813 004 Aug 07, 1990 Oct DISC N 019813 006 Jan 24, 2018 Oct DISC N 019813 006 Jan 24, 2018 Oct DISC N 019813 003 Aug 07, 1990 Oct DISC N 019813 003 Aug 07, 1990 Oct DISC N 019813 002 Aug 07, 1990 Oct DISC N 019813 002 Aug 07, 1990 Oct DISC A 077154 001 Feb 09, 2011 Oct CHRS A 077154 001 Feb 09, 2011 Oct CHRS A 212086 001 Sep 01, 2020 Jun CMFD A 212086 001 Sep 01, 2020 Mar DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -59 SPRAY, METERED;NASAL LAZANDA >D> + @ BTCP PHARMA EQ 0.1MG BASE >A> + EQ 0.1MG BASE + @ EQ 0.1MG BASE >D> + @ EQ 0.4MG BASE >A> +! EQ 0.4MG BASE + @ EQ 0.4MG BASE FERRIC CARBOXYMALTOSE SOLUTION;INTRAVENOUS INJECTAFER +! AM REGENT 1GM IRON/20ML (50MG IRON/ML) FERRIC MALTOL CAPSULE;ORAL ACCRUFER +! SHIELD TX 30MG IRON FERRIC OXYHYDROXIDE INJECTABLE;INJECTION DEXFERRUM @ AM REGENT FERRLECIT EQ 50MG IRON/ML AB +! SANOFI AVENTIS US AB +! INFED EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML) 62.5MG/5ML BP +! ALLERGAN IRON DEXTRAN EQ 100MG IRON/2ML (EQ 50MG IRON/ML) @ SANOFI AVENTIS US PROFERDEX EQ 50MG IRON/ML @ NEW RIVER EQ 50MG IRON/ML SODIUM FERRIC GLUCONATE COMPLEX IN SUCROSE AB WEST-WARD PHARMS INT EQ 62.5MG IRON/5ML (EQ 12.5MG IRON/ML) AB 62.5MG/5ML INJECTABLE;INTRAVENOUS VENOFER + AM REGENT + @ @ @ @ +! +! + + TABLET, CHEWABLE;ORAL VELPHORO EQ 50MG IRON/2.5ML (EQ 20MG IRON/ML) EQ 50MG BASE/2.5ML (EQ 20MG BASE/ML) EQ 65MG IRON/3.25ML (EQ 20MG IRON/ML) EQ 65MG BASE/3.25ML (EQ 20MG BASE/ML) EQ 75MG IRON/3.75ML (EQ 20MG IRON/ML) EQ 75MG BASE/3.75ML (EQ 20MG BASE/ML) EQ 100MG IRON/5ML (EQ 20MG IRON/ML) EQ 100MG BASE/5ML (EQ 20MG BASE/ML) EQ 200MG IRON/10ML (EQ 20MG IRON/ML) EQ 200MG BASE/10ML (EQ 20MG BASE/ML) +! VIFOR FRESENIUS +! EQ 500MG IRON 500MG FERUMOXYTOL SOLUTION;INTRAVENOUS FERAHEME AB +! AMAG PHARMS INC AB +! COVIS FERUMOXYTOL AB SANDOZ INC EQ 510MG IRON/17ML (EQ 30MG IRON/ML) EQ 510MG IRON/17ML (EQ 30MG IRON/ML) EQ 510MG IRON/17ML (EQ 30MG IRON/ML) N 022569 N 022569 N 022569 N 022569 N 022569 N 022569 001 Jun 30, 2011 001 Jun 30, 2011 001 Jun 30, 2011 002 Jun 30, 2011 002 Jun 30, 2011 002 Jun 30, 2011 Oct CMFD Oct CMFD Sep DISC Oct CMFD Oct CMFD Sep DISC N 203565 003 Apr 28, 2021 May NEWA N 212320 001 Jul 25, 2019 Apr CMFD N 040024 001 Feb 23, 1996 May CAIN N 020955 001 Feb 18, 1999 May CPOT N 020955 001 Feb 18, 1999 May CAIN N 017441 001 May CAIN N 010787 002 May CAIN N 017807 001 May CAIN A 078215 001 Mar 31, 2011 May CPOT A 078215 001 Mar 31, 2011 May CAIN N 021135 002 Mar 20, 2005 May CPOT N 021135 002 Mar 20, 2005 May CAIN N 021135 005 Mar 29, 2013 May CPOT N 021135 005 Mar 29, 2013 May CAIN N 021135 003 Mar 29, 2005 May CPOT N 021135 003 Mar 29, 2005 May CAIN N 021135 001 Nov 06, 2000 May CPOT N 021135 001 Nov 06, 2000 May CAIN N 021135 004 Feb 09, 2007 May CPOT N 021135 004 Feb 09, 2007 May CAIN N 205109 001 Nov 27, 2013 May CPOT N 205109 001 Nov 27, 2013 May CAIN N 022180 001 Jun 30, 2009 Jan CFTG N 022180 001 Jun 30, 2009 Mar CAHN A 206604 001 Jan 15, 2021 Jan NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -60 FEXINIDAZOLE TABLET;ORAL FEXINIDAZOLE +! DNDI +! SANOFI 600MG 600MG FINASTERIDE TABLET;ORAL FINASTERIDE @ ACTAVIS TOTOWA TEVA 5MG FINERENONE TABLET;ORAL KERENDIA + BAYER HLTHCARE +! 10MG 20MG FINGOLIMOD HYDROCHLORIDE CAPSULE;ORAL FINGOLIMOD HYDROCHLORIDE @ ALKEM LABS LTD EQ 0.5MG BASE @ APOTEX EQ 0.5MG BASE @ GLENMARK PHARMS LTD EQ 0.5MG BASE @ MYLAN EQ 0.5MG BASE AB EQ 0.5MG BASE @ STRIDES PHARMA EQ 0.5MG BASE @ SUN PHARM EQ 0.5MG BASE @ ZYDUS PHARMS EQ 0.5MG BASE FLECAINIDE ACETATE TABLET;ORAL TAMBOCOR + @ ALVOGEN + @ + @ @ + @ CNTY LINE PHARMS + @ + @ 50MG 100MG 150MG 200MG 50MG 100MG 150MG FLORBETABEN F-18 SOLUTION;INTRAVENOUS NEURACEQ >D> +! LIFE MOLECULAR >A> +! 30ML (1.4-135mCi/ML) 30ML (1.4-135mCi/ML) AP >D> AP >A> AP AP AP FLUDEOXYGLUCOSE F-18 INJECTABLE;INTRAVENOUS FLUDEOXYGLUCOSE F18 CARDINAL HEALTH 414 CPDC ISOLOGIC INNOVATIVE NUKEMED PHARMALOGIC HLDGS PRECISION NUCLEAR 20-500mCi/ML 20-300mCi/ML 20-300mCi/ML 4-500mCi/ML 20-200mCi/ML 20-500mCi/ML FLUMAZENIL INJECTABLE;INJECTION FLUMAZENIL AP BAXTER HLTHCARE CORP AP 0.5MG/5ML (0.1MG/ML) 1MG/10ML (0.1MG/ML) FLUOCINOLONE ACETONIDE CREAM;TOPICAL FLUOCINOLONE ACETONIDE @ ALLIED @ @ OIL;TOPICAL FLUOCINOLONE ACETONIDE @ AKORN 0.01% 0.025% 0.025% 0.01% N 214429 001 Jul 16, 2021 Jul NEWA N 214429 001 Jul 16, 2021 Jul CAHN A 077914 001 Mar 28, 2007 May DISC N 215341 001 Jul 09, 2021 Jul NEWA N 215341 002 Jul 09, 2021 Jul NEWA A 208004 A 207993 A 207985 A 208005 A 208005 A 207971 A 208014 A 207994 001 Dec 30, 2020 001 Dec 18, 2020 001 Jun 18, 2020 001 Jan 19, 2021 001 Jan 19, 2021 001 Jun 29, 2020 001 Dec 04, 2019 001 Oct 14, 2020 Aug DISC Jun DISC Aug DISC Jan DISC Jan NEWA Aug DISC Aug DISC Mar DISC N 018830 N 018830 N 018830 N 018830 N 018830 N 018830 N 018830 004 Aug 23, 1988 001 Oct 31, 1985 003 Jun 03, 1988 002 Oct 31, 1985 004 Aug 23, 1988 001 Oct 31, 1985 003 Jun 03, 1988 Jun CAHN Jun CAHN Jun CAHN Jun CAHN Jan DISC Jan DISC Jan DISC N 204677 001 Mar 19, 2014 Oct CAHN N 204677 001 Mar 19, 2014 Oct CAHN A 203603 A 204525 A 204525 A 203911 A 203664 A 204546 002 Sep 27, 2018 001 Oct 29, 2014 001 Oct 29, 2014 001 Apr 22, 2015 001 Feb 04, 2014 001 Apr 07, 2015 Mar NEWA Oct CAHN Oct CAHN Jan CAHN Jan CAHN Mar CTEC A 076755 002 Oct 12, 2004 Mar CMFD A 076755 001 Oct 12, 2004 Mar CMFD A 088047 001 Dec 16, 1982 A 088045 001 Dec 16, 1982 A 088045 001 Dec 16, 1982 Sep CAHN Sep CAHN Sep CAHN A 091514 001 Jun 25, 2015 Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -61 OIL;TOPICAL FLUOCINOLONE ACETONIDE AT QUAGEN 0.01% AT 0.01% AT SOLARIS PHARMA CORP 0.01% AT 0.01% OIL/DROPS;OTIC FLUOCINOLONE ACETONIDE @ AKORN 0.01% AT QUAGEN 0.01% AT SOLARIS PHARMA CORP 0.01% AT TASMAN PHARMA 0.01% SOLUTION;TOPICAL FLUOCINOLONE ACETONIDE @ ALLIED 0.01% FLUOCINONIDE CREAM;TOPICAL LIDEX + @ ALVOGEN LIDEX-E AB2 + ALVOGEN VANOS AB +! BAUSCH GEL;TOPICAL FLUOCINONIDE AB + ALVOGEN OINTMENT;TOPICAL LIDEX AB + ALVOGEN SOLUTION;TOPICAL LIDEX AT + ALVOGEN 0.05% 0.05% 0.1% 0.05% 0.05% 0.05% >A> AB AP AP AP AP AP FLUOROURACIL CREAM;TOPICAL FLUOROPLEX + @ ALMIRALL FLUOROURACIL ACCORD HLTHCARE INJECTABLE;INJECTION FLUOROURACIL FRESENIUS KABI USA @ NOVAST LABS TEVA PHARMS USA 1% 5% 500MG/10ML (50MG/ML) 1GM/20ML (50MG/ML) 2.5GM/50ML (50MG/ML) 5GM/100ML (50MG/ML) 5GM/100ML (50MG/ML) 500MG/10ML (50MG/ML) FLUOXETINE HYDROCHLORIDE CAPSULE;ORAL FLUOXETINE HYDROCHLORIDE @ ACCORD HLTHCARE EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE @ GRANULES EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE AB1 HERITAGE PHARMS INC EQ 10MG BASE AB1 EQ 20MG BASE AB EQ 40MG BASE TABLET;ORAL FLUOXETINE HYDROCHLORIDE AB +! ALMATICA EQ 60MG BASE AB ! DR REDDYS LABS LTD EQ 20MG BASE @ MYLAN EQ 10MG BASE @ EQ 20MG BASE TORRENT EQ 10MG BASE ! EQ 20MG BASE AB UPSHER SMITH LABS EQ 10MG BASE AB EQ 20MG BASE A 212760 A 212761 A 212760 A 212761 001 Apr 02, 2021 001 Apr 02, 2021 001 Apr 02, 2021 001 Apr 02, 2021 Sep CAHN Sep CAHN Mar NEWA Mar NEWA A 202705 A 212762 A 212762 A 213264 001 Sep 09, 2016 001 Apr 02, 2021 001 Apr 02, 2021 001 Feb 05, 2021 Jul DISC Sep CAHN Mar NEWA Jan NEWA A 088048 001 Dec 16, 1982 Sep CAHN N 016908 002 Jun CAHN N 016908 003 Jun CAHN N 021758 001 Feb 11, 2005 May CAHN N 017373 001 Jun CAHN N 016909 002 Jun CAHN N 018849 001 Apr 06, 1984 Jun CAHN N 016988 001 Aug DISC A 214845 001 Oct 07, 2021 Oct NEWA A 040279 A 040279 A 040278 A 040278 A 209271 A 040333 002 Sep 30, 1998 001 Sep 30, 1998 001 Sep 30, 1998 002 Sep 30, 1998 001 Dec 11, 2019 001 Jan 27, 2000 May CHRS May CHRS May CHRS May CHRS Mar CPOT May CHRS A 202729 A 202729 A 202729 A 078143 A 078143 A 078143 A 201336 A 201336 A 201336 001 Aug 27, 2020 002 Aug 27, 2020 003 Aug 27, 2020 001 Jan 16, 2008 002 Jan 16, 2008 003 Jan 16, 2008 001 Oct 01, 2012 002 Oct 01, 2012 003 Oct 01, 2012 Feb DISC Feb DISC Feb DISC Jun CAHN Jun CAHN Jun CAHN Aug CMFD Aug CMFD Aug CMFD N 202133 A 076006 A 075755 A 075755 A 206937 A 206937 A 211696 A 211696 001 Oct 06, 2011 002 Apr 23, 2018 001 Aug 02, 2001 002 Aug 02, 2001 001 Oct 21, 2016 002 Oct 21, 2016 001 Jan 30, 2019 002 Jan 30, 2019 Sep CAHN Jul CHRS Jul DISC Jul DISC Mar CHRS Mar CHRS May CAHN May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -62 TABLET;ORAL SARAFEM + @ APIL + @ EQ 10MG BASE EQ 20MG BASE FLUOXYMESTERONE TABLET;ORAL FLUOXYMESTERONE @ UPSHER SMITH LABS 10MG AB AB AB AB >A> AB >A> AB >A> AB >A> AB AB AB AB AB AB AB AB AB FLUPHENAZINE HYDROCHLORIDE TABLET;ORAL FLUPHENAZINE HYDROCHLORIDE CEROVENE INC ENALTEC NOVITIUM PHARMA ZYDUS 1MG 2.5MG 5MG 10MG 1MG 2.5MG 5MG 10MG 1MG 2.5MG 5MG 10MG 1MG 2.5MG 5MG 10MG FLURBIPROFEN SODIUM SOLUTION/DROPS;OPHTHALMIC FLURBIPROFEN SODIUM ! BAUSCH AND LOMB OCUFEN 0.03% 0.03% + @ ALLERGAN 0.03% FLUTAMIDE CAPSULE;ORAL FLUTAMIDE @ CIPLA ! PAR PHARM ! WAYLIS THERAP 125MG 125MG 125MG 125MG FLUTICASONE PROPIONATE POWDER;INHALATION ARMONAIR RESPICLICK + @ TEVA PHARM + 0.03MG/INH 0.03MG/INH FLUVASTATIN SODIUM TABLET, EXTENDED RELEASE;ORAL FLUVASTATIN SODIUM AB BEIJING EQ 80MG BASE FLUVOXAMINE MALEATE CAPSULE, EXTENDED RELEASE;ORAL FLUVOXAMINE MALEATE @ BIONPHARMA INC 100MG FOLIC ACID TABLET;ORAL FOLIC ACID AA +! WATSON LABS 1MG N 021860 001 May 19, 2006 Mar DISC N 021860 003 May 19, 2006 Mar DISC A 088342 001 Oct 21, 1983 Jan DISC A 214534 001 Jan 07, 2021 A 214534 002 Jan 07, 2021 A 214534 003 Jan 07, 2021 A 214534 004 Jan 07, 2021 A 215141 001 Oct 20, 2021 A 215141 002 Oct 20, 2021 A 215141 003 Oct 20, 2021 A 215141 004 Oct 20, 2021 A 214674 001 Mar 01, 2021 A 214674 002 Mar 01, 2021 A 214674 003 Mar 01, 2021 A 214674 004 Mar 01, 2021 A 214552 001 May 27, 2021 A 214552 002 May 27, 2021 A 214552 003 May 27, 2021 A 214552 004 May 27, 2021 Jan NEWA Jan NEWA Jan NEWA Jan NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA Feb NEWA Feb NEWA Feb NEWA Feb NEWA May NEWA May NEWA May NEWA May NEWA A 074447 001 Jan 04, 1995 Jan CHRS A 074447 001 Jan 04, 1995 Jan CTEC N 019404 001 Dec 31, 1986 Jan DISC A 075780 A 075298 A 075298 A 075298 001 Sep 19, 2001 001 Sep 18, 2001 001 Sep 18, 2001 001 Sep 18, 2001 Mar DISC Mar CHRS Mar CTEC Jun CAHN N 208798 007 Jul 09, 2021 Sep DISC N 208798 007 Jul 09, 2021 Jul NEWA A 209397 001 Apr 26, 2021 Apr NEWA A 212182 002 Sep 16, 2020 Feb DISC A 080680 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -63 FORMOTEROL FUMARATE SOLUTION;INHALATION FORMOTEROL FUMARATE AN TEVA PHARMS USA INC PERFOROMIST AN +! MYLAN SPECLT 0.02MG/2ML 0.02MG/2ML A 091141 001 Jun 22, 2021 Jun NFTG N 022007 001 May 11, 2007 Jun CFTG FORMOTEROL FUMARATE; MOMETASONE FUROATE AEROSOL, METERED;INHALATION DULERA + ORGANON 0.005MG/INH;0.05MG/INH +! 0.005MG/INH;0.1MG/INH +! 0.005MG/INH;0.2MG/INH N 022518 003 Aug 12, 2019 N 022518 001 Jun 22, 2010 N 022518 002 Jun 22, 2010 Jun CAHN Jun CAHN Jun CAHN FOSAPREPITANT DIMEGLUMINE POWDER;INTRAVENOUS FOSAPREPITANT DIMEGLUMINE AP ASPIRO EQ 150MG BASE/VIAL @ MYLAN LABS LTD EQ 115MG BASE/VIAL AP PRAXGEN EQ 150MG BASE/VIAL AP EQ 150MG BASE/VIAL A 214616 A 204015 A 211624 A 213199 001 Jul 29, 2021 001 Sep 05, 2019 001 Sep 05, 2019 001 Oct 04, 2021 Jul NEWA Mar DISC Jun CAHN Sep NEWA FOSCARNET SODIUM INJECTABLE;INJECTION FOSCARNET SODIUM AP FRESENIUS KABI USA AP GLAND PHARMA LTD FOSCAVIR AP +! CLINIGEN HLTHCARE 2.4GM/100ML 2.4GM/100ML 2.4GM/100ML A 212483 001 Jan 29, 2021 Jan NEWA A 213001 001 Apr 21, 2021 Apr NEWA N 020068 001 Sep 27, 1991 Jan CTEC FOSDENOPTERIN HYDROBROMIDE POWDER;INTRAVENOUS NULIBRY +! ORIGIN EQ 9.5MG BASE/VIAL N 214018 001 Feb 26, 2021 Feb NEWA >A> AA FOSFOMYCIN TROMETHAMINE FOR SOLUTION;ORAL FOSFOMYCIN TROMETHAMINE ALKEM LABS LTD EQ 3GM BASE/PACKET A 214554 001 Oct 21, 2021 Oct NEWA FOSINOPRIL SODIUM TABLET;ORAL FOSINOPRIL SODIUM AB CHARTWELL RX AB AB 10MG 20MG 40MG A 076483 001 Apr 23, 2004 A 076483 002 Apr 23, 2004 A 076483 003 Apr 23, 2004 Aug CAHN Aug CAHN Aug CAHN FOSPHENYTOIN SODIUM SOLUTION;INTRAVENOUS SESQUIENT + @ SEDOR PHARMS LLC + @ EQ 100MG PHENYTOIN NA/2ML (EQ 50MG PHENYTOIN NA/ML) EQ 500MG PHENYTOIN NA/10ML (EQ 50MG PHENYTOIN NA/ML) N 210864 N 210864 001 Nov 05, 2020 002 Nov 05, 2020 Jul DISC Jul DISC FULVESTRANT INJECTABLE;INTRAMUSCULAR FULVESTRANT AO APOTEX AO AUROMEDICS PHARMA AO CHEMO RESEARCH SL AO EUGIA PHARMA AO XIROMED AO ZYDUS PHARMS 50MG/ML 50MG/ML 50MG/ML 50MG/ML 50MG/ML 50MG/ML A 211730 A 208811 A 213553 A 208811 A 213553 A 215234 001 Jun 11, 2021 001 Jul 23, 2019 001 Aug 13, 2021 001 Jul 23, 2019 001 Aug 13, 2021 001 Jul 29, 2021 Jun NEWA Jan CAHN Aug NEWA Aug CAHN Aug CAHN Jul NEWA FUROSEMIDE INJECTABLE;INJECTION FUROSEMIDE AP ACCORD HLTHCARE AP ATHENEX INC @ HIKMA 10MG/ML 10MG/ML 10MG/ML A 070017 001 Dec 15, 1986 A 214766 001 Jan 27, 2021 N 018267 001 Apr CMFD Jan NEWA Jun CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -64 INJECTABLE;INJECTION FUROSEMIDE @ HIKMA PHARMS TABLET;ORAL LASIX AB + VALIDUS PHARMS AB + AB +! 10MG/ML 20MG 40MG 80MG GABAPENTIN CAPSULE;ORAL GABAPENTIN AB ASCENT PHARMS INC AB AB AB GRAVITI PHARMS AB AB AB ZHEJIANG YONGTAI @ AB @ AB @ SOLUTION;ORAL GABAPENTIN @ NOVITIUM PHARMA TABLET;ORAL GABAPENTIN AB ASCENT PHARMS INC AB 100MG 300MG 400MG 100MG 300MG 400MG 100MG 100MG 300MG 300MG 400MG 400MG 250MG/5ML 600MG 800MG GALANTAMINE HYDROBROMIDE TABLET;ORAL GALANTAMINE HYDROBROMIDE AB ! YABAO PHARM RAZADYNE EQ 4MG BASE + @ JANSSEN PHARMS + @ + @ EQ 4MG BASE EQ 8MG BASE EQ 12MG BASE GANCICLOVIR SODIUM INJECTABLE;INJECTION CYTOVENE + @ CHEPLAPHARM GANCICLOVIR SODIUM AP ! PHARMASCIENCE INC EQ 500MG BASE/VIAL EQ 500MG BASE/VIAL AT >A> AT GATIFLOXACIN SOLUTION/DROPS;OPHTHALMIC GATIFLOXACIN AKORN @ MYLAN TORRENT 0.5% 0.5% 0.5% GEMCITABINE HYDROCHLORIDE INJECTABLE;INJECTION GEMCITABINE HYDROCHLORIDE AP HIKMA INTL PHARMS EQ 200MG BASE/VIAL AP EQ 1GM BASE/VIAL AP ! JIANGSU HANSOH PHARM EQ 200MG BASE/VIAL AP ! EQ 1GM BASE/VIAL AP MEITHEAL 200MG/5.26ML (38MG/ML) AP 1GM/26.3ML (38MG/ML) AP 2GM/52.6ML (38MG/ML) GEMZAR + @ LILLY + @ EQ 200MG BASE/VIAL EQ 1GM BASE/VIAL N 018267 001 N 016273 002 N 016273 001 N 016273 003 Jul CAHN Feb CAHN Feb CAHN Feb CAHN A 214956 001 May 10, 2021 A 214956 002 May 10, 2021 A 214956 003 May 10, 2021 A 207099 001 Mar 24, 2017 A 207099 002 Mar 24, 2017 A 207099 003 Mar 24, 2017 A 213603 001 Aug 17, 2020 A 213603 001 Aug 17, 2020 A 213603 002 Aug 17, 2020 A 213603 002 Aug 17, 2020 A 213603 003 Aug 17, 2020 A 213603 003 Aug 17, 2020 Apr NEWA Apr NEWA Apr NEWA Jun CAHN Jun CAHN Jun CAHN Apr CMFD Feb DISC Apr CMFD Feb DISC Apr CMFD Feb DISC A 211330 001 Dec 03, 2019 Sep CAHN A 214957 001 Oct 01, 2021 Sep NEWA A 214957 002 Oct 01, 2021 Sep NEWA A 077604 001 Feb 06, 2009 May CHRS N 021169 001 Feb 28, 2001 N 021169 002 Feb 28, 2001 N 021169 003 Feb 28, 2001 May DISC May DISC May DISC N 019661 001 Jun 23, 1989 Jul DISC A 207645 001 Dec 08, 2017 Jul CHRS A 203189 001 Sep 03, 2014 A 206446 001 Jun 08, 2018 A 213542 001 Nov 03, 2021 Feb CAHN Jun DISC Oct NEWA A 206617 A 206617 A 202485 A 202485 A 212129 A 212129 A 212129 001 Jun 25, 2021 002 Jun 25, 2021 001 May 07, 2013 002 May 07, 2013 001 Dec 11, 2020 002 Dec 11, 2020 003 Dec 11, 2020 Jun NEWA Jun NEWA Feb CHRS Feb CHRS Jan CAHN Jan CAHN Jan CAHN N 020509 001 May 15, 1996 Feb DISC N 020509 002 May 15, 1996 Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -65 GEMFIBROZIL TABLET;ORAL GEMFIBROZIL AB ASCENT PHARMS INC 600MG GLECAPREVIR; PIBRENTASVIR PELLETS;ORAL MAVYRET +! ABBVIE INC 50MG;20MG/PACKET GLIPIZIDE TABLET;ORAL GLUCOTROL + @ PFIZER 2.5MG GLYBURIDE TABLET;ORAL GLYBURIDE AB1 SUNNY AB1 AB1 GLYNASE AB + PFIZER AB + + @ AB +! MICRONASE + @ PFIZER @ + @ 1.25MG 2.5MG 5MG 1.5MG 3MG 4.5MG 6MG 1.25MG 2.5MG 5MG AP AP AP >A> AP AP >A> AP >D> >A> >D> >A> >D> >A> >D> >A> AA AA AA AA GLYCOPYRROLATE INJECTABLE;INJECTION GLYCOPYRROLATE ATHENEX INC HONG KONG MEITHEAL NIVAGEN PHARMS INC XIROMED ZYDUS PHARMS ROBINUL 0.2MG/ML 0.2MG/ML 0.2MG/ML 0.2MG/ML 0.2MG/ML 0.2MG/ML + @ HIKMA PHARMS 0.2MG/ML SOLUTION;INTRAMUSCULAR, INTRAVENOUS GLYRX-PF EXELA PHARMA +! +! +! +! 0.2MG/ML (0.2MG/ML) 0.2MG/ML (0.2MG/ML) 0.4MG/2ML (0.2MG/ML) 0.4MG/2ML (0.2MG/ML) 0.6MG/3ML (0.2MG/ML) 0.6MG/3ML (0.2MG/ML) 1MG/5ML (0.2MG/ML) 1MG/5ML (0.2MG/ML) SOLUTION;ORAL CUVPOSA +! MERZ PHARMS GLYCOPYRROLATE 1MG/5ML PAR PHARM INC 1MG/5ML TABLET;ORAL ROBINUL + CASPER PHARMA LLC 1MG ROBINUL FORTE + CASPER PHARMA LLC 2MG GLYCOPYRRONIUM TOSYLATE CLOTH;TOPICAL QBREXZA +! JOURNEY EQ 2.4% BASE A 214603 001 Jan 13, 2021 Jan NEWA N 215110 001 Jun 10, 2021 Jun NEWA N 017783 003 May 11, 1993 Aug CRLD A 203581 001 Apr 14, 2016 A 203581 002 Apr 14, 2016 A 203581 003 Apr 14, 2016 Sep CAHN Sep CAHN Sep CAHN N 020051 N 020051 N 020051 N 020051 001 Mar 04, 1992 002 Mar 04, 1992 003 Sep 24, 1993 004 Sep 24, 1993 Feb CAHN Feb CAHN Feb CAHN Feb CAHN N 017498 001 May 01, 1984 N 017498 002 May 01, 1984 N 017498 003 May 01, 1984 Feb CAHN Feb CAHN Feb CAHN A 210083 A 212802 A 212802 A 212591 A 212227 A 214213 001 Feb 21, 2020 001 Jul 06, 2021 001 Jul 06, 2021 001 Oct 13, 2021 001 Mar 04, 2021 001 Nov 09, 2021 Jan CAHN Jun NEWA Sep CAHN Oct NEWA Feb NEWA Oct NEWA N 017558 001 Jul CAHN N 210997 N 210997 N 210997 N 210997 N 210997 N 210997 N 210997 N 210997 001 Jul 11, 2018 001 Jul 11, 2018 002 Jul 11, 2018 002 Jul 11, 2018 004 Dec 14, 2020 004 Dec 14, 2020 003 Apr 09, 2020 003 Apr 09, 2020 Oct CHRS Oct CHRS Oct CHRS Oct CHRS Oct CHRS Oct CHRS Oct CHRS Oct CHRS N 022571 001 Jul 28, 2010 Jul CFTG A 204438 001 Aug 09, 2021 Jul NFTG N 012827 001 N 012827 002 Jun CMFD Jun CMFD N 210361 001 Jun 28, 2018 May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -66 GONADORELIN HYDROCHLORIDE INJECTABLE;INJECTION FACTREL @ HIKMA PHARMS @ @ EQ 0.1MG BASE/VIAL EQ 0.2MG BASE/VIAL EQ 0.5MG BASE/VIAL GRANISETRON HYDROCHLORIDE SOLUTION;ORAL GRANISOL @ INTRA SANA LABS EQ 2MG BASE/10ML GUANABENZ ACETATE TABLET;ORAL GUANABENZ ACETATE @ CHARTWELL RX @ EQ 4MG BASE EQ 8MG BASE GUANFACINE HYDROCHLORIDE TABLET;ORAL GUANFACINE HYDROCHLORIDE AB ! AMNEAL PHARM @ MYLAN @ AB UNICHEM AB EQ 2MG BASE EQ 1MG BASE EQ 2MG BASE EQ 1MG BASE EQ 2MG BASE TABLET, EXTENDED RELEASE;ORAL GUANFACINE HYDROCHLORIDE @ YICHANG HUMANWELL @ @ @ EQ 1MG BASE EQ 2MG BASE EQ 3MG BASE EQ 4MG BASE HALCINONIDE CREAM;TOPICAL HALCINONIDE AB GLASSHOUSE PHARMS SOLUTION;TOPICAL HALOG +! SUN PHARM INDS INC 0.1% 0.1% HALOBETASOL PROPIONATE OINTMENT;TOPICAL HALOBETASOL PROPIONATE @ COSETTE ULTRAVATE + @ SUN PHARM INDS INC 0.05% 0.05% HALOPERIDOL TABLET;ORAL HALOPERIDOL AB CYCLE PHARMS LTD AB AB 2MG 5MG 10MG HALOPERIDOL DECANOATE INJECTABLE;INJECTION HALOPERIDOL DECANOATE AO HONG KONG AO AO MEITHEAL AO EQ 50MG BASE/ML EQ 100MG BASE/ML EQ 50MG BASE/ML EQ 100MG BASE/ML HALOPERIDOL LACTATE CONCENTRATE;ORAL HALDOL + @ ORTHO MCNEIL EQ 2MG BASE/ML N 018123 001 Sep 30, 1982 N 018123 002 Sep 30, 1982 N 018123 003 Sep 30, 1982 Jul CAHN Jul CAHN Jul CAHN A 078334 001 Feb 28, 2008 Jan CAHN A 074517 001 Sep 30, 1998 Aug CAHN A 074517 002 Sep 30, 1998 Aug CAHN A 075109 A 074796 A 074796 A 214689 A 214689 002 Nov 25, 1998 001 Jan 27, 1997 002 Jan 27, 1997 001 Mar 03, 2021 002 Mar 03, 2021 Jan CHRS Jan DISC Jan DISC Feb NEWA Feb NEWA A 213428 A 213428 A 213428 A 213428 001 Nov 25, 2020 002 Nov 25, 2020 003 Nov 25, 2020 004 Nov 25, 2020 May DISC May DISC May DISC May DISC A 214723 001 Sep 08, 2021 Aug NEWA N 017823 001 Apr CRLD A 077721 001 Sep 07, 2006 Mar DISC N 019968 001 Dec 17, 1990 Mar DISC A 071130 001 Feb 17, 1987 A 071131 001 Feb 17, 1987 A 071132 001 May 12, 1987 Apr CMFD Apr CMFD Apr CMFD A 214507 A 214507 A 214507 A 214507 001 Jul 26, 2021 002 Jul 26, 2021 001 Jul 26, 2021 002 Jul 26, 2021 Jul NEWA Jul NEWA Sep CAHN Sep CAHN N 015922 001 Mar CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -67 HEPARIN SODIUM INJECTABLE;INJECTION HEPARIN SODIUM @ BE PHARMS 1,000 UNITS/ML A 214804 001 Dec 29, 2020 AP +! HIKMA PHARMS 1,000 UNITS/ML N 017037 001 AP +! 5,000 UNITS/ML N 017037 002 @ 5,000 UNITS/0.5ML N 017037 013 Apr 07, 1986 AP +! 10,000 UNITS/ML N 017037 003 @ NANJING KING-FRIEND 5,000 UNITS/ML A 212061 001 Jul 15, 2020 HEPARIN SODIUM 1,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 200 UNITS/100ML A 212441 001 Jul 24, 2020 @ 200 UNITS/100ML A 212441 001 Jul 24, 2020 HEPARIN SODIUM 2,000 UNITS IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER AP FRESENIUS KABI USA 200 UNITS/100ML A 212441 002 Jul 24, 2020 @ 200 UNITS/100ML HEPARIN SODIUM PRESERVATIVE FREE A 212441 002 Jul 24, 2020 @ NANJING KING-FRIEND 10,000 UNITS/ML A 212060 001 Apr 02, 2020 @ SHENZHEN TECHDOW 1,000 UNITS/ML A 202732 001 Jun 12, 2014 Jun DISC Jul CAHN Jul CAHN Jul CAHN Jul CAHN Aug DISC Apr CMFD Jan DISC Apr CMFD Jan DISC Aug DISC Apr DISC HISTRELIN ACETATE IMPLANT;SUBCUTANEOUS VANTAS + @ ENDO PHARM 50MG N 021732 001 Oct 12, 2004 Sep DISC HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE TABLET;ORAL HYCODAN AA + GENUS 1.5MG;5MG N 005213 001 Jul 26, 1988 Sep CMFD HYDRALAZINE HYDROCHLORIDE TABLET;ORAL HYDRALAZINE HYDROCHLORIDE AA +! PLIVA 25MG AA +! 50MG @ UPSHER SMITH LABS 10MG AA 10MG @ 25MG AA 25MG @ 50MG AA 50MG @ 100MG AA 100MG A 088467 A 088468 A 209251 A 209251 A 209251 A 209251 A 209251 A 209251 A 209251 A 209251 001 May 01, 1984 001 May 01, 1984 001 Jul 09, 2018 001 Jul 09, 2018 002 Jul 09, 2018 002 Jul 09, 2018 003 Jul 09, 2018 003 Jul 09, 2018 004 Jul 09, 2018 004 Jul 09, 2018 Aug CRLD Aug CRLD Aug DISC May CAHN Aug DISC May CAHN Aug DISC May CAHN Aug DISC May CAHN HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE CAPSULE;ORAL APRESAZIDE + @ NOVARTIS 25MG;25MG + @ 50MG;50MG A 084735 001 A 084810 001 Aug CRLD Aug CRLD HYDROCHLOROTHIAZIDE CAPSULE;ORAL MICROZIDE AB +! TEVA BRANDED PHARM SOLUTION;ORAL HYDROCHLOROTHIAZIDE + @ ROXANE TABLET;ORAL HYDROCHLOROTHIAZIDE AB + IVAX SUB TEVA PHARMS AB +! + @ 12.5MG 50MG/5ML 25MG 50MG 100MG N 020504 001 Dec 27, 1996 Mar CAHN A 088587 001 Jul 02, 1984 Aug CRLD A 083177 001 A 083177 002 A 085022 001 Aug CRLD Aug CRLD Aug CRLD HYDROCHLOROTHIAZIDE; LISINOPRIL TABLET;ORAL ZESTORETIC AB + ALMATICA 12.5MG;10MG AB +! 12.5MG;20MG AB +! 25MG;20MG N 019888 003 Nov 18, 1993 N 019888 001 Sep 20, 1990 N 019888 002 Jul 20, 1989 Jan CAHN Jan CAHN Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -68 HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM TABLET;ORAL HYZAAR AB + ORGANON 12.5MG;50MG AB + 25MG;100MG LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE AB JUBILANT CADISTA 12.5MG;50MG AB 12.5MG;100MG AB 25MG;100MG HYDROCHLOROTHIAZIDE; METHYLDOPA TABLET;ORAL METHYLDOPA AND HYDROCHLOROTHIAZIDE @ CHARTWELL RX 15MG;250MG @ 25MG;250MG @ 30MG;500MG @ 50MG;500MG @ MYLAN 15MG;250MG @ 25MG;250MG HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL DUTOPROL + @ CONCORDIA 12.5MG;EQ 25MG TARTRATE + @ 12.5MG;EQ 50MG TARTRATE + @ 12.5MG;EQ 100MG TARTRATE HYDROCHLOROTHIAZIDE; METOPROLOL TARTRATE TABLET;ORAL LOPRESSOR HCT AB + VALIDUS PHARMS 25MG;50MG + @ 25MG;100MG + @ 50MG;100MG HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE @ ANI PHARMS 25MG;40MG @ MYLAN 25MG;40MG @ 25MG;40MG @ 25MG;80MG @ 25MG;80MG HYDROCHLOROTHIAZIDE; SPIRONOLACTONE TABLET;ORAL SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE @ CHARTWELL RX 25MG;25MG HYDROCHLOROTHIAZIDE; VALSARTAN TABLET;ORAL VALSARTAN AND HYDROCHLOROTHIAZIDE @ CADILA 12.5MG;80MG @ 12.5MG;160MG @ 12.5MG;320MG @ 25MG;160MG @ 25MG;320MG >D> AB >A> >D> AB >A> >D> AB >A> >D> AB >A> >D> AB >A> >D> AB HYDROCODONE BITARTRATE CAPSULE, EXTENDED RELEASE;ORAL HYDROCODONE BITARTRATE ALVOGEN 10MG ! 10MG 15MG 15MG 20MG 20MG 30MG 30MG 40MG 40MG 50MG N 020387 001 Apr 28, 1995 Aug CMFD N 020387 002 Nov 10, 1998 Aug CMFD A 201845 001 Sep 18, 2012 A 201845 002 Sep 18, 2012 A 201845 003 Sep 18, 2012 Jun CAHN Jun CAHN Jun CAHN A 070182 A 070183 A 070543 A 070544 A 070265 A 070265 001 Jan 15, 1986 001 Jan 15, 1986 001 Jan 15, 1986 001 Jan 15, 1986 002 Jan 23, 1986 001 Jan 23, 1986 Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep DISC Sep DISC N 021956 001 Aug 28, 2006 N 021956 002 Aug 28, 2006 N 021956 003 Aug 28, 2006 Jun DISC Jun DISC Jun DISC N 018303 001 Dec 31, 1984 N 018303 002 Dec 31, 1984 N 018303 003 Dec 31, 1984 Feb CAHN Feb CAHN Feb CAHN A 070705 A 070947 A 070947 A 070947 A 070947 002 Oct 01, 1986 002 Mar 04, 1987 002 Mar 04, 1987 001 Apr 01, 1987 001 Apr 01, 1987 Jul CMS1 Aug CAHN Aug DISC Aug CAHN Aug DISC A 086881 001 Sep CAHN A 203000 A 203000 A 203000 A 203000 A 203000 001 Mar 15, 2019 002 Mar 15, 2019 003 Mar 15, 2019 004 Mar 15, 2019 005 Mar 15, 2019 Aug CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 A 206986 001 Jan 21, 2020 001 Jan 21, 2020 002 Jan 21, 2020 002 Jan 21, 2020 003 Jan 21, 2020 003 Jan 21, 2020 004 Jan 21, 2020 004 Jan 21, 2020 005 Jan 21, 2020 005 Jan 21, 2020 006 Jan 21, 2020 Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -69 >A> >D> >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB >D> AB >A> AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB CAPSULE, EXTENDED RELEASE;ORAL HYDROCODONE BITARTRATE 50MG ZOHYDRO ER +! RECRO GAINESVILLE 10MG + @ 10MG +! 10MG + 15MG + @ 15MG + 15MG + 20MG + @ 20MG + 20MG + 30MG + @ 30MG + 30MG + 40MG + @ 40MG + 40MG + 50MG + @ 50MG + 50MG TABLET, EXTENDED RELEASE;ORAL HYDROCODONE BITARTRATE ALVOGEN PINE BROOK 20MG 30MG 40MG 60MG 80MG 100MG 120MG HYSINGLA ER +! PURDUE PHARMA LP 20MG + 30MG + 40MG + 60MG + 80MG + 100MG + 120MG HYDROCODONE BITARTRATE; IBUPROFEN TABLET;ORAL HYDROCODONE BITARTRATE AND IBUPROFEN AB NOSTRUM LABS INC AB AB REPREXAIN 5MG;200MG 7.5MG;200MG 10MG;200MG 10MG;200MG @ AMNEAL PHARMS NY @ 2.5MG;200MG 10MG;200MG HYDROCORTISONE CREAM;TOPICAL HYTONE + @ VALEANT INTL + @ SYNACORT @ BAUSCH + @ @ + @ @ ENEMA;RECTAL COLOCORT AB CHARTWELL LOTION;TOPICAL HYTONE + @ VALEANT INTL + @ OINTMENT;TOPICAL HYDROCORTISONE AT +! FOUGERA PHARMS 1% 2.5% 0.5% 1% 1% 2.5% 2.5% 100MG/60ML 1% 2.5% 1% A 206986 006 Jan 21, 2020 Oct CTEC N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 N 202880 001 Oct 25, 2013 001 Oct 25, 2013 001 Oct 25, 2013 002 Oct 25, 2013 002 Oct 25, 2013 002 Oct 25, 2013 003 Oct 25, 2013 003 Oct 25, 2013 003 Oct 25, 2013 004 Oct 25, 2013 004 Oct 25, 2013 004 Oct 25, 2013 005 Oct 25, 2013 005 Oct 25, 2013 005 Oct 25, 2013 006 Oct 25, 2013 006 Oct 25, 2013 006 Oct 25, 2013 Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN A 208269 A 208269 A 208269 A 208269 A 208269 A 208269 A 208269 001 Mar 01, 2021 002 Mar 01, 2021 003 Mar 01, 2021 004 Mar 01, 2021 005 Mar 01, 2021 006 Mar 01, 2021 007 Mar 01, 2021 Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG Feb NFTG N 206627 N 206627 N 206627 N 206627 N 206627 N 206627 N 206627 001 Nov 20, 2014 002 Nov 20, 2014 003 Nov 20, 2014 004 Nov 20, 2014 005 Nov 20, 2014 006 Nov 20, 2014 007 Nov 20, 2014 Feb CFTG Feb CFTG Feb CFTG Feb CFTG Feb CFTG Feb CFTG Feb CFTG A 077727 A 077723 A 077723 A 077723 001 Nov 06, 2006 001 Nov 06, 2006 002 Nov 06, 2006 002 Nov 06, 2006 Jan CAHN Jan CAHN Mar CTEC Jan CAHN A 076642 003 Oct 19, 2007 Mar DISC A 076642 004 Oct 19, 2007 Mar DISC A 080472 003 A 080472 004 A 087459 001 A 087458 001 A 087458 001 A 087457 001 A 087457 001 Aug CRLD Aug CRLD May CAHN Aug CRLD May CAHN Aug CRLD May CAHN A 075172 001 Dec 03, 1999 Apr CAHN A 080473 003 Aug CRLD A 080473 004 Nov 30, 1982 Aug CRLD A 080692 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -70 OINTMENT;TOPICAL HYTONE + @ DERMIK LABS + @ SOLUTION;TOPICAL PENECORT + @ ALLERGAN HERBERT 1% 2.5% 1% HYDROCORTISONE ACETATE CREAM;TOPICAL CARMOL HC + @ FOUGERA PHARMS 1% HYDROCORTISONE ACETATE + @ PUREPAC PHARM 1% HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE CREAM;TOPICAL CORTISPORIN + @ MONARCH PHARMS 0.5%;EQ 3.5MG BASE/GM;10,000 UNITS/GM HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE AEROSOL, METERED;TOPICAL PROCTOFOAM HC BX +! MYLAN SPECIALITY LP 1%;1% BX + 1%;1% HYDROCORTISONE PROBUTATE CREAM;TOPICAL PANDEL +! ANI PHARMS 0.1% HYDROCORTISONE SODIUM PHOSPHATE INJECTABLE;INJECTION HYDROCORTONE + @ MERCK EQ 50MG BASE/ML AB >A> AB HYDROCORTISONE VALERATE CREAM;TOPICAL HYDROCORTISONE VALERATE COSETTE ENCUBE ETHICALS 0.2% 0.2% >D> AB >D> AB >D> AB >D> AB >A> AB >A> AB >A> AB >A> AB HYDROMORPHONE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL HYDROMORPHONE HYDROCHLORIDE OSMOTICA 8MG 12MG 16MG ! 32MG OSMOTICA PHARM US 8MG 12MG 16MG ! 32MG HYDROXYCHLOROQUINE SULFATE TABLET;ORAL HYDROXYCHLOROQUINE SULFATE ACCORD HLTHCARE 100MG 300MG 400MG AB SENORES PHARMS 200MG HYDROXYPROGESTERONE CAPROATE SOLUTION;INTRAMUSCULAR MAKENA AP1 +! COVIS 1250MG/5ML (250MG/ML) MAKENA PRESERVATIVE FREE AP +! COVIS 250MG/ML (250MG/ML) A 080474 003 A 080474 004 Aug CRLD Aug CRLD A 088214 001 Jun 06, 1984 Aug CRLD A 080505 001 A 086052 001 Aug CRLD Aug CRLD N 050218 001 Aug 09, 1985 Jul DISC A 086195 001 A 086195 001 Aug CHRS Aug CRLD N 020453 001 Feb 28, 1997 Apr CAHN N 012052 001 Feb CRLD A 213724 001 Feb 11, 2021 Feb NEWA A 211047 001 Nov 04, 2021 Oct NEWA A 205629 A 205629 A 205629 A 205629 A 205629 A 205629 A 205629 A 205629 001 Jul 07, 2016 002 Jul 07, 2016 003 Jul 07, 2016 004 Jul 07, 2016 001 Jul 07, 2016 002 Jul 07, 2016 003 Jul 07, 2016 004 Jul 07, 2016 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 213342 A 213342 A 213342 A 212902 002 Aug 18, 2021 003 Aug 18, 2021 004 Aug 18, 2021 001 May 14, 2020 Aug NEWA Aug NEWA Aug NEWA Jul CAHN N 021945 001 Feb 03, 2011 Mar CAHN N 021945 002 Feb 19, 2016 Mar CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -71 SOLUTION;SUBCUTANEOUS MAKENA (AUTOINJECTOR) +! COVIS 275MG/1.1ML (250MG/ML) HYDROXYUREA TABLET;ORAL SIKLOS +! ADDMEDICA SAS 1GM HYDROXYZINE HYDROCHLORIDE SYRUP;ORAL HYDROXYZINE HYDROCHLORIDE AA +! WOCKHARDT BIO AG 10MG/5ML TABLET;ORAL HYDROXYZINE HYDROCHLORIDE AB BIOPHARM AB AB AB +! PLIVA AB +! AB +! AB PRINSTON INC AB 10MG 25MG 50MG 10MG 25MG 50MG 10MG 25MG HYDROXYZINE PAMOATE CAPSULE;ORAL HYDROXYZINE PAMOATE BX HERITAGE PHARMA BX EQ 25MG HYDROCHLORIDE EQ 50MG HYDROCHLORIDE IBANDRONATE SODIUM INJECTABLE;INTRAVENOUS IBANDRONATE SODIUM AP NANG KUANG PHARM CO EQ 3MG BASE/3ML IBREXAFUNGERP CITRATE TABLET;ORAL BREXAFEMME +! SCYNEXIS EQ 150MG BASE IBRUTINIB CAPSULE;ORAL IBRUTINIB @ ZYDUS AB @ AB IMBRUVICA + PHARMACYCLICS INC AB + +! AB +! 70MG 70MG 140MG 140MG 70MG 70MG 140MG 140MG IBUPROFEN SUSPENSION;ORAL IBUPROFEN AB PADAGIS US TABLET;ORAL IBUPROFEN AB ALKEM LABS LTD AB AB AB L PERRIGO CO AB AB @ VINTAGE PHARMS 100MG/5ML 400MG 600MG 800MG 400MG 600MG 800MG 400MG N 021945 004 Feb 14, 2018 Mar CAHN N 208843 002 Dec 21, 2017 Mar CHRS A 087294 001 Apr 12, 1982 Aug CRLD A 040804 001 Jun 30, 2008 A 040804 002 Jun 30, 2008 A 040804 003 Jun 30, 2008 A 088617 001 Jan 10, 1986 A 088618 001 Jan 10, 1986 A 088619 001 Jan 10, 1986 A 040580 003 May 27, 2005 A 040580 002 May 27, 2005 Sep CAHN Sep CAHN Sep CAHN Aug CRLD Aug CRLD Aug CRLD Feb CMS1 Feb CMS1 A 201507 001 Jun 03, 2013 Sep CTEC A 201507 002 Jun 03, 2013 Sep CTEC A 204329 001 Jun 16, 2021 Jun NEWA N 214900 001 Jun 01, 2021 Jun NEWA A 211344 A 211344 A 211344 A 211344 001 Mar 31, 2021 001 Mar 31, 2021 002 Mar 31, 2021 002 Mar 31, 2021 Jul DISC Mar NFTG Jul DISC Mar NFTG N 205552 N 205552 N 205552 N 205552 002 Dec 20, 2017 002 Dec 20, 2017 001 Nov 13, 2013 001 Nov 13, 2013 Jul CTEC Mar CFTG Jul CTEC Mar CFTG A 076925 001 Sep 23, 2004 Jul CAHN A 214699 A 214699 A 214699 A 077114 A 077114 A 077114 A 071644 001 Sep 13, 2021 002 Sep 13, 2021 003 Sep 13, 2021 001 Jul 18, 2005 002 Jul 18, 2005 003 Jul 18, 2005 001 Feb 01, 1988 Sep NEWA Sep NEWA Sep NEWA Jul CAHN Jul CAHN Jul CAHN Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -72 IBUTILIDE FUMARATE INJECTABLE;INJECTION CORVERT AP +! PFIZER 0.1MG/ML N 020491 001 Dec 28, 1995 Feb CAHN ICATIBANT ACETATE INJECTABLE;SUBCUTANEOUS ICATIBANT ACETATE @ DR REDDYS AP GLENMARK PHARMS LTD EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 213054 001 Oct 05, 2020 May DISC EQ 30MG BASE/3ML (EQ 10MG BASE/ML) A 213222 001 May 21, 2021 May NEWA ICOSAPENT ETHYL CAPSULE;ORAL ICOSAPENT ETHYL AB APOTEX @ TEVA PHARMS USA @ VASCEPA + AMARIN PHARMS 1GM 500MG 1GM 500MG A 209437 001 Jun 30, 2021 A 209525 001 Sep 11, 2020 A 209525 002 Sep 11, 2020 Jun NEWA Mar DISC Mar DISC N 202057 002 Feb 16, 2017 Mar CTEC ILOPROST SOLUTION;INHALATION VENTAVIS +! ACTELION @ +! 10MCG/ML (10MCG/ML) 20MCG/2ML (10MCG/ML) 20MCG/ML (20MCG/ML) N 021779 002 Dec 08, 2005 N 021779 001 Dec 29, 2004 N 021779 003 Aug 07, 2009 Feb CAHN Feb CAHN Feb CAHN IMIPRAMINE HYDROCHLORIDE TABLET;ORAL IMIPRAMINE HYDROCHLORIDE AB + SPECGX LLC 10MG AB + TOFRANIL 25MG AB +! SPECGX LLC 50MG A 087846 002 May 22, 1984 Aug CRLD A 087846 003 May 22, 1984 Aug CRLD A 087846 001 May 22, 1984 Aug CRLD IMIQUIMOD CREAM;TOPICAL IMIQUIMOD AB TARO ZYCLARA AB +! BAUSCH 3.75% 3.75% A 205971 001 Jan 26, 2021 Jan NFTG N 022483 001 Mar 25, 2010 Jan CFTG INDAPAMIDE TABLET;ORAL INDAPAMIDE AB ! ANI PHARMS @ MYLAN @ 2.5MG 1.25MG 2.5MG A 074299 001 Jul 27, 1995 A 074461 002 Mar 26, 1997 A 074461 001 Mar 27, 1996 Jul CHRS Jul DISC Jul DISC INDOCYANINE GREEN INJECTABLE;INJECTION INDOCYANINE GREEN AP RENEW PHARMS 25MG/VIAL A 040811 001 Nov 21, 2007 Jun CAHN INDOMETHACIN CAPSULE;ORAL INDOMETHACIN @ JUBILANT GENERICS 25MG @ TIVORBEX 50MG + @ GENUS 20MG + @ 40MG CAPSULE, EXTENDED RELEASE;ORAL INDOMETHACIN @ AUROBINDO PHARMA LTD 75MG @ JUBILANT GENERICS 75MG A 205215 001 Aug 25, 2017 Jan DISC A 205215 002 Aug 25, 2017 Jan DISC N 204768 001 Feb 24, 2014 Apr DISC N 204768 002 Feb 24, 2014 Apr DISC A 204243 001 Dec 27, 2016 Jan DISC A 202706 001 Oct 05, 2015 Jun DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -73 INFIGRATINIB PHOSPHATE CAPSULE;ORAL TRUSELTIQ + HELSINN HLTHCARE +! + QED THERAP +! 25MG 100MG 25MG 100MG IOPAMIDOL INJECTABLE;INJECTION ISOVUE-300 +! BRACCO 61% ISOVUE-370 +! BRACCO 76% SCANLUX-300 @ SANOCHEMIA CORP USA 61% SCANLUX-370 @ SANOCHEMIA CORP USA 76% IOVERSOL INJECTABLE;INJECTION OPTIRAY 240 + @ LIEBEL-FLARSHEIM 51% AN >D> >A> IPRATROPIUM BROMIDE SOLUTION;INHALATION IPRATROPIUM BROMIDE LUOXIN AUROVITAS @ PHARMASCIENCE INC @ ZENNOVA 0.02% 0.02% 0.02% IRBESARTAN TABLET;ORAL IRBESARTAN >A> @ PICKET PHARMS >A> @ >A> @ >D> @ US ANTIBIOTICS @ >D> @ @ >D> @ @ 75MG 150MG 300MG 75MG 75MG 150MG 150MG 300MG 300MG IRINOTECAN HYDROCHLORIDE INJECTABLE;INJECTION IRINOTECAN HYDROCHLORIDE >A> @ PICKET PHARMS 40MG/2ML (20MG/ML) >A> @ 100MG/5ML (20MG/ML) >D> @ US ANTIBIOTICS 40MG/2ML (20MG/ML) @ 40MG/2ML (20MG/ML) >D> @ 100MG/5ML (20MG/ML) @ 100MG/5ML (20MG/ML) ISOETHARINE HYDROCHLORIDE SOLUTION;INHALATION ISOETHARINE HYDROCHLORIDE + @ ASTRAZENECA 0.062% + @ 0.125% + @ 0.167% + @ 0.2% + @ 0.25% + @ DEY 1% ISOFLURANE LIQUID;INHALATION ISOFLURANE AN PIRAMAL PHARMA 99.9% N 214622 N 214622 N 214622 N 214622 001 May 28, 2021 002 May 28, 2021 001 May 28, 2021 002 May 28, 2021 Sep CAHN Sep CAHN May NEWA May NEWA N 018735 002 Dec 31, 1985 Jan CTEC N 018735 003 Dec 31, 1985 Jan CTEC A 090394 001 Jun 18, 2010 Jan DISC A 090394 002 Jun 18, 2010 Jan DISC N 019710 002 Dec 30, 1988 Sep DISC A 206543 001 Oct 27, 2016 A 075507 001 Jan 19, 2001 A 075507 001 Jan 19, 2001 Aug CAHN Oct CAHN Oct CAHN A 203161 A 203161 A 203161 A 203161 A 203161 A 203161 A 203161 A 203161 A 203161 001 Sep 27, 2012 002 Sep 27, 2012 003 Sep 27, 2012 001 Sep 27, 2012 001 Sep 27, 2012 002 Sep 27, 2012 002 Sep 27, 2012 003 Sep 27, 2012 003 Sep 27, 2012 Oct CAHN Oct CAHN Oct CAHN Oct CAHN May CAHN Oct CAHN May CAHN Oct CAHN May CAHN A 078953 A 078953 A 078953 A 078953 A 078953 A 078953 001 Apr 15, 2010 002 Apr 15, 2010 001 Apr 15, 2010 001 Apr 15, 2010 002 Apr 15, 2010 002 Apr 15, 2010 Oct CAHN Oct CAHN Oct CAHN May CAHN Oct CAHN May CAHN A 087937 A 087938 A 088470 A 088471 A 088472 A 086763 001 Nov 15, 1982 001 Nov 15, 1982 001 Mar 14, 1984 001 Mar 14, 1984 001 Mar 14, 1984 001 Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD A 074502 001 Jun 27, 1995 Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -74 ISONIAZID SYRUP;ORAL ISONIAZID +! CMP PHARMA INC 50MG/5ML ISOPROTERENOL HYDROCHLORIDE INJECTABLE;INJECTION ISOPROTERENOL HYDROCHLORIDE AP AMRING PHARMS @ CIPLA AP MICRO LABS 0.2MG/ML 0.2MG/ML 0.2MG/ML ISOSULFAN BLUE INJECTABLE;INJECTION ISOSULFAN BLUE >A> AP HONG KONG 1% ISOTRETINOIN CAPSULE;ORAL ABSORICA AB2 + SUN PHARM INDS INC AB2 + AB2 + AB2 + AB2 + AB2 +! AMNESTEEM AB1 MYLAN PHARMS INC AB1 AB1 CLARAVIS AB1 TEVA PHARMS USA AB1 AB1 AB1 ! ISOTRETINOIN AB2 ACTAVIS LABS FL AB2 AB2 AB2 AB2 AB2 AB1 AMNEAL PHARMS NY AB1 AB1 AB1 AB2 UPSHER SMITH LABS AB2 AB2 AB2 MYORISAN AB1 DOUGLAS PHARMS AB1 AB1 AB1 ZENATANE AB1 DR REDDYS LABS LTD AB1 AB1 AB1 10MG 20MG 25MG 30MG 35MG 40MG 10MG 20MG 40MG 10MG 20MG 30MG 40MG 10MG 20MG 25MG 30MG 35MG 40MG 10MG 20MG 30MG 40MG 10MG 20MG 30MG 40MG 10MG 20MG 30MG 40MG 10MG 20MG 30MG 40MG ITRACONAZOLE CAPSULE;ORAL ITRACONAZOLE BX STRIDES PHARMA TABLET;ORAL ONMEL + @ SEBELA IRELAND LTD 100MG 200MG A 088235 001 Nov 10, 1983 Aug CRLD A 211237 001 May 19, 2021 A 211738 001 Jun 28, 2019 A 210845 001 Feb 16, 2021 May NEWA Aug DISC Feb NEWA A 213130 001 Nov 03, 2021 Oct NEWA N 021951 N 021951 N 021951 N 021951 N 021951 N 021951 001 May 25, 2012 002 May 25, 2012 005 Aug 15, 2014 003 May 25, 2012 006 Aug 15, 2014 004 May 25, 2012 Mar CFTG Mar CFTG Mar CFTG Mar CFTG Mar CFTG Mar CFTG A 075945 001 Nov 08, 2002 A 075945 002 Nov 08, 2002 A 075945 003 Nov 08, 2002 Mar CTEC Mar CTEC Mar CTEC A 076356 A 076135 A 076135 A 076135 001 Apr 11, 2003 002 Apr 11, 2003 003 May 11, 2006 001 Apr 11, 2003 Mar CTEC Mar CTEC Mar CTEC Mar CTEC A 205063 A 205063 A 205063 A 205063 A 205063 A 205063 A 207792 A 207792 A 207792 A 207792 A 212333 A 212333 A 212333 A 213571 001 Mar 31, 2021 002 Mar 31, 2021 003 Mar 31, 2021 004 Mar 31, 2021 005 Mar 31, 2021 006 Mar 31, 2021 001 Sep 29, 2017 002 Sep 29, 2017 003 Sep 29, 2017 004 Sep 29, 2017 001 Sep 21, 2021 002 Sep 21, 2021 003 Sep 21, 2021 001 Apr 12, 2021 Mar NFTG Mar NFTG Mar NFTG Mar NFTG Mar NFTG Mar NFTG Mar CTEC Mar CTEC Mar CTEC Mar CTEC Sep NEWA Sep NEWA Sep NEWA Apr NEWA A 076485 A 076485 A 076485 A 076485 001 Jan 19, 2012 002 Jan 19, 2012 004 Aug 25, 2015 003 Jan 19, 2012 Mar CTEC Mar CTEC Mar CTEC Mar CTEC A 202099 A 202099 A 202099 A 202099 001 Mar 25, 2013 002 Mar 25, 2013 004 Feb 23, 2015 003 Mar 25, 2013 Mar CTEC Mar CTEC Mar CTEC Mar CTEC A 206410 001 Jul 02, 2019 Sep CTEC N 022484 001 Apr 29, 2010 Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -75 IVACAFTOR; IVACAFTOR, TEZACAFTOR TABLET;ORAL SYMDEKO (COPACKAGED) + VERTEX PHARMS INC + +! +! 75MG;75MG, 50MG 75MG,N/A;75MG, 50MG 150MG;150MG, 100MG 150MG,N/A;150MG, 100MG IVOSIDENIB TABLET;ORAL TIBSOVO +! SERVIER 250MG IXAZOMIB CITRATE CAPSULE;ORAL NINLARO + TAKEDA PHARMS USA + +! EQ 2.3MG BASE EQ 3MG BASE EQ 4MG BASE KETAMINE HYDROCHLORIDE INJECTABLE;INJECTION KETAMINE HYDROCHLORIDE AP AUROMEDICS PHARMA AP AP AP EUGIA PHARMA AP AP EQ 10MG BASE/ML EQ 50MG BASE/ML EQ 100MG BASE/ML EQ 10MG BASE/ML EQ 50MG BASE/ML EQ 100MG BASE/ML KETOCONAZOLE AEROSOL, FOAM;TOPICAL EXTINA AB +! MYLAN KETOCONAZOLE AB PADAGIS ISRAEL AB XIROMED AT CREAM;TOPICAL KETOCONAZOLE AB ENCUBE TABLET;ORAL KETOCONAZOLE @ MYLAN AB SENORES PHARMS 2% 2% 2% 2% 2% 200MG 200MG KETOPROFEN CAPSULE;ORAL KETOPROFEN ! HERITAGE PHARMS INC AB ! @ RISING @ @ TEVA 75MG 75MG 50MG 75MG 75MG KETOROLAC TROMETHAMINE INJECTABLE;INJECTION KETOROLAC TROMETHAMINE @ HOSPIRA 15MG/ML LABETALOL HYDROCHLORIDE INJECTABLE;INJECTION LABETALOL HYDROCHLORIDE AP BAXTER HLTHCARE CORP 5MG/ML AP CAPLIN 5MG/ML SOLUTION;INTRAVENOUS LABETALOL HYDROCHLORIDE IN DEXTROSE +! HIKMA PHARMS 200MG/200ML (1MG/ML) LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE +! HIKMA PHARMS +! 100MG/100ML (1MG/ML) 200MG/200ML (1MG/ML) N 210491 N 210491 N 210491 N 210491 002 Jun 21, 2019 002 Jun 21, 2019 001 Feb 12, 2018 001 Feb 12, 2018 Jul CPOT Jul CDFR Jul CPOT Jul CDFR N 211192 001 Jul 20, 2018 Apr CAHN N 208462 001 Nov 20, 2015 N 208462 002 Nov 20, 2015 N 208462 003 Nov 20, 2015 May CAHN May CAHN May CAHN A 076092 A 076092 A 076092 A 076092 A 076092 A 076092 001 Sep 30, 2008 002 Dec 28, 2001 003 Oct 25, 2002 001 Sep 30, 2008 002 Dec 28, 2001 003 Oct 25, 2002 Jan CAHN Jan CAHN Jan CAHN Aug CAHN Aug CAHN Aug CAHN N 021738 001 Jun 12, 2007 Sep CTEC A 091550 001 Aug 25, 2011 A 213601 001 May 21, 2021 A 213601 001 May 21, 2021 Sep CTEC Sep CTEC May NEWA A 212443 001 May 20, 2021 May NEWA A 075597 001 Dec 23, 1999 Mar DISC A 075912 001 Jan 10, 2002 Aug CAHN A 074014 A 074014 A 074024 A 074024 A 073517 003 Jan 29, 1993 003 Jan 29, 1993 001 Dec 29, 1995 002 Dec 29, 1995 001 Dec 22, 1992 Jul CTEC Jul CHRS Jan CAHN Jan CAHN Jul DISC A 074993 001 Jan 27, 1999 Mar DISC A 076051 001 Jul 05, 2002 Mar CMFD A 214533 001 Sep 07, 2021 Aug NEWA N 213330 001 Nov 09, 2020 Sep CAHN N 213330 002 Nov 09, 2020 Sep CAHN N 213330 003 Nov 09, 2020 Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -76 AB AB AB AB AB >D> >A> AB AB >D> >A> AB AB AB SOLUTION;INTRAVENOUS LABETALOL HYDROCHLORIDE IN SODIUM CHLORIDE +! 300MG/300ML (1MG/ML) TABLET;ORAL LABETALOL HYDROCHLORIDE ! PAR FORM 200MG RUBICON 100MG 200MG 300MG TRANDATE + @ ALVOGEN 100MG + 100MG + @ 200MG + 200MG + @ 200MG +! 200MG + @ 300MG + 300MG + @ 300MG + 300MG + @ 400MG +! CNTY LINE PHARMS 200MG LACTULOSE SOLUTION;ORAL LACTULOSE AA TORRENT SOLUTION;ORAL, RECTAL LACTULOSE AA TORRENT 10GM/15ML 10GM/15ML LAMIVUDINE TABLET;ORAL LAMIVUDINE AB APPCO AB AB BRECKENRIDGE AB CENTAUR PHARMS PVT 150MG 300MG 150MG 150MG LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE TABLET;ORAL LAMIVUDINE AND TENOFOVIR DISOPROXIL FUMARATE + @ AUROBINDO PHARMA LTD 300MG;300MG TEMIXYS + @ CELLTRION 300MG;300MG LAMOTRIGINE TABLET;ORAL LAMOTRIGINE @ GRANULES @ @ @ @ ZENNOVA @ @ @ 25MG 100MG 150MG 200MG 25MG 100MG 150MG 200MG TABLET, CHEWABLE;ORAL LAMOTRIGINE @ JUBILANT GENERICS @ 5MG 25MG TABLET, EXTENDED RELEASE;ORAL LAMOTRIGINE AB ACTAVIS ELIZABETH 250MG TABLET, ORALLY DISINTEGRATING;ORAL LAMOTRIGINE AB AJANTA PHARMA LTD 25MG AB 50MG AB 100MG AB 200MG N 213330 004 Nov 09, 2020 Sep CAHN A 200908 A 211953 A 211953 A 211953 002 Jul 10, 2012 001 Aug 18, 2021 002 Aug 18, 2021 003 Aug 18, 2021 Jul CHRS Aug NEWA Aug NEWA Aug NEWA N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 N 018716 001 May 24, 1985 001 May 24, 1985 002 Aug 01, 1984 002 Aug 01, 1984 002 Aug 01, 1984 002 Aug 01, 1984 003 Aug 01, 1984 003 Aug 01, 1984 003 Aug 01, 1984 003 Aug 01, 1984 004 Aug 01, 1984 002 Aug 01, 1984 Jul DISC Jul CAHN Oct CMFD Oct CMFD Jul DISC Jul CAHN Oct CMFD Oct CMFD Jul DISC Jul CAHN Jul CAHN Apr CHRS A 207786 001 Jun 11, 2018 Jun CMFD A 203762 001 Mar 27, 2015 Jun CMFD A 206974 A 206974 A 203586 A 203586 001 Nov 21, 2016 002 Nov 21, 2016 001 Nov 21, 2016 001 Nov 21, 2016 Sep CAHN Sep CAHN Sep CAHN Jun CAHN N 022344 001 May 15, 2018 Feb DISC N 211284 001 Nov 16, 2018 Aug DISC A 078982 A 078982 A 078982 A 078982 A 078310 A 078310 A 078310 A 078310 001 Jan 27, 2009 002 Jan 27, 2009 003 Jan 27, 2009 004 Jan 27, 2009 001 Feb 04, 2009 002 Feb 04, 2009 003 Feb 04, 2009 004 Feb 04, 2009 Jun CAHN Jun CAHN Jun CAHN Jun CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN A 200220 001 Feb 28, 2011 Jun DISC A 200220 002 Feb 28, 2011 Jun DISC A 200672 006 Nov 13, 2013 Jul CMS1 A 213271 A 213271 A 213271 A 213271 001 Jan 19, 2021 002 Jan 19, 2021 003 Jan 19, 2021 004 Jan 19, 2021 Jan NEWA Jan NEWA Jan NEWA Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -77 LANSOPRAZOLE CAPSULE, DELAYED REL PELLETS;ORAL PREVACID + @ TAKEDA PHARMS USA 15MG TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL LANSOPRAZOLE AB DR REDDYS LABS LTD 15MG AB 30MG LASMIDITAN SUCCINATE TABLET;ORAL REYVOW + ELI LILLY AND CO +! + +! + @ +! + EQ 50MG BASE EQ 100MG BASE EQ 100MG BASE EQ 100MG BASE EQ 200MG BASE EQ 200MG BASE EQ 200MG BASE LATANOPROST EMULSION;OPHTHALMIC XELPROS >A> +! SUN PHARM >D> +! SUN PHARMA GLOBAL 0.005% 0.005% LEFLUNOMIDE TABLET;ORAL LEFLUNOMIDE AB AUROBINDO PHARMA LTD AB 10MG 20MG AB AB AB AB >A> AB >A> AB AB AB AB AB >D> >A> AB AB AB AB >D> >A> AB AB LENALIDOMIDE CAPSULE;ORAL LENALIDOMIDE ARROW INTL DR REDDYS NATCO PHARMA LTD REVLIMID + CELGENE + + + + + + +! 5MG 10MG 15MG 25MG 2.5MG 20MG 5MG 10MG 15MG 25MG 2.5MG 2.5MG 5MG 10MG 15MG 20MG 20MG 25MG LETROZOLE TABLET;ORAL LETROZOLE @ APOTEX INC 2.5MG LETROZOLE; RIBOCICLIB SUCCINATE TABLET;ORAL KISQALI FEMARA CO-PACK (COPACKAGED) +! NOVARTIS 2.5MG;EQ 200MG BASE +! 2.5MG,N/A;N/A,EQ 200MG BASE N 020406 001 May 10, 1995 Jun DISC A 210465 001 Feb 01, 2021 Jan NEWA A 210465 002 Feb 01, 2021 Jan NEWA N 211280 N 211280 N 211280 N 211280 N 211280 N 211280 N 211280 001 Jan 31, 2020 002 Jan 31, 2020 002 Jan 31, 2020 002 Jan 31, 2020 003 Dec 18, 2020 003 Dec 18, 2020 003 Dec 18, 2020 May CPOT Aug CHRS May CHRS May CPOT Aug DISC May CHRS May CPOT N 206185 001 Sep 12, 2018 Oct CAHN N 206185 001 Sep 12, 2018 Oct CAHN A 213652 001 Mar 29, 2021 Mar NEWA A 213652 002 Mar 29, 2021 Mar NEWA A 201452 A 201452 A 201452 A 201452 A 209348 A 209348 A 201452 A 201452 A 201452 A 201452 001 May 21, 2021 002 May 21, 2021 003 May 21, 2021 004 May 21, 2021 001 Oct 14, 2021 002 Oct 14, 2021 001 May 21, 2021 002 May 21, 2021 003 May 21, 2021 004 May 21, 2021 Jul CAHN Jul CAHN Jul CAHN Jul CAHN Oct NFTG Oct NFTG May NFTG May NFTG May NFTG May NFTG N 021880 N 021880 N 021880 N 021880 N 021880 N 021880 N 021880 N 021880 005 Dec 21, 2011 005 Dec 21, 2011 001 Dec 27, 2005 002 Dec 27, 2005 003 Jun 29, 2006 006 Jun 05, 2013 006 Jun 05, 2013 004 Jun 29, 2006 Oct CFTG Oct CFTG May CFTG May CFTG May CFTG Oct CFTG Oct CFTG May CFTG A 091303 001 Apr 19, 2012 Jan DISC N 209935 001 May 04, 2017 Jul CPOT N 209935 001 May 04, 2017 Jul CDFR RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -78 LEUCOVORIN CALCIUM INJECTABLE;INJECTION LEUCOVORIN CALCIUM AP ! HIKMA PHARMS AP ! @ NOVAST LABS TABLET;ORAL LEUCOVORIN CALCIUM AB EPIC PHARMA LLC AB EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 10MG BASE/ML EQ 10MG BASE EQ 15MG BASE LEUPROLIDE ACETATE INJECTABLE;INJECTION LEUPROLIDE ACETATE AP VGYAAN 1MG/0.2ML LEUPROLIDE ACETATE; NORETHINDRONE ACETATE INJECTABLE, TABLET;INTRAMUSCULAR, ORAL LUPANETA PACK + @ ABBVIE ENDOCRINE + @ 3.75MG/VIAL,N/A;N/A,5MG 11.25MG/VIAL,N/A;N/A,5MG LEUPROLIDE MESYLATE EMULSION;SUBCUTANEOUS CAMCEVI KIT +! FORESEE PHARMS EQ 42MG BASE LEVALBUTEROL HYDROCHLORIDE SOLUTION;INHALATION LEVALBUTEROL HYDROCHLORIDE AN LUOXIN AUROVITAS EQ 0.25% BASE AN EQ 0.0103% BASE AN EQ 0.021% BASE AN EQ 0.042% BASE LEVETIRACETAM INJECTABLE;INTRAVENOUS LEVETIRACETAM @ JUBILANT GENERICS 500MG/5ML (100MG/ML) LEVETIRACETAM IN SODIUM CHLORIDE AP GLAND PHARMA LTD 1GM/100ML (10MG/ML) AP 1.5GM/100ML (15MG/ML) AP +! HQ SPECIALITY PHARMA 1GM/100ML (10MG/ML) AP +! 1.5GM/100ML (15MG/ML) AP NEXUS PHARMS 1GM/100ML (10MG/ML) AP 1.5GM/100ML (15MG/ML) SOLUTION;ORAL LEVETIRACETAM AA AKORN 100MG/ML TABLET;ORAL LEVETIRACETAM @ LOTUS PHARM CO LTD 250MG @ 750MG @ 1GM @ NOSTRUM LABS INC 250MG AB 250MG @ 500MG AB 500MG @ 750MG AB 750MG @ 1GM AB 1GM AB SCIEGEN PHARMS INC 750MG AB 1GM TABLET, EXTENDED RELEASE;ORAL ELEPSIA XR + TRIPOINT +! LEVETIRACETAM 1GM 1.5GM AB GENUS LIFESCIENCES 500MG AB 750MG A 089384 001 Sep 14, 1987 A 089717 001 Mar 28, 1988 A 210917 001 Nov 23, 2018 Jul CAHN Jul CAHN Sep CAHN A 074544 003 May 19, 2021 May NEWA A 074544 004 May 19, 2021 May NEWA A 213829 001 Aug 13, 2021 Aug NEWA N 203696 001 Dec 14, 2012 Aug DISC N 203696 002 Dec 14, 2012 Aug DISC N 211488 001 May 25, 2021 May NEWA A 207628 A 207625 A 207625 A 207625 001 Jan 31, 2017 001 Dec 30, 2016 002 Dec 30, 2016 003 Dec 30, 2016 Aug CAHN Aug CAHN Aug CAHN Aug CAHN A 206838 001 Jun 02, 2016 Jun DISC A 206880 A 206880 N 202543 N 202543 A 213532 A 213532 002 Oct 25, 2017 003 Oct 25, 2017 002 Nov 09, 2011 003 Nov 09, 2011 002 Jul 06, 2020 003 Jul 06, 2020 Feb CPOT Feb CDFR Feb CPOT Feb CPOT Feb CPOT Feb CPOT A 090601 001 Feb 28, 2012 Feb CAHN A 090906 A 090906 A 090906 A 090511 A 090511 A 090511 A 090511 A 090511 A 090511 A 090511 A 090511 A 215069 A 215069 002 Oct 31, 2016 003 Oct 31, 2016 004 Oct 31, 2016 001 Aug 18, 2011 001 Aug 18, 2011 002 Aug 18, 2011 002 Aug 18, 2011 003 Aug 18, 2011 003 Aug 18, 2011 004 Aug 18, 2011 004 Aug 18, 2011 001 Jun 11, 2021 002 Jun 11, 2021 Aug DISC Aug DISC Aug DISC Mar DISC Jan CAHN Mar DISC Jan CAHN Mar DISC Jan CAHN Mar DISC Jan CAHN Jun NEWA Jun NEWA N 204417 001 Dec 20, 2018 Jan CAHN N 204417 002 Dec 20, 2018 Jan CAHN A 204754 001 Aug 26, 2016 Sep CAHN A 204754 002 Aug 26, 2016 Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -79 AB >D> AB >A> >D> AB >A> TABLET, EXTENDED RELEASE;ORAL LEVETIRACETAM @ LOTUS PHARM CO LTD 500MG @ 750MG OVERSEAS 750MG ROUSES POINT PHARMS 500MG @ 500MG 750MG @ 750MG LEVOBUNOLOL HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC AKBETA @ AKORN @ BETAGAN 0.25% 0.5% + @ ALLERGAN 0.25% LEVOCETIRIZINE DIHYDROCHLORIDE SOLUTION;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AA ! PADAGIS US 2.5MG/5ML XYZAL + @ SANOFI 2.5MG/5ML TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE AB ! GLENMARK GENERICS 5MG @ GRANULES 5MG @ NEOPHARMA 5MG @ US ANTIBIOTICS 5MG XYZAL + @ SANOFI 5MG LEVOFLOXACIN TABLET;ORAL LEVOFLOXACIN AB CADILA AB AB @ JUBILANT GENERICS @ 250MG 500MG 750MG 250MG 500MG AP >A> AP LEVOLEUCOVORIN CALCIUM POWDER;INTRAVENOUS LEVOLEUCOVORIN CALCIUM HIKMA PHARMS SOLUTION;INTRAVENOUS LEVOLEUCOVORIN CALCIUM PRAXGEN EQ 50MG BASE/VIAL EQ 175MG BASE/17.5ML (EQ 10MG BASE/ML) LEVONORGESTREL INTRAUTERINE DEVICE;INTRAUTERINE LILETTA >D> MEDICINES360 52MG >A> +! 52MG LEVORPHANOL TARTRATE TABLET;ORAL LEVORPHANOL TARTRATE NOVITIUM PHARMA 1MG AB 3MG AB ! SENTYNL THERAPS INC 3MG AB SUN PHARM INDS INC 2MG LEVOTHYROXINE SODIUM CAPSULE;ORAL LEVOTHYROXINE SODIUM @ TEVA PHARMS USA INC @ @ AB 0.075MG 0.088MG 0.1MG 0.112MG A 202095 A 202095 A 212688 A 202524 A 202524 A 202524 A 202524 002 Jun 06, 2016 001 Jun 06, 2016 001 Jun 11, 2020 001 Aug 27, 2012 001 Aug 27, 2012 002 Aug 27, 2012 002 Aug 27, 2012 Aug DISC Aug DISC May CMFD Oct DISC Oct DISC Oct DISC Oct DISC A 074779 001 Oct 29, 1996 Jul DISC A 074780 001 Oct 29, 1996 Jul DISC N 019814 001 Jun 28, 1989 Jun DISC A 091263 001 Nov 07, 2011 Jul CAHN N 022157 001 Jan 28, 2008 Apr DISC A 090385 001 Feb 24, 2011 A 090486 001 Mar 26, 2013 A 204323 001 Dec 20, 2016 A 204323 001 Dec 20, 2016 Apr CHRS Apr CAHN Mar DISC May CAHN N 022064 001 May 25, 2007 Apr DISC A 077652 001 Sep 07, 2012 A 077652 002 Sep 07, 2012 A 077652 003 Sep 07, 2012 A 203613 001 Jun 19, 2015 A 203613 002 Jun 19, 2015 Jun CAHN Jun CAHN Jun CAHN Jun DISC Jun DISC A 206263 001 Jun 16, 2016 Jul CAHN A 213797 001 Nov 02, 2021 Oct NEWA N 206229 001 Feb 26, 2015 Oct CRLD N 206229 001 Feb 26, 2015 Oct CRLD A 213479 A 213479 A 074278 A 213906 003 Jul 20, 2021 002 Jan 12, 2021 003 Jun 18, 2018 001 Jun 17, 2021 Jul NEWA Jan NEWA Jan CTEC Jun NEWA A 211369 A 213256 A 213256 A 211369 001 Oct 28, 2020 001 Jan 06, 2021 002 Jan 06, 2021 003 Apr 16, 2021 Apr DISC Jul DISC Jul DISC Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -80 >D> AB >A> >D> AB >A> AB >D> AB >A> CAPSULE;ORAL LEVOTHYROXINE SODIUM @ @ TIROSINT + INSTITUT BIOCHIMIQUE + + + + + + + + POWDER;INTRAVENOUS LEVOTHYROXINE SODIUM @ DR REDDYS SOLUTION;INTRAVENOUS LEVOTHYROXINE SODIUM +! CUSTOPHARM INC SOLUTION;ORAL THYQUIDITY +! VISTAPHARM TIROSINT-SOL + INSTITUT BIOCHIMIQUE + + 0.125MG 0.15MG 0.075MG 0.088MG 0.088MG 0.1MG 0.1MG 0.112MG 0.125MG 0.125MG 0.15MG 100MCG/VIAL 100MCG/ML 100MCG/5ML 37.5MCG/ML 44MCG/ML 62.5MCG/ML A 213256 003 Jan 06, 2021 Jul DISC A 211369 002 Oct 28, 2020 Apr DISC N 021924 N 021924 N 021924 N 021924 N 021924 N 021924 N 021924 N 021924 N 021924 004 Oct 13, 2006 010 Oct 02, 2009 010 Oct 02, 2009 005 Oct 13, 2006 005 Oct 13, 2006 008 Oct 02, 2009 006 Oct 13, 2006 006 Oct 13, 2006 007 Oct 13, 2006 Apr CTEC Oct CTEC Oct CTEC Oct CTEC Oct CTEC Apr CFTG Oct CTEC Oct CTEC Apr CTEC A 208837 001 Mar 27, 2020 Feb DISC N 214253 001 May 17, 2021 May NEWA N 214047 001 Nov 30, 2020 Apr CAHN N 206977 013 Jan 13, 2021 N 206977 014 Jan 13, 2021 N 206977 015 Jan 13, 2021 Jan NEWA Jan NEWA Jan NEWA LEVOTHYROXINE SODIUM ** **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium TABLET;ORAL THYRO-TABS AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 AB2, + AB4 ALVOGEN 0.025MG 0.05MG 0.075MG 0.088MG 0.1MG 0.112MG 0.125MG 0.137MG 0.15MG 0.175MG 0.2MG 0.3MG N 021116 001 Oct 24, 2002 N 021116 002 Oct 24, 2002 N 021116 003 Oct 24, 2002 N 021116 010 Oct 24, 2002 N 021116 004 Oct 24, 2002 N 021116 011 Oct 24, 2002 N 021116 005 Oct 24, 2002 N 021116 012 Dec 07, 2004 N 021116 006 Oct 24, 2002 N 021116 007 Oct 24, 2002 N 021116 008 Oct 24, 2002 N 021116 009 Oct 24, 2002 Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN LIDOCAINE OINTMENT;TOPICAL LIDOCAINE AT +! FOUGERA PHARMS INC 5% AT QUAGEN 5% @ RISING 5% PATCH;TOPICAL LIDOCAINE AB NAL PHARM 5% @ NOVEN PHARMS INC 5% A 080198 001 A 212695 001 Apr 20, 2021 A 208604 001 Sep 20, 2017 Aug CRLD Apr NEWA May CAHN A 205882 001 Apr 29, 2021 Apr NEWA A 203265 001 Dec 01, 2020 Jun DISC >A> AP >A> AP >A> AP LIDOCAINE HYDROCHLORIDE INJECTABLE;INJECTION LIDOCAINE HYDROCHLORIDE ASPIRO 1% 1% 2% A 214336 001 Nov 08, 2021 A 214339 001 Nov 08, 2021 A 214339 002 Nov 08, 2021 Oct NEWA Oct NEWA Oct NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -81 JELLY;TOPICAL XYLOCAINE + @ AKORN 2% SOLUTION;ORAL LIDOCAINE HYDROCHLORIDE VISCOUS AT LANNETT CO INC 2% LIDOCAINE; PRILOCAINE CREAM;TOPICAL LIDOCAINE AND PRILOCAINE AB ACRUX DDS PTY 2.5%;2.5% LINACLOTIDE CAPSULE;ORAL LINACLOTIDE @ MYLAN AB @ AB LINZESS +! ALLERGAN AB +! + AB + 145MCG 145MCG 290MCG 290MCG 145MCG 145MCG 290MCG 290MCG LINAGLIPTIN TABLET;ORAL LINAGLIPTIN AB SUNSHINE 5MG TRADJENTA AB +! BOEHRINGER INGELHEIM 5MG LINAGLIPTIN; METFORMIN HYDROCHLORIDE TABLET;ORAL JENTADUETO AB + BOEHRINGER INGELHEIM 2.5MG;500MG AB + 2.5MG;850MG AB +! 2.5MG;1GM LINAGLIPTIN AND METFORMIN HYDROCHLORIDE AB SUNSHINE AB AB 2.5MG;500MG 2.5MG;850MG 2.5MG;1GM >A> AP LINCOMYCIN INJECTABLE;INJECTION LINCOMYCIN MICRO LABS EQ 300MG BASE/ML LINCOMYCIN HYDROCHLORIDE INJECTABLE;INJECTION LINCOCIN AP +! PFIZER EQ 300MG BASE/ML LINCOMYCIN HYDROCHLORIDE @ PRAXGEN AP EQ 300MG BASE/ML EQ 300MG BASE/ML LIOTHYRONINE SODIUM TABLET;ORAL LIOTHYRONINE SODIUM AB ZYDUS AB AB EQ 0.005MG BASE EQ 0.025MG BASE EQ 0.05MG BASE >D> >A> AB >D> >A> AB >D> >A> AB LISINOPRIL TABLET;ORAL LISINOPRIL @ ASCENT PHARMS INC @ @ 2.5MG 2.5MG 5MG 5MG 10MG 10MG N 008816 001 Jan DISC A 040708 001 Feb 27, 2007 Jan CMFD A 212482 001 Jul 27, 2021 Jul NEWA A 209564 001 Feb 09, 2021 A 209564 001 Feb 09, 2021 A 209564 002 Feb 09, 2021 A 209564 002 Feb 09, 2021 Feb DISC Jan NFTG Feb DISC Jan NFTG N 202811 001 Aug 30, 2012 N 202811 001 Aug 30, 2012 N 202811 002 Aug 30, 2012 N 202811 002 Aug 30, 2012 Feb CTEC Jan CFTG Feb CTEC Jan CFTG A 208335 001 Aug 31, 2021 Aug NFTG N 201280 001 May 02, 2011 Aug CFTG N 201281 001 Jan 30, 2012 N 201281 002 Jan 30, 2012 N 201281 003 Jan 30, 2012 Aug CFTG Aug CFTG Aug CFTG A 208336 001 Aug 30, 2021 A 208336 002 Aug 30, 2021 A 208336 003 Aug 30, 2021 Aug NFTG Aug NFTG Aug NFTG A 215082 001 Nov 08, 2021 Oct NEWA N 050317 001 Feb CAHN A 212770 001 Mar 12, 2021 Sep DISC A 212770 001 Mar 12, 2021 Mar NEWA A 214803 001 Jan 22, 2021 A 214803 002 Jan 22, 2021 A 214803 003 Jan 22, 2021 Jan NEWA Jan NEWA Jan NEWA A 075903 A 075903 A 075903 A 075903 A 075903 A 075903 001 Jul 01, 2002 001 Jul 01, 2002 002 Jul 01, 2002 002 Jul 01, 2002 003 Jul 01, 2002 003 Jul 01, 2002 Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -82 >D> >A> AB >D> >A> AB >D> >A> AB AB AB AB TABLET;ORAL LISINOPRIL @ @ @ YILING 20MG 20MG 30MG 30MG 40MG 40MG 20MG 30MG 40MG >A> AB AB LOPERAMIDE HYDROCHLORIDE CAPSULE;ORAL LOPERAMIDE HYDROCHLORIDE BIONPHARMA INC 2MG EDENBRIDGE PHARMS 2MG LOPINAVIR; RITONAVIR TABLET;ORAL KALETRA AB + ABBVIE 100MG;25MG AB +! 200MG;50MG LOPINAVIR AND RITONAVIR AB HETERO LABS LTD III 100MG;25MG AB 200MG;50MG LORAZEPAM CAPSULE, EXTENDED RELEASE;ORAL LOREEV XR + ALMATICA 1MG + 2MG +! 3MG CONCENTRATE;ORAL LORAZEPAM AA AKORN 2MG/ML INJECTABLE;INJECTION ATIVAN AP +! HIKMA PHARMS 2MG/ML AP +! 4MG/ML LOSARTAN POTASSIUM TABLET;ORAL COZAAR AB + ORGANON AB + LOSARTAN POTASSIUM AB HIKMA PHARMS AB AB AB JUBILANT CADISTA AB AB 25MG 50MG 25MG 50MG 100MG 25MG 50MG 100MG LOTEPREDNOL ETABONATE GEL;OPHTHALMIC LOTEMAX AB +! BAUSCH AND LOMB INC 0.5% LOTEPREDNOL ETABONATE AB AKORN 0.5% SUSPENSION/DROPS;OPHTHALMIC LOTEPREDNOL ETABONATE AB SUN PHARM 0.5% LOXAPINE SUCCINATE CAPSULE;ORAL LOXAPINE SUCCINATE @ MYLAN @ @ @ @ EQ 5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 10MG BASE EQ 25MG BASE A 075903 A 075903 A 075903 A 075903 A 075903 A 075903 A 208920 A 208920 A 208920 004 Jul 01, 2002 004 Jul 01, 2002 005 Jul 01, 2002 005 Jul 01, 2002 006 Jul 01, 2002 006 Jul 01, 2002 001 Mar 04, 2021 002 Mar 04, 2021 003 Mar 04, 2021 Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Feb NEWA Feb NEWA Feb NEWA A 215579 001 Oct 22, 2021 Oct NEWA A 215001 001 Oct 06, 2021 Sep NEWA N 021906 002 Nov 09, 2007 May CFTG N 021906 001 Oct 28, 2005 May CFTG A 091677 001 Jun 04, 2021 May NFTG A 091677 002 Jun 04, 2021 May NFTG N 214826 001 Aug 27, 2021 N 214826 002 Aug 27, 2021 N 214826 003 Aug 27, 2021 Aug NEWA Aug NEWA Aug NEWA A 200169 001 Jan 30, 2012 Feb CAHN N 018140 001 N 018140 002 Jul CAHN Jul CAHN N 020386 001 Apr 14, 1995 Aug CMFD N 020386 002 Apr 14, 1995 Aug CMFD A 077459 A 077459 A 077459 A 201170 A 201170 A 201170 001 Oct 06, 2010 002 Oct 06, 2010 003 Oct 06, 2010 001 Sep 18, 2012 002 Sep 18, 2012 003 Sep 18, 2012 Jul CMFD Jul CMFD Jul CMFD Jun CAHN Jun CAHN Jun CAHN N 202872 001 Sep 28, 2012 Jan CFTG A 212080 001 Feb 10, 2021 Jan NFTG A 212450 001 Feb 26, 2021 Feb NEWA A 076762 A 076762 A 076762 A 076762 A 076762 001 Nov 01, 2004 001 Nov 01, 2004 002 Nov 01, 2004 002 Nov 01, 2004 003 Nov 01, 2004 Aug CAHN Jul DISC Aug CAHN Jul DISC Aug CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -83 CAPSULE;ORAL LOXAPINE SUCCINATE @ @ @ EQ 25MG BASE EQ 50MG BASE EQ 50MG BASE LULICONAZOLE CREAM;TOPICAL LUZU +! BAUSCH 1% LURASIDONE HYDROCHLORIDE TABLET;ORAL LURASIDONE HYDROCHLORIDE AB ALEMBIC PHARMS LTD 20MG AB 40MG AB 60MG AB 80MG AB 120MG AB DR REDDYS LABS LTD 20MG AB 40MG AB 60MG AB 80MG @ PIRAMAL HLTHCARE UK 20MG @ 40MG @ 60MG @ 80MG @ 120MG @ WATSON LABS TEVA 20MG AB 20MG @ 40MG AB 40MG @ 60MG AB 60MG @ 80MG AB 80MG @ 120MG AB 120MG MACITENTAN TABLET;ORAL MACITENTAN @ ZYDUS AB OPSUMIT +! ACTELION AB +! +! 10MG 10MG 10MG 10MG 10MG AP AP AP AP AP AP AP >A> AP >A> AP >A> AP MAGNESIUM SULFATE INJECTABLE;INJECTION MAGNESIUM SULFATE B BRAUN MEDICAL INC 2GM/50ML (40MG/ML) 4GM/100ML (40MG/ML) 4GM/50ML (80MG/ML) MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER BAXTER HLTHCARE CORP 1GM/100ML MAGNESIUM SULFATE IN PLASTIC CONTAINER BAXTER HLTHCARE CORP 2GM/50ML (40MG/ML) 4GM/50ML (80MG/ML) 4GM/100ML (40MG/ML) PTS CONSULTING 2GM/50ML (40MG/ML) 4GM/100ML (40MG/ML) 4GM/50ML (80MG/ML) MAPROTILINE HYDROCHLORIDE TABLET;ORAL MAPROTILINE HYDROCHLORIDE @ HERITAGE PHARMA 50MG @ MYLAN 25MG @ 50MG @ 75MG A 076762 003 Nov 01, 2004 A 076762 004 Nov 01, 2004 A 076762 004 Nov 01, 2004 Jul DISC Aug CAHN Jul DISC N 204153 001 Nov 14, 2013 May CAHN A 213248 001 May 13, 2021 A 213248 002 May 13, 2021 A 213248 003 May 13, 2021 A 213248 004 May 13, 2021 A 213248 005 May 13, 2021 A 208047 001 Aug 24, 2021 A 208047 002 Aug 24, 2021 A 208047 003 Aug 24, 2021 A 208047 004 Aug 24, 2021 A 212091 001 Dec 28, 2020 A 212091 002 Dec 28, 2020 A 212091 003 Dec 28, 2020 A 212091 004 Dec 28, 2020 A 212091 005 Dec 28, 2020 A 208016 001 Feb 02, 2021 A 208016 001 Feb 02, 2021 A 208016 002 Feb 02, 2021 A 208016 002 Feb 02, 2021 A 208016 003 Feb 02, 2021 A 208016 003 Feb 02, 2021 A 208016 004 Feb 02, 2021 A 208016 004 Feb 02, 2021 A 208016 005 Feb 02, 2021 A 208016 005 Feb 02, 2021 May NEWA May NEWA May NEWA May NEWA May NEWA Aug NEWA Aug NEWA Aug NEWA Aug NEWA Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC Sep DISC Jan NEWA Sep DISC Jan NEWA Sep DISC Jan NEWA Sep DISC Jan NEWA Sep DISC Jan NEWA A 211224 001 Apr 06, 2021 Aug DISC A 211224 001 Apr 06, 2021 Mar NFTG N 204410 001 Oct 18, 2013 N 204410 001 Oct 18, 2013 N 204410 001 Oct 18, 2013 Aug CTEC Mar CFTG Feb CAHN A 207967 001 Apr 26, 2021 A 207967 002 Apr 26, 2021 A 207967 003 Apr 26, 2021 Apr NEWA Apr NEWA Apr NEWA A 211965 001 Aug 11, 2020 Feb CMFD A 211966 001 Jun 01, 2020 A 211966 002 Jun 01, 2020 A 211966 003 Jun 01, 2020 A 209642 001 Nov 08, 2021 A 209642 002 Nov 08, 2021 A 209642 003 Nov 08, 2021 Feb CMFD Feb CMFD Feb CMFD Oct NEWA Oct NEWA Oct NEWA A 072163 A 072285 A 072285 A 072285 001 Jun 01, 1988 002 Oct 03, 1988 001 Oct 03, 1988 003 Oct 03, 1988 Jun CAHN Jul DISC Jul DISC Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -84 MARALIXIBAT CHLORIDE SOLUTION;ORAL LIVMARLI +! MIRUM EQ 9.5MG BASE/ML MECLIZINE HYDROCHLORIDE TABLET;ORAL MECLIZINE HYDROCHLORIDE AA ANI PHARMS AA 12.5MG 25MG MEDROXYPROGESTERONE ACETATE INJECTABLE;INJECTION DEPO-PROVERA + @ PFIZER AB +! + @ +! 100MG/ML 150MG/ML 400MG/ML 400MG/ML INJECTABLE;SUBCUTANEOUS DEPO-SUBQ PROVERA 104 +! PFIZER 104MG/0.65ML TABLET;ORAL PROVERA AB + PFIZER AB + AB +! 2.5MG 5MG 10MG MEFENAMIC ACID CAPSULE;ORAL MEFENAMIC ACID @ STRIDES PHARMA 250MG MEFLOQUINE HYDROCHLORIDE TABLET;ORAL MEFLOQUINE HYDROCHLORIDE AB ! BARR AB HIKMA PHARMS 250MG 250MG AB AB AB AB >A> >A> >D> >D> MELOXICAM CAPSULE;ORAL MELOXICAM LUPIN LTD ! NOVITIUM PHARMA TABLET;ORAL MELOXICAM @ AIPING PHARM INC @ @ NOSTRUM LABS INC @ 5MG 10MG 5MG 10MG 7.5MG 15MG 7.5MG 15MG MELPHALAN TABLET;ORAL MELPHALAN ! ALVOGEN 2MG MELPHALAN HYDROCHLORIDE INJECTABLE;INJECTION ALKERAN + @ APOTEX EQ 50MG BASE/VIAL MELPHALAN HYDROCHLORIDE AP ALMAJECT EQ 50MG BASE/VIAL AP HIKMA PHARMS EQ 50MG BASE/VIAL AP HONG KONG EQ 50MG BASE/VIAL AP MEITHEAL EQ 50MG BASE/VIAL @ SCINOPHARM TAIWAN EQ 50MG BASE/VIAL N 214662 001 Sep 29, 2021 Sep NEWA A 084657 002 A 084657 001 Sep CMFD Sep CMFD N 012541 N 020246 N 012541 N 012541 002 001 Oct 29, 1992 003 003 Mar CAHN Mar CAHN May DISC Mar CAHN N 021583 001 Dec 17, 2004 Mar CAHN N 011839 001 N 011839 003 N 011839 004 Mar CAHN Mar CAHN Mar CAHN A 209209 001 Sep 18, 2020 Mar DISC A 076392 001 Dec 29, 2003 Aug CTEC A 076523 001 Oct 01, 2004 Aug CMFD A 209487 A 209487 A 211398 A 211398 001 Jun 01, 2020 002 Jun 01, 2020 001 Mar 09, 2021 002 Mar 09, 2021 Feb CTEC Feb CTEC Feb NEWA Feb NEWA A 077920 A 077920 A 077920 A 077920 001 Jul 19, 2006 002 Jul 19, 2006 001 Jul 19, 2006 002 Jul 19, 2006 Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 207809 001 Mar 22, 2017 Jan CAHN N 020207 001 Nov 18, 1992 Jan DISC A 204817 A 090303 A 212960 A 212960 A 211463 001 May 17, 2019 001 Oct 28, 2010 001 May 28, 2021 001 May 28, 2021 001 Sep 13, 2019 Jul CAHN Jul CAHN May NEWA Aug CAHN Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -85 AB AB AB AB AB AB AB AB >A> AB >A> AB >A> AB >A> AB >D> AB >D> AB >D> AB >D> AB AA MEMANTINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL MEMANTINE HYDROCHLORIDE AUROBINDO PHARMA LTD 7MG 14MG 21MG 28MG @ MYLAN 7MG @ 14MG @ 21MG @ 28MG YICHANG HUMANWELL 7MG 14MG 21MG 28MG NAMENDA XR + ALLERGAN 7MG + 14MG + 21MG +! 28MG + FOREST LABS LLC 7MG + 14MG + 21MG +! 28MG SOLUTION;ORAL MEMANTINE HYDROCHLORIDE SETON PHARMS 2MG/ML TABLET;ORAL MEMANTINE HYDROCHLORIDE @ JUBILANT GENERICS 5MG @ 10MG MEPERIDINE HYDROCHLORIDE INJECTABLE;INJECTION DEMEROL @ VALIDUS PHARMS 25MG/ML @ 50MG/ML @ 75MG/ML @ 100MG/ML MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE + @ ICU MEDICAL INC 10MG/ML SYRUP;ORAL DEMEROL @ VALIDUS PHARMS 50MG/5ML TABLET;ORAL DEMEROL + @ VALIDUS PHARMS + @ 50MG 100MG MEPROBAMATE TABLET;ORAL MEPROBAMATE AA ! ALEMBIC PHARMS LTD AA ! + @ WATSON LABS @ + @ @ 200MG 400MG 200MG 200MG 400MG 400MG MEROPENEM INJECTABLE;INJECTION MEROPENEM AP EUGIA PHARMA AP 500MG/VIAL 1GM/VIAL MEROPENEM; VABORBACTAM POWDER;INTRAVENOUS VABOMERE +! REMPEX 1GM/VIAL;1GM/VIAL A 214651 A 214651 A 214651 A 214651 A 206032 A 206032 A 206032 A 206032 A 211100 A 211100 A 211100 A 211100 001 Aug 09, 2021 002 Aug 09, 2021 003 Aug 09, 2021 004 Aug 09, 2021 001 Sep 28, 2016 002 Sep 28, 2016 003 Sep 28, 2016 004 Sep 28, 2016 001 Apr 02, 2021 002 Apr 02, 2021 003 Apr 02, 2021 004 Apr 02, 2021 Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul DISC Jul DISC Jul DISC Jul DISC Mar NEWA Mar NEWA Mar NEWA Mar NEWA N 022525 N 022525 N 022525 N 022525 N 022525 N 022525 N 022525 N 022525 001 Jun 21, 2010 002 Jun 21, 2010 003 Jun 21, 2010 004 Jun 21, 2010 001 Jun 21, 2010 002 Jun 21, 2010 003 Jun 21, 2010 004 Jun 21, 2010 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 210319 001 Aug 31, 2020 May CAHN A 091585 001 Oct 13, 2015 Jun DISC A 091585 002 Oct 13, 2015 Jun DISC N 005010 007 N 005010 002 N 005010 009 N 005010 003 Feb CAHN Feb CAHN Feb CAHN Feb CAHN A 088432 001 Aug 16, 1984 Aug CRLD N 005010 005 Feb CAHN N 005010 001 N 005010 004 Feb CAHN Feb CAHN A 090122 A 090122 A 083304 A 083304 A 083308 A 083308 001 Feb 18, 2009 002 Feb 18, 2009 001 001 001 001 Mar CHRS Mar CHRS Aug CRLD Mar DISC Aug CRLD Mar DISC A 205835 001 Mar 27, 2017 Aug CAHN A 205835 002 Mar 27, 2017 Aug CAHN N 209776 001 Aug 29, 2017 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -86 AB AB >D> AB AB >A> AB MESALAMINE CAPSULE, EXTENDED RELEASE;ORAL MESALAMINE ALKEM LABS LTD 375MG ZYDUS PHARMS 375MG SUPPOSITORY;RECTAL MESALAMINE APTAPHARMA INC 1GM 1GM PHARM SOURCING 1GM METARAMINOL BITARTRATE INJECTABLE;INJECTION METARAMINOL BITARTRATE SLAYBACK PHARMA LLC EQ 10MG BASE/ML >A> BX >D> BX BX METAXALONE TABLET;ORAL METAXALONE APPCO RISING 800MG 800MG 800MG METFORMIN HYDROCHLORIDE TABLET;ORAL METFORMIN HYDROCHLORIDE AB CHARTWELL AB AB @ INDICUS PHARMA @ @ 500MG 625MG 750MG 850MG 1GM 500MG 850MG 1GM TABLET, EXTENDED RELEASE;ORAL METFORMIN HYDROCHLORIDE AB3 AJANTA PHARMA LTD AB3 AB ! ALKEM LABS LTD BX AMNEAL PHARMS NY BX BX ! AB2 AMTA AB2 @ APOTEX AB3 GRANULES AB3 AB3 SCIEGEN PHARMS INC AB3 AB2 TWI PHARMS AB2 AB1 UNICHEM AB 500MG 1GM 750MG 500MG 750MG 750MG 500MG 1GM 500MG 500MG 1GM 500MG 1GM 500MG 1GM 500MG 750MG METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE TABLET;ORAL PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE @ SANDOZ @ @ TORRENT PHARMS LTD @ 500MG;EQ 15MG BASE 850MG;EQ 15MG BASE 500MG;EQ 15MG BASE 850MG;EQ 15MG BASE METHADONE HYDROCHLORIDE CONCENTRATE;ORAL METHADONE HYDROCHLORIDE @ LANNETT CO INC AA 10MG/ML 10MG/ML SOLUTION;ORAL METHADONE HYDROCHLORIDE AA +! HIKMA PHARMS AA +! 5MG/5ML 10MG/5ML A 214242 001 Jul 15, 2021 Jul NEWA A 208954 001 Aug 12, 2021 Aug NEWA A 207448 001 Apr 19, 2019 A 207448 001 Apr 19, 2019 A 207448 001 Apr 19, 2019 Oct CAHN Sep CAHN Oct CAHN A 211304 001 Aug 24, 2021 Aug NEWA A 208774 001 Sep 24, 2018 A 208774 001 Sep 24, 2018 A 208774 001 Sep 24, 2018 Oct CAHN Oct CAHN Sep CTEC A 075972 A 075972 A 075972 A 075972 A 075972 A 079148 A 079148 A 079148 001 Jan 24, 2002 005 Jan 24, 2002 004 Jan 24, 2002 002 Jan 24, 2002 003 Jan 24, 2002 001 Nov 25, 2008 002 Nov 25, 2008 003 Nov 25, 2008 Jun CAHN Jun CAHN Jun CAHN Jun CAHN Jun CAHN May DISC May DISC May DISC A 213962 A 213962 A 206145 A 078596 A 078596 A 078596 A 213394 A 213394 A 076706 A 213344 A 213344 A 213334 A 213334 A 213247 A 213247 A 213359 A 213359 001 Mar 09, 2021 002 Mar 09, 2021 002 Oct 22, 2018 001 Jan 03, 2008 002 Jan 03, 2008 002 Jan 03, 2008 001 Aug 03, 2021 002 Aug 03, 2021 001 Dec 14, 2004 001 Jan 12, 2021 002 Jan 12, 2021 001 Apr 16, 2021 002 Apr 16, 2021 001 Sep 29, 2021 002 Sep 29, 2021 001 Aug 11, 2021 002 Aug 11, 2021 Feb NEWA Feb NEWA Sep CHRS Sep CTEC Sep CHRS Sep CTEC Jul NEWA Jul NEWA Apr DISC Jan NEWA Jan NEWA Apr NEWA Apr NEWA Sep NEWA Sep NEWA Jul NEWA Jul NEWA A 091273 A 091273 A 202001 A 202001 001 Apr 16, 2013 002 Apr 16, 2013 001 Feb 13, 2013 002 Feb 13, 2013 Sep DISC Sep DISC Jan DISC Jan DISC A 212094 001 Mar 03, 2021 Aug DISC A 212094 001 Mar 03, 2021 Feb NEWA A 087393 001 Aug CRLD A 087997 001 Aug 30, 1982 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -87 METHENAMINE HIPPURATE TABLET;ORAL HIPREX + @ VALIDUS PHARMS 1GM AB +! 1GM METHENAMINE HIPPURATE AB ! AUROBINDO PHARMA LTD 1GM AB NOVAST LABS 1GM UREX AB ALVOGEN 1GM N 017681 001 N 017681 001 Mar DISC Feb CAHN A 205661 001 Jul 05, 2016 Mar CHRS A 210068 001 Nov 27, 2020 Sep CAHN N 016151 001 Jul CAHN METHIMAZOLE TABLET;ORAL METHIMAZOLE AB BIOPHARM AB @ 5MG 10MG 20MG A 040547 001 Feb 18, 2005 A 040547 002 Feb 18, 2005 A 040547 004 Feb 18, 2005 Sep CAHN Sep CAHN Sep CAHN METHOCARBAMOL SOLUTION;IM-IV ROBAXIN AP +! HIKMA PHARMS TABLET;ORAL METHOCARBAMOL @ AUROBINDO PHARMA LTD AA GRANULATION TECH AA AA MLV AA 1GM/10ML (100MG/ML) 750MG 500MG 750MG 500MG 750MG N 011790 001 Jul CAHN A 213967 A 212623 A 212623 A 212623 A 212623 001 Aug 12, 2020 001 Apr 30, 2021 002 Apr 30, 2021 001 Apr 30, 2021 002 Apr 30, 2021 Feb DISC Apr NEWA Apr NEWA Jun CAHN Jun CAHN METHOTREXATE SODIUM INJECTABLE;INJECTION FOLEX + @ PHARMACIA AND UPJOHN EQ 25MG BASE/VIAL A 087695 001 Apr 08, 1983 + @ METHOTREXATE SODIUM EQ 100MG BASE/VIAL A 087695 003 Apr 08, 1983 AP ! HIKMA PHARMS EQ 100MG BASE/4ML (EQ 25MG BASE/ML) ! EQ 200MG BASE/8ML (EQ 25MG BASE/ML) METHOTREXATE SODIUM PRESERVATIVE FREE A 089341 001 Sep 16, 1986 A 089342 001 Sep 16, 1986 AP ! HIKMA PHARMS EQ 50MG BASE/2ML (EQ 25MG BASE/ML) A 089340 001 Sep 16, 1986 AP ! @ MYLAN EQ 250MG BASE/10ML (EQ 25MG A 089343 001 Sep 16, 1986 BASE/ML) EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A 201530 001 Mar 29, 2012 @ MYLAN LABS LTD @ MEXATE EQ 250MG BASE/10ML (EQ 25MG A 201529 004 Mar 29, 2012 BASE/ML) EQ 1GM BASE/40ML (EQ 25MG BASE/ML) A 201530 001 Mar 29, 2012 + @ BRISTOL EQ 20MG BASE/VIAL A 086358 001 + @ EQ 50MG BASE/VIAL A 086358 002 + @ EQ 100MG BASE/VIAL A 086358 003 + @ EQ 250MG BASE/VIAL A 086358 004 TABLET;ORAL METHOTREXATE SODIUM AB LOTUS PHARM CO LTD EQ 2.5MG BASE A 209787 001 Apr 23, 2021 Aug CRLD Aug CRLD Jul CAHN Jul CAHN Jul CAHN Jul CAHN Aug CAHN May DISC Aug DISC Aug CRLD Aug CRLD Aug CRLD Aug CRLD Apr NEWA METHYCLOTHIAZIDE TABLET;ORAL METHYCLOTHIAZIDE @ CHARTWELL RX @ 2.5MG 5MG A 089835 001 Aug 18, 1988 Sep CAHN A 089837 001 Aug 18, 1988 Sep CAHN METHYLDOPA TABLET;ORAL METHYLDOPA ACCORD HLTHCARE ! @ CHARTWELL RX @ @ 250MG 500MG 500MG 125MG 250MG 500MG A 070084 A 070085 A 070085 A 071700 N 018934 N 018934 001 Oct 15, 1985 001 Oct 15, 1985 001 Oct 15, 1985 001 Mar 02, 1988 001 Jun 29, 1984 002 Jun 29, 1984 Sep CTEC Sep CHRS Sep CTEC Sep CAHN Sep CAHN Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -88 TABLET;ORAL METHYLDOPA @ MYLAN @ 250MG 500MG METHYLERGONOVINE MALEATE TABLET;ORAL METHYLERGONOVINE MALEATE AB RISING 0.2MG METHYLPHENIDATE HYDROCHLORIDE SOLUTION;ORAL METHYLPHENIDATE HYDROCHLORIDE AA ASCENT PHARMS INC 5MG/5ML AA 10MG/5ML @ LANNETT CO INC 5MG/5ML @ 10MG/5ML TABLET;ORAL METHYLPHENIDATE HYDROCHLORIDE @ ALVOGEN @ @ AB BIONPHARMA INC AB AB 5MG 10MG 20MG 5MG 10MG 20MG TABLET, EXTENDED RELEASE;ORAL METHYLPHENIDATE HYDROCHLORIDE AB ALVOGEN AB AB AB AB AB BX AMNEAL PHARMS BX BX BX 10MG 18MG 20MG 27MG 36MG 54MG 18MG 27MG 36MG 54MG METHYLPREDNISOLONE TABLET;ORAL METHYLPREDNISOLONE AB AMNEAL AB AB AB AB PRAXGEN 4MG 8MG 16MG 32MG 4MG AP AP AP AP AP >D> AP >A> AP >D> AP >A> AP >D> AP >A> AP >D> AP >A> AP >D> AP >A> AP METHYLPREDNISOLONE SODIUM SUCCINATE INJECTABLE;INJECTION METHYLPREDNISOLONE SODIUM SUCCINATE GENEYORK PHARMS TIANJIN KINGYORK @ @ @ @ @ EQ 40MG BASE/VIAL EQ 125MG BASE/VIAL EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL EQ 40MG BASE/VIAL EQ 40MG BASE/VIAL EQ 40MG BASE/VIAL EQ 125MG BASE/VIAL EQ 125MG BASE/VIAL EQ 125MG BASE/VIAL EQ 500MG BASE/VIAL EQ 500MG BASE/VIAL EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 1GM BASE/VIAL EQ 1GM BASE/VIAL EQ 2GM BASE/VIAL EQ 2GM BASE/VIAL EQ 2GM BASE/VIAL A 070076 002 Apr 18, 1985 Sep DISC A 070076 001 Apr 18, 1985 Sep DISC A 211919 001 Jan 15, 2021 Jan NEWA A 207417 001 Jan 29, 2021 A 207417 002 Jan 29, 2021 A 207414 001 Dec 16, 2020 A 207414 002 Dec 16, 2020 Jan NEWA Jan NEWA Jan DISC Jan DISC A 206840 A 206840 A 206840 A 209753 A 209753 A 209753 001 Sep 15, 2016 002 Sep 15, 2016 003 Sep 15, 2016 001 Mar 02, 2018 002 Mar 02, 2018 003 Mar 02, 2018 Jun CAHN Jun CAHN Jun CAHN Sep CAHN Sep CAHN Sep CAHN A 204772 A 210818 A 204772 A 210818 A 210818 A 210818 A 207515 A 207515 A 207515 A 207515 001 Feb 29, 2016 001 Nov 30, 2018 002 Feb 29, 2016 002 Nov 30, 2018 003 Nov 30, 2018 004 Nov 30, 2018 001 Feb 01, 2018 002 Feb 01, 2018 003 Feb 01, 2018 004 Feb 01, 2018 Jun CAHN Aug CAHN Jun CAHN Aug CAHN Aug CAHN Aug CAHN Sep CTEC Sep CTEC Sep CTEC Sep CTEC A 207481 001 Sep 21, 2021 A 207481 002 Sep 21, 2021 A 207481 003 Sep 21, 2021 A 207481 004 Sep 21, 2021 A 212262 001 Jun 27, 2019 Sep NEWA Sep NEWA Sep NEWA Sep NEWA Feb CAHN A 212396 001 Apr 20, 2021 A 212396 002 Apr 20, 2021 A 212396 003 Apr 20, 2021 A 212396 004 Apr 20, 2021 A 212396 005 Apr 20, 2021 A 212396 001 Apr 20, 2021 A 212396 001 Apr 20, 2021 A 212396 001 Apr 20, 2021 A 212396 002 Apr 20, 2021 A 212396 002 Apr 20, 2021 A 212396 002 Apr 20, 2021 A 212396 003 Apr 20, 2021 A 212396 003 Apr 20, 2021 A 212396 003 Apr 20, 2021 A 212396 004 Apr 20, 2021 A 212396 004 Apr 20, 2021 A 212396 004 Apr 20, 2021 A 212396 005 Apr 20, 2021 A 212396 005 Apr 20, 2021 A 212396 005 Apr 20, 2021 Apr NEWA Apr NEWA Apr NEWA Apr NEWA Apr NEWA Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN Oct DISC Oct DISC May CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -89 METHYLTESTOSTERONE CAPSULE;ORAL TESTRED + @ BAUSCH 10MG METOCLOPRAMIDE HYDROCHLORIDE INJECTABLE;INJECTION REGLAN @ HIKMA PHARMS @ EQ 5MG BASE/ML EQ 10MG BASE/ML METOLAZONE TABLET;ORAL METOLAZONE AB BAYSHORE PHARMS LLC AB AB AB INNOGENIX AB AB AB RUBICON AB AB AB ! SANDOZ AB ! ZAROXOLYN + @ LANNETT CO INC + @ + @ 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 5MG 10MG 2.5MG 5MG 10MG AB AB AB AB >D> AB >D> AB >D> AB >D> AB >A> AB >A> AB >A> AB >A> AB >A> AB AB AB METOPROLOL SUCCINATE TABLET, EXTENDED RELEASE;ORAL METOPROLOL SUCCINATE ACTAVIS ELIZABETH EQ 25MG TARTRATE EQ 50MG TARTRATE EQ 100MG TARTRATE EQ 200MG TARTRATE TWI PHARMS EQ 25MG TARTRATE EQ 50MG TARTRATE EQ 100MG TARTRATE EQ 200MG TARTRATE VISUM PHARM EQ 25MG TARTRATE EQ 50MG TARTRATE EQ 100MG TARTRATE EQ 200MG TARTRATE YICHANG HUMANWELL EQ 50MG TARTRATE EQ 100MG TARTRATE EQ 200MG TARTRATE METOPROLOL TARTRATE TABLET;ORAL LOPRESSOR AB + VALIDUS PHARMS AB + 50MG 100MG AB >A> AB AB AB METRONIDAZOLE GEL;TOPICAL METRONIDAZOLE ALEOR DERMACEUTICALS GEL;VAGINAL METRONIDAZOLE SOLARIS PHARMA CORP TABLET;ORAL METRONIDAZOLE AMICI 1% 0.75% 250MG 500MG A 083976 001 Aug CRLD N 017862 001 Jul CAHN N 017862 004 May 28, 1987 Jul CAHN A 214799 A 214799 A 214799 A 213827 A 213827 A 213827 A 215184 A 215184 A 215184 A 076466 A 076466 001 Mar 30, 2021 002 Mar 30, 2021 003 Mar 30, 2021 001 Mar 30, 2021 002 Mar 30, 2021 003 Mar 30, 2021 001 Aug 20, 2021 002 Aug 20, 2021 003 Aug 20, 2021 001 Dec 19, 2003 002 Dec 19, 2003 Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Aug NEWA Aug NEWA Aug NEWA May CHRS May CHRS N 017386 001 N 017386 002 N 017386 003 May DISC May DISC May DISC A 204161 A 204161 A 204161 A 204161 A 207206 A 207206 A 207206 A 207206 A 207206 A 207206 A 207206 A 207206 A 213854 A 213854 A 213854 001 Nov 25, 2016 002 Nov 25, 2016 003 Nov 25, 2016 004 Nov 25, 2016 001 Dec 19, 2018 002 Dec 19, 2018 003 Dec 19, 2018 004 Dec 19, 2018 001 Dec 19, 2018 002 Dec 19, 2018 003 Dec 19, 2018 004 Dec 19, 2018 003 Nov 08, 2021 001 Feb 12, 2021 002 Feb 12, 2021 May CMFD May CMFD May CMFD May CMFD Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct NEWA Feb NEWA Feb NEWA N 017963 001 N 017963 002 Feb CAHN Feb CAHN A 212646 001 Sep 03, 2021 Aug NEWA A 213648 001 Oct 14, 2021 Oct NEWA A 070772 001 Jul 16, 1986 Sep CAHN A 070772 002 Jul 16, 1986 Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -90 METYROSINE CAPSULE;ORAL DEMSER +! BAUSCH METYROSINE BX AMNEAL 250MG 250MG >D> AB AB >D> AB AB >D> AB AB AB AB AB AB AB AB >A> AB >A> AB >A> AB MEXILETINE HYDROCHLORIDE CAPSULE;ORAL MEXILETINE HYDROCHLORIDE HAVIX 150MG 150MG 200MG 200MG 250MG 250MG NOVAST LABS 150MG 200MG 250MG RICONPHARMA LLC 150MG 200MG 250MG SENORES PHARMS 150MG 200MG 250MG MICAFUNGIN SODIUM INJECTABLE;INTRAVENOUS MICAFUNGIN SODIUM AP HIKMA AP AP JIANGSU HANSOH PHARM AP AP XELLIA PHARMS APS AP POWDER;INTRAVENOUS MICAFUNGIN +! PAR STERILE PRODUCTS +! + @ TEVA PHARMS USA INC +! + @ +! EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 50MG BASE/VIAL EQ 50MG BASE/VIAL EQ 100MG BASE/VIAL EQ 100MG BASE/VIAL MIDAZOLAM SOLUTION;INTRAVENOUS MIDAZOLAM IN 0.9% SODIUM CHLORIDE +! INFORLIFE 50MG/50ML (1MG/ML) +! 100MG/100ML (1MG/ML) MIDAZOLAM HYDROCHLORIDE INJECTABLE;INJECTION MIDAZOLAM HYDROCHLORIDE @ HOSPIRA EQ 1MG BASE/ML @ EQ 5MG BASE/ML MIDODRINE HYDROCHLORIDE TABLET;ORAL MIDODRINE HYDROCHLORIDE AB ALEMBIC PHARMS LTD 2.5MG AB 5MG AB 10MG MIGALASTAT HYDROCHLORIDE CAPSULE;ORAL GALAFOLD +! AMICUS THERAP US EQ 123MG BASE N 017871 001 Sep CTEC A 213734 001 Jul 24, 2020 Sep CTEC A 214089 A 214089 A 214089 A 214089 A 214089 A 214089 A 214352 A 214352 A 214352 A 214352 A 214352 A 214352 A 214089 A 214089 A 214089 001 Oct 01, 2021 001 Oct 01, 2021 002 Oct 01, 2021 002 Oct 01, 2021 003 Oct 01, 2021 003 Oct 01, 2021 001 Jan 25, 2021 002 Jan 25, 2021 003 Jan 25, 2021 001 Jan 25, 2021 002 Jan 25, 2021 003 Jan 25, 2021 001 Oct 01, 2021 002 Oct 01, 2021 003 Oct 01, 2021 Oct CAHN Sep NEWA Oct CAHN Sep NEWA Oct CAHN Sep NEWA Sep CAHN Sep CAHN Sep CAHN Jan NEWA Jan NEWA Jan NEWA Oct CAHN Oct CAHN Oct CAHN A 213261 A 213261 A 213363 A 213363 A 211713 A 211713 001 Jul 09, 2021 002 Jul 09, 2021 001 Jul 09, 2021 002 Jul 09, 2021 001 Jun 02, 2021 002 Jun 02, 2021 Jul NEWA Jul NEWA Jul NEWA Jul NEWA May NEWA May NEWA N 212156 N 212156 N 212125 N 212125 N 212125 N 212125 001 Jun 16, 2021 002 Jun 16, 2021 001 Jul 30, 2021 001 Jul 30, 2021 002 Jul 30, 2021 002 Jul 30, 2021 Jun NEWA Jun NEWA Sep DISC Jul NEWA Sep DISC Jul NEWA N 211844 001 Mar 22, 2021 Mar NEWA N 211844 002 Mar 22, 2021 Mar NEWA A 075856 001 Jun 13, 2002 Aug DISC A 075856 002 Jun 13, 2002 Aug DISC A 214734 001 Jan 21, 2021 A 214734 002 Jan 21, 2021 A 214734 003 Jan 21, 2021 Jan NEWA Jan NEWA Jan NEWA N 208623 001 Aug 10, 2018 Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -91 MIGLITOL TABLET;ORAL GLYSET AB +! PFIZER AB + AB + 25MG 50MG 100MG MILNACIPRAN HYDROCHLORIDE TABLET;ORAL MILNACIPRAN HYDROCHLORIDE @ LIBERTY PHARMA INC @ @ @ @ USPHARMA WINDLAS @ @ @ 12.5MG 25MG 50MG 100MG 12.5MG 25MG 50MG 100MG MILRINONE LACTATE INJECTABLE;INJECTION MILRINONE LACTATE AP CAPLIN EQ 1MG BASE/ML AB AB AB >D> >A> >D> AB >A> >D> AB >A> AB AB AB AB AB MINOCYCLINE HYDROCHLORIDE AEROSOL, FOAM;TOPICAL AMZEEQ +! VYNE ZILXI EQ 4% BASE +! VYNE EQ 1.5% BASE CAPSULE;ORAL DYNACIN ALVOGEN EQ 50MG BASE EQ 75MG BASE EQ 100MG BASE INJECTABLE;INJECTION MINOCIN +! REMPEX EQ 100MG BASE/VIAL TABLET, EXTENDED RELEASE;ORAL MINOCYCLINE HYDROCHLORIDE @ BARR LABS INC @ @ @ @ MYLAN @ @ @ MINOLIRA EQ 65MG BASE EQ 80MG BASE EQ 105MG BASE EQ 115MG BASE EQ 55MG BASE EQ 55MG BASE EQ 80MG BASE EQ 80MG BASE EQ 105MG BASE EQ 105MG BASE ! EPI HLTH SOLODYN EQ 135MG BASE + @ BAUSCH + + + + @ + +! + @ EQ 45MG BASE EQ 55MG BASE EQ 65MG BASE EQ 80MG BASE EQ 90MG BASE EQ 105MG BASE EQ 115MG BASE EQ 135MG BASE MINOXIDIL TABLET;ORAL LONITEN + @ PFIZER + @ 2.5MG 10MG N 020682 001 Dec 18, 1996 N 020682 002 Dec 18, 1996 N 020682 003 Dec 18, 1996 Feb CAHN Feb CAHN Feb CAHN A 205071 A 205071 A 205071 A 205071 A 205071 A 205071 A 205071 A 205071 001 Jan 27, 2016 002 Jan 27, 2016 003 Jan 27, 2016 004 Jan 27, 2016 001 Jan 27, 2016 002 Jan 27, 2016 003 Jan 27, 2016 004 Jan 27, 2016 Aug CAHN Aug CAHN Aug CAHN Aug CAHN Sep CAHN Sep CAHN Sep CAHN Sep CAHN A 214380 001 Apr 16, 2021 Apr NEWA N 212379 001 Oct 18, 2019 Mar CAHN N 213690 001 May 28, 2020 Mar CAHN A 063067 003 Aug 14, 1990 A 063067 002 Sep 15, 1999 A 063067 001 Jul 31, 1990 Jun CAHN Jun CAHN Jun CAHN N 050444 001 May CAHN A 065485 A 065485 A 065485 A 065485 A 203443 A 203443 A 203443 A 203443 A 203443 A 203443 004 May 18, 2012 007 Apr 26, 2017 008 Apr 26, 2017 005 May 18, 2012 001 Aug 21, 2019 001 Aug 21, 2019 002 Aug 22, 2014 002 Aug 22, 2014 003 Aug 22, 2014 003 Aug 22, 2014 May DISC May DISC May DISC May DISC Oct CAHN Oct CAHN Oct DISC Oct DISC Oct DISC Oct DISC N 209269 002 May 08, 2017 Sep CHRS N 050808 N 050808 N 050808 N 050808 N 050808 N 050808 N 050808 N 050808 001 May 08, 2006 008 Aug 27, 2010 004 Jul 23, 2009 007 Aug 27, 2010 002 May 08, 2006 006 Aug 27, 2010 005 Jul 23, 2009 003 May 08, 2006 May CAHN May CAHN May CAHN May CAHN May CAHN May CAHN May CAHN May CAHN N 018154 001 N 018154 003 Feb CAHN Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -92 MIRABEGRON FOR SUSPENSION, EXTENDED RELEASE;ORAL MYRBETRIQ GRANULES +! APGDI 8MG/ML N 213801 001 Mar 25, 2021 Mar NEWA MISOPROSTOL TABLET;ORAL CYTOTEC + PFIZER +! MISOPROSTOL BX NOVEL LABS INC BX 0.1MG 0.2MG 0.1MG 0.2MG N 019268 003 Sep 21, 1990 Sep CTEC N 019268 001 Dec 27, 1988 Sep CTEC A 091667 001 Jul 25, 2012 Sep CTEC A 091667 002 Jul 25, 2012 Sep CTEC >A> AP >A> AP >A> >A> AP >A> AP >A> AP >A> AP >D> >D> AP >D> AP >D> AP >D> AP MITOMYCIN INJECTABLE;INJECTION MITOMYCIN GLAND PHARMA LTD @ HIKMA PHARMS @ WEST-WARD PHARMS INT 5MG/VIAL 20MG/VIAL 5MG/VIAL 5MG/VIAL 20MG/VIAL 20MG/VIAL 40MG/VIAL 5MG/VIAL 5MG/VIAL 20MG/VIAL 20MG/VIAL 40MG/VIAL A 215687 A 215687 A 064117 A 064180 A 064117 A 064180 A 064117 A 064117 A 064180 A 064117 A 064180 A 064117 001 Oct 20, 2021 002 Oct 20, 2021 001 Apr 19, 1995 001 Dec 23, 1999 002 Apr 19, 1995 002 Dec 23, 1999 003 Jun 02, 1999 001 Apr 19, 1995 001 Dec 23, 1999 002 Apr 19, 1995 002 Dec 23, 1999 003 Jun 02, 1999 Oct NEWA Oct NEWA Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN MIVACURIUM CHLORIDE SOLUTION;INTRAVENOUS MIVACURIUM CHLORIDE >A> WOODWARD >A> EQ 10MG BASE/5ML (EQ 2MG BASE/ML) A 209708 001 Oct 12, 2021 Oct NFTG EQ 20MG BASE/10ML (EQ 2MG BASE/ML) A 209708 002 Oct 12, 2021 Oct NFTG MOBOCERTINIB SUCCINATE CAPSULE;ORAL EXKIVITY +! TAKEDA PHARMS USA EQ 40MG BASE N 215310 001 Sep 15, 2021 Sep NEWA MODAFINIL TABLET;ORAL MODAFINIL @ MYLAN PHARMS INC @ 100MG 200MG A 076594 001 Jul 16, 2012 Jul DISC A 076594 002 Jul 16, 2012 Jul DISC MOMETASONE FUROATE AEROSOL, METERED;INHALATION ASMANEX HFA + ORGANON 0.05MG/INH + 0.10MG/INH +! 0.20MG/INH OINTMENT;TOPICAL MOMETASONE FUROATE @ TORRENT 0.1% POWDER;INHALATION ASMANEX TWISTHALER + ORGANON 0.11MG/INH +! 0.22MG/INH SPRAY, METERED;NASAL MOMETASONE FUROATE AB ! APOTEX INC NASONEX 0.05MG/SPRAY + @ ORGANON 0.05MG/SPRAY AB +! 0.05MG/SPRAY N 205641 003 Aug 12, 2019 N 205641 001 Apr 25, 2014 N 205641 002 Apr 25, 2014 Jun CAHN Jun CAHN Jun CAHN A 207899 001 Jul 13, 2018 Jan DISC N 021067 002 Feb 01, 2008 Jun CAHN N 021067 001 Mar 30, 2005 Jun CAHN A 091161 001 Mar 22, 2016 May CHRS N 020762 001 Oct 01, 1997 May DISC N 020762 001 Oct 01, 1997 Feb CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -93 MONTELUKAST SODIUM TABLET;ORAL MONTELUKAST SODIUM @ AJANTA PHARMA LTD @ BRECKENRIDGE TABLET, CHEWABLE;ORAL MONTELUKAST SODIUM @ AJANTA PHARMA LTD @ @ HIKMA PHARMS @ AB UNICHEM AB EQ 10MG BASE EQ 10MG BASE EQ 4MG BASE EQ 5MG BASE EQ 4MG BASE EQ 5MG BASE EQ 4MG BASE EQ 5MG BASE MORPHINE SULFATE CAPSULE, EXTENDED RELEASE;ORAL KADIAN + @ ALLERGAN + @ + @ + @ + @ + @ + @ + @ + @ + @ + @ + @ MORPHINE SULFATE 10MG 20MG 30MG 40MG 50MG 60MG 70MG 80MG 100MG 130MG 150MG 200MG IMPAX LABS INC AB NORTEC DEV ASSOC AB AB AB AB AB ! UPSHER SMITH LABS AB ! 40MG 20MG 30MG 50MG 60MG 80MG 100MG 10MG 10MG 100MG INJECTABLE;INJECTION MORPHINE SULFATE +! HOSPIRA INC 50MG/ML SOLUTION;ORAL MORPHINE SULFATE @ ANI PHARMS @ @ @ WINDER LABS LLC AA @ AA @ AA 10MG/5ML 20MG/5ML 100MG/5ML 10MG/5ML 10MG/5ML 20MG/5ML 20MG/5ML 100MG/5ML 100MG/5ML TABLET;ORAL MORPHINE SULFATE AB UPSHER SMITH LABS 15MG AB 30MG MOXIFLOXACIN HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC MOXIFLOXACIN HYDROCHLORIDE AT1 UPSHER SMITH LABS EQ 0.5% BASE MUPIROCIN CALCIUM CREAM;TOPICAL MUPIROCIN AB ENCUBE EQ 2% BASE A 203432 001 Jul 31, 2015 Jul DISC A 205319 001 Oct 30, 2020 Sep CAHN A 203328 A 203328 A 091128 A 091128 A 208621 A 208621 001 Jul 31, 2015 002 Jul 31, 2015 001 Aug 03, 2012 002 Aug 03, 2012 001 Jul 02, 2018 002 Jul 02, 2018 Jul DISC Jul DISC Jul DISC Jul DISC Aug CMFD Aug CMFD N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 N 020616 008 Apr 20, 2007 001 Jul 03, 1996 004 Mar 09, 2001 009 Jul 09, 2012 002 Jul 03, 1996 005 Mar 09, 2001 010 Jul 09, 2012 006 Oct 27, 2006 003 Jul 03, 1996 011 Jul 09, 2012 012 Jul 09, 2012 007 Feb 27, 2007 Sep DISC Sep DISC Sep DISC May DISC Sep DISC Sep DISC May DISC Sep DISC Sep DISC May DISC May DISC May DISC A 200411 A 203158 A 203158 A 203158 A 203158 A 203158 A 203158 A 202104 A 202104 A 202104 007 Jul 25, 2018 001 Aug 04, 2021 002 Aug 04, 2021 003 Aug 04, 2021 004 Aug 04, 2021 005 Aug 04, 2021 006 Aug 04, 2021 001 Jun 03, 2013 001 Jun 03, 2013 007 Jun 03, 2013 May CTEC Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA Sep CHRS Sep CTEC Sep CHRS N 202515 006 Apr 29, 2021 Apr NEWA A 205509 A 205509 A 205509 A 211454 A 211454 A 211454 A 211454 A 211454 A 211454 001 Apr 17, 2018 002 Apr 17, 2018 003 Apr 17, 2018 001 Feb 12, 2021 001 Feb 12, 2021 002 Feb 12, 2021 002 Feb 12, 2021 003 Feb 12, 2021 003 Feb 12, 2021 Jan DISC Jan DISC Jan DISC Aug DISC Feb NEWA Aug DISC Feb NEWA Aug DISC Feb NEWA A 210610 001 Jul 22, 2019 May CAHN A 210610 002 Jul 22, 2019 May CAHN A 212616 001 Feb 10, 2021 Jan NEWA A 213076 001 Aug 31, 2021 Aug NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -94 >A> >A> >A> AB >A> >A> AB >A> AB >A> AB >D> >D> >D> AB >D> >D> AB >A> AB >D> AB AB >D> AB MYCOPHENOLATE MOFETIL FOR SUSPENSION;ORAL CELLCEPT +! ROCHE PALO MYCOPHENOLATE MOFETIL ALKEM LABS LTD LANNETT CO INC VISTAPHARM SUSPENSION;ORAL CELLCEPT +! ROCHE PALO MYCOPHENOLATE MOFETIL ALKEM LABS LTD AMNEAL LANNETT CO INC VISTAPHARM 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML 200MG/ML MYCOPHENOLATE MOFETIL HYDROCHLORIDE INJECTABLE;INJECTION MYCOPHENOLATE MOFETIL HYDROCHLORIDE @ AMNEAL 500MG/VIAL AP 500MG/VIAL AP MEITHEAL 500MG/VIAL AP NANJING KING-FRIEND 500MG/VIAL AB AB AB AB >A> AB >A> AB MYCOPHENOLIC ACID TABLET, DELAYED RELEASE;ORAL MYCOPHENOLIC ACID ALKEM LABS LTD AMTA TWI PHARMS 180MG 360MG 180MG 360MG 180MG 360MG NABUMETONE TABLET;ORAL NABUMETONE AB ANNORA PHARMA AB 500MG 750MG NADOLOL TABLET;ORAL NADOLOL @ NOVAST LABS @ @ AB VGYAAN AB AB 20MG 40MG 80MG 20MG 40MG 80MG AP >D> AP >A> >A> >A> >A> NALOXONE HYDROCHLORIDE INJECTABLE;INJECTION NALOXONE HYDROCHLORIDE @ BAXTER HLTHCARE CORP ! HOSPIRA @ 0.4MG/ML 0.4MG/ML 0.4MG/ML 0.4MG/ML SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS ZIMHI +! ADAMIS PHARMS CORP 5MG/0.5ML (5MG/0.5ML) SPRAY;NASAL KLOXXADO +! HIKMA PHARMS 8MG/SPRAY N 050759 001 Oct 01, 1998 Oct CDFR A 203005 001 Nov 14, 2014 A 214525 001 Jul 29, 2021 A 210370 001 Feb 12, 2019 Oct CDFR Oct CDFR Oct CDFR N 050759 001 Oct 01, 1998 Oct CDFR A 203005 A 214871 A 214525 A 214525 A 210370 001 Nov 14, 2014 001 Nov 02, 2021 001 Jul 29, 2021 001 Jul 29, 2021 001 Feb 12, 2019 Oct CDFR Oct NEWA Oct CDFR Jul NEWA Oct CDFR A 211374 A 211374 A 212130 A 212130 001 Mar 05, 2021 001 Mar 05, 2021 001 Jan 15, 2021 001 Jan 15, 2021 Sep DISC Feb NEWA Jan CAHN Jan NEWA A 208315 A 208315 A 214376 A 214376 A 214289 A 214289 001 Sep 23, 2021 002 Sep 23, 2021 001 Feb 10, 2021 002 Feb 10, 2021 001 Nov 03, 2021 002 Nov 03, 2021 Sep NEWA Sep NEWA Jan NEWA Jan NEWA Oct NEWA Oct NEWA A 090445 001 Jan 12, 2011 Mar CAHN A 090445 002 Jan 12, 2011 Mar CAHN A 210786 A 210786 A 210786 A 212856 A 212856 A 212856 001 Jun 01, 2018 002 Jun 01, 2018 003 Jun 01, 2018 001 Sep 13, 2019 002 Sep 13, 2019 003 Sep 13, 2019 May DISC May DISC May DISC May CMFD May CMFD May CMFD A 214785 A 214785 A 070254 A 070254 001 Jan 29, 2021 001 Jan 29, 2021 001 Jan 07, 1987 001 Jan 07, 1987 Jul DISC Jan NEWA Oct DISC Oct DISC N 212854 001 Oct 15, 2021 Oct NEWA N 212045 001 Apr 29, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -95 NALTREXONE HYDROCHLORIDE TABLET;ORAL REVIA + @ TEVA WOMENS 50MG NANDROLONE DECANOATE INJECTABLE;INJECTION NANDROLONE DECANOATE + @ WATSON LABS 200MG/ML NAPHAZOLINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC NAPHCON FORTE + @ ALCON 0.1% NAPROXEN SUSPENSION;ORAL NAPROXEN AB NOVITIUM PHARMA TABLET;ORAL NAPROXEN AB GRANULES AB AB AB L PERRIGO CO AB AB 25MG/ML 250MG 375MG 500MG 250MG 375MG 500MG NEBIVOLOL HYDROCHLORIDE TABLET;ORAL NEBIVOLOL HYDROCHLORIDE AB ANI PHARMS EQ 2.5MG BASE AB EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB INDCHEMIE HEALTH EQ 2.5MG BASE AB EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB TORRENT EQ 2.5MG BASE AB EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE NEOSTIGMINE METHYLSULFATE SOLUTION;INTRAVENOUS NEOSTIGMINE METHYLSULFATE AP CAPLIN AP AP HONG KONG AP AP INDOCO AP AP MEITHEAL AP 5MG/10ML (0.5MG/ML) 10MG/10ML (1MG/ML) 5MG/10ML (0.5MG/ML) 10MG/10ML (1MG/ML) 5MG/10ML (0.5MG/ML) 10MG/10ML (1MG/ML) 5MG/10ML (0.5MG/ML) 10MG/10ML (1MG/ML) NIACIN TABLET;ORAL NICOLAR + @ SANOFI AVENTIS US 500MG TABLET, EXTENDED RELEASE;ORAL NIACIN @ JUBILANT GENERICS @ @ AB ! SUN PHARM AB ! NIASPAN 500MG 750MG 1GM 750MG 1GM + @ ABBVIE + @ + @ 500MG 750MG 1GM N 018932 001 Nov 20, 1984 Jul CRLD A 088128 001 Dec 05, 1983 Aug CRLD A 080229 001 Aug CRLD A 211910 001 Mar 10, 2021 Feb NEWA A 074140 A 074140 A 074140 A 077339 A 077339 A 077339 001 Dec 21, 1993 002 Dec 21, 1993 003 Dec 21, 1993 001 Apr 27, 2005 002 Apr 27, 2005 003 Apr 27, 2005 Feb CMFD Feb CMFD Feb CMFD Jul CAHN Jul CAHN Jul CAHN A 203659 A 203659 A 203659 A 203659 A 203828 A 203828 A 203828 A 203828 A 203966 A 203966 A 203966 A 203966 001 Apr 16, 2015 002 Apr 16, 2015 003 Apr 16, 2015 004 Apr 16, 2015 001 Jul 29, 2015 002 Jul 29, 2015 003 Jul 29, 2015 004 Jul 29, 2015 001 Mar 02, 2018 002 Mar 02, 2018 003 Mar 02, 2018 004 Mar 02, 2018 Jul CMFD Jul CMFD Jul CMFD Jul CMFD Jul CMFD Jul CMFD Jul CMFD Jul CMFD Aug CMFD Aug CMFD Aug CMFD Aug CMFD A 213074 A 213074 A 212804 A 212804 A 210652 A 210652 A 212804 A 212804 001 Apr 20, 2021 002 Apr 20, 2021 001 Apr 05, 2021 002 Apr 05, 2021 001 Oct 01, 2021 002 Oct 01, 2021 001 Apr 05, 2021 002 Apr 05, 2021 Apr NEWA Apr NEWA Mar NEWA Mar NEWA Sep NEWA Sep NEWA Apr CAHN Apr CAHN A 083823 001 Aug CRLD A 209156 A 209156 A 209156 A 201273 A 200484 001 May 14, 2018 002 May 14, 2018 003 May 14, 2018 001 Apr 23, 2014 002 Apr 23, 2014 Jun DISC Jun DISC Jun DISC Aug CHRS Aug CHRS N 020381 002 Jul 28, 1997 N 020381 003 Jul 28, 1997 N 020381 004 Jul 28, 1997 Aug DISC Aug DISC Aug DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -96 NICARDIPINE HYDROCHLORIDE CAPSULE;ORAL NICARDIPINE HYDROCHLORIDE AB ANI PHARMS AB AB EPIC PHARMA AB ! 20MG 30MG 20MG 30MG INJECTABLE;INJECTION NICARDIPINE HYDROCHLORIDE AP ! AM REGENT ! AP SUN PHARM @ 25MG/10ML (2.5MG/ML) 25MG/10ML (2.5MG/ML) 25MG/10ML (2.5MG/ML) 25MG/10ML (2.5MG/ML) NIFEDIPINE TABLET, EXTENDED RELEASE;ORAL NIFEDIPINE AB1 AB1 AB1 >D> >A> AB2 AUROBINDO PHARMA LTD @ ELITE @ ELITE PHARM SOLUTION @ @ MYLAN @ @ @ PAR PHARM @ @ 30MG 60MG 90MG 90MG 90MG 90MG 90MG 30MG 60MG 90MG 30MG 60MG 90MG NIMODIPINE CAPSULE;ORAL NIMODIPINE BX SOFGEN PHARMS 30MG NISOLDIPINE TABLET, EXTENDED RELEASE;ORAL NISOLDIPINE ! MYLAN 20MG 30MG NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL NITROFURANTOIN AB ALEMBIC PHARMS LTD 25MG AB 50MG AB 100MG NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINE CAPSULE;ORAL NITROFURANTOIN (MONOHYDRATE/MACROCRYSTALS) @ MYLAN 75MG;25MG NITROGLYCERIN FILM, EXTENDED RELEASE;TRANSDERMAL MINITRAN @ BAUSCH NITRO-DUR 0.4MG/HR +! USPHARMA +! +! +! 0.1MG/HR 0.2MG/HR 0.4MG/HR 0.6MG/HR POWDER;SUBLINGUAL GONITRO + @ POHL BOSKAMP +! + @ 0.4MG/PACKET 0.4MG/PACKET 0.4MG/PACKET TABLET;SUBLINGUAL NITROGLYCERIN AB RUBICON 0.3MG A 074670 A 074670 A 074928 A 074928 001 Oct 28, 1996 002 Oct 28, 1996 001 Mar 19, 1998 002 Mar 19, 1998 May CMFD May CMFD May CTEC May CTEC A 090534 A 090534 N 078405 N 078405 001 Nov 17, 2009 001 Nov 17, 2009 001 Nov 17, 2009 001 Nov 17, 2009 Apr CTEC Feb CHRS Jun CMFD Jun CAHN A 213361 A 213361 A 213361 A 212016 A 212016 A 212016 A 212016 A 201071 A 201071 A 201071 A 077899 A 077899 A 077899 001 Jul 19, 2021 002 Jul 19, 2021 003 Jul 19, 2021 001 Nov 18, 2020 001 Nov 18, 2020 001 Nov 18, 2020 001 Nov 18, 2020 001 Dec 03, 2010 002 Dec 03, 2010 003 Dec 03, 2010 001 Dec 13, 2006 002 Dec 13, 2006 003 May 25, 2012 Jul NEWA Jul NEWA Jul NEWA Jun DISC Oct CMFD Oct CMFD Sep CAHN Jul DISC Jul DISC Jul DISC Apr DISC Apr DISC Apr DISC A 201832 001 Jul 24, 2015 Sep CTEC A 079051 001 Jul 25, 2008 Jan CHRS A 079051 002 Jul 25, 2008 Jan CHRS A 211935 001 Jun 25, 2021 A 211935 002 Jun 25, 2021 A 211935 003 Jun 25, 2021 Jun NEWA Jun NEWA Jun NEWA A 076648 001 Mar 22, 2004 Jul DISC A 089773 001 Aug 30, 1996 May CAHN N 020145 N 020145 N 020145 N 020145 001 Apr 04, 1995 002 Apr 04, 1995 004 Apr 04, 1995 005 Apr 04, 1995 Aug CTEC Aug CTEC Aug CTEC Aug CTEC N 208424 001 Jun 08, 2016 N 208424 001 Jun 08, 2016 N 208424 001 Jun 08, 2016 Sep DISC Jul CMFD Jun DISC A 209779 001 May 03, 2021 Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -97 TABLET;SUBLINGUAL NITROGLYCERIN AB AB 0.4MG 0.6MG NOREPINEPHRINE BITARTRATE INJECTABLE;INJECTION NOREPINEPHRINE BITARTRATE AP ANDERSEN GLOBAL EQ 1MG BASE/ML AP BRECKENRIDGE EQ 1MG BASE/ML AP GLAND PHARMA LTD EQ 1MG BASE/ML AP SUN PHARM EQ 1MG BASE/ML SOLUTION;INTRAVENOUS NOREPINEPHRINE BITARTRATE IN 5% DEXTROSE +! BAXTER HLTHCARE CORP + @ +! +! + @ +! EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) EQ 4MG BASE/250ML (EQ 16MCG BASE/ML) EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) EQ 8MG BASE/250ML (EQ 32MCG BASE/ML) NORTRIPTYLINE HYDROCHLORIDE CAPSULE;ORAL NORTRIPTYLINE HYDROCHLORIDE @ ZYDUS AB @ AB @ AB @ AB EQ 10MG BASE EQ 10MG BASE EQ 25MG BASE EQ 25MG BASE EQ 50MG BASE EQ 50MG BASE EQ 75MG BASE EQ 75MG BASE AT AT AT >A> AA >D> AA AA >A> >D> NYSTATIN CREAM;TOPICAL NYSTATIN MACLEODS PHARMS LTD OINTMENT;TOPICAL NYSTATIN MACLEODS PHARMS LTD POWDER;TOPICAL NYSTATIN ZYDUS PHARMS SUSPENSION;ORAL NYSTATIN DASTECH GENERICS NIVAGEN PHARMS INC TABLET;ORAL NYSTATIN @ CHARTWELL RX @ UPSHER SMITH LABS 100,000 UNITS/GM 100,000 UNITS/GM 100,000 UNITS/GM 100,000 UNITS/ML 100,000 UNITS/ML 100,000 UNITS/ML 500,000 UNITS 500,000 UNITS NYSTATIN; TRIAMCINOLONE ACETONIDE CREAM;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE AT ALEOR DERMACEUTICALS 100,000 UNITS/GM;0.1% OINTMENT;TOPICAL NYSTATIN AND TRIAMCINOLONE ACETONIDE AT MACLEODS PHARMS LTD 100,000 UNITS/GM;0.1% ODEVIXIBAT CAPSULE;ORAL BYLVAY + ALBIREO +! 0.4MG 1.2MG A 209779 002 May 03, 2021 Apr NEWA A 209779 003 May 03, 2021 Apr NEWA A 214455 A 214455 A 214323 A 211980 001 Jan 22, 2021 001 Jan 22, 2021 001 May 06, 2021 001 Jan 29, 2021 Jan NEWA Mar CAHN Apr NEWA Jan NEWA N 214313 001 Jan 15, 2021 Sep CMFD N 214313 001 Jan 15, 2021 Jul DISC N 214313 001 Jan 15, 2021 Jan NEWA N 214313 002 Jan 15, 2021 Sep CMFD N 214313 002 Jan 15, 2021 Jul DISC N 214313 002 Jan 15, 2021 Jan NEWA A 213441 001 Feb 24, 2021 A 213441 001 Feb 24, 2021 A 213441 002 Feb 24, 2021 A 213441 002 Feb 24, 2021 A 213441 003 Feb 24, 2021 A 213441 003 Feb 24, 2021 A 213441 004 Feb 24, 2021 A 213441 004 Feb 24, 2021 Aug DISC Feb NEWA Aug DISC Feb NEWA Aug DISC Feb NEWA Aug DISC Feb NEWA A 213566 001 Aug 10, 2021 Jul NEWA A 213826 001 Jan 14, 2021 Jan NEWA A 208581 001 Jun 08, 2017 Jul CAHN A 062832 001 Dec 27, 1991 A 062832 001 Dec 27, 1991 A 062832 001 Dec 27, 1991 Oct CAHN Oct CAHN Jun CAHN A 062524 001 Nov 26, 1985 Oct CAHN A 062524 001 Nov 26, 1985 Oct CAHN A 214090 001 Mar 31, 2021 Mar NEWA A 214751 001 Aug 17, 2021 Aug NEWA N 215498 002 Jul 20, 2021 Jul NEWA N 215498 004 Jul 20, 2021 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -98 CAPSULE, PELLETS;ORAL BYLVAY + ALBIREO +! 0.2MG 0.6MG OFLOXACIN SOLUTION/DROPS;OPHTHALMIC OFLOXACIN @ ALVOGEN @ 0.3% 0.3% SOLUTION/DROPS;OTIC OFLOXACIN @ ALVOGEN 0.3% TABLET;ORAL FLOXIN + @ JANSSEN PHARMS + @ + @ OFLOXACIN 200MG 300MG 400MG AB LARKEN LABS 400MG AB AB AB AB AB AB >D> >A> AB >D> >A> AB >D> >A> AB >D> >A> AB AB AB AB AB AB AB AB AB OLANZAPINE TABLET;ORAL OLANZAPINE @ HISUN PHARM HANGZHOU 2.5MG 2.5MG @ 5MG 5MG @ 7.5MG 7.5MG @ 10MG 10MG @ 15MG 15MG @ 20MG 20MG TABLET, ORALLY DISINTEGRATING;ORAL OLANZAPINE @ HEC PHARM 5MG 5MG @ 10MG 10MG @ 15MG 15MG @ 20MG 20MG @ HISUN PHARM HANGZHOU 5MG 5MG @ 10MG 10MG @ 15MG 15MG @ 20MG 20MG TORRENT 5MG 10MG 15MG 20MG OLANZAPINE; SAMIDORPHAN L-MALATE TABLET;ORAL LYBALVI +! ALKERMES INC 5MG;EQ 10MG BASE + 10MG;EQ 10MG BASE + 15MG;EQ 10MG BASE + 20MG;EQ 10MG BASE N 215498 001 Jul 20, 2021 Jul NEWA N 215498 003 Jul 20, 2021 Jul NEWA A 076830 001 Aug 31, 2004 Jun CAHN A 076830 001 Aug 31, 2004 Jan DISC A 090395 001 Aug 11, 2009 Jun CAHN N 019735 001 Dec 28, 1990 N 019735 002 Dec 28, 1990 N 019735 003 Dec 28, 1990 Jan CRLD Jan CRLD Jan CRLD A 076093 003 Sep 02, 2003 May CMFD A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 A 206924 001 Dec 31, 2020 001 Dec 31, 2020 002 Dec 31, 2020 002 Dec 31, 2020 003 Dec 31, 2020 003 Dec 31, 2020 004 Dec 31, 2020 004 Dec 31, 2020 005 Dec 31, 2020 005 Dec 31, 2020 006 Dec 31, 2020 006 Dec 31, 2020 Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN A 208146 A 208146 A 208146 A 208146 A 208146 A 208146 A 208146 A 208146 A 206892 A 206892 A 206892 A 206892 A 206892 A 206892 A 206892 A 206892 A 091415 A 091415 A 091415 A 091415 001 Jul 02, 2018 001 Jul 02, 2018 002 Jul 02, 2018 002 Jul 02, 2018 003 Jul 02, 2018 003 Jul 02, 2018 004 Jul 02, 2018 004 Jul 02, 2018 001 Dec 31, 2020 001 Dec 31, 2020 002 Dec 31, 2020 002 Dec 31, 2020 003 Dec 31, 2020 003 Dec 31, 2020 004 Dec 31, 2020 004 Dec 31, 2020 001 Oct 25, 2011 002 Oct 25, 2011 003 Oct 25, 2011 004 Oct 25, 2011 Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN Jul DISC Feb CAHN Aug CAHN Aug CAHN Aug CAHN Aug CAHN N 213378 N 213378 N 213378 N 213378 001 May 28, 2021 002 May 28, 2021 003 May 28, 2021 004 May 28, 2021 May NEWA May NEWA May NEWA May NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -99 OLMESARTAN MEDOXOMIL TABLET;ORAL OLMESARTAN MEDOXOMIL @ LUPIN LTD @ @ @ MYLAN @ @ 5MG 20MG 40MG 5MG 20MG 40MG A 206631 001 Apr 27, 2017 A 206631 002 Apr 27, 2017 A 206631 003 Apr 27, 2017 A 078276 001 Oct 26, 2016 A 078276 002 Oct 26, 2016 A 078276 003 Oct 26, 2016 Aug DISC Aug DISC Aug DISC Jul DISC Jul DISC Jul DISC OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE AKORN SOMERSET THERAPS LLC @ WOCKHARDT LTD EQ 0.2% BASE EQ 0.1% BASE EQ 0.1% BASE SPRAY, METERED;NASAL OLOPATADINE HYDROCHLORIDE AB AMNEAL @ 0.665MG/SPRAY 0.665MG/SPRAY A 204723 001 Dec 05, 2017 Mar CTEC A 206306 001 Dec 07, 2015 Jul CTEC A 200810 001 Jun 28, 2017 Jul DISC A 210901 001 Jan 28, 2020 Mar CMFD A 210901 001 Jan 28, 2020 Jan DISC >A> >D> OLSALAZINE SODIUM CAPSULE;ORAL DIPENTUM +! MYLAN SPCLT VIATRIS +! MYLAN SPECIALITY LP 250MG 250MG N 019715 001 Jul 31, 1990 Oct CAHN N 019715 001 Jul 31, 1990 Oct CAHN OMEGA-3-ACID ETHYL ESTERS CAPSULE;ORAL LOVAZA AB +! WOODWARD 1GM CONTAINS AT LEAST 900MG OF THE N 021654 001 Nov 10, 2004 Feb CAHN ETHYL ESTERS OF OMEGA-3 FATTY ACIDS >D> >A> OMEGA-3-ACID ETHYL ESTERS TYPE A CAPSULE;ORAL OMTRYG + @ OSMOTICA + @ OSMOTICA PHARM US 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS 1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS N 204977 001 Apr 23, 2014 N 204977 001 Apr 23, 2014 Oct CAHN Oct CAHN ONDANSETRON FILM;ORAL ZUPLENZ + @ AQUESTIVE + @ 4MG 8MG TABLET, ORALLY DISINTEGRATING;ORAL ONDANSETRON >D> AB >A> AB AUROBINDO PHARMA ! ZOFRAN ODT 8MG 8MG >D> AB >A> >D> AB >A> + NOVARTIS + @ +! + @ 4MG 4MG 8MG 8MG N 022524 001 Jul 02, 2010 Feb CAHN N 022524 002 Jul 02, 2010 Feb CAHN A 090469 002 Apr 12, 2010 Oct CHRS A 090469 002 Apr 12, 2010 Oct CHRS N 020781 001 Jan 27, 1999 N 020781 001 Jan 27, 1999 N 020781 002 Jan 27, 1999 N 020781 002 Jan 27, 1999 Oct DISC Oct DISC Oct DISC Oct DISC ONDANSETRON HYDROCHLORIDE INJECTABLE;INJECTION ONDANSETRON HYDROCHLORIDE @ HOSPIRA EQ 2MG BASE/ML ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE @ EMCURE PHARMS LTD EQ 2MG BASE/ML A 077840 001 Jan 19, 2007 Jun DISC A 078945 001 Jan 03, 2013 May DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -100 ORITAVANCIN DIPHOSPHATE POWDER;INTRAVENOUS KIMYRSA +! MELINTA THERAP ORBACTIV +! MELINTA THERAP EQ 1.2GM BASE/VIAL EQ 400MG BASE/VIAL ORPHENADRINE CITRATE TABLET, EXTENDED RELEASE;ORAL NORFLEX + @ BAUSCH 100MG ORPHENADRINE CITRATE @ IMPAX PHARMS 100MG AB AB AB AB AB AB >D> AB >D> AB >D> AB >A> AB >A> AB >A> AB AB >D> AB >A> AB OSELTAMIVIR PHOSPHATE CAPSULE;ORAL OSELTAMIVIR PHOSPHATE EPIC PHARMA LLC @ MYLAN @ @ NESHER PHARMS ZYDUS PHARMS FOR SUSPENSION;ORAL OSELTAMIVIR PHOSPHATE APTAPHARMA INC NESHER PHARMS ZYDUS PHARMS EQ 30MG BASE EQ 45MG BASE EQ 75MG BASE EQ 30MG BASE EQ 30MG BASE EQ 45MG BASE EQ 45MG BASE EQ 75MG BASE EQ 75MG BASE EQ 30MG BASE EQ 45MG BASE EQ 75MG BASE EQ 30MG BASE EQ 45MG BASE EQ 75MG BASE EQ 6MG BASE/ML EQ 6MG BASE/ML EQ 6MG BASE/ML OXALIPLATIN INJECTABLE;INTRAVENOUS OXALIPLATIN @ CIPLA @ AP NOVAST LABS AP AP QILU PHARM HAINAN AP ! 50MG/10ML (5MG/ML) 100MG/20ML (5MG/ML) 50MG/10ML (5MG/ML) 100MG/20ML (5MG/ML) 50MG/10ML (5MG/ML) 100MG/20ML (5MG/ML) 200MG/40ML (5MG/ML) OXCARBAZEPINE SUSPENSION;ORAL OXCARBAZEPINE AB AKORN AB GLASSHOUSE PHARMS 300MG/5ML 300MG/5ML OXICONAZOLE NITRATE LOTION;TOPICAL OXISTAT +! ANI PHARMS EQ 1% BASE OXYBUTYNIN CHLORIDE TABLET;ORAL OXYBUTYNIN CHLORIDE AB APPCO 5MG BX EMCURE PHARMS LTD 5MG BX EYWA 5MG >A> AB ! STRIDES PHARMA 5MG @ 5MG >D> AB ! VINTAGE PHARMS 5MG N 214155 001 Mar 12, 2021 Mar NEWA N 206334 001 Aug 06, 2014 May CAHN N 012157 001 May CAHN A 040368 001 Jun 23, 2000 Jan DISC A 215208 A 215208 A 215208 A 210157 A 210157 A 210157 A 210157 A 210157 A 210157 A 208578 A 208578 A 208578 A 208578 A 208578 A 208578 001 Oct 01, 2021 002 Oct 01, 2021 003 Oct 01, 2021 001 Jan 21, 2021 001 Jan 21, 2021 002 Jan 21, 2021 002 Jan 21, 2021 003 Jan 21, 2021 003 Jan 21, 2021 001 Feb 24, 2017 002 Feb 24, 2017 003 Feb 24, 2017 001 Feb 24, 2017 002 Feb 24, 2017 003 Feb 24, 2017 Sep NEWA Sep NEWA Sep NEWA Jan DISC Jan NEWA Jan DISC Jan NEWA Jan DISC Jan NEWA Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 212858 001 Aug 30, 2021 A 209113 001 Sep 14, 2017 A 209113 001 Sep 14, 2017 Aug NEWA Oct CAHN Oct CAHN A 208523 A 208523 A 207562 A 207562 A 204368 A 204368 A 204368 001 Feb 10, 2017 002 Feb 10, 2017 001 Oct 16, 2018 002 Oct 16, 2018 001 Jun 07, 2016 002 Jun 07, 2016 003 Jun 07, 2016 May DISC May DISC Sep CAHN Sep CAHN Aug CAHN Aug CAHN Aug CAHN A 211420 001 Jul 09, 2021 Jul NEWA A 212428 001 Jun 21, 2021 Jun NEWA N 020209 001 Sep 30, 1992 Apr CAHN A 209025 A 211682 A 211062 A 075079 A 208165 A 075079 001 Dec 21, 2017 001 May 10, 2019 001 Feb 06, 2019 001 Oct 31, 1997 001 Dec 17, 2020 001 Oct 31, 1997 Jan CAHN Sep CTEC Sep CTEC Oct CAHN Jun DISC Oct CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -101 AA AA AB AB AB >A> AB >A> AB OXYCODONE HYDROCHLORIDE CAPSULE;ORAL OXYCODONE HYDROCHLORIDE @ LANNETT CO INC 5MG SOLUTION;ORAL OXYCODONE HYDROCHLORIDE QUAGEN 5MG/5ML 100MG/5ML TABLET;ORAL OXAYDO + ZYLA 5MG + 7.5MG OXYCODONE HYDROCHLORIDE ALVOGEN 5MG 15MG 30MG SPECGX LLC 10MG 20MG A 203823 001 Aug 01, 2014 Apr DISC A 213761 001 Jun 02, 2021 May NEWA A 213761 002 Jun 02, 2021 May NEWA N 202080 001 Jun 17, 2011 Mar CRLD N 202080 002 Jun 17, 2011 Mar CRLD A 202116 A 202116 A 202116 A 076758 A 076758 001 Dec 30, 2011 002 Dec 30, 2011 003 Dec 30, 2011 004 Oct 12, 2021 005 Oct 12, 2021 Apr CAHN Apr CAHN Apr CAHN Oct NEWA Oct NEWA >D> >D> AB >A> AB >D> AB >A> AB OXYMETAZOLINE HYDROCHLORIDE CREAM;TOPICAL OXYMETAZOLINE HYDROCHLORIDE TARO PHARMS 1% @ 1% 1% RHOFADE +! EPI HLTH 1% +! 1% +! 1% A 213584 001 Oct 04, 2021 A 213584 001 Oct 04, 2021 A 213584 001 Oct 04, 2021 Oct DISC Oct DISC Sep NFTG N 208552 001 Jan 18, 2017 N 208552 001 Jan 18, 2017 N 208552 001 Jan 18, 2017 Oct CTEC Oct CTEC Sep CFTG OXYMETHOLONE TABLET;ORAL ANADROL-50 + @ MYLAN SPECIALITY LP 50MG N 016848 001 Apr DISC OXYTOCIN INJECTABLE;INJECTION OXYTOCIN AP +! HIKMA PHARMS AP +! 10USP UNITS/ML (10USP UNITS/ML) N 018243 001 Jul CAHN 100USP UNITS/10ML (10USP UNITS/ML) N 018243 002 Jan 10, 2007 Jul CAHN OZANIMOD HYDROCHLORIDE CAPSULE;ORAL ZEPOSIA + CELGENE INTL + +! EQ 0.23MG BASE EQ 0.46MG BASE EQ 0.92MG BASE N 209899 001 Mar 25, 2020 N 209899 002 Mar 25, 2020 N 209899 003 Mar 25, 2020 May CPOT May CPOT May CPOT PACLITAXEL INJECTABLE;INJECTION PACLITAXEL AP ACCORD HLTHCARE @ MYLAN LABS LTD 6MG/ML 6MG/ML A 205720 001 Aug 17, 2018 May CMFD A 091540 001 Sep 29, 2011 Mar DISC PALIPERIDONE TABLET, EXTENDED RELEASE;ORAL PALIPERIDONE BX AMNEAL PHARMS 1.5MG BX 3MG BX 6MG BX 9MG A 204707 A 204707 A 204707 A 204707 001 Sep 23, 2019 002 Sep 23, 2019 003 Sep 23, 2019 004 Sep 23, 2019 Sep CTEC Sep CTEC Sep CTEC Sep CTEC PALIPERIDONE PALMITATE SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR INVEGA HAFYERA + JANSSEN PHARMS 1.092GM/3.5ML (312MG/ML) + INVEGA SUSTENNA 1.560GM/5ML (312MG/ML) AB + JANSSEN PHARMS 39MG/0.25ML (39MG/0.25ML) AP + 39MG/0.25ML (39MG/0.25ML) AB + 78MG/0.5ML (78MG/0.5ML) N 207946 005 Aug 30, 2021 Sep NEWA N 207946 006 Aug 30, 2021 Sep NEWA N 022264 001 Jul 31, 2009 N 022264 001 Jul 31, 2009 N 022264 002 Jul 31, 2009 Jul CTEC Jun CFTG Jul CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -102 SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR INVEGA SUSTENNA AP + 78MG/0.5ML (78MG/0.5ML) AB + 117MG/0.75ML (117MG/0.75ML) AP + 117MG/0.75ML (117MG/0.75ML) AB +! 156MG/ML (156MG/ML) AP +! 156MG/ML (156MG/ML) AB + 234MG/1.5ML (156MG/ML) AP + 234MG/1.5ML (156MG/ML) PALIPERIDONE PALMITATE AB TEVA PHARMS USA 39MG/0.25ML (39MG/0.25ML) AP 39MG/0.25ML (39MG/0.25ML) AB 78MG/0.5ML (78MG/0.5ML) AP 78MG/0.5ML (78MG/0.5ML) AB 117MG/0.75ML (117MG/0.75ML) AP 117MG/0.75ML (117MG/0.75ML) AB 156MG/ML (156MG/ML) AP 156MG/ML (156MG/ML) AB 234MG/1.5ML (156MG/ML) AP 234MG/1.5ML (156MG/ML) PALONOSETRON HYDROCHLORIDE INJECTABLE;INTRAVENOUS ALOXI + @ HELSINN HLTHCARE EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) + @ EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) PALONOSETRON HYDROCHLORIDE @ ACCORD HLTHCARE EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) AP EQ 0.25MG BASE/5ML (EQ 0.05MG AP ! DR REDDYS LABS LTD BASE/ML) EQ 0.25MG BASE/5ML (EQ 0.05MG EMCURE PHARMS LTD BASE/ML) EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) AP EQ 0.25MG BASE/5ML (EQ 0.05MG @ HOSPIRA INC BASE/ML) EQ 0.075MG BASE/1.5ML (EQ 0.05MG @ QILU BASE/ML) EQ 0.075MG BASE/1.5ML (EQ 0.05MG @ TEVA PHARMS USA BASE/ML) EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML) SOLUTION;INTRAVENOUS PALONOSETRON HYDROCHLORIDE + @ FRESENIUS KABI USA EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML) PAMIDRONATE DISODIUM INJECTABLE;INJECTION PAMIDRONATE DISODIUM AP +! HIKMA PHARMS AP +! 30MG/10ML (3MG/ML) 90MG/10ML (9MG/ML) PANTOPRAZOLE SODIUM INJECTABLE;IV (INFUSION) PANTOPRAZOLE SODIUM AP ACIC PHARMS EQ 40MG BASE/VIAL TABLET, DELAYED RELEASE;ORAL PANTOPRAZOLE SODIUM @ JUBILANT GENERICS @ EQ 20MG BASE EQ 40MG BASE PAROXETINE HYDROCHLORIDE SUSPENSION;ORAL PAROXETINE HYDROCHLORIDE AB NOVITIUM PHARMA EQ 10MG BASE/5ML PAXIL AB +! APOTEX TECHNOLOGIES EQ 10MG BASE/5ML >A> AB TABLET;ORAL PAROXETINE HYDROCHLORIDE YILING EQ 10MG BASE N 022264 002 Jul 31, 2009 N 022264 003 Jul 31, 2009 N 022264 003 Jul 31, 2009 N 022264 004 Jul 31, 2009 N 022264 004 Jul 31, 2009 N 022264 005 Jul 31, 2009 N 022264 005 Jul 31, 2009 Jun CFTG Jul CTEC Jun CFTG Jul CTEC Jun CFTG Jul CTEC Jun CFTG A 211149 001 Jul 06, 2021 A 211149 001 Jul 06, 2021 A 211149 002 Jul 06, 2021 A 211149 002 Jul 06, 2021 A 211149 003 Jul 06, 2021 A 211149 003 Jul 06, 2021 A 211149 004 Jul 06, 2021 A 211149 004 Jul 06, 2021 A 211149 005 Jul 06, 2021 A 211149 005 Jul 06, 2021 Jul CTEC Jun NFTG Jul CTEC Jun NFTG Jul CTEC Jun NFTG Jul CTEC Jun NFTG Jul CTEC Jun NFTG N 021372 002 Feb 29, 2008 Apr DISC N 021372 001 Jul 25, 2003 Apr DISC A 204615 001 Mar 15, 2021 Sep DISC A 204615 001 Mar 15, 2021 Mar NEWA A 201533 002 Apr 21, 2016 Apr CHRS A 202951 001 Jun 29, 2021 Jun NEWA A 202951 002 Jun 29, 2021 Jun NEWA A 207005 002 Sep 19, 2018 Apr DISC A 205648 002 Sep 19, 2018 Apr DISC A 090713 002 Mar 23, 2018 Apr DISC N 208109 001 Nov 21, 2017 May DISC N 021113 001 Mar 04, 2002 Jul CAHN N 021113 002 Mar 04, 2002 Jul CAHN A 209524 001 Aug 30, 2021 Aug NEWA A 090901 001 Aug 30, 2011 Jun DISC A 090901 002 Aug 30, 2011 Jun DISC A 215003 001 Sep 03, 2021 Aug NEWA N 020710 001 Jun 25, 1997 Aug CTEC A 211248 001 Nov 02, 2021 Oct NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -103 >A> AB >A> AB >A> AB AB AB AB AB AB AB AB AB TABLET;ORAL PAROXETINE HYDROCHLORIDE EQ 20MG BASE EQ 30MG BASE EQ 40MG BASE TABLET, EXTENDED RELEASE;ORAL PAROXETINE HYDROCHLORIDE CADILA PHARMS LTD EQ 12.5MG BASE EQ 25MG BASE EQ 37.5MG BASE CSPC OUYI EQ 12.5MG BASE EQ 25MG BASE EQ 37.5MG BASE SINOTHERAPEUTICS INC EQ 12.5MG BASE EQ 25MG BASE PATIROMER SORBITEX CALCIUM POWDER;ORAL VELTASSA + VIFOR PHARMA + +! EQ 8.4GM BASE/PACKET EQ 16.8GM BASE/PACKET EQ 25.2GM BASE/PACKET PEGCETACOPLAN SOLUTION;SUBCUTANEOUS EMPAVELI +! APELLIS PHARMS 1080MG/20ML (54MG/ML) PEMETREXED SOLUTION;INTRAVENOUS PEMETREXED + @ ACTAVIS LLC + @ + @ 100MG/4ML (25MG/ML) 500MG/20ML (25MG/ML) 1GM/40ML (25MG/ML) AB AB AB >A> AB PENICILLAMINE CAPSULE;ORAL PENICILLAMINE AGGREGA BRECKENRIDGE INVAGEN PHARMS NAVINTA LLC 250MG 250MG 250MG 250MG PENICILLIN G POTASSIUM INJECTABLE;INJECTION PENICILLIN G POTASSIUM HQ SPECLT PHARMA AP AP 1,000,000 UNITS/VIAL 5,000,000 UNITS/VIAL 20,000,000 UNITS/VIAL PENICILLIN V POTASSIUM FOR SOLUTION;ORAL PENICILLIN V POTASSIUM @ DAVA PHARMS INC @ PENICILLIN-VK TEVA ! EQ 125MG BASE/5ML EQ 250MG BASE/5ML EQ 125MG BASE/5ML EQ 250MG BASE/5ML PENTAMIDINE ISETHIONATE INJECTABLE;INJECTION PENTAMIDINE ISETHIONATE AP EMCURE PHARMS LTD 300MG/VIAL PENTOBARBITAL SODIUM INJECTABLE;INJECTION NEMBUTAL SODIUM AP +! AKORN 50MG/ML A 211248 002 Nov 02, 2021 A 211248 003 Nov 02, 2021 A 211248 004 Nov 02, 2021 Oct NEWA Oct NEWA Oct NEWA A 212645 A 212645 A 212645 A 213485 A 213485 A 213485 A 213612 A 213612 001 Aug 27, 2021 002 Aug 27, 2021 003 Aug 27, 2021 001 Feb 16, 2021 002 Feb 16, 2021 003 Feb 16, 2021 001 Aug 11, 2021 002 Aug 11, 2021 Aug NEWA Aug NEWA Aug NEWA Feb NEWA Feb NEWA Feb NEWA Jul NEWA Jul NEWA N 205739 001 Oct 21, 2015 N 205739 002 Oct 21, 2015 N 205739 003 Oct 21, 2015 Jun CAHN Jun CAHN Jun CAHN N 215014 001 May 14, 2021 May NEWA N 208419 001 Aug 21, 2020 N 208419 002 Aug 21, 2020 N 208419 003 Aug 21, 2020 Jan DISC Jan DISC Jan DISC A 215409 A 215409 A 213293 A 214363 001 Aug 23, 2021 001 Aug 23, 2021 001 Aug 19, 2021 001 Oct 08, 2021 Aug NEWA Sep CAHN Aug NEWA Oct NEWA A 065149 001 Jul 23, 2009 A 065149 002 Jul 23, 2009 A 065149 003 Jul 23, 2009 Mar CAHN Mar CAHN Mar CAHN A 062981 001 Feb 10, 1989 Mar DISC A 062981 002 Feb 10, 1989 Mar DISC A 060456 001 A 060456 002 Mar CTEC Mar CTEC A 213806 001 Jan 07, 2021 Jan NEWA A 083246 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -104 PENTOXIFYLLINE TABLET, EXTENDED RELEASE;ORAL PENTOXIL @ UPSHER SMITH LABS TRENTAL 400MG + @ VALIDUS PHARMS 400MG A 074962 001 Mar 31, 1999 May DISC N 018631 001 Aug 30, 1984 Feb CAHN PERAMPANEL TABLET;ORAL FYCOMPA + EISAI INC AB + + AB + + AB + + AB + + AB + +! AB +! 2MG 2MG 4MG 4MG 6MG 6MG 8MG 8MG 10MG 10MG 12MG 12MG N 202834 001 Oct 22, 2012 N 202834 001 Oct 22, 2012 N 202834 002 Oct 22, 2012 N 202834 002 Oct 22, 2012 N 202834 003 Oct 22, 2012 N 202834 003 Oct 22, 2012 N 202834 004 Oct 22, 2012 N 202834 004 Oct 22, 2012 N 202834 005 Oct 22, 2012 N 202834 005 Oct 22, 2012 N 202834 006 Oct 22, 2012 N 202834 006 Oct 22, 2012 Jun CTEC May CFTG Jun CTEC May CFTG Jun CTEC May CFTG Jun CTEC May CFTG Jun CTEC May CFTG Jun CTEC May CFTG PERMETHRIN CREAM;TOPICAL ELIMITE + @ MYLAN 5% N 019855 001 Aug 25, 1989 Sep CAHN PHENDIMETRAZINE TARTRATE TABLET;ORAL BONTRIL PDM AA +! VALEANT 35MG A 085272 001 Aug CRLD PHENTERMINE HYDROCHLORIDE CAPSULE;ORAL ADIPEX-P AA +! TEVA 37.5MG PHENTERMINE HYDROCHLORIDE AA +! SANDOZ AA +! 15MG 30MG TABLET;ORAL ADIPEX-P AA +! TEVA 37.5MG PHENTERMINE HYDROCHLORIDE AA MERRO PHARM USA + @ USL PHARMA 37.5MG 8MG A 088023 001 Aug 02, 1983 Aug CRLD A 087190 002 Aug CRLD A 086945 001 Jul 20, 1983 Aug CRLD A 085128 001 Aug CRLD A 206342 001 Nov 18, 2016 Sep CAHN A 083804 001 Aug CRLD PHENYLEPHRINE HYDROCHLORIDE SOLUTION;INTRAVENOUS BIORPHEN +! ETON PHARMS 0.5MG/5ML (0.1MG/ML) + @ 10MG/ML (10MG/ML) +! 10MG/ML (10MG/ML) PHENYLEPHRINE HYDROCHLORIDE AP1 CAPLIN AP1 AP1 AP1 GLAND PHARMA LTD AP2 +! HIKMA AP2 +! AP2 +! AP1 PROVEPHARM SAS AP1 AP1 10MG/ML (10MG/ML) 50MG/5ML (10MG/ML) 100MG/10ML (10MG/ML) 10MG/ML (10MG/ML) 10MG/ML (10MG/ML) 50MG/5ML (10MG/ML) 100MG/10ML (10MG/ML) 10MG/ML (10MG/ML) 50MG/5ML (10MG/ML) 100MG/10ML (10MG/ML) N 212909 001 Oct 21, 2019 N 212909 002 Mar 11, 2021 N 212909 002 Mar 11, 2021 Feb CPOT Apr DISC Mar NEWA A 213318 001 Jun 11, 2020 A 213318 002 Jun 11, 2020 A 213318 003 Jun 11, 2020 A 211920 003 Apr 08, 2021 N 203826 001 Dec 20, 2012 N 203826 002 Jun 19, 2019 N 203826 003 Jun 19, 2019 A 211081 001 Jul 17, 2020 A 211081 002 Jul 17, 2020 A 211081 003 Jul 17, 2020 Jul CMFD Jul CMFD Jul CMFD Apr NEWA Jan CAHN Jan CAHN Jan CAHN Jan CAHN Jan CAHN Jan CAHN PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE AA AKORN PROMETH VC PLAIN 5MG/5ML;6.25MG/5ML A 040675 001 Dec 23, 2014 + @ G AND W LABS INC 5MG/5ML;6.25MG/5ML A 088761 001 Nov 08, 1984 Feb CAHN Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -105 PHENYTOIN TABLET, CHEWABLE;ORAL DILANTIN AB +! PHARMACIA 50MG PHENYTOIN SODIUM CAPSULE;ORAL DILANTIN +! UPJOHN AB +! INJECTABLE;INJECTION PHENYTOIN SODIUM AP +! WEST-WARD PHARMS INT 30MG EXTENDED 100MG EXTENDED 50MG/ML BP >D> BP >A> BP AB PHYTONADIONE INJECTABLE;INJECTION PHYTONADIONE +! INTL MEDICATION VITAMIN K1 ! HOSPIRA +! +! 1MG/0.5ML 1MG/0.5ML 1MG/0.5ML 10MG/ML PIFLUFOLASTAT F-18 SOLUTION;INTRAVENOUS PYLARIFY +! PROGENICS PHARMS INC 50ML (1-80mCi/ML) >A> >A> AB AB AB AB PILOCARPINE HYDROCHLORIDE SOLUTION;OPHTHALMIC VUITY +! ABBVIE INC 1.25% TABLET;ORAL PILOCARPINE HYDROCHLORIDE AMICI 5MG 7.5MG INNOGENIX 5MG 7.5MG AB AB AB >A> >A> >A> AB AB AB >D> >D> >D> PIOGLITAZONE HYDROCHLORIDE TABLET;ORAL PIOGLITAZONE HYDROCHLORIDE ANNORA PHARMA EQ 15MG BASE EQ 30MG BASE EQ 45MG BASE @ PICKET PHARMS EQ 15MG BASE @ EQ 30MG BASE @ EQ 45MG BASE SHUANGCHENG EQ 15MG BASE EQ 30MG BASE EQ 45MG BASE @ US ANTIBIOTICS EQ 15MG BASE @ EQ 15MG BASE @ EQ 30MG BASE @ EQ 30MG BASE @ EQ 45MG BASE @ EQ 45MG BASE PIPERACILLIN SODIUM; TAZOBACTAM SODIUM INJECTABLE;INJECTION PIPERACILLIN AND TAZOBACTAM @ MYLAN LABS LTD @ @ AP PROVEPHARM SAS AP AP EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM A 084427 001 Aug CRLD A 084349 001 A 084349 002 A 084307 001 Aug CRLD Aug CRLD Aug CRLD A 083722 001 May CRLD A 087954 001 Jul 25, 1983 A 087954 001 Jul 25, 1983 A 087955 001 Jul 25, 1983 Oct CRLD Oct CRLD Aug CRLD N 214793 001 May 26, 2021 May NEWA N 214028 001 Oct 28, 2021 Oct NEWA A 076963 A 076963 A 076963 A 076963 001 Dec 22, 2004 002 Feb 27, 2007 001 Dec 22, 2004 002 Feb 27, 2007 Sep CAHN Sep CAHN Aug CAHN Aug CAHN A 204133 A 204133 A 204133 A 078383 A 078383 A 078383 A 210165 A 210165 A 210165 A 078383 A 078383 A 078383 A 078383 A 078383 A 078383 001 Apr 07, 2014 002 Apr 07, 2014 003 Apr 07, 2014 001 Mar 12, 2013 002 Mar 12, 2013 003 Mar 12, 2013 001 Jan 22, 2021 002 Jan 22, 2021 003 Jan 22, 2021 001 Mar 12, 2013 001 Mar 12, 2013 002 Mar 12, 2013 002 Mar 12, 2013 003 Mar 12, 2013 003 Mar 12, 2013 Jan CAHN Jan CAHN Jan CAHN Oct CAHN Oct CAHN Oct CAHN Jan NEWA Jan NEWA Jan NEWA Oct CAHN May CAHN Oct CAHN May CAHN Oct CAHN May CAHN A 065458 001 Aug 15, 2014 Apr DISC A 065458 002 Aug 15, 2014 Mar DISC A 065458 003 Aug 15, 2014 Jul DISC A 207847 001 Jan 13, 2017 Jan CAHN A 207847 002 Jan 13, 2017 Jan CAHN A 207848 002 Jan 13, 2017 Jan CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -106 INJECTABLE;INJECTION PIPERACILLIN AND TAZOBACTAM BASE/VIAL AP AP AP SAGENT PHARMS INC AP AP AP AP SANDOZ INC AP ! WOCKHARDT BIO AG AP ! AP ! AP ! ZOSYN EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 12GM BASE/VIAL;EQ 1.5GM BASE/VIAL EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL + @ WYETH PHARMS + @ + @ + @ EQ 2GM BASE/VIAL;EQ 250MG BASE/VIAL EQ 3GM BASE/VIAL;EQ 375MG BASE/VIAL EQ 4GM BASE/VIAL;EQ 500MG BASE/VIAL EQ 36GM BASE/VIAL;EQ 4.5GM BASE/VIAL A 207847 003 Jan 13, 2017 Jan CAHN A 207848 001 May 11, 2018 Jan CAHN A 208674 001 Feb 16, 2021 Feb NEWA A 208674 002 Feb 16, 2021 Feb NEWA A 208674 003 Feb 16, 2021 Feb NEWA A 208675 001 Feb 16, 2021 Feb NEWA A 203557 002 Jul 08, 2021 Jul NEWA A 206996 001 Mar 22, 2017 Jan CHRS A 206996 002 Mar 22, 2017 Jan CHRS A 206996 003 Mar 22, 2017 Jan CHRS A 207146 001 Mar 17, 2017 Jan CHRS N 050684 001 Oct 22, 1993 Jan DISC N 050684 002 Oct 22, 1993 Jan DISC N 050684 003 Oct 22, 1993 Jan DISC N 050684 004 Oct 22, 1993 Jan DISC PIRBUTEROL ACETATE AEROSOL, METERED;INHALATION MAXAIR @ BAUSCH EQ 0.2MG BASE/INH N 020014 001 Nov 30, 1992 May CAHN PIROXICAM CAPSULE;ORAL PIROXICAM AB NOSTRUM LABS INC BX UNICHEM BX 10MG 10MG 20MG A 074118 002 Jun 15, 1993 A 208340 001 Apr 13, 2017 A 208340 002 Apr 13, 2017 Jan CMS1 Sep CTEC Sep CTEC AA >D> >D> AA >A> POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE FOR SOLUTION;ORAL LAX-LYTE WITH FLAVOR PACKS L PERRIGO CO TRILYTE 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 A 079232 001 Feb 25, 2010 .2GM/BOT MYLAN @ 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT 420GM/BOT;1.48GM/BOT;5.72GM/BOT;11 .2GM/BOT A 076491 A 076491 001 Feb 05, 2004 001 Feb 05, 2004 Aug CAHN Oct DISC Oct DISC POLYMYXIN B SULFATE INJECTABLE;INJECTION POLYMYXIN B SULFATE @ GLAND AP ! XELLIA PHARMS APS EQ 500,000 UNITS BASE/VIAL EQ 500,000 UNITS BASE/VIAL A 207322 001 Apr 14, 2016 May DISC A 202766 001 Jan 15, 2014 May CHRS POMALIDOMIDE CAPSULE;ORAL POMALIDOMIDE @ BRECKENRIDGE 1MG @ 2MG @ 3MG @ 4MG @ EUGIA PHARMA 1MG @ 2MG @ 3MG @ 4MG A 210111 A 210111 A 210111 A 210111 A 210249 A 210249 A 210249 A 210249 001 Oct 30, 2020 002 Oct 30, 2020 003 Oct 30, 2020 004 Oct 30, 2020 001 Oct 30, 2020 002 Oct 30, 2020 003 Oct 30, 2020 004 Oct 30, 2020 Feb DISC Feb DISC Feb DISC Feb DISC Apr DISC Apr DISC Apr DISC Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -107 CAPSULE;ORAL POMALYST + CELGENE 1MG + 2MG + 3MG +! 4MG PONATINIB HYDROCHLORIDE TABLET;ORAL ICLUSIG + TAKEDA PHARMS USA + + +! EQ 10MG BASE EQ 15MG BASE EQ 30MG BASE EQ 45MG BASE PONESIMOD TABLET;ORAL PONVORY + JANSSEN PHARMS + + + + + + + + +! 2MG 3MG 4MG 5MG 6MG 7MG 8MG 9MG 10MG 20MG POSACONAZOLE FOR SUSPENSION, DELAYED RELEASE;ORAL NOXAFIL POWDERMIX KIT +! MSD MERCK CO 300MG TABLET, DELAYED RELEASE;ORAL POSACONAZOLE AB AET PHARMA 100MG >A> AP POTASSIUM ACETATE INJECTABLE;INJECTION POTASSIUM ACETATE EXELA PHARMA 2MEQ/ML POTASSIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE AB GRANULES AB 8MEQ 10MEQ FOR SOLUTION;ORAL POTASSIUM CHLORIDE @ STRIDES PHARMA AA 20MEQ 20MEQ INJECTABLE;INJECTION POTASSIUM CHLORIDE + @ ABRAXIS PHARM 2MEQ/ML AP + FRESENIUS KABI USA 2MEQ/ML POTASSIUM CHLORIDE 10MEQ @ FRESENIUS KABI USA 14.9MG/ML @ 746MG/100ML AP NEXUS PHARMS 14.9MG/ML AP 745MG/100ML POTASSIUM CHLORIDE 20MEQ @ FRESENIUS KABI USA 29.8MG/ML AP 1.49GM/100ML AP NEXUS PHARMS 29.8MG/ML AP 1.49GM/100ML POTASSIUM CHLORIDE 40MEQ @ FRESENIUS KABI USA 2.98GM/100ML AP NEXUS PHARMS 2.98GM/100ML SOLUTION;ORAL POTASSIUM CHLORIDE AA GRANULES AA 20MEQ/15ML 40MEQ/15ML N 204026 N 204026 N 204026 N 204026 001 Feb 08, 2013 002 Feb 08, 2013 003 Feb 08, 2013 004 Feb 08, 2013 Apr CTEC Apr CTEC Apr CTEC Apr CTEC N 203469 004 Dec 18, 2020 N 203469 001 Dec 14, 2012 N 203469 003 Apr 23, 2015 N 203469 002 Dec 14, 2012 May CAHN May CAHN May CAHN May CAHN N 213498 001 Mar 18, 2021 N 213498 002 Mar 18, 2021 N 213498 003 Mar 18, 2021 N 213498 004 Mar 18, 2021 N 213498 005 Mar 18, 2021 N 213498 006 Mar 18, 2021 N 213498 007 Mar 18, 2021 N 213498 008 Mar 18, 2021 N 213498 009 Mar 18, 2021 N 213498 010 Mar 18, 2021 Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA Mar NEWA N 214770 001 May 31, 2021 May NEWA A 213454 001 Feb 01, 2021 Jan NEWA A 212692 001 Oct 20, 2021 Oct NEWA A 214686 001 Feb 16, 2021 Feb NEWA A 214686 002 Feb 16, 2021 Feb NEWA A 211667 001 Mar 11, 2021 Aug DISC A 211667 001 Mar 11, 2021 Mar NEWA A 080204 001 A 080225 001 Aug CRLD Aug CRLD A 211087 A 211087 A 214727 A 214727 001 Sep 09, 2020 002 Sep 09, 2020 001 Mar 18, 2021 002 Mar 18, 2021 Mar DISC Mar DISC Mar NFTG Mar NFTG A 211087 A 211087 A 214727 A 214727 003 Sep 09, 2020 005 May 07, 2021 003 Mar 18, 2021 004 Mar 18, 2021 Mar DISC Apr NEWA Mar NFTG Mar NFTG A 211087 004 Sep 09, 2020 Mar DISC A 214727 005 Mar 18, 2021 Mar NFTG A 213392 001 Jan 29, 2021 Jan NEWA A 213392 002 Jan 29, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -108 SOLUTION;ORAL POTASSIUM CHLORIDE AA SAPTALIS PHARMS 20MEQ/15ML AA 40MEQ/15ML TABLET, EXTENDED RELEASE;ORAL POTASSIUM CHLORIDE @ AMTA 10MEQ AB1 10MEQ @ 20MEQ AB1 20MEQ @ AUROBINDO PHARMA LTD 10MEQ AB1 10MEQ @ 15MEQ AB1 15MEQ @ 20MEQ AB1 20MEQ @ BRECKENRIDGE 10MEQ @ 20MEQ @ CENTAUR PHARMS PVT 10MEQ @ 20MEQ POTASSIUM CHLORIDE; SODIUM CHLORIDE INJECTABLE;INJECTION POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.45% +! BAXTER HLTHCARE 150MG/100ML;450MG/100ML +! 150MG/100ML;450MG/100ML @ FRESENIUS KABI USA 150MG/100ML;450MG/100ML POTASSIUM CHLORIDE 0.15% IN SODIUM CHLORIDE 0.9% AP +! BAXTER HLTHCARE 150MG/100ML;900MG/100ML AP +! 150MG/100ML;900MG/100ML AP FRESENIUS KABI USA 150MG/100ML;900MG/100ML POTASSIUM CHLORIDE 0.3% AND SODIUM CHLORIDE 0.9% +! BAXTER HLTHCARE 300MG/100ML;900MG/100ML +! 300MG/100ML;900MG/100ML + 300MG/100ML;900MG/100ML @ FRESENIUS KABI USA 300MG/100ML;900MG/100ML SODIUM CHLORIDE 0.9% AND POTASSIUM CHLORIDE 0.075% @ BAXTER HLTHCARE 75MG/100ML;900MG/100ML POTASSIUM CITRATE TABLET, EXTENDED RELEASE;ORAL POTASSIUM CITRATE AB ASCENT PHARMS INC 5MEQ AB 10MEQ AB 15MEQ AB BIONPHARMA INC 10MEQ @ 10MEQ AB 15MEQ @ 15MEQ AB EYWA 5MEQ AB 10MEQ AB 15MEQ PRALSETINIB CAPSULE;ORAL GAVRETO +! GENENTECH INC 100MG PRAMIPEXOLE DIHYDROCHLORIDE TABLET;ORAL PRAMIPEXOLE DIHYDROCHLORIDE @ NOSTRUM LABS INC 0.125MG AB 0.125MG @ 0.25MG AB 0.25MG @ 0.5MG AB 0.5MG @ 1MG AB 1MG @ 1.5MG AB 1.5MG A 211648 001 May 21, 2021 May NEWA A 211648 002 May 21, 2021 May NEWA A 214395 A 214395 A 214395 A 214395 A 214728 A 214728 A 214728 A 214728 A 214728 A 214728 A 213588 A 213588 A 213588 A 213588 001 Jan 28, 2021 001 Jan 28, 2021 002 Jan 28, 2021 002 Jan 28, 2021 001 Mar 31, 2021 001 Mar 31, 2021 002 Mar 31, 2021 002 Mar 31, 2021 003 Mar 31, 2021 003 Mar 31, 2021 001 Aug 21, 2020 002 Aug 21, 2020 001 Aug 21, 2020 002 Aug 21, 2020 Jul DISC Jan NEWA Jul DISC Jan NEWA Sep DISC Mar NEWA Sep DISC Mar NEWA Sep DISC Mar NEWA Sep CAHN Sep CAHN Mar DISC Mar DISC N 017648 005 Nov 26, 2002 N 017648 005 Nov 26, 2002 A 212347 001 Sep 17, 2020 Mar CTNA Mar CTEC Mar DISC N 017648 001 N 017648 001 A 212347 003 Jun 02, 2021 Mar CTNA Mar CHRS May NEWA N 017648 N 017648 N 017648 A 212347 002 002 002 002 Sep 17, 2020 Mar CTNA Mar CHRS Mar CTEC Mar DISC N 017648 004 Mar CTNA A 214420 A 214420 A 214420 A 212799 A 212799 A 212799 A 212799 A 214426 A 214426 A 214426 001 Feb 05, 2021 002 Feb 05, 2021 003 Feb 05, 2021 001 Jun 29, 2020 001 Jun 29, 2020 002 Jun 29, 2020 002 Jun 29, 2020 001 Feb 19, 2021 002 Feb 19, 2021 003 Feb 19, 2021 Jan NEWA Jan NEWA Jan NEWA Apr CMFD Feb DISC Apr CMFD Feb DISC Feb NEWA Feb NEWA Feb NEWA N 213721 001 Sep 04, 2020 Mar CAHN A 091450 A 091450 A 091450 A 091450 A 091450 A 091450 A 091450 A 091450 A 091450 A 091450 001 Oct 08, 2010 001 Oct 08, 2010 002 Oct 08, 2010 002 Oct 08, 2010 003 Oct 08, 2010 003 Oct 08, 2010 004 Oct 08, 2010 004 Oct 08, 2010 005 Oct 08, 2010 005 Oct 08, 2010 Jul DISC Apr CAHN Jul DISC Apr CAHN Jul DISC Apr CAHN Jul DISC Apr CAHN Jul DISC Apr CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -109 TABLET, EXTENDED RELEASE;ORAL PRAMIPEXOLE DIHYDROCHLORIDE AB XIAMEN LP PHARM CO 0.375MG AB 0.75MG PRASUGREL HYDROCHLORIDE TABLET;ORAL PRASUGREL BX AMNEAL PHARMS BX @ DR REDDYS LABS LTD @ AB PANACEA AB AB USPHARMA WINDLAS AB EQ 5MG BASE EQ 10MG BASE EQ 5MG BASE EQ 10MG BASE EQ 5MG BASE EQ 10MG BASE EQ 5MG BASE EQ 10MG BASE PRAVASTATIN SODIUM TABLET;ORAL PRAVACHOL + @ BRISTOL MYERS SQUIBB + @ + @ PRAVASTATIN SODIUM AB BIOCON PHARMA AB AB AB @ HISUN PHARM HANGZHOU @ @ AB ! TEVA PHARMS 20MG 40MG 80MG 10MG 20MG 40MG 80MG 20MG 40MG 80MG 80MG PRAZOSIN HYDROCHLORIDE CAPSULE;ORAL PRAZOSIN HYDROCHLORIDE AB ANI PHARMS AB AB EQ 1MG BASE EQ 2MG BASE EQ 5MG BASE PREDNISOLONE SYRUP;ORAL PREDNISOLONE AA CHARTWELL RX TABLET;ORAL PREDNISOLONE @ RISING 15MG/5ML 5MG PREDNISOLONE SODIUM PHOSPHATE SOLUTION;ORAL PREDNISOLONE SODIUM PHOSPHATE @ BAUSCH EQ 15MG BASE/5ML SOLUTION/DROPS;OPHTHALMIC INFLAMASE FORTE + @ NOVARTIS EQ 0.9% PHOSPHATE INFLAMASE MILD + @ NOVARTIS EQ 0.11% PHOSPHATE TABLET, ORALLY DISINTEGRATING;ORAL ORAPRED ODT + CONCORDIA PHARMS INC EQ 10MG BASE + EQ 15MG BASE +! EQ 30MG BASE PREDNISOLONE SODIUM PHOSPHATE @ MYLAN PHARMS INC EQ 10MG BASE @ EQ 15MG BASE @ EQ 30MG BASE A 212797 001 Jun 11, 2021 Jun NEWA A 212797 002 Jun 11, 2021 Jun NEWA A 205913 A 205913 A 205926 A 205926 A 205897 A 205897 A 205790 A 205790 001 Jun 19, 2018 002 Jun 19, 2018 001 Jul 07, 2020 002 Jul 07, 2020 001 Oct 16, 2017 002 Oct 16, 2017 001 Oct 16, 2017 002 Oct 16, 2017 Sep CTEC Sep CTEC Jan DISC Jan DISC Jul CAHN Jul CAHN Sep CAHN Sep CAHN N 019898 003 Oct 31, 1991 N 019898 004 Mar 22, 1993 N 019898 008 Dec 18, 2001 Jun DISC Jun DISC Jun DISC A 209869 A 209869 A 209869 A 209869 A 206061 A 206061 A 206061 A 077793 001 Apr 13, 2018 002 Apr 13, 2018 003 Apr 13, 2018 004 Apr 13, 2018 001 Nov 23, 2018 002 Nov 23, 2018 003 Nov 23, 2018 001 Jan 15, 2008 Jan CAHN Jan CAHN Jan CAHN Jan CAHN Jan DISC Jan DISC Jan DISC Jun CHRS A 072577 002 May 16, 1989 A 072577 001 May 16, 1989 A 072577 003 May 16, 1989 Feb CMFD Feb CMFD Feb CMFD A 040323 001 May 13, 1999 Mar CMFD A 084773 001 Jan CAHN A 075250 001 Jul 12, 2002 May CAHN A 080751 002 A 080751 001 Aug CRLD Aug CRLD N 021959 001 Jun 01, 2006 N 021959 002 Jun 01, 2006 N 021959 003 Jun 01, 2006 Jul CTEC Jul CTEC Jul CTEC A 202179 001 Apr 10, 2013 A 202179 002 Apr 10, 2013 A 202179 003 Apr 10, 2013 Jul DISC Jul DISC Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -110 >D> >A> AB >D> >A> AB >D> >A> AB >D> >A> AB AB AB AB AB AB AB PREDNISONE TABLET;ORAL PREDNISONE @ AMNEAL @ @ @ +! HIKMA PHARMS +! +! NOVITIUM PHARMA @ RISING @ @ STRIDES PHARMA 1MG 1MG 5MG 5MG 10MG 10MG 20MG 20MG 1MG 10MG 20MG 1MG 10MG 20MG 50MG 10MG 20MG TABLET, DELAYED RELEASE;ORAL RAYOS + HORIZON 1MG + 2MG +! 5MG PREGABALIN CAPSULE;ORAL LYRICA AB + UPJOHN AB + AB + AB + AB + AB + AB + AB +! PREGABALIN 25MG 50MG 75MG 100MG 150MG 200MG 225MG 300MG AB ALKEM LABS LTD 25MG AB 50MG AB APOTEX 25MG AB 50MG AB 75MG AB 100MG AB 150MG AB 200MG AB 225MG AB 300MG AB CHANGZHOU PHARM 50MG AB 75MG AB 100MG AB 150MG AB 200MG AB 225MG AB 300MG SOLUTION;ORAL LYRICA AA +! UPJOHN 20MG/ML TABLET, EXTENDED RELEASE;ORAL LYRICA CR AB + PFIZER AB + AB +! AB + UPJOHN AB + AB +! PREGABALIN 82.5MG 165MG 330MG 82.5MG 165MG 330MG AB ALVOGEN 82.5MG AB 165MG AB 330MG AB ALVOGEN PINE BROOK 82.5MG AB 165MG A 213385 A 213385 A 213385 A 213385 A 213386 A 213386 A 213386 A 213386 A 087800 A 084122 A 087342 A 215246 A 089983 A 085813 A 089984 A 208412 A 208412 001 Jun 16, 2020 001 Jun 16, 2020 002 Jun 16, 2020 002 Jun 16, 2020 001 Jun 24, 2020 001 Jun 24, 2020 002 Jun 24, 2020 002 Jun 24, 2020 001 Apr 22, 1982 001 001 001 Jul 06, 2021 001 Jan 12, 1989 001 001 Jan 12, 1989 001 Feb 11, 2021 002 Feb 11, 2021 Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Oct CMFD Aug CRLD Aug CRLD Aug CRLD Jun NEWA Jan CAHN Jan CAHN Jan CAHN Feb NEWA Feb NEWA N 202020 001 Jul 26, 2012 N 202020 002 Jul 26, 2012 N 202020 003 Jul 26, 2012 Apr CAHN Apr CAHN Apr CAHN N 021446 N 021446 N 021446 N 021446 N 021446 N 021446 N 021446 N 021446 001 Dec 30, 2004 002 Dec 30, 2004 003 Dec 30, 2004 004 Dec 30, 2004 005 Dec 30, 2004 006 Dec 30, 2004 007 Dec 30, 2004 008 Dec 30, 2004 Apr CAHN Apr CAHN Apr CAHN Apr CAHN Apr CAHN Apr CAHN Apr CAHN Apr CAHN A 207799 A 207799 A 211685 A 211685 A 211685 A 211685 A 211685 A 211685 A 211685 A 211685 A 214322 A 214322 A 214322 A 214322 A 214322 A 214322 A 214322 007 Sep 30, 2019 008 Sep 30, 2019 001 Jul 07, 2021 002 Jul 07, 2021 003 Jul 07, 2021 004 Jul 07, 2021 005 Jul 07, 2021 006 Jul 07, 2021 007 Jul 07, 2021 008 Jul 07, 2021 001 Jul 15, 2021 002 Jul 15, 2021 003 Jul 15, 2021 004 Jul 15, 2021 005 Jul 15, 2021 006 Jul 15, 2021 007 Jul 15, 2021 Feb CMS1 Feb CMS1 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA Jul NEWA N 022488 001 Jan 04, 2010 Apr CAHN N 209501 N 209501 N 209501 N 209501 N 209501 N 209501 001 Oct 11, 2017 002 Oct 11, 2017 003 Oct 11, 2017 001 Oct 11, 2017 002 Oct 11, 2017 003 Oct 11, 2017 Apr CFTG Apr CFTG Apr CFTG Apr CAHN Apr CAHN Apr CAHN A 211687 A 211687 A 211687 A 211593 A 211593 001 Jul 06, 2021 002 Jul 06, 2021 003 Jul 06, 2021 001 Apr 13, 2021 002 Apr 13, 2021 Jun NEWA Jun NEWA Jun NEWA Apr NFTG Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -111 AB AB AB AB AB AB AB >A> AB AB AB AB AB TABLET, EXTENDED RELEASE;ORAL PREGABALIN 330MG APOTEX 165MG 330MG MSN 82.5MG 165MG 330MG MYLAN 82.5MG 165MG 330MG SUN PHARM 82.5MG 165MG 330MG PROBENECID TABLET;ORAL PROBENECID @ MYLAN @ AB ! WATSON LABS TEVA 500MG 500MG 500MG PROCAINAMIDE HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL PROCAN SR + @ PARKE DAVIS + @ PARKEDALE + @ 250MG 500MG 750MG >D> >A> AP AP AP AP PROCHLORPERAZINE EDISYLATE CONCENTRATE;ORAL COMPAZINE @ GLAXOSMITHKLINE + @ EQ 10MG BASE/ML EQ 10MG BASE/ML INJECTABLE;INJECTION PROCHLORPERAZINE EDISYLATE CAPLIN GLAND PHARMA LTD @ HIKMA PHARMS VIWIT PHARM EQ 5MG BASE/ML EQ 5MG BASE/ML EQ 5MG BASE/ML EQ 5MG BASE/ML EQ 5MG BASE/ML PROGESTERONE CAPSULE;ORAL PROGESTERONE BX SOFGEN PHARMS BX 100MG 200MG PROMETHAZINE HYDROCHLORIDE SYRUP;ORAL PROMETHAZINE HYDROCHLORIDE AA AMNEAL PHARMS @ AA QUAGEN PROMETHAZINE PLAIN 6.25MG/5ML 6.25MG/5ML 6.25MG/5ML AA +! WOCKHARDT BIO AG 6.25MG/5ML TABLET;ORAL PROMETHAZINE HYDROCHLORIDE AB + SANDOZ AB +! 25MG 50MG PROPAFENONE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL PROPAFENONE HYDROCHLORIDE @ MYLAN 225MG @ 325MG @ 425MG BX SINOTHERAPEUTICS INC 225MG BX 325MG BX 425MG AB ZYDUS 225MG AB 325MG A 211593 A 213313 A 213313 A 213226 A 213226 A 213226 A 211948 A 211967 A 211431 A 211889 A 211889 A 211889 003 Apr 13, 2021 001 Apr 13, 2021 002 Apr 13, 2021 001 Apr 13, 2021 002 Apr 13, 2021 003 Apr 13, 2021 001 Apr 13, 2021 001 Nov 04, 2021 001 Jul 02, 2021 001 Apr 13, 2021 002 Apr 13, 2021 003 Apr 13, 2021 Apr NFTG Apr NFTG Apr NFTG Apr NFTG Apr NFTG Apr NFTG Apr NFTG Oct NEWA Jun NEWA Apr NFTG Apr NFTG Apr NFTG A 084211 002 A 084211 002 A 084442 004 Mar 29, 1983 Aug CAHN Aug DISC Aug CTEC A 086468 001 A 086065 001 A 087510 001 Apr 01, 1982 Aug CRLD Aug CRLD Aug CRLD N 011276 001 N 011276 001 Oct CRLD Oct CRLD A 214379 A 214107 A 089523 A 089903 A 213626 001 Apr 22, 2021 001 Sep 22, 2021 001 May 03, 1988 001 Aug 29, 1989 001 Sep 28, 2021 Apr NEWA Sep NEWA Jul CAHN Jul CAHN Sep NEWA A 200456 001 Sep 28, 2012 Sep CTEC A 200456 002 Sep 28, 2012 Sep CTEC A 040882 001 Dec 30, 2009 A 040882 001 Dec 30, 2009 A 213890 001 Jul 12, 2021 Aug CMFD Feb DISC Jul NEWA A 087953 001 Nov 15, 1982 Aug CRLD A 084176 003 A 084176 001 Aug CRLD Aug CRLD A 203803 A 203803 A 203803 A 210339 A 210339 A 210339 A 214184 A 214184 001 Apr 29, 2016 002 Apr 29, 2016 003 Apr 29, 2016 001 Jan 04, 2019 002 Jan 04, 2019 003 Jan 04, 2019 001 Apr 21, 2021 002 Apr 21, 2021 Jul DISC Jul DISC Jul DISC Sep CTEC Sep CTEC Sep CTEC Apr NEWA Apr NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -112 AB >A> AB >A> AB >A> AB >D> AB >D> AB >D> AB CAPSULE, EXTENDED RELEASE;ORAL PROPAFENONE HYDROCHLORIDE 425MG TABLET;ORAL PROPAFENONE HYDROCHLORIDE STRIDES PHARMA 150MG 225MG ! 300MG VINTAGE PHARMS 150MG 225MG ! 300MG PROPANTHELINE BROMIDE TABLET;ORAL PROPANTHELINE BROMIDE @ HIKMA PHARMS 15MG >A> AB PROPOFOL INJECTABLE;INJECTION PROPOFOL EMCURE PHARMS LTD 10MG/ML PROPRANOLOL HYDROCHLORIDE TABLET;ORAL PROPRANOLOL HYDROCHLORIDE AB IMPAX LABS INC AB AB @ WATSON LABS 10MG 20MG 40MG 60MG PROPYLTHIOURACIL TABLET;ORAL PROPYLTHIOURACIL BD QUAGEN 50MG PROTAMINE SULFATE INJECTABLE;INJECTION PROTAMINE SULFATE @ HIKMA PHARMS @ 10MG/ML 10MG/ML PYRAZINAMIDE TABLET;ORAL PYRAZINAMIDE AB + NOVITIUM PHARMA AB 500MG 500MG PYRIDOXINE HYDROCHLORIDE INJECTABLE;INJECTION PYRIDOXINE HYDROCHLORIDE +! FRESENIUS KABI USA 100MG/ML PYRIMETHAMINE TABLET;ORAL PYRIMETHAMINE AB ALVOGEN AB FERA PHARMS LLC AB TEVA PHARMS 25MG 25MG 25MG QUETIAPINE FUMARATE TABLET;ORAL QUETIAPINE FUMARATE @ JUBILANT GENERICS EQ 25MG BASE TABLET, EXTENDED RELEASE;ORAL QUETIAPINE FUMARATE @ ANCHEN PHARMS @ @ @ @ MYLAN AB @ EQ 150MG BASE EQ 200MG BASE EQ 300MG BASE EQ 400MG BASE EQ 50MG BASE EQ 50MG BASE EQ 150MG BASE A 214184 003 Apr 21, 2021 Apr NEWA A 075938 A 075938 A 075938 A 075938 A 075938 A 075938 001 Oct 17, 2002 002 Oct 17, 2002 003 Oct 17, 2002 001 Oct 17, 2002 002 Oct 17, 2002 003 Oct 17, 2002 Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN Oct CAHN A 080927 002 Apr DISC A 206408 001 Oct 12, 2021 Oct NEWA A 071972 001 Apr 06, 1988 A 071972 002 Apr 06, 1988 A 071972 003 Apr 06, 1988 A 070178 002 Apr 23, 2018 Sep CMFD Sep CMFD Aug CMFD Apr DISC A 080154 001 Mar CMFD A 089474 001 Nov 05, 1986 Jul CAHN A 089475 001 Nov 05, 1986 Jul CAHN A 080157 001 A 080157 001 Aug CRLD Apr CMFD A 080618 001 Aug CRLD A 211271 001 Jul 27, 2021 A 211271 001 Jul 27, 2021 A 215506 001 Aug 13, 2021 Aug CAHN Jul NEWA Aug NEWA A 203150 001 Nov 26, 2013 Jun DISC A 090757 A 090757 A 090757 A 090757 A 202228 A 202228 A 202228 001 Dec 01, 2017 002 Dec 01, 2017 003 Dec 01, 2017 004 Dec 01, 2017 001 Feb 02, 2021 001 Feb 02, 2021 002 Feb 02, 2021 Jun DISC Jun DISC Jun DISC Jun DISC Feb DISC Jan NEWA Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -113 TABLET, EXTENDED RELEASE;ORAL QUETIAPINE FUMARATE AB EQ 150MG BASE @ EQ 200MG BASE AB EQ 200MG BASE @ EQ 300MG BASE AB EQ 300MG BASE @ EQ 400MG BASE AB EQ 400MG BASE BX SCIEGEN PHARMS INC EQ 50MG BASE BX EQ 150MG BASE BX EQ 200MG BASE BX EQ 300MG BASE BX EQ 400MG BASE QUINIDINE GLUCONATE TABLET, EXTENDED RELEASE;ORAL QUINIDINE GLUCONATE AB EYWA 324MG @ RISING 324MG AB ! SUN PHARM INDUSTRIES 324MG QUINIDINE SULFATE TABLET;ORAL CIN-QUIN + @ SOLVAY + @ QUINORA + @ SCHERING 100MG 200MG 300MG RABEPRAZOLE SODIUM TABLET, DELAYED RELEASE;ORAL ACIPHEX + @ WOODWARD 10MG AB +! 20MG RANITIDINE HYDROCHLORIDE CAPSULE;ORAL RANITIDINE HYDROCHLORIDE @ AUROBINDO PHARMA LTD EQ 150MG BASE @ EQ 300MG BASE SYRUP;ORAL RANITIDINE HYDROCHLORIDE @ AUROBINDO PHARMA LTD EQ 15MG BASE/ML TABLET;ORAL RANITIDINE HYDROCHLORIDE @ WOCKHARDT LTD EQ 150MG BASE @ EQ 300MG BASE RANOLAZINE TABLET, EXTENDED RELEASE;ORAL RANOLAZINE AB ACCORD HLTHCARE 500MG AB 1GM @ AMNEAL 500MG AB 500MG @ 1GM AB 1GM AB GRAVITI PHARMS 500MG AB 1GM AB PRAXGEN 500MG AB 1GM REPAGLINIDE TABLET;ORAL REPAGLINIDE AB PADAGIS US AB AB AB AB AB 0.5MG 0.5MG 1MG 1MG 2MG 2MG A 202228 A 202228 A 202228 A 202228 A 202228 A 202228 A 202228 A 209635 A 209635 A 209635 A 209635 A 209635 002 Feb 02, 2021 003 Feb 02, 2021 003 Feb 02, 2021 004 Feb 02, 2021 004 Feb 02, 2021 005 Feb 02, 2021 005 Feb 02, 2021 005 Nov 16, 2018 001 Nov 29, 2017 002 Nov 29, 2017 003 Nov 29, 2017 004 Nov 29, 2017 Jan NEWA Feb DISC Jan NEWA Feb DISC Jan NEWA Feb DISC Jan NEWA Sep CTEC Sep CTEC Sep CTEC Sep CTEC Sep CTEC A 212589 001 Sep 17, 2021 A 089894 001 Dec 15, 1988 A 089338 001 Feb 11, 1987 Sep NEWA Jan CAHN Sep CTEC A 085299 001 A 084932 001 A 085222 001 Aug CRLD Aug CRLD Aug CRLD N 020973 001 May 29, 2002 Jul CAHN N 020973 002 Aug 19, 1999 Jul CAHN A 211058 001 Jul 16, 2018 Jun DISC A 211058 002 Jul 16, 2018 Jun DISC A 090623 001 Jul 28, 2010 Jun DISC A 075208 001 Dec 17, 1998 Jan DISC A 075208 002 Dec 17, 1998 Jan DISC A 212930 001 May 18, 2021 A 212930 002 May 18, 2021 A 207690 001 Mar 11, 2021 A 207690 001 Mar 11, 2021 A 207690 002 Mar 11, 2021 A 207690 002 Mar 11, 2021 A 212889 001 Jan 28, 2021 A 212889 002 Jan 28, 2021 A 212781 001 Mar 23, 2020 A 212781 002 Mar 23, 2020 May NEWA May NEWA Apr DISC Mar NEWA Apr DISC Mar NEWA Jan NEWA Jan NEWA Feb CAHN Feb CAHN A 201189 A 201189 A 201189 A 201189 A 201189 A 201189 001 Jul 17, 2013 001 Jul 17, 2013 002 Jan 22, 2014 002 Jan 22, 2014 003 Jan 22, 2014 003 Jan 22, 2014 Jul CAHN Jul CAHN Jul CAHN Jul CAHN Jul CAHN Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -114 >A> AP >D> AP RIFAMPIN INJECTABLE;INJECTION RIFAMPIN HIKMA PHARMS WEST-WARD PHARMS INT 600MG/VIAL 600MG/VIAL RIFAXIMIN TABLET;ORAL XIFAXAN +! SALIX PHARMS 550MG RILUZOLE FILM;ORAL EXSERVAN +! MITSUBISHI HOLDINGS 50MG RIMEGEPANT SULFATE TABLET, ORALLY DISINTEGRATING;ORAL NURTEC ODT +! BIOHAVEN IRELAND EQ 75MG BASE RISPERIDONE TABLET, ORALLY DISINTEGRATING;ORAL RISPERDAL + @ JANSSEN PHARMS + @ + @ + @ + @ RISPERIDONE 0.5MG 1MG 2MG 3MG 4MG AB ! JUBILANT GENERICS 1MG RITONAVIR CAPSULE;ORAL RITONAVIR @ HIKMA PHARMS 100MG RIZATRIPTAN BENZOATE TABLET, ORALLY DISINTEGRATING;ORAL RIZATRIPTAN BENZOATE @ JUBILANT GENERICS EQ 5MG BASE @ EQ 10MG BASE AB PANACEA EQ 5MG BASE AB EQ 10MG BASE >D> AB >A> ROFLUMILAST TABLET;ORAL ROFLUMILAST BRECKENRIDGE @ 500MCG 500MCG >D> >A> AP >A> AP ROMIDEPSIN POWDER;INTRAVENOUS ISTODAX +! CELGENE +! ROMIDEPSIN FRESENIUS KABI USA 10MG/VIAL 10MG/VIAL 10MG/VIAL ROPINIROLE HYDROCHLORIDE TABLET;ORAL REQUIP + @ GLAXOSMITHKLINE LLC + @ + @ + @ + @ + @ + @ EQ 0.25MG BASE EQ 0.5MG BASE EQ 1MG BASE EQ 2MG BASE EQ 3MG BASE EQ 4MG BASE EQ 5MG BASE A 064217 001 Oct 29, 1999 Oct CAHN A 064217 001 Oct 29, 1999 Oct CAHN N 021361 002 Mar 24, 2010 Aug CMS1 N 212640 001 Nov 22, 2019 Feb CAHN N 212728 001 Feb 27, 2020 Jul CAHN N 021444 N 021444 N 021444 N 021444 N 021444 001 Apr 02, 2003 002 Apr 02, 2003 003 Apr 02, 2003 004 Dec 23, 2004 005 Dec 23, 2004 Feb DISC Feb DISC Feb DISC Feb DISC Feb DISC A 090839 002 Nov 04, 2011 Feb CHRS A 205801 001 Dec 03, 2020 Mar DISC A 203334 A 203334 A 204722 A 204722 001 Oct 16, 2015 002 Oct 16, 2015 001 Jan 11, 2017 002 Jan 11, 2017 Jun DISC Jun DISC Jul CAHN Jul CAHN A 208236 001 Oct 03, 2018 Oct DISC A 208236 001 Oct 03, 2018 Oct DISC N 022393 001 Nov 05, 2009 Oct CFTG N 022393 001 Nov 05, 2009 Oct CFTG A 206254 001 Oct 12, 2021 Oct NFTG N 020658 N 020658 N 020658 N 020658 N 020658 N 020658 N 020658 001 Sep 19, 1997 002 Sep 19, 1997 003 Sep 19, 1997 004 Sep 19, 1997 006 Jan 27, 1999 007 Jan 27, 1999 005 Sep 19, 1997 Jul DISC Jul DISC Jul DISC Jul DISC Jul DISC Jul DISC Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -115 TABLET;ORAL ROPINIROLE HYDROCHLORIDE AB ! PRINSTON INC EQ 0.25MG BASE TABLET, EXTENDED RELEASE;ORAL REQUIP XL + @ GLAXOSMITHKLINE LLC EQ 2MG BASE AB + EQ 2MG BASE + @ EQ 6MG BASE + @ EQ 12MG BASE ROPINIROLE HYDROCHLORIDE AB ! DR REDDYS LABS LTD EQ 2MG BASE ROPIVACAINE HYDROCHLORIDE SOLUTION;INJECTION NAROPIN + @ FRESENIUS KABI USA 50MG/10ML (5MG/ML) + @ 75MG/10ML (7.5MG/ML) ROPIVACAINE HYDROCHLORIDE @ MYLAN ASI @ 150MG/30ML (5MG/ML) 200MG/20ML (10MG/ML) ROSIGLITAZONE MALEATE TABLET;ORAL AVANDIA + WOODWARD + + @ EQ 2MG BASE EQ 4MG BASE EQ 8MG BASE ROSUVASTATIN CALCIUM TABLET;ORAL CRESTOR AB + IPR AB + AB +! ROSUVASTATIN CALCIUM AB ACCORD HLTHCARE AB AB AB AB ALKEM LABS LTD AB AB AB AB ALLIED AB AB AB @ AMNEAL PHARMS CO @ @ @ @ APOTEX INC @ @ @ AB AUROBINDO PHARMA LTD AB AB AB AB BIOCON LTD AB AB AB AB BIOCON PHARMA AB AB AB AB CADILA PHARMS LTD AB AB AB AB CHANGZHOU PHARM AB EQ 5MG BASE EQ 10MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE A 078110 001 May 05, 2008 Jul CHRS N 022008 N 022008 N 022008 N 022008 001 Jun 13, 2008 001 Jun 13, 2008 006 Apr 10, 2009 005 Oct 31, 2008 Jun DISC Jun CHRS Jun DISC Jun DISC A 201576 001 Jun 06, 2012 Jun CHRS N 020533 013 May 01, 1998 Mar CRLD N 020533 012 Sep 24, 1996 Mar CRLD A 090318 002 Sep 23, 2014 Jan DISC A 090318 004 Sep 23, 2014 Jan DISC N 021071 002 May 25, 1999 N 021071 003 May 25, 1999 N 021071 004 May 25, 1999 Jul CAHN Jul CAHN Jul CAHN N 021366 002 Aug 12, 2003 N 021366 003 Aug 12, 2003 N 021366 005 Aug 12, 2003 Apr CPOT Apr CPOT Apr CPOT A 206434 001 Oct 31, 2016 A 206434 002 Oct 31, 2016 A 206434 003 Oct 31, 2016 A 206434 004 Oct 31, 2016 A 206465 001 Mar 21, 2017 A 206465 002 Mar 21, 2017 A 206465 003 Mar 21, 2017 A 206465 004 Mar 21, 2017 A 079168 001 Jul 19, 2016 A 079168 002 Jul 19, 2016 A 079168 003 Jul 19, 2016 A 079168 004 Jul 19, 2016 A 208850 001 Oct 16, 2018 A 208850 002 Oct 16, 2018 A 208850 003 Oct 16, 2018 A 208850 004 Oct 16, 2018 A 079145 001 Jul 19, 2016 A 079145 002 Jul 19, 2016 A 079145 003 Jul 19, 2016 A 079145 004 Jul 19, 2016 A 079170 001 Jul 19, 2016 A 079170 002 Jul 19, 2016 A 079170 003 Jul 19, 2016 A 079170 004 Jul 19, 2016 A 207752 001 Oct 31, 2016 A 207752 002 Oct 31, 2016 A 207752 003 Oct 31, 2016 A 207752 004 Oct 31, 2016 A 207752 001 Oct 31, 2016 A 207752 002 Oct 31, 2016 A 207752 003 Oct 31, 2016 A 207752 004 Oct 31, 2016 A 207453 001 Nov 23, 2016 A 207453 002 Nov 23, 2016 A 207453 003 Nov 23, 2016 A 207453 004 Nov 23, 2016 A 207408 001 Oct 31, 2016 A 207408 002 Oct 31, 2016 Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Jul CAHN Jul CAHN Jul CAHN Jul CAHN Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -116 TABLET;ORAL ROSUVASTATIN CALCIUM AB EQ 20MG BASE AB EQ 40MG BASE AB CHARTWELL RX EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE AB GLENMARK PHARMS EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE AB HETERO LABS LTD V EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE @ INVENTIA EQ 5MG BASE AB EQ 5MG BASE AB 5MG @ EQ 10MG BASE AB EQ 10MG BASE AB 10MG @ EQ 20MG BASE AB EQ 20MG BASE AB 20MG @ EQ 40MG BASE AB EQ 40MG BASE AB 40MG AB LUPIN EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE AB MSN EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE @ MYLAN EQ 5MG BASE @ EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE AB RENATA EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE AB SANDOZ INC EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE @ SCIEGEN PHARMS INC EQ 5MG BASE @ EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE AB SHANDONG EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE AB SUN PHARM EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE @ SUNSHINE EQ 5MG BASE @ EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE @ TEVA PHARMS USA EQ 5MG BASE @ EQ 10MG BASE @ EQ 20MG BASE @ EQ 40MG BASE AB TORRENT EQ 5MG BASE AB EQ 10MG BASE AB EQ 20MG BASE AB EQ 40MG BASE @ UMEDICA LABS PVT LTD EQ 5MG BASE @ EQ 10MG BASE A 207408 A 207408 A 079168 A 079168 A 079168 A 079168 A 079172 A 079172 A 079172 A 079172 A 207616 A 207616 A 207616 A 207616 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 207653 A 205587 A 205587 A 205587 A 205587 A 208898 A 208898 A 208898 A 208898 A 079161 A 079161 A 079161 A 079161 A 207062 A 207062 A 207062 A 207062 A 079171 A 079171 A 079171 A 079171 A 206381 A 206381 A 206381 A 206381 A 207375 A 207375 A 207375 A 207375 A 079169 A 079169 A 079169 A 079169 A 210667 A 210667 A 210667 A 210667 A 079166 A 079166 A 079166 A 079166 A 201619 A 201619 A 201619 A 201619 A 207626 A 207626 003 Oct 31, 2016 004 Oct 31, 2016 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Oct 31, 2016 002 Oct 31, 2016 003 Oct 31, 2016 004 Oct 31, 2016 001 Feb 05, 2021 001 Feb 05, 2021 001 Feb 05, 2021 002 Feb 05, 2021 002 Feb 05, 2021 002 Feb 05, 2021 003 Feb 05, 2021 003 Feb 05, 2021 003 Feb 05, 2021 004 Feb 05, 2021 004 Feb 05, 2021 004 Feb 05, 2021 001 Jul 31, 2017 002 Jul 31, 2017 003 Jul 31, 2017 004 Jul 31, 2017 001 Nov 22, 2017 002 Nov 22, 2017 003 Nov 22, 2017 004 Nov 22, 2017 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Oct 31, 2016 002 Oct 31, 2016 003 Oct 31, 2016 004 Oct 31, 2016 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Apr 24, 2019 002 Apr 24, 2019 003 Apr 24, 2019 004 Apr 24, 2019 001 May 07, 2019 002 May 07, 2019 003 May 07, 2019 004 May 07, 2019 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Apr 01, 2020 002 Apr 01, 2020 003 Apr 01, 2020 004 Apr 01, 2020 001 Jul 19, 2016 002 Jul 19, 2016 003 Jul 19, 2016 004 Jul 19, 2016 001 Oct 31, 2016 002 Oct 31, 2016 003 Oct 31, 2016 004 Oct 31, 2016 001 Apr 09, 2019 002 Apr 09, 2019 Apr CPOT Apr CPOT Sep CAHN Sep CAHN Sep CAHN Sep CAHN Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT May DISC Apr CPOT Jan NEWA May DISC Apr CPOT Jan NEWA May DISC Apr CPOT Jan NEWA May DISC Apr CPOT Jan NEWA Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -117 TABLET;ORAL ROSUVASTATIN CALCIUM @ @ AB WATSON LABS INC AB AB AB AB ZHEJIANG YONGTAI AB AB AB AB AB AB AB @ ZYDUS PHARMS @ @ @ EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE EQ 5MG BASE 5MG EQ 10MG BASE 10MG EQ 20MG BASE 20MG EQ 40MG BASE 40MG EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE EQ 40MG BASE RUFINAMIDE SUSPENSION;ORAL RUFINAMIDE AB ALKEM LABS LTD TABLET;ORAL RUFINAMIDE AB HETERO LABS LTD III AB AB MYLAN AB 40MG/ML 200MG 400MG 200MG 400MG RUXOLITINIB PHOSPHATE CREAM;TOPICAL OPZELURA +! INCYTE CORP EQ 1.5% BASE SAFINAMIDE MESYLATE TABLET;ORAL XADAGO + MDD US +! EQ 50MG BASE EQ 100MG BASE SAPROPTERIN DIHYDROCHLORIDE POWDER;ORAL SAPROPTERIN DIHYDROCHLORIDE AB DR REDDYS 100MG/PACKET TABLET;ORAL SAPROPTERIN DIHYDROCHLORIDE AB DR REDDYS 100MG SCOPOLAMINE SYSTEM;TRANSDERMAL SCOPOLAMINE AB PADAGIS US TRANSDERM SCOP AB +! BAXTER HLTHCARE CORP 1MG/72HR 1MG/72HR SELEGILINE HYDROCHLORIDE CAPSULE;ORAL SELEGILINE HYDROCHLORIDE AB NOVITIUM PHARMA 5MG SELENIOUS ACID SOLUTION;INTRAVENOUS SELENIOUS ACID +! AM REGENT +! EQ 12MCG BASE/2ML (EQ 6MCG BASE/ML) EQ 60MCG BASE/ML (EQ 60MCG BASE/ML) A 207626 A 207626 A 079167 A 079167 A 079167 A 079167 A 212059 A 212059 A 212059 A 212059 A 212059 A 212059 A 212059 A 212059 A 206513 A 206513 A 206513 A 206513 003 Apr 09, 2019 004 Apr 09, 2019 001 Apr 29, 2016 002 Apr 29, 2016 003 Apr 29, 2016 004 Apr 29, 2016 001 Nov 04, 2019 001 Nov 04, 2019 002 Nov 04, 2019 002 Nov 04, 2019 003 Nov 04, 2019 003 Nov 04, 2019 004 Nov 04, 2019 004 Nov 04, 2019 001 Mar 01, 2019 002 Mar 01, 2019 003 Mar 01, 2019 004 Mar 01, 2019 Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Apr CPOT Feb CMFD Apr CPOT Feb CMFD Apr CPOT Feb CMFD Apr CPOT Feb CMFD Apr CPOT Apr CPOT Apr CPOT Apr CPOT A 213410 001 Feb 23, 2021 Feb NEWA A 204993 001 May 11, 2021 A 204993 002 May 11, 2021 A 205095 001 May 16, 2016 A 205095 002 May 16, 2016 Apr NEWA Apr NEWA May CMFD May CMFD N 215309 001 Sep 21, 2021 Sep NEWA N 207145 001 Mar 21, 2017 Jul CPOT N 207145 002 Mar 21, 2017 Jul CPOT A 209452 001 Mar 30, 2021 Mar NEWA A 207685 001 Jun 15, 2021 Jun NEWA A 078830 001 Jan 30, 2015 Jul CAHN N 017874 001 Mar CAHN A 075352 001 Nov 30, 1998 Apr CMFD N 209379 003 Aug 30, 2021 Aug NEWA N 209379 002 Jan 25, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -118 SELEXIPAG POWDER;INTRAVENOUS UPTRAVI +! ACTELION TABLET;ORAL UPTRAVI + ACTELION +! + + + + + + 1.8MG/VIAL 0.2MG 0.4MG 0.6MG 0.8MG 1MG 1.2MG 1.4MG 1.6MG SELINEXOR TABLET;ORAL XPOVIO + KARYOPHARM THERAPS + + 40MG 50MG 60MG SEMAGLUTIDE SOLUTION;SUBCUTANEOUS WEGOVY +! NOVO +! +! +! +! 0.25MG/0.5ML (0.25MG/0.5ML) 0.5MG/0.5ML (0.5MG/0.5ML) 1MG/0.5ML (1MG/0.5ML) 1.7MG/0.75ML (1.7MG/0.75ML) 2.4MG/0.75ML (2.4MG/0.75ML) >A> >A> >A> >A> AB AB AB AB AB AB AB AB AB AB AB AB AB AB AB SERTRALINE HYDROCHLORIDE CAPSULE;ORAL SERTRALINE HYDROCHLORIDE + ALMATICA +! EQ 150MG BASE EQ 200MG BASE TABLET;ORAL SERTRALINE HYDROCHLORIDE ACI ASCENT PHARMS INC GRANULES HANGZHOU BINJIANG SCIEGEN PHARMS INC EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE SEVELAMER CARBONATE FOR SUSPENSION;ORAL SEVELAMER CARBONATE AB BIONPHARMA INC AB IMPAX @ AB @ TABLET;ORAL SEVELAMER CARBONATE AB ANXIN AB LUPIN LTD 800MG/PACKET 800MG/PACKET 800MG/PACKET 2.4GM/PACKET 2.4GM/PACKET 800MG 800MG N 214275 001 Jul 29, 2021 Jul NEWA N 207947 N 207947 N 207947 N 207947 N 207947 N 207947 N 207947 N 207947 001 Dec 21, 2015 002 Dec 21, 2015 003 Dec 21, 2015 004 Dec 21, 2015 005 Dec 21, 2015 006 Dec 21, 2015 007 Dec 21, 2015 008 Dec 21, 2015 Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN N 212306 002 Apr 15, 2021 N 212306 003 Apr 15, 2021 N 212306 004 Apr 15, 2021 Apr NEWA Apr NEWA Apr NEWA N 215256 N 215256 N 215256 N 215256 N 215256 001 Jun 04, 2021 002 Jun 04, 2021 003 Jun 04, 2021 004 Jun 04, 2021 005 Jun 04, 2021 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA N 215133 001 Oct 04, 2021 Oct NEWA N 215133 002 Oct 04, 2021 Oct NEWA A 076881 A 076881 A 076881 A 214790 A 214790 A 214790 A 078403 A 078403 A 078403 A 078677 A 078677 A 078677 A 076442 A 076442 A 076442 001 Feb 06, 2007 002 Feb 06, 2007 003 Feb 06, 2007 001 May 03, 2021 002 May 03, 2021 003 May 03, 2021 001 Jan 08, 2008 002 Jan 08, 2008 003 Jan 08, 2008 001 Mar 04, 2009 002 Mar 04, 2009 003 Mar 04, 2009 001 Apr 30, 2007 002 Apr 30, 2007 003 Apr 30, 2007 Jan CMFD Jan CMFD Jan CMFD Apr NEWA Apr NEWA Apr NEWA May CAHN May CAHN May CAHN Sep CAHN Sep CAHN Sep CAHN Apr CMFD Apr CMFD Apr CMFD A 209374 A 211316 A 211316 A 211316 A 211316 001 May 17, 2021 001 Nov 20, 2020 001 Nov 20, 2020 002 Nov 20, 2020 002 Nov 20, 2020 May NEWA Aug CMFD Mar DISC Aug CMFD Mar DISC A 212970 001 Apr 09, 2020 Mar CMFD A 204600 001 Jan 14, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -119 SEVELAMER HYDROCHLORIDE TABLET;ORAL SEVELAMER HYDROCHLORIDE AB LUPIN LTD AB 400MG 800MG AB AB >A> AB AB AB AB AB >D> AB SILDENAFIL CITRATE FOR SUSPENSION;ORAL SILDENAFIL CITRATE APPCO HETERO LABS LTD V TABLET;ORAL SILDENAFIL CITRATE CHARTWELL RX REYOUNG UMEDICA LABS PVT LTD @ WATSON LABS INC @ @ YILING EQ 10MG BASE/ML EQ 10MG BASE/ML EQ 20MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 25MG BASE EQ 25MG BASE EQ 50MG BASE EQ 100MG BASE EQ 20MG BASE SIMVASTATIN TABLET;ORAL SIMVASTATIN AB BIOCON PHARMA AB AB AB AB AB HISUN PHARM HANGZHOU AB AB AB AB ! LUPIN ZOCOR AB + ORGANON AB + AB + AB + + @ AB +! 5MG 10MG 20MG 40MG 80MG 10MG 20MG 40MG 80MG 80MG 5MG 10MG 20MG 40MG 80MG 80MG SINECATECHINS OINTMENT;TOPICAL VEREGEN +! ANI PHARMS 15% SIPONIMOD FUMARIC ACID TABLET;ORAL MAYZENT + NOVARTIS EQ 1MG BASE SIROLIMUS TABLET;ORAL SIROLIMUS AB ALKEM LABS LTD AB AB 0.5MG 1MG 2MG SODIUM ACETATE INJECTABLE;INJECTION SODIUM ACETATE AP +! HOSPIRA AP MILLA PHARMS 2MEQ/ML 2MEQ/ML A 213145 001 Jun 16, 2021 Jun NEWA A 213145 002 Jun 16, 2021 Jun NEWA A 213814 001 Apr 29, 2021 Apr NEWA A 213014 001 May 11, 2021 Apr NEWA A 202598 A 208494 A 208494 A 208494 A 209302 A 202506 A 202506 A 202506 A 202598 001 Nov 06, 2012 001 Jun 12, 2020 002 Jun 12, 2020 003 Jun 12, 2020 003 Jun 15, 2021 001 Nov 25, 2020 002 Nov 25, 2020 003 Nov 25, 2020 001 Nov 06, 2012 Oct CAHN Mar CAHN Mar CAHN Mar CAHN Jun NEWA May DISC May DISC May DISC Oct CAHN A 078034 A 078034 A 078034 A 078034 A 078034 A 206557 A 206557 A 206557 A 206557 A 078103 001 Dec 20, 2006 002 Dec 20, 2006 003 Dec 20, 2006 004 Dec 20, 2006 005 Dec 20, 2006 001 Nov 13, 2017 002 Nov 13, 2017 003 Nov 13, 2017 004 Nov 13, 2017 004 May 11, 2007 Mar CAHN Mar CAHN Mar CAHN Mar CAHN Mar CAHN Apr CMFD Apr CMFD Apr CMFD Apr CMFD Jun CHRS N 019766 N 019766 N 019766 N 019766 N 019766 N 019766 001 Dec 23, 1991 002 Dec 23, 1991 003 Dec 23, 1991 004 Dec 23, 1991 005 Jul 10, 1998 005 Jul 10, 1998 Feb CAHN Feb CAHN Feb CAHN Feb CAHN Jun DISC Feb CAHN N 021902 001 Oct 31, 2006 Apr CAHN N 209884 003 Aug 24, 2021 Aug NEWA A 214753 001 Mar 12, 2021 A 214753 002 Mar 12, 2021 A 214753 003 Mar 12, 2021 Mar NEWA Mar NEWA Mar NEWA N 018893 001 May 04, 1983 Apr CFTG A 214805 001 May 04, 2021 Apr NFTG RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -120 SODIUM BENZOATE; SODIUM PHENYLACETATE SOLUTION;INTRAVENOUS SODIUM PHENYLACETATE AND SODIUM BENZOATE +! MAIA PHARMS INC 10%;10% (2GM/20ML;2GM/20ML) N 215025 001 Jun 10, 2021 Jun NEWA SODIUM CHLORIDE INJECTABLE;INJECTION SODIUM CHLORIDE 0.9% HIKMA PHARMS 9MG/ML AP 9MG/ML + @ MEDEFIL INC 9MG/ML (9MG/ML) + @ 18MG/2ML (9MG/ML) + @ 22.5MG/2.5ML (9MG/ML) + @ 27MG/3ML (9MG/ML) + @ 45MG/5ML (9MG/ML) SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER @ JUBILANT CADISTA 9MG/ML SODIUM CHLORIDE 23.4% FRESENIUS KABI USA 234MG/ML SOLUTION;INTRAVENOUS SODIUM CHLORIDE 14.6% FRESENIUS KABI USA 50MEQ/20ML (2.5MEQ/ML) AP 100MEQ/40ML (2.5MEQ/ML) AP +! HOSPIRA 100MEQ/40ML (2.5MEQ/ML) SOLUTION FOR SLUSH;IRRIGATION SODIUM CHLORIDE 0.9% IN STERILE PLASTIC CONTAINER +! BAXTER HLTHCARE 900MG/100ML + 900MG/100ML A 201833 A 201850 N 202832 N 202832 N 202832 N 202832 N 202832 001 Sep 24, 2013 001 Jan 20, 2012 001 Jan 06, 2012 002 Jan 06, 2012 003 Jan 06, 2012 004 Jan 06, 2012 005 Jan 06, 2012 Jul CAHN Jul CAHN Aug DISC Aug DISC Aug DISC Aug DISC Aug DISC A 203352 001 May 18, 2016 Jun DISC A 212248 001 Apr 28, 2021 Apr NFTG A 212070 001 Apr 28, 2021 A 212070 002 Apr 28, 2021 N 018897 002 Jul 20, 1984 Apr NFTG Apr NFTG Apr CFTG N 019319 002 May 17, 1985 Jul CHRS N 019319 002 May 17, 1985 Jul CRLD SODIUM FLUORIDE F-18 INJECTABLE;INTRAVENOUS SODIUM FLUORIDE F-18 @ DECATUR AP NUKEMED 10-200mCi/ML 10-200mCi/ML A 204464 001 Oct 21, 2014 Aug DISC A 203912 001 Apr 22, 2015 Jan CAHN SODIUM NITROPRUSSIDE INJECTABLE;INJECTION SODIUM NITROPRUSSIDE AP BE PHARMS @ CIPLA 25MG/ML 25MG/ML A 214971 001 Jul 12, 2021 Jul NEWA A 210855 001 Jul 16, 2018 Aug DISC SODIUM PHOSPHATE, DIBASIC, ANHYDROUS; SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE TABLET;ORAL MONOBASIC SODIUM PHOSPHATE AND DIBASIC SODIUM PHOSPHATE AB NOVEL LABS INC OSMOPREP 0.398GM;1.102GM A 079247 001 Dec 30, 2011 AB +! SALIX PHARMS 0.398GM;1.102GM N 021892 001 Mar 16, 2006 Jan CMFD Jan CTEC SODIUM POLYSTYRENE SULFONATE POWDER;ORAL, RECTAL KIONEX AA ANI PHARMS 454GM/BOT AA L PERRIGO CO 454GM/BOT SODIUM POLYSTYRENE SULFONATE AA BIOPHARM 453.6GM/BOT AA CHARTWELL RX 454GM/BOT + @ WOCKHARDT 453.6GM/BOT SUSPENSION;ORAL, RECTAL KIONEX @ ANI PHARMS 15GM/60ML @ L PERRIGO CO 15GM/60ML SODIUM POLYSTYRENE SULFONATE @ ANI PHARMS 15GM/60ML @ L PERRIGO CO SPS 15GM/60ML +! CMP PHARMA INC 15GM/60ML A 040029 001 Feb 06, 1998 Mar CAHN A 040029 001 Feb 06, 1998 Mar CAHN A 090313 001 Dec 21, 2011 A 206815 001 Feb 18, 2016 A 088786 001 Sep 11, 1984 Sep CAHN Sep CAHN Aug CRLD A 040028 001 Sep 17, 2007 Mar CAHN A 040028 001 Sep 17, 2007 Mar CAHN A 090590 001 May 13, 2011 Mar CAHN A 090590 001 May 13, 2011 Mar CAHN A 087859 001 Dec 08, 1982 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -121 SOFOSBUVIR; VELPATASVIR PELLETS;ORAL EPCLUSA + GILEAD SCIENCES INC +! 150MG;37.5MG/PACKET 200MG;50MG/PACKET SOLIFENACIN SUCCINATE TABLET;ORAL SOLIFENACIN SUCCINATE @ AJANTA PHARMA LTD @ AB AUSTARPHARMA AB @ BRECKENRIDGE @ @ ZYDUS PHARMS @ 5MG 10MG 5MG 10MG 5MG 10MG 5MG 10MG SORAFENIB TOSYLATE TABLET;ORAL NEXAVAR +! BAYER HLTHCARE SORAFENIB TOSYLATE @ TEVA PHARMS USA INC EQ 200MG BASE EQ 200MG BASE SOTALOL HYDROCHLORIDE TABLET;ORAL SOTALOL HYDROCHLORIDE @ MYLAN @ @ 80MG 120MG 160MG SOTORASIB TABLET;ORAL LUMAKRAS +! AMGEN INC 120MG SPIRONOLACTONE TABLET;ORAL SPIRONOLACTONE @ OXFORD PHARMS @ @ 25MG 50MG 100MG AP >D> >A> STERILE WATER FOR INJECTION LIQUID;N/A STERILE WATER FOR INJECTION HIKMA PHARMS 100% (10ML) @ 100% (20ML) ! NEPHRON 100% (5ML) @ 100% (5ML) ! 100% (5ML) AP AP >A> AP AP SUCCINYLCHOLINE CHLORIDE INJECTABLE;INJECTION SUCCINYLCHOLINE CHLORIDE ACCORD HLTHCARE 20MG/ML HIKMA 20MG/ML @ 20MG/ML HONG KONG 20MG/ML SAGENT PHARMS INC 20MG/ML SOLUTION;INTRAMUSCULAR, INTRAVENOUS SUCCINYLCHOLINE CHLORIDE +! HIKMA PHARMS 100MG/5ML (20MG/ML) SULFACETAMIDE SODIUM SOLUTION/DROPS;OPHTHALMIC BLEPH-10 AT +! ALLERGAN 10% N 214187 001 Jun 10, 2021 Jun NEWA N 214187 002 Jun 10, 2021 Jun NEWA A 205483 A 205483 A 210281 A 210281 A 209818 A 209818 A 207721 A 207721 001 May 20, 2019 002 May 20, 2019 001 May 20, 2019 002 May 20, 2019 001 May 20, 2019 002 May 20, 2019 001 Oct 19, 2020 002 Oct 19, 2020 Jun DISC Jun DISC Sep CAHN Sep CAHN Aug DISC Aug DISC Mar DISC Mar DISC N 021923 001 Dec 20, 2005 May CTEC A 209567 001 Nov 12, 2020 May DISC A 077616 001 Feb 07, 2007 A 077616 002 Feb 07, 2007 A 077616 003 Feb 07, 2007 Feb DISC Feb DISC Feb DISC N 214665 001 May 28, 2021 May NEWA A 040750 001 Aug 29, 2006 A 040750 002 Aug 29, 2006 A 040750 003 Aug 29, 2006 Aug DISC Aug DISC Aug DISC A 206369 A 206369 A 211222 A 211222 A 211222 001 Sep 02, 2015 002 Sep 02, 2015 001 Feb 10, 2021 001 Feb 10, 2021 001 Feb 10, 2021 Jul CAHN Jul CAHN Oct DISC Oct DISC Jan NEWA A 213705 A 213229 A 213229 A 214514 A 215022 001 May 20, 2020 001 Jun 12, 2020 001 Jun 12, 2020 001 Oct 19, 2021 001 Mar 29, 2021 Mar CMFD Apr CMFD Feb DISC Oct NEWA Mar NEWA N 215143 001 Aug 20, 2021 Aug NEWA A 080028 001 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -122 SULFADIAZINE TABLET;ORAL SULFADIAZINE >D> @ IMPAX LABS >A> + @ 500MG 500MG SULFAMETHOXAZOLE TABLET;ORAL SULFAMETHOXAZOLE @ RISING 500MG SULFASALAZINE TABLET;ORAL AZULFIDINE AB +! PFIZER SULFASALAZINE 500MG AB CHARTWELL 500MG TABLET, DELAYED RELEASE;ORAL AZULFIDINE EN-TABS AB +! PFIZER 500MG SULFISOXAZOLE TABLET;ORAL SULFISOXAZOLE @ RISING 500MG SULINDAC TABLET;ORAL SULINDAC @ MYLAN @ @ @ 150MG 150MG 200MG 200MG SUMATRIPTAN SPRAY;NASAL SUMATRIPTAN AB CIPLA AB FLORIDA AB PHARMASERVE NW 20MG/SPRAY 20MG/SPRAY 20MG/SPRAY SUMATRIPTAN SUCCINATE INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE AP CAPLIN @ MYLAN ASI @ EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) SUNITINIB MALATE CAPSULE;ORAL SUNITINIB MALATE AB SUN PHARM AB AB AB SUTENT AB + CPPI CV AB + AB + AB +! EQ 12.5MG BASE EQ 25MG BASE EQ 37.5MG BASE EQ 50MG BASE EQ 12.5MG BASE EQ 25MG BASE EQ 37.5MG BASE EQ 50MG BASE TACROLIMUS CAPSULE;ORAL TACROLIMUS @ CONCORD BIOTECH LTD AB PANACEA AB AB EQ 0.5MG BASE EQ 0.5MG BASE EQ 1MG BASE EQ 5MG BASE A 080081 001 A 080081 001 Oct CRLD Oct CRLD A 085844 001 Jan CAHN N 007073 001 A 080197 001 Mar CAHN Jun CMFD N 007073 002 Apr 06, 1983 Mar CAHN A 085628 001 Jan CAHN A 073039 A 073039 A 073039 A 073039 002 Jun 22, 1993 002 Jun 22, 1993 001 Jun 22, 1993 001 Jun 22, 1993 Aug CAHN Aug DISC Aug CAHN Aug DISC A 214209 001 Feb 22, 2021 A 208967 001 Feb 17, 2021 A 208967 001 Feb 17, 2021 Feb NEWA Mar CAHN Feb NEWA A 213998 001 Jul 13, 2021 Jul NEWA A 090314 001 Jun 10, 2010 May DISC A 090641 001 Jul 28, 2010 Jan DISC A 213914 A 213914 A 213914 A 213914 001 Aug 16, 2021 002 Aug 16, 2021 003 Aug 16, 2021 004 Aug 16, 2021 Aug NFTG Aug NFTG Aug NFTG Aug NFTG N 021938 N 021938 N 021938 N 021938 001 Jan 26, 2006 002 Jan 26, 2006 004 Mar 31, 2009 003 Jan 26, 2006 Aug CTEC Aug CTEC Aug CTEC Aug CTEC A 213112 A 090802 A 090802 A 090802 001 Nov 10, 2020 001 Sep 28, 2012 002 Sep 28, 2012 003 Sep 28, 2012 Apr DISC Jul CAHN Jul CAHN Jul CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -123 TADALAFIL TABLET;ORAL CIALIS AB1 + LILLY AB1 + AB1 + TADALAFIL AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 >D> AB2 >A> AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 AB1 BX ACCORD HLTHCARE AJANTA PHARMA LTD ALEMBIC PHARMS LTD AMNEAL PHARMS CO AUROBINDO PHARMA LTD CIPLA DR REDDYS LABS LTD @ GLENMARK PHARMS LTD @ @ @ HETERO LABS LTD III LUPIN LTD MACLEODS PHARMS LTD @ MYLAN @ @ @ @ @ @ @ @ QILU SUN PHARM SUNSHINE TEVA PHARMS USA TORRENT UMEDICA LABS PVT LTD UNICHEM 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 20MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 2.5MG 2.5MG 5MG 5MG 5MG 10MG 10MG 10MG 20MG 20MG 20MG 20MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG 2.5MG N 021368 004 Jan 07, 2008 N 021368 001 Nov 21, 2003 N 021368 002 Nov 21, 2003 Feb CTEC Feb CTEC Feb CTEC A 209167 A 209167 A 209167 A 209654 A 209654 A 209654 A 204809 A 204809 A 204809 A 209744 A 209744 A 209744 A 206285 A 206285 A 206285 A 209539 A 209539 A 209539 A 210069 A 210069 A 210069 A 210716 A 210716 A 210716 A 210716 A 209908 A 209908 A 209908 A 210567 A 210567 A 210567 A 207244 A 207244 A 207244 A 206956 A 206956 A 206956 A 206957 A 206957 A 206957 A 206956 A 206956 A 206956 A 200630 A 200630 A 206956 A 206956 A 210420 A 210420 A 210420 A 208934 A 208934 A 208934 A 211335 A 211335 A 211335 A 090141 A 090141 A 090141 A 211839 A 211839 A 211839 A 211298 A 211298 A 211298 A 209250 001 Mar 26, 2019 002 Mar 26, 2019 003 Oct 23, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Dec 29, 2020 002 Dec 29, 2020 003 Dec 29, 2020 004 Dec 29, 2020 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Oct 07, 2019 002 Oct 07, 2019 003 Oct 07, 2019 001 Apr 29, 2019 001 Apr 29, 2019 001 Apr 29, 2019 001 Apr 29, 2019 001 Apr 29, 2019 001 Apr 29, 2019 002 Apr 29, 2019 002 Apr 29, 2019 002 Apr 29, 2019 001 Aug 03, 2018 001 Aug 03, 2018 003 Apr 29, 2019 003 Apr 29, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 May 22, 2018 002 May 22, 2018 003 May 22, 2018 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 001 Oct 23, 2020 002 Oct 23, 2020 003 Oct 23, 2020 001 Mar 26, 2019 Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb DISC Feb DISC Feb DISC Feb DISC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Aug CAHN Aug DISC Feb CTEC Aug CAHN Aug DISC Feb CTEC Aug CAHN Aug DISC Feb CTEC Oct DISC Oct DISC Aug CAHN Aug DISC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -124 AB1 BX AB1 BX AB1 BX >A> AB1 >A> AB1 >A> AB1 >A> AB1 AB1 AB1 AB1 AB1 AB1 AB1 TABLET;ORAL TADALAFIL VKT PHARMA YANGLING BUCHANG ZYDUS PHARMS 2.5MG 5MG 5MG 10MG 10MG 20MG 2.5MG 5MG 10MG 20MG 2.5MG 5MG 10MG 2.5MG 5MG 10MG TAFAMIDIS CAPSULE;ORAL VYNDAMAX >D> +! FOLDRX PHARMS >A> +! 61MG 61MG TAFAMIDIS MEGLUMINE CAPSULE;ORAL VYNDAQEL >D> +! FOLDRX PHARMS >A> +! 20MG 20MG TALAZOPARIB TOSYLATE CAPSULE;ORAL TALZENNA >A> + PFIZER >A> + EQ 0.5MG BASE EQ 0.75MG BASE TALC AEROSOL;INTRAPLEURAL SCLEROSOL +! SCIARRA LABS POWDER;INTRAPLEURAL TALC +! SCIARRA LABS 4GM/SPRAY 5GM/BOT TAMSULOSIN HYDROCHLORIDE CAPSULE;ORAL TAMSULOSIN HYDROCHLORIDE AB ANBISON LAB @ ANCHEN PHARMS 0.4MG 0.4MG TAVABOROLE SOLUTION;TOPICAL TAVABOROLE AB CIPLA AB FLATWING AB @ IDENTIRX AB AB LUPIN LTD AB TARO PHARMS 5% 5% 5.0% 5% 5% 5% 5% TECHNETIUM TC-99M MEDRONATE KIT INJECTABLE;INJECTION CIS-MDP AP SUN PHARM INDS INC N/A TECHNETIUM TC-99M MEDRONATE KIT AP CARDINAL HEALTH 414 N/A AP N/A A 209250 A 209250 A 209250 A 209250 A 209250 A 209250 A 215556 A 215556 A 215556 A 215556 A 208824 A 208824 A 208824 A 206693 A 206693 A 206693 001 Mar 26, 2019 002 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 003 Mar 26, 2019 004 Mar 26, 2019 001 Nov 04, 2021 002 Nov 04, 2021 003 Nov 04, 2021 004 Nov 04, 2021 001 Oct 27, 2020 002 Oct 27, 2020 003 Oct 27, 2020 001 Mar 26, 2019 002 Mar 26, 2019 003 Mar 26, 2019 Feb CTEC Sep CTEC Feb CTEC Sep CTEC Feb CTEC Sep CTEC Oct NEWA Oct NEWA Oct NEWA Oct NEWA Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC Feb CTEC N 212161 001 May 03, 2019 Oct CAHN N 212161 001 May 03, 2019 Oct CAHN N 211996 001 May 03, 2019 Oct CAHN N 211996 001 May 03, 2019 Oct CAHN N 211651 003 Sep 20, 2021 Oct NEWA N 211651 004 Sep 20, 2021 Oct NEWA N 020587 001 Dec 24, 1997 Sep CAHN N 021388 001 Dec 15, 2003 Sep CAHN A 211885 001 Oct 17, 2019 Aug CMFD A 202010 001 Jan 04, 2013 Jun DISC A 212224 A 211963 A 211963 A 211963 A 211963 A 212168 A 212215 001 Feb 09, 2021 001 Feb 03, 2021 001 Feb 03, 2021 001 Feb 03, 2021 001 Feb 03, 2021 001 Feb 08, 2021 001 May 07, 2021 Jan NEWA Feb CPOT Jan NEWA Sep DISC Feb CAHN Jan NEWA Apr NEWA N 018124 001 N 018107 001 N 018107 001 Jul CTEC Jul CTNA Jul CMFD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -125 TECHNETIUM TC-99M SUCCIMER KIT INJECTABLE;INJECTION MPI DMSA KIDNEY REAGENT + @ GE HEALTHCARE N/A TELMISARTAN TABLET;ORAL TELMISARTAN AB CELLTRION AB AB AB MYLAN AB AB 20MG 40MG 80MG 20MG 40MG 80MG TEMAZEPAM CAPSULE;ORAL TEMAZEPAM @ MYLAN @ @ @ @ @ @ @ 7.5MG 7.5MG 15MG 15MG 22.5MG 22.5MG 30MG 30MG TEMOZOLOMIDE CAPSULE;ORAL TEMOZOLOMIDE @ HERITAGE @ @ @ @ @ @ WATSON LABS TEVA @ @ @ @ 5MG 20MG 100MG 140MG 180MG 250MG 5MG 20MG 100MG 140MG 250MG TEPOTINIB HYDROCHLORIDE TABLET;ORAL TEPMETKO +! EMD SERONO INC EQ 225MG BASE TERAZOSIN HYDROCHLORIDE CAPSULE;ORAL TERAZOSIN HYDROCHLORIDE AB HERITAGE PHARMA AB AB AB @ MYLAN @ @ @ @ @ @ @ EQ 1MG BASE EQ 2MG BASE EQ 5MG BASE EQ 10MG BASE EQ 1MG BASE EQ 1MG BASE EQ 2MG BASE EQ 2MG BASE EQ 5MG BASE EQ 5MG BASE EQ 10MG BASE EQ 10MG BASE TERBINAFINE HYDROCHLORIDE TABLET;ORAL TERBINAFINE HYDROCHLORIDE AB ! AUROBINDO PHARMA EQ 250MG BASE N 017944 001 May 18, 1982 Sep CRLD A 078710 A 078710 A 078710 A 202397 A 202397 A 202397 001 Jan 08, 2014 002 Jan 08, 2014 003 Jan 08, 2014 001 Jul 07, 2014 002 Jul 07, 2014 003 Jul 07, 2014 Feb CMFD Feb CMFD Feb CMFD Aug CAHN Aug CAHN Aug CAHN A 070920 A 070920 A 070920 A 070920 A 070920 A 070920 A 070920 A 070920 002 May 21, 2010 002 May 21, 2010 004 Jul 07, 1986 004 Jul 07, 1986 003 Jun 12, 2009 003 Jun 12, 2009 001 Jul 10, 1986 001 Jul 10, 1986 Sep CAHN Sep DISC Sep CAHN Sep DISC Sep CAHN Sep DISC Sep CAHN Sep DISC A 078879 A 078879 A 078879 A 078879 A 078879 A 078879 A 203959 A 203959 A 203959 A 203959 A 203959 001 Mar 01, 2010 002 Mar 01, 2010 003 Mar 01, 2010 005 Mar 01, 2010 006 Mar 01, 2010 004 Mar 01, 2010 001 Apr 18, 2017 002 Apr 18, 2017 003 Apr 18, 2017 004 Apr 18, 2017 005 Apr 18, 2017 Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Feb CAHN Jan DISC Jan DISC Jan DISC Jan DISC Jan DISC N 214096 001 Feb 03, 2021 Feb NEWA A 075614 A 075614 A 075614 A 075614 A 075140 A 075140 A 075140 A 075140 A 075140 A 075140 A 075140 A 075140 002 Jan 30, 2001 001 Jan 30, 2001 003 Jan 30, 2001 004 Jan 30, 2001 002 Feb 11, 2000 002 Feb 11, 2000 003 Feb 11, 2000 003 Feb 11, 2000 001 Feb 11, 2000 001 Feb 11, 2000 004 Feb 11, 2000 004 Feb 11, 2000 May CMFD May CMFD May CMFD May CMFD Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC Aug CAHN Aug DISC A 078297 001 Jul 02, 2007 Sep CHRS RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -126 AB AB >D> >A> TERIFLUNOMIDE TABLET;ORAL TERIFLUNOMIDE BRECKENRIDGE @ IMPAX @ @ SOLA PHARMS 7MG 14MG 14MG 14MG 14MG TESTOSTERONE GEL;TRANSDERMAL TESTOSTERONE AB2 AB2 >A> AB1 ACTAVIS LABS UT INC ENCUBE 1.62% (20.25MG/1.25GM PACKET) 1.62% (40.5MG/2.5GM PACKET) 50MG/5GM PACKET GEL, METERED;TRANSDERMAL TESTOSTERONE @ ALEOR DERMACEUTICALS 1.62% (20.25MG/1.25GM ACTUATION) AB 1.62% (20.25MG/1.25GM ACTUATION) SOLUTION, METERED;TRANSDERMAL TESTOSTERONE AT ALEOR DERMACEUTICALS 30MG/1.5ML ACTUATION @ APOTEX 30MG/1.5ML ACTUATION AT DASH PHARMS 30MG/1.5ML ACTUATION AT FEMPHARM 30MG/1.5ML ACTUATION AT TWI PHARMS 30MG/1.5ML ACTUATION TESTOSTERONE CYPIONATE INJECTABLE;INJECTION DEPO-TESTOSTERONE @ PFIZER AO +! AO ! AO +! AO ! TESTOSTERONE CYPIONATE AO HIKMA PHARMS AO 50MG/ML 100MG/ML 100MG/ML 200MG/ML 200MG/ML 100MG/ML 200MG/ML TETRABENAZINE TABLET;ORAL TETRABENAZINE @ AJANTA PHARMA LTD @ 12.5MG 25MG TETRACAINE HYDROCHLORIDE SOLUTION;OPHTHALMIC TETRACAINE HYDROCHLORIDE +! BAUSCH LOMB IRELAND 0.5% THALLOUS CHLORIDE TL-201 INJECTABLE;INJECTION THALLOUS CHLORIDE TL 201 + @ GE HEALTHCARE 1mCi/ML THEOPHYLLINE CAPSULE, EXTENDED RELEASE;ORAL SLO-PHYLLIN + @ SANOFI AVENTIS US SOMOPHYLLIN-CRT 125MG + @ GRAHAM DM THEO-24 250MG + AUXILIUM PHARMS LLC 200MG ELIXIR;ORAL THEOPHYLLINE + @ PRECISION DOSE 80MG/15ML SOLUTION;ORAL THEOPHYLLINE + @ ROXANE 80MG/15ML A 209583 001 Sep 24, 2021 A 209583 002 Sep 24, 2021 A 209677 001 Jun 17, 2020 A 209677 001 Jun 17, 2020 A 209677 001 Jun 17, 2020 Sep NEWA Sep NEWA Oct CAHN Feb DISC Oct CAHN A 204570 002 Jul 17, 2020 A 204570 003 Jul 17, 2020 A 212984 001 Nov 09, 2021 Feb NEWA Feb NEWA Oct NEWA A 213922 001 Mar 03, 2021 Sep DISC A 213922 001 Mar 03, 2021 Feb NEWA A 212882 001 Jun 14, 2021 A 209181 001 Nov 25, 2020 A 212301 001 Jan 11, 2021 A 212301 001 Jan 11, 2021 A 209836 001 Sep 03, 2021 Jun NEWA May DISC May CAHN Jan NEWA Aug NEWA A 085635 001 A 085635 002 A 085635 002 A 085635 003 A 085635 003 Mar CAHN Aug CRLD Mar CAHN Aug CRLD Mar CAHN A 090387 001 Jul 15, 2010 Jul CAHN A 090387 002 Jul 15, 2010 Jul CAHN A 213621 001 Dec 04, 2020 May DISC A 213621 002 Dec 04, 2020 May DISC N 210821 001 Mar 12, 2019 May CAHN N 018110 002 Feb 27, 1996 Jun DISC A 085203 001 May 24, 1982 Aug CRLD A 087193 001 Aug CRLD A 087943 001 Aug 22, 1983 Aug CRLD A 085863 001 Aug CRLD A 087449 001 Sep 15, 1983 Aug CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -127 SOLUTION, ELIXIR;ORAL ELIXOPHYLLIN AA +! NOSTRUM LABS INC 80MG/15ML SYRUP;ORAL THEOPHYLLINE + @ ALPHARMA US PHARMS 150MG/15ML TABLET, EXTENDED RELEASE;ORAL THEO-DUR + @ SCHERING 200MG + @ 300MG THEOPHYLLINE AB ALEMBIC PHARMS LTD 300MG AB ! 450MG AB GLENMARK PHARMS LTD 300MG AB 450MG @ HERITAGE PHARMA 100MG @ 200MG AB + RHODES PHARMS 400MG THIAMINE HYDROCHLORIDE INJECTABLE;INJECTION BETALIN S + @ LILLY THIAMINE HYDROCHLORIDE AP +! FRESENIUS KABI USA AP WEST-WARD PHARMS INT 100MG/ML 100MG/ML 100MG/ML THIORIDAZINE HYDROCHLORIDE TABLET;ORAL THIORIDAZINE HYDROCHLORIDE MYLAN ! @ SUN PHARM INDUSTRIES @ @ @ 10MG 25MG 50MG 100MG 10MG 25MG 50MG 100MG THIOTEPA POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL THIOTEPA AP GLAND PHARMA LTD 15MG/VIAL THIOTHIXENE HYDROCHLORIDE CONCENTRATE;ORAL NAVANE >D> @ PFIZER >A> + @ EQ 5MG BASE/ML EQ 5MG BASE/ML TIAGABINE HYDROCHLORIDE TABLET;ORAL TIAGABINE HYDROCHLORIDE @ WILSHIRE PHARMS INC @ @ @ 2MG 4MG 12MG 16MG TICAGRELOR TABLET;ORAL BRILINTA AB + ASTRAZENECA TICAGRELOR AB MYLAN AB 60MG 60MG 90MG A 085186 001 Aug CRLD A 086545 001 Aug CRLD A 086998 001 A 085328 002 Aug CRLD Sep CRLD A 090430 A 090430 A 212184 A 212184 A 089807 A 089808 A 040086 001 Oct 27, 2010 002 Oct 27, 2010 001 Jun 03, 2021 002 Jun 03, 2021 001 Apr 30, 1990 001 Apr 30, 1990 002 Sep 01, 1982 May CTEC May CTEC May NEWA May NEWA Jul DISC Jul DISC Aug CRLD A 080853 001 A 080556 001 A 080575 001 Aug CRLD Aug CRLD Apr CMFD A 088004 A 088004 A 088004 A 088004 A 089953 A 089953 A 089953 A 089953 002 Mar 15, 1983 003 Mar 15, 1983 004 Mar 15, 1983 001 Nov 18, 1983 004 Aug 01, 1986 003 Aug 01, 1986 002 Aug 01, 1986 001 Oct 07, 1988 Jan CTEC Jan CTEC Jan CTEC Jan CTEC Jan DISC Jan DISC Jan DISC Jan DISC A 214222 001 Mar 08, 2021 Feb NEWA N 016758 001 N 016758 001 Oct CRLD Oct CRLD A 206857 A 206857 A 206857 A 206857 001 Oct 13, 2017 002 Oct 13, 2017 003 Oct 13, 2017 004 Oct 13, 2017 Jan DISC Jan DISC Jan DISC Jan DISC N 022433 002 Sep 03, 2015 Jul CFTG A 208597 001 Jul 09, 2021 Jul NFTG A 208597 002 Jul 09, 2021 Jul NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -128 TICLOPIDINE HYDROCHLORIDE TABLET;ORAL TICLOPIDINE HYDROCHLORIDE @ CHARTWELL RX @ 250MG 250MG TIGECYCLINE POWDER;INTRAVENOUS TIGECYCLINE AP HONG KONG AP MEITHEAL 50MG/VIAL 50MG/VIAL TIMOLOL MALEATE SOLUTION, GEL FORMING/DROPS;OPHTHALMIC TIMOLOL MALEATE AB ! ALEMBIC PHARMS LTD AB ! TIMOPTIC-XE EQ 0.25% BASE EQ 0.5% BASE AB + VALEANT PHARMS LLC AB + EQ 0.25% BASE EQ 0.5% BASE SOLUTION/DROPS;OPHTHALMIC TIMOLOL MALEATE AT MANKIND PHARMA AT1 EQ 0.25% BASE EQ 0.5% BASE TIOPRONIN TABLET;ORAL THIOLA AB +! MISSION PHARMA TIOPRONIN AB TEVA PHARMS USA INC 100MG 100MG TIOTROPIUM BROMIDE SPRAY, METERED;INHALATION SPIRIVA RESPIMAT +! BOEHRINGER INGELHEIM EQ 0.00125MG BASE/INH TIROFIBAN HYDROCHLORIDE SOLUTION;INTRAVENOUS AGGRASTAT + MEDICURE EQ 5MG BASE/100ML (EQ 0.05MG BASE/ML) AP +! EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) @ EQ 25MG BASE/500ML (EQ 0.05MG BASE/ML) TIROFIBAN HYDROCHLORIDE AP GLAND PHARMA LTD EQ 12.5MG BASE/250ML (EQ 0.05MG BASE/ML) TIVOZANIB HYDROCHLORIDE CAPSULE;ORAL FOTIVDA + AVEO PHARMS +! EQ 0.89MG BASE EQ 1.34MG BASE TIZANIDINE HYDROCHLORIDE CAPSULE;ORAL TIZANIDINE HYDROCHLORIDE @ PAR PHARM INC @ @ EQ 2MG BASE EQ 4MG BASE EQ 6MG BASE TABLET;ORAL TIZANIDINE HYDROCHLORIDE AB CADILA AB @ MYLAN @ EQ 2MG BASE EQ 4MG BASE EQ 2MG BASE EQ 4MG BASE A 075318 001 Aug 20, 1999 Aug CAHN A 075326 001 Aug 20, 1999 Aug CAHN A 214020 001 May 13, 2021 May NEWA A 214020 001 May 13, 2021 Aug CAHN A 212942 001 Oct 22, 2020 Apr CHRS A 212942 002 Oct 22, 2020 Apr CHRS N 020330 001 Nov 04, 1993 Apr CHRS N 020330 002 Nov 04, 1993 Apr CHRS A 078771 001 Sep 28, 2009 Apr CAHN A 078771 002 Sep 28, 2009 Apr CAHN N 019569 001 Aug 11, 1988 Apr CFTG A 214326 001 Apr 26, 2021 Apr NFTG N 021936 002 Sep 15, 2015 Mar CHRS N 020913 002 May 17, 2002 Apr CDFR N 020913 003 Apr 20, 2000 Apr CFTG N 020913 001 May 14, 1998 Apr CDFR A 206888 001 Apr 08, 2021 Apr NFTG N 212904 001 Mar 10, 2021 Mar NEWA N 212904 002 Mar 10, 2021 Mar NEWA A 207199 001 Mar 14, 2017 Jun DISC A 207199 002 Mar 14, 2017 Jun DISC A 207199 003 Mar 14, 2017 Jun DISC A 208187 001 Mar 09, 2018 A 208187 002 Mar 09, 2018 A 076354 001 Mar 28, 2003 A 076354 002 Mar 28, 2003 Feb CAHN Feb CAHN Jan DISC Feb DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -129 TOBRAMYCIN SOLUTION;INHALATION TOBRAMYCIN AN ALKEM LABS LTD 300MG/5ML @ AUROBINDO PHARMA LTD 300MG/5ML AN 300MG/5ML @ LUOXIN AUROVITAS 300MG/5ML SOLUTION/DROPS;OPHTHALMIC TOBRAMYCIN AT GLAND PHARMA LTD 0.3% TOBRAMYCIN SULFATE INJECTABLE;INJECTION TOBRAMYCIN SULFATE AP GLAND PHARMA LTD EQ 10MG BASE/ML AP EQ 40MG BASE/ML AP EQ 1.2GM BASE/VIAL TOBRAMYCIN SULFATE (PHARMACY BULK) AP ! FRESENIUS KABI USA AP GLAND PHARMA LTD EQ 40MG BASE/ML EQ 40MG BASE/ML TOFACITINIB CITRATE SOLUTION;ORAL XELJANZ +! PFIZER EQ 1MG/ML BASE TABLET, EXTENDED RELEASE;ORAL TOFACITINIB AB ZYDUS PHARMS EQ 11MG BASE AB EQ 22MG BASE XELJANZ XR AB + PFIZER AB +! EQ 11MG BASE EQ 22MG BASE TOLAZAMIDE TABLET;ORAL TOLAZAMIDE @ CHARTWELL RX @ @ 100MG 250MG 500MG TOLBUTAMIDE TABLET;ORAL TOLBUTAMIDE @ CHARTWELL RX >D> ! MYLAN PHARMS INC >A> @ 500MG 500MG 500MG TOLCAPONE TABLET;ORAL TOLCAPONE @ ALVOGEN @ MAYNE PHARMA 100MG 100MG TOLMETIN SODIUM CAPSULE;ORAL TOLMETIN SODIUM @ MYLAN @ TEVA TABLET;ORAL TOLMETIN SODIUM @ MYLAN EQ 400MG BASE EQ 400MG BASE EQ 600MG BASE TOLTERODINE TARTRATE CAPSULE, EXTENDED RELEASE;ORAL TOLTERODINE TARTRATE AB AJANTA PHARMA LTD 2MG AB 4MG AB AMTA 2MG AB 4MG @ MYLAN 2MG @ 4MG A 212848 A 210871 A 210871 A 210871 001 Apr 01, 2021 001 Jan 22, 2021 001 Jan 22, 2021 001 Jan 22, 2021 Mar NEWA Jul DISC Jan NEWA Aug CAHN A 212628 001 Mar 09, 2021 Feb NEWA A 209621 001 Feb 11, 2021 A 209621 002 Feb 11, 2021 A 211189 001 May 18, 2021 Feb NEWA Feb NEWA May NEWA A 065120 001 Nov 29, 2002 Jan CTEC A 209346 001 Feb 09, 2021 Jan NEWA N 213082 001 Sep 25, 2020 Feb CMS1 A 214264 001 Aug 19, 2021 Aug NFTG A 214264 002 Aug 19, 2021 Aug NFTG N 208246 001 Feb 23, 2016 Aug CFTG N 208246 002 Dec 12, 2019 Aug CFTG A 071633 001 Dec 09, 1987 A 070289 001 Mar 13, 1986 A 070290 001 Mar 13, 1986 Aug CAHN Aug CAHN Aug CAHN A 086574 001 A 086445 001 A 086445 001 Aug CAHN Oct DISC Oct DISC A 207729 001 Jul 29, 2020 Jan DISC A 210095 001 Aug 01, 2019 Sep DISC A 073393 001 May 27, 1993 Aug DISC A 073290 001 Nov 27, 1991 Aug DISC A 074473 001 Aug 30, 1994 Aug DISC A 213397 A 213397 A 213858 A 213858 A 201486 A 201486 001 May 19, 2020 002 May 19, 2020 001 Feb 02, 2021 002 Feb 02, 2021 001 Oct 31, 2013 002 Oct 31, 2013 Jan CMFD Jan CMFD Jan NEWA Jan NEWA Jul DISC Jul DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -130 TABLET;ORAL TOLTERODINE TARTRATE AB HETERO LABS LTD V 1MG AB 2MG TOLVAPTAN TABLET;ORAL SAMSCA + OTSUKA AB +! + @ TOLVAPTAN ALKEM LABS LTD AB APOTEX AB HETERO LABS LTD V 15MG 30MG 60MG 60MG 30MG 30MG TOPIRAMATE CAPSULE, EXTENDED RELEASE;ORAL QUDEXY XR AB2 + UPSHER SMITH LABS 25MG AB2 + 50MG AB2 + 100MG AB2 + 150MG AB2 +! 200MG TOPIRAMATE AB2 GLENMARK PHARMS LTD 25MG AB2 50MG AB2 100MG AB2 150MG AB2 200MG AB1 ZYDUS PHARMS 25MG AB1 50MG AB1 100MG TROKENDI XR AB1 + SUPERNUS PHARMS 25MG AB1 + 50MG AB1 + 100MG TABLET;ORAL TOPIRAMATE AB ASCENT PHARMS INC 25MG AB 50MG AB 100MG AB 200MG TOPOTECAN HYDROCHLORIDE INJECTABLE;INJECTION TOPOTECAN HYDROCHLORIDE @ MEITHEAL EQ 4MG BASE/VIAL TORSEMIDE TABLET;ORAL SOAANZ +! SARFE PHARMS + + +! 20MG 20MG 60MG 60MG TRAMADOL HYDROCHLORIDE TABLET;ORAL TRAMADOL HYDROCHLORIDE @ GRAVITI PHARMS 50MG AB MERRO PHARM USA 50MG AB POLYGEN PHARMS 50MG @ RISING 50MG TABLET, EXTENDED RELEASE;ORAL TRAMADOL HYDROCHLORIDE @ ANCHEN PHARMS 100MG @ 200MG @ 300MG A 204397 001 Aug 02, 2021 Jul NEWA A 204397 002 Aug 02, 2021 Jul NEWA N 022275 001 May 19, 2009 N 022275 002 May 19, 2009 N 022275 003 May 19, 2009 Feb CAHN Feb CAHN Feb CAHN A 211891 002 May 19, 2020 A 207605 001 May 19, 2020 A 205646 001 Jul 16, 2021 Jul CTEC Aug CMFD Jul NEWA N 205122 001 Mar 11, 2014 N 205122 002 Mar 11, 2014 N 205122 003 Mar 11, 2014 N 205122 004 Mar 11, 2014 N 205122 005 Mar 11, 2014 Jan CFTG Jan CFTG Jan CFTG Jan CFTG Jan CFTG A 210278 001 Feb 01, 2021 A 210278 002 Feb 01, 2021 A 210278 003 Feb 01, 2021 A 210278 004 Feb 01, 2021 A 210278 005 Feb 01, 2021 A 207382 001 Nov 24, 2017 A 207382 002 Nov 24, 2017 A 207382 003 Nov 24, 2017 Jan NFTG Jan NFTG Jan NFTG Jan NFTG Jan NFTG Jan CTEC Jan CTEC Jan CTEC N 201635 001 Aug 16, 2013 N 201635 002 Aug 16, 2013 N 201635 003 Aug 16, 2013 Jan CTEC Jan CTEC Jan CTEC A 215414 001 Aug 26, 2021 A 215414 002 Aug 26, 2021 A 215414 003 Aug 26, 2021 A 215414 004 Aug 26, 2021 Aug NEWA Aug NEWA Aug NEWA Aug NEWA A 201166 001 Aug 08, 2012 Aug DISC N 213218 N 213218 N 213218 N 213218 001 Jun 14, 2021 001 Jun 14, 2021 002 Jun 14, 2021 002 Jun 14, 2021 Jul CHRS Jun NEWA Jul CHRS Jun NEWA A 075968 A 206706 A 206706 A 075968 001 Jun 25, 2002 001 Jul 02, 2019 001 Jul 02, 2019 001 Jun 25, 2002 Apr CAHN Sep CAHN Feb CMFD Aug CAHN A 200491 001 Jun 27, 2012 A 200491 002 Jun 27, 2012 A 200491 003 Jun 27, 2012 Apr DISC Apr DISC Apr DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -131 TRANDOLAPRIL; VERAPAMIL HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL TARKA + @ ABBVIE 2MG;180MG + @ 2MG;240MG + @ 4MG;240MG TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE GLENMARK GENERICS 2MG;180MG 2MG;240MG ! 4MG;240MG AB ! 4MG;240MG TRANEXAMIC ACID INJECTABLE;INJECTION CYKLOKAPRON AP +! PFIZER TRANEXAMIC ACID AP CAPLIN AP PROVEPHARM SAS @ ZYDUS PHARMS TABLET;ORAL TRANEXAMIC ACID AB ANI PHARMS @ APOTEX INC 100MG/ML 100MG/ML 100MG/ML 100MG/ML 650MG 650MG AB >D> AB >A> AB >A> AB TRANYLCYPROMINE SULFATE TABLET;ORAL TRANYLCYPROMINE SULFATE NOVITIUM PHARMA PAR PHARM STRIDES PHARMA EQ 10MG BASE EQ 10MG BASE EQ 10MG BASE EQ 10MG BASE TRAVOPROST SOLUTION/DROPS;OPHTHALMIC TRAVOPROST AT MICRO LABS 0.004% TRAZODONE HYDROCHLORIDE TABLET;ORAL TRAZODONE HYDROCHLORIDE @ ALVOGEN 50MG @ 100MG AB AUROLIFE PHARMA LLC 50MG AB 100MG AB 150MG AB 300MG @ RISING 50MG TREPROSTINIL INJECTABLE;IV (INFUSION), SUBCUTANEOUS REMODULIN +! UNITED THERAP TREPROSTINIL 20MG/ML AP ALEMBIC GLOBAL AP AP AP 1MG/ML 2.5MG/ML 5MG/ML 10MG/ML SOLUTION;INTRAVENOUS, SUBCUTANEOUS REMODULIN @ UNITED THERAP @ @ @ 20MG/20ML (1MG/ML) 50MG/20ML (2.5MG/ML) 100MG/20ML (5MG/ML) 200MG/20ML (10MG/ML) TRETINOIN CREAM;TOPICAL RENOVA +! VALEANT PHARMS NORTH 0.05% N 020591 001 Oct 22, 1996 N 020591 004 Oct 22, 1996 N 020591 002 Oct 22, 1996 Aug DISC Aug DISC Aug DISC A 079135 A 079135 A 079135 A 079135 001 May 26, 2010 002 May 26, 2010 003 May 05, 2010 003 May 05, 2010 Aug CTEC Aug CTEC Aug CTEC Aug CHRS N 019281 001 Dec 30, 1986 Mar CAHN A 212360 001 Jul 17, 2019 A 212676 001 Jul 17, 2019 A 205228 001 Jul 17, 2017 Jun CMFD Jan CAHN Apr DISC A 203256 001 Jul 25, 2016 Jun CMFD A 202286 001 Jan 27, 2014 Mar DISC A 206856 A 040640 A 040640 A 040640 001 Apr 17, 2018 001 Jun 29, 2006 001 Jun 29, 2006 001 Jun 29, 2006 Apr CAHN Oct CAHN Oct CAHN Oct CAHN A 203767 001 Mar 19, 2021 Mar NEWA A 071636 A 071514 A 204852 A 204852 A 204852 A 204852 A 072484 001 Apr 18, 1988 001 Apr 18, 1988 001 Feb 05, 2020 002 Feb 05, 2020 003 Feb 05, 2020 004 Feb 05, 2020 001 Apr 30, 1990 Jun DISC Jun DISC Feb CMFD Feb CMFD Feb CMFD Feb CMFD Jan CAHN N 021272 005 Jul 30, 2021 Aug NEWA A 211574 A 211574 A 211574 A 211574 001 Feb 11, 2021 002 Feb 11, 2021 003 Feb 11, 2021 004 Feb 11, 2021 Feb NEWA Feb NEWA Feb NEWA Feb NEWA N 208276 N 208276 N 208276 N 208276 001 Jul 30, 2018 002 Jul 30, 2018 003 Jul 30, 2018 004 Jul 30, 2018 Jun DISC Jun DISC Jun DISC Jun DISC N 019963 001 Dec 29, 1995 Sep CTEC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -132 CREAM;TOPICAL TRETINOIN @ ZO SKIN HEALTH 0.05% AT AT AT AT AT AT AT BX AT AT AT AT >A> >A> TRIAMCINOLONE ACETONIDE CREAM;TOPICAL ARISTOCORT + @ ASTELLAS KENALOG + @ DELCOR ASSET CORP TRIAMCINOLONE ACETONIDE +! FOUGERA PHARMS +! +! MICRO LABS SAPTALIS PHARMS INJECTABLE;INJECTION TRIAMCINOLONE ACETONIDE AMNEAL LOTION;TOPICAL TRIAMCINOLONE ACETONIDE MICRO LABS OINTMENT;TOPICAL ARISTOCORT + @ ASTELLAS ARISTOCORT A + @ ASTELLAS KENALOG + @ DELCOR ASSET CORP TRIAMCINOLONE ACETONIDE +! PADAGIS US +! +! SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE @ PERRIGO SUSPENSION;INJECTION XIPERE +! CLEARSIDE 0.5% 0.5% 0.025% 0.1% 0.5% 0.025% 0.1% 0.025% 0.1% 40MG/ML 0.1% 0.5% 0.5% 0.5% 0.025% 0.1% 0.5% 0.055MG/SPRAY 40MG/ML TRIAZOLAM TABLET;ORAL HALCION AB + PFIZER AB +! @ TRIAZOLAM AB NOVAST LABS AB 0.125MG 0.25MG 0.5MG 0.125MG 0.25MG TRIENTINE HYDROCHLORIDE CAPSULE;ORAL CLOVIQUE @ CHARTWELL RX 250MG AB 250MG TRIENTINE HYDROCHLORIDE AB ACCORD HLTHCARE @ AMNEAL @ CHARTWELL RX AB AB ECI PHARMS LLC BX MSN AB PHARMA LIFE 250MG 250MG 250MG 250MG 250MG 250MG 250MG A 076498 001 Sep 15, 2005 Sep DISC A 083015 002 Aug CRLD A 083943 001 Aug CRLD A 085692 A 085692 A 085692 A 040671 A 040671 A 040671 A 040671 001 003 002 001 Jun 09, 2006 002 Jun 09, 2006 001 Jun 09, 2006 002 Jun 09, 2006 Aug CRLD Aug CRLD Aug CRLD Aug CAHN Aug CAHN Jan CAHN Jan CAHN A 207550 001 Dec 11, 2017 Sep CTEC A 040672 002 Dec 13, 2006 Aug CAHN A 080745 002 A 080745 003 A 083944 001 A 087385 002 A 087385 003 A 087385 001 Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD Aug CRLD A 078104 001 Jul 30, 2009 Jul CAHN N 211950 001 Oct 22, 2021 Oct NEWA N 017892 003 Apr 26, 1985 N 017892 001 Nov 15, 1982 N 017892 002 Nov 15, 1982 Feb CAHN Feb CAHN Feb CAHN A 214219 001 Oct 20, 2020 Sep CAHN A 214219 002 Oct 20, 2020 Sep CAHN A 209731 001 Oct 21, 2019 Jun DISC A 209731 001 Oct 21, 2019 Mar CAHN A 212929 A 210619 A 209415 A 209415 A 209945 A 211134 A 209945 001 Aug 30, 2021 001 Feb 08, 2019 001 Sep 16, 2019 001 Sep 16, 2019 001 Aug 13, 2021 001 May 22, 2019 001 Aug 13, 2021 Aug NEWA Sep DISC Jun DISC Mar CAHN Aug NEWA Sep CTEC Sep CAHN RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -133 TRILACICLIB DIHYDROCHLORIDE POWDER;INTRAVENOUS COSELA +! G1 THERAP EQ 300MG BASE/VIAL TRIMETHOBENZAMIDE HYDROCHLORIDE CAPSULE;ORAL TIGAN + @ KING PHARMS LLC 300MG TRIMETHOBENZAMIDE HYDROCHLORIDE AB ! SUN PHARM INDUSTRIES 300MG TROPICAMIDE SOLUTION/DROPS;OPHTHALMIC MYDRIACYL AT +! ALCON LABS INC 1% AT +! SANDOZ INC 0.5% TROSPIUM CHLORIDE CAPSULE, EXTENDED RELEASE;ORAL TROSPIUM CHLORIDE AB AMTA 60MG UMBRALISIB TOSYLATE TABLET;ORAL UKONIQ +! TG THERAPS EQ 200MG BASE >A> AB AB >D> AB AB URSODIOL CAPSULE;ORAL URSODIOL CHARTWELL RX STRIDES PHARMA UPSHER SMITH LABS VGYAAN 300MG 300MG 300MG 300MG VALACYCLOVIR HYDROCHLORIDE TABLET;ORAL VALACYCLOVIR HYDROCHLORIDE AB CADILA EQ 500MG BASE AB EQ 1GM BASE VALBENAZINE TOSYLATE CAPSULE;ORAL INGREZZA + NEUROCRINE EQ 60MG BASE >D> AB AB >A> AB VALGANCICLOVIR HYDROCHLORIDE TABLET;ORAL VALGANCICLOVIR HYDROCHLORIDE ENDO PHARMS INC EQ 450MG BASE MYLAN EQ 450MG BASE STRIDES PHARMA EQ 450MG BASE VALPROIC ACID CAPSULE;ORAL VALPROIC ACID BX EYWA SYRUP;ORAL VALPROIC ACID AA BIOPHARM AA CHARTWELL RX 250MG 250MG/5ML 250MG/5ML >A> >A> AB VALSARTAN SOLUTION;ORAL VALSARTAN NOVITIUM PHARMA TABLET;ORAL VALSARTAN DR REDDYS 20MG/5ML 40MG N 214200 001 Feb 12, 2021 Feb NEWA N 017531 006 Dec 13, 2001 Apr DISC A 076570 001 Aug 28, 2003 Apr CHRS A 084306 001 A 084305 001 Aug CRLD Aug CRLD A 214760 001 Apr 30, 2021 Apr NEWA N 213176 001 Feb 05, 2021 Feb NEWA A 213555 A 210344 A 213555 A 214329 001 Aug 17, 2020 001 Jan 22, 2021 001 Aug 17, 2020 001 Jul 28, 2021 Oct CAHN Jan NEWA Oct CAHN Jul NEWA A 079137 001 Dec 29, 2017 Aug CAHN A 079137 002 Dec 29, 2017 Aug CAHN N 209241 003 Apr 23, 2021 May NEWA A 200790 001 Nov 04, 2014 A 205151 001 Mar 03, 2021 A 200790 001 Nov 04, 2014 Oct CAHN Feb NEWA Oct CAHN A 207611 001 Aug 05, 2019 Sep CTEC A 090517 001 May 28, 2010 Sep CAHN A 075782 001 Dec 22, 2000 Mar CMFD A 214102 001 Nov 02, 2021 Oct NFTG A 201618 001 Oct 05, 2021 Sep NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -134 AB AB AB >A> AB >A> AB >A> AB >A> AB TABLET;ORAL VALSARTAN SCIEGEN PHARMS INC 80MG 160MG 320MG 40MG 80MG 160MG 320MG VANCOMYCIN SOLUTION;INTRAVENOUS, ORAL VANCOMYCIN +! XELLIA PHARMS APS 5GM/100ML (50MG/ML) VANCOMYCIN HYDROCHLORIDE INJECTABLE;INJECTION VANCOMYCIN HYDROCHLORIDE @ HIKMA @ ! HOSPIRA EQ 500MG BASE/VIAL EQ 1GM BASE/VIAL EQ 1.5GM BASE/VIAL VARDENAFIL HYDROCHLORIDE TABLET;ORAL LEVITRA + @ BAYER HLTHCARE + @ EQ 5MG BASE EQ 10MG BASE VARENICLINE TABLET;ORAL VARENICLINE TARTRATE AB PAR PHARM INC AB EQ 0.5MG BASE EQ 1MG BASE >A> >A> >A> AB AB AB AB AB AB VARENICLINE TARTRATE SOLUTION;NASAL TYRVAYA +! OYSTER POINT PHARMA TABLET;ORAL CHANTIX + PF PRISM CV +! VARENICLINE TARTRATE PAR PHARM INC EQ 0.03MG BASE/SPRAY EQ 0.5MG BASE EQ 1MG BASE EQ 0.5MG BASE EQ 0.5MG BASE EQ 1MG BASE EQ 1MG BASE VASOPRESSIN SOLUTION;INTRAVENOUS VASOSTRICT +! PAR STERILE PRODUCTS 20UNITS/100ML (0.2UNITS/ML) VENLAFAXINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE AB TORRENT EQ 37.5MG BASE AB EQ 75MG BASE AB EQ 150MG BASE AB YICHANG HUMANWELL EQ 37.5MG BASE AB EQ 75MG BASE AB EQ 150MG BASE TABLET;ORAL VENLAFAXINE HYDROCHLORIDE @ MYLAN EQ 25MG BASE @ EQ 37.5MG BASE @ EQ 50MG BASE @ EQ 75MG BASE @ EQ 100MG BASE A 201618 A 201618 A 201618 A 204038 A 204038 A 204038 A 204038 002 Oct 05, 2021 003 Oct 05, 2021 004 Oct 05, 2021 001 Oct 27, 2021 002 Oct 27, 2021 003 Oct 27, 2021 004 Oct 27, 2021 Sep NEWA Sep NEWA Sep NEWA Oct NEWA Oct NEWA Oct NEWA Oct NEWA N 213895 001 Aug 26, 2021 Aug NEWA A 203300 001 Aug 11, 2020 A 203300 002 Aug 11, 2020 A 062912 003 Jul 10, 2020 Feb DISC Feb DISC May CMFD N 021400 001 Aug 19, 2003 Apr DISC N 021400 002 Aug 19, 2003 Apr DISC A 201785 001 Aug 11, 2021 Jul NFTG A 201785 002 Aug 11, 2021 Jul NFTG N 213978 001 Oct 15, 2021 Oct NEWA N 021928 001 May 10, 2006 Jul CFTG N 021928 002 May 10, 2006 Jul CFTG A 201785 A 201785 A 201785 A 201785 001 Aug 11, 2021 001 Aug 11, 2021 002 Aug 11, 2021 002 Aug 11, 2021 Sep CTNA Sep CAIN Sep CTNA Sep CAIN N 204485 005 Apr 21, 2021 Apr NEWA A 090899 A 090899 A 090899 A 214654 A 214654 A 214654 001 Jun 01, 2011 002 Jun 01, 2011 003 Jun 01, 2011 001 Aug 06, 2021 002 Aug 06, 2021 003 Aug 06, 2021 Aug CAHN Aug CAHN Aug CAHN Jul NEWA Jul NEWA Jul NEWA A 077166 A 077166 A 077166 A 077166 A 077166 001 Jun 13, 2008 002 Jun 13, 2008 003 Jun 13, 2008 004 Jun 13, 2008 005 Jun 13, 2008 Jan DISC Jan DISC Jan DISC Jan DISC Jan DISC RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -135 TABLET, EXTENDED RELEASE;ORAL VENLAFAXINE HYDROCHLORIDE AB ALKEM LABS LTD EQ 37.5MG BASE AB EQ 75MG BASE AB EQ 150MG BASE AB EQ 225MG BASE AB APPCO EQ 150MG BASE AB EQ 225MG BASE AB DEXCEL PHARMA EQ 75MG BASE VERAPAMIL HYDROCHLORIDE TABLET, EXTENDED RELEASE;ORAL VERAPAMIL HYDROCHLORIDE @ MYLAN @ @ @ @ @ 120MG 120MG 180MG 180MG 240MG 240MG VERICIGUAT TABLET;ORAL VERQUVO + MERCK SHARP DOHME + +! 2.5MG 5MG 10MG VIGABATRIN FOR SOLUTION;ORAL VIGABATRIN AA ANNORA PHARMA AA AUROBINDO PHARMA LTD AA DEXCEL PHARMA AA SPECGX LLC TABLET;ORAL VIGABATRIN AB DEXCEL PHARMA AB DR REDDYS 500MG/PACKET 500MG/PACKET 500MG/PACKET 500MG/PACKET 500MG 500MG VILAZODONE HYDROCHLORIDE TABLET;ORAL VILAZODONE HYDROCHLORIDE AB ACCORD HLTHCARE 10MG AB 20MG AB 40MG AB INVAGEN PHARMS 10MG AB 40MG VILOXAZINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE;ORAL QELBREE + SUPERNUS PHARMS + +! EQ 100MG BASE EQ 150MG BASE EQ 200MG BASE VINBLASTINE SULFATE INJECTABLE;INJECTION VINBLASTINE SULFATE ! HIKMA PHARMS 10MG/VIAL VINORELBINE TARTRATE INJECTABLE;INJECTION VINORELBINE TARTRATE @ FRESENIUS KABI USA EQ 10MG BASE/ML VOCLOSPORIN CAPSULE;ORAL LUPKYNIS +! AURINIA 7.9MG A 214127 A 214127 A 214127 A 214127 A 214609 A 214609 A 213927 001 Jun 10, 2021 002 Jun 10, 2021 003 Jun 10, 2021 004 Jun 10, 2021 001 Jun 30, 2021 002 Jun 30, 2021 001 Jan 21, 2021 Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jun NEWA Jan NEWA A 074587 002 Feb 21, 1997 A 074587 002 Feb 21, 1997 A 074587 003 Sep 09, 1997 A 074587 003 Sep 09, 1997 A 074587 001 Mar 23, 1996 A 074587 001 Mar 23, 1996 Sep CAHN Sep DISC Sep CAHN Sep DISC Sep CAHN Sep DISC N 214377 001 Jan 19, 2021 N 214377 002 Jan 19, 2021 N 214377 003 Jan 19, 2021 Jan NEWA Jan NEWA Jan NEWA A 213519 A 213899 A 214992 A 212626 001 Jan 26, 2021 001 Sep 29, 2021 001 May 13, 2021 001 Jul 28, 2021 Jan NEWA Sep NEWA May NEWA Jul NEWA A 215109 001 Sep 23, 2021 Sep NEWA A 211539 001 Jan 29, 2021 Jan NEWA A 208209 A 208209 A 208209 A 208200 A 208200 001 Apr 27, 2021 002 Apr 27, 2021 003 Apr 27, 2021 001 Apr 07, 2021 002 Apr 07, 2021 Apr NEWA Apr NEWA Apr NEWA Mar NEWA Mar NEWA N 211964 001 Apr 02, 2021 N 211964 002 Apr 02, 2021 N 211964 003 Apr 02, 2021 Apr NEWA Apr NEWA Apr NEWA A 089395 001 Apr 09, 1987 Jul CAHN A 076849 001 Apr 18, 2005 Jan DISC N 213716 001 Jan 22, 2021 Jan NEWA RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -136 VORICONAZOLE INJECTABLE;INTRAVENOUS VORICONAZOLE AP ALMAJECT 200MG/VIAL VORTIOXETINE HYDROBROMIDE TABLET;ORAL TRINTELLIX AB + TAKEDA PHARMS USA EQ 5MG BASE AB + EQ 10MG BASE AB +! EQ 20MG BASE VORTIOXETINE HYDROBROMIDE AB ZYDUS PHARMS AB AB EQ 5MG BASE EQ 10MG BASE EQ 20MG BASE ZIDOVUDINE INJECTABLE;INJECTION RETROVIR +! VIIV HLTHCARE 10MG/ML ZILEUTON TABLET, EXTENDED RELEASE;ORAL ZILEUTON AB DASH PHARMS 600MG BX LUPIN LTD 600MG ZINC CHLORIDE INJECTABLE;INJECTION ZINC CHLORIDE AP EXELA PHARMA EQ 1MG ZINC/ML ZINC CHLORIDE IN PLASTIC CONTAINER AP +! HOSPIRA EQ 1MG ZINC/ML ZIPRASIDONE HYDROCHLORIDE CAPSULE;ORAL ZIPRASIDONE HYDROCHLORIDE AB CHARTWELL RX AB AB AB EQ 20MG BASE EQ 40MG BASE EQ 60MG BASE EQ 80MG BASE ZOLEDRONIC ACID INJECTABLE;INTRAVENOUS ZOLEDRONIC ACID @ EMCURE PHARMS LTD EQ 4MG BASE/5ML ZOLMITRIPTAN SPRAY;NASAL ZOLMITRIPTAN AB PADAGIS ISRAEL AB ZOMIG AB + ASTRAZENECA AB +! 2.5MG/SPRAY 5MG/SPRAY 2.5MG/SPRAY 5MG/SPRAY >D> AB >A> >D> AB >A> ZOLPIDEM TARTRATE TABLET, EXTENDED RELEASE;ORAL ZOLPIDEM TARTRATE ACTAVIS ELIZABETH 6.25MG @ 6.25MG 12.5MG @ 12.5MG TABLET, ORALLY DISINTEGRATING;ORAL TOVALT ODT + @ BIOVAIL LABS INTL 5MG + @ 10MG A 206398 001 Mar 23, 2016 Feb CAHN N 204447 001 Sep 30, 2013 N 204447 002 Sep 30, 2013 N 204447 004 Sep 30, 2013 Sep CFTG Sep CFTG Sep CFTG A 211146 001 Sep 17, 2021 A 211146 002 Sep 17, 2021 A 211146 003 Sep 17, 2021 Sep NFTG Sep NFTG Sep NFTG N 019951 001 Feb 02, 1990 Sep CTEC A 211390 001 Oct 23, 2020 Sep CAHN A 211972 001 Nov 05, 2019 Sep CTEC A 212007 001 May 21, 2021 May NFTG N 018959 001 Jun 26, 1986 May CFTG A 090348 A 090348 A 090348 A 090348 001 Sep 05, 2012 002 Sep 05, 2012 003 Sep 05, 2012 004 Sep 05, 2012 Jul CAHN Jul CAHN Jul CAHN Jul CAHN A 201783 001 Mar 12, 2013 Aug DISC A 212469 001 Sep 30, 2021 Sep NFTG A 212469 002 Sep 30, 2021 Sep NFTG N 021450 003 Sep 16, 2013 Sep CFTG N 021450 004 Sep 30, 2003 Sep CFTG A 078179 A 078179 A 078179 A 078179 002 Oct 13, 2010 002 Oct 13, 2010 001 Jun 06, 2011 001 Jun 06, 2011 Oct DISC Oct DISC Oct DISC Oct DISC N 021412 001 Apr 25, 2007 Apr CRLD N 021412 002 Apr 25, 2007 Apr CRLD RX DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 1 -137 ZONISAMIDE CAPSULE;ORAL ZONEGRAN AB + CONCORDIA + @ AB +! ZONISAMIDE AB CADILA AB AB AB GRANULES AB AB AB UNICHEM AB AB 25MG 50MG 100MG 25MG 50MG 100MG 25MG 50MG 100MG 25MG 50MG 100MG N 020789 003 Aug 22, 2003 N 020789 002 Aug 22, 2003 N 020789 001 Mar 27, 2000 Mar CAHN Mar CAHN Mar CAHN A 077625 A 077625 A 077625 A 077636 A 077636 A 077636 A 214492 A 214492 A 214492 001 Oct 16, 2006 002 Oct 16, 2006 003 Oct 16, 2006 003 Jul 27, 2006 002 Jul 27, 2006 001 Dec 22, 2005 001 Jan 26, 2021 002 Jan 26, 2021 003 Jan 26, 2021 Jul CAHN Jul CAHN Jul CAHN Jun CAHN Jun CAHN Jun CAHN Jan NEWA Jan NEWA Jan NEWA OTC DRUG PRODUCT LIST - 41ST EDITION OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 2 -1 ACETAMINOPHEN SUPPOSITORY;RECTAL NEOPAP @ POLYMEDICA 120MG TABLET, EXTENDED RELEASE;ORAL ACETAMINOPHEN MARKSANS PHARMA 650MG ACETAMINOPHEN; ASPIRIN; CAFFEINE TABLET;ORAL ACETAMINOPHEN, ASPIRIN AND CAFFEINE GRANULES 250MG;250MG;65MG ASPIRIN CAPSULE;ORAL VAZALORE + PLX PHARMA 81MG AZELASTINE HYDROCHLORIDE SPRAY, METERED;NASAL ASTEPRO ALLERGY +! BAYER HLTHCARE 0.2055MG/SPRAY CHILDREN'S ASTEPRO ALLERGY +! BAYER HLTHCARE 0.2055MG/SPRAY BUDESONIDE SPRAY, METERED;NASAL RHINOCORT ALLERGY +! J AND J CONSUMER INC 0.032MG/SPRAY CETIRIZINE HYDROCHLORIDE CAPSULE;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY APOTEX @ >D> @ CATALENT >A> 10MG 10MG 10MG 10MG SYRUP;ORAL CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY MICRO LABS 5MG/5ML CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF MICRO LABS 5MG/5ML TABLET;ORAL CETIRIZINE HYDROCHLORIDE ALLERGY @ CIPLA LTD @ 5MG 10MG TABLET, CHEWABLE;ORAL CHILDREN'S ZYRTEC ALLERGY + @ J AND J CONSUMER INC 2.5MG DEXTROMETHORPHAN HYDROBROMIDE; GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN AND DEXTROMETHORPHAN HYDROBROMIDE SUN PHARM 30MG;600MG 60MG;1.2GM DICLOFENAC SODIUM GEL;TOPICAL DICLOFENAC SODIUM AUROLIFE PHARMA LLC 1% PERRIGO 1% PERRIGO PHARMA INTL 1% FAMOTIDINE TABLET;ORAL FAMOTIDINE >A> ANNORA PHARMA >A> >A> ASCENT PHARMS INC 10MG 20MG 10MG N 016401 001 Sep DISC A 215486 001 Aug 25, 2021 Aug NEWA A 214039 001 Feb 23, 2021 Feb NEWA N 203697 002 Feb 26, 2021 Jun NEWA N 213872 001 Jun 17, 2021 Jun NEWA N 213872 002 Jun 17, 2021 Jun NEWA N 020746 003 Mar 23, 2015 Mar CAHN A 207235 A 207235 A 213105 A 213105 001 Aug 12, 2016 001 Aug 12, 2016 001 Sep 21, 2020 001 Sep 21, 2020 Mar CMFD Jan DISC Oct CMFD Oct CMFD A 091327 001 Oct 17, 2011 Sep CAHN A 091327 002 Oct 17, 2011 Sep CAHN A 077318 001 Jul 25, 2013 May DISC A 077318 002 Jul 25, 2013 May DISC N 021621 007 Nov 30, 2020 Apr DISC A 214781 001 Jul 01, 2021 Jun NEWA A 214781 002 Jul 01, 2021 Jun NEWA A 204306 001 May 06, 2019 A 211253 001 May 16, 2019 A 211253 001 May 16, 2019 May CAHN Jun CAHN Jul CAHN A 215766 001 Nov 08, 2021 A 215766 002 Nov 08, 2021 A 216030 001 Nov 03, 2021 Oct NEWA Oct NEWA Oct NEWA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 2 -2 TABLET;ORAL FAMOTIDINE >A> 20MG FEXOFENADINE HYDROCHLORIDE SUSPENSION;ORAL CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY TARO 30MG/5ML CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES TARO 30MG/5ML TABLET;ORAL FEXOFENADINE HYDROCHLORIDE L PERRIGO CO 60MG 180MG FLUTICASONE PROPIONATE SPRAY, METERED;NASAL FLONASE ALLERGY RELIEF + GLAXOSMITHKLINE CONS FLUTICASONE PROPIONATE ! HIKMA PHARMS 0.05MG/SPRAY 0.05MG/SPRAY GUAIFENESIN TABLET, EXTENDED RELEASE;ORAL GUAIFENESIN OHM LABS INC 600MG 1.2GM IBUPROFEN SUSPENSION;ORAL IBUPROFEN GUARDIAN DRUG @ STRIDES PHARMA TABLET;ORAL IBUPROFEN @ YICHANG HUMANWELL 100MG/5ML 100MG/5ML 100MG/5ML 200MG ISOPROPYL ALCOHOL SOLUTION;TOPICAL ZURAGARD + @ ZUREX PHARMA 70% IVERMECTIN LOTION;TOPICAL IVERMECTIN TARO 0.5% KETOCONAZOLE SHAMPOO;TOPICAL NIZORAL ANTI-DANDRUFF +! KRAMER 1% LEVOCETIRIZINE DIHYDROCHLORIDE TABLET;ORAL LEVOCETIRIZINE DIHYDROCHLORIDE APOTEX 5MG LOPERAMIDE HYDROCHLORIDE CAPSULE;ORAL LOPERAMIDE HYDROCHLORIDE STRIDES PHARMA 2MG LOPERAMIDE HYDROCHLORIDE; SIMETHICONE TABLET;ORAL LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE BIONPHARMA INC GUARDIAN DRUG HETERO LABS LTD V 2MG;125MG 2MG;125MG 2MG;125MG A 216030 002 Nov 03, 2021 Oct NEWA A 208123 001 Nov 09, 2017 Jun CMFD A 208123 002 Nov 09, 2017 Jun CMFD A 212971 001 Feb 24, 2020 Jun CMFD A 212971 002 Feb 24, 2020 Jun CMFD N 205434 001 Jul 23, 2014 Apr CHRS A 207957 001 May 26, 2016 Apr CHRS A 209254 001 Jul 16, 2018 Aug CMFD A 209254 002 Jul 16, 2018 Aug CMFD A 210149 001 Aug 17, 2018 A 211666 001 Feb 22, 2021 A 211666 001 Feb 22, 2021 Jan CMFD Aug DISC Feb NEWA A 214003 001 Oct 19, 2020 Apr DISC N 210872 001 Apr 26, 2019 Jul CPOT A 210720 001 May 06, 2020 May CMKT N 020310 001 Oct 10, 1997 Feb CTNA A 211443 001 Apr 21, 2021 Apr NEWA A 213070 001 Aug 11, 2021 Jul NEWA A 213484 001 Sep 10, 2021 A 214541 001 May 27, 2021 A 211438 001 Jun 17, 2021 Sep NEWA May NEWA Jun NEWA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 2 -3 LORATADINE SYRUP;ORAL LORATADINE HETERO LABS LTD III 1MG/ML TABLET;ORAL LORATADINE APPCO UNIQUE PHARM 10MG 10MG TABLET, ORALLY DISINTEGRATING;ORAL LORATADINE @ GLAXOSMITHKLINE 10MG TENSHI 5MG @ 5MG 10MG @ 10MG MICONAZOLE NITRATE CREAM, INSERT;TOPICAL, VAGINAL MICONAZOLE NITRATE PERRIGO R AND D 2%,1.2GM MONISTAT 1 COMBINATION PACK +! MEDTECH PRODUCTS 2%,1.2GM CREAM, SUPPOSITORY;TOPICAL, VAGINAL MICONAZOLE NITRATE COMBINATION PACK L PERRIGO CO 2%,200MG MINOXIDIL AEROSOL, FOAM;TOPICAL MINOXIDIL PERRIGO 5% NICOTINE POLACRILEX TROCHE/LOZENGE;ORAL NICORETTE + GLAXOSMITHKLINE +! NICOTINE POLACRILEX AUROBINDO PHARMA LTD EQ 2MG BASE EQ 4MG BASE EQ 2MG BASE EQ 4MG BASE OLOPATADINE HYDROCHLORIDE SOLUTION/DROPS;OPHTHALMIC OLOPATADINE HYDROCHLORIDE AKORN EQ 0.1% BASE EQ 0.2% BASE ALEMBIC PHARMS LTD EQ 0.1% BASE EQ 0.2% BASE APOTEX INC EQ 0.2% BASE BARR LABS INC EQ 0.2% BASE @ BAUSCH EQ 0.1% BASE @ CIPLA EQ 0.2% BASE >D> FDC LTD EQ 0.1% BASE >A> @ EQ 0.1% BASE EQ 0.1% BASE MYLAN EQ 0.1% BASE EQ 0.2% BASE USV EQ 0.1% BASE @ WOCKHARDT LTD EQ 0.1% BASE OMEPRAZOLE TABLET, DELAYED RELEASE;ORAL OMEPRAZOLE APOTEX 20MG POLYETHYLENE GLYCOL 3350 FOR SOLUTION;ORAL POLYETHYLENE GLYCOL 3350 ANNORA PHARMA 17GM/SCOOPFUL A 210409 001 May 07, 2021 Apr NEWA A 207569 001 Mar 12, 2019 Sep CAHN A 214684 001 Jan 07, 2021 Jan NEWA A 075822 001 Feb 10, 2003 A 212795 001 Sep 18, 2020 A 212795 001 Sep 18, 2020 A 213294 001 Oct 30, 2020 A 213294 001 Oct 30, 2020 Jan DISC Jun CMFD Mar DISC Jun CMFD Mar DISC A 079114 001 Jun 02, 2010 Jul CDFR N 021308 001 Jun 29, 2001 Jul CDFR A 075329 001 Apr 20, 1999 Sep CAHN A 091344 001 Apr 28, 2011 Jul CAHN N 022360 001 May 18, 2009 Mar CAHN N 022360 002 May 18, 2009 Mar CAHN A 213266 001 Aug 03, 2021 Jul NEWA A 213266 002 Aug 03, 2021 Jul NEWA A 204532 001 Jan 10, 2017 A 204723 001 Dec 05, 2017 A 209919 001 Dec 07, 2018 A 209420 001 Apr 29, 2019 A 090918 001 Dec 05, 2017 A 090848 001 Jul 13, 2015 A 206046 001 Jul 26, 2017 A 206087 001 Dec 05, 2017 A 209282 001 Sep 26, 2019 A 209282 001 Sep 26, 2019 A 209282 001 Sep 26, 2019 A 204392 001 Mar 21, 2018 A 204620 001 Jun 16, 2020 A 203152 001 Dec 07, 2015 A 200810 001 Jun 28, 2017 Jun CMKT Jun CMKT Feb CMKT Jan CMKT Jan CMKT Feb CMKT Jun CAHN Mar CMKT Oct DISC Oct DISC Feb CMKT Feb CMKT Jun CAHN Apr CMKT Aug CMKT A 210070 001 Feb 11, 2019 May CMFD A 214990 001 Apr 14, 2021 Apr NEWA OTC DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 2 -4 POTASSIUM IODIDE TABLET;ORAL THYROSAFE ! BTG INTL 65MG RANITIDINE HYDROCHLORIDE TABLET;ORAL RANITIDINE HYDROCHLORIDE @ AUROBINDO PHARMA LTD @ @ WOCKHARDT ZANTAC 150 EQ 75MG BASE EQ 150MG BASE EQ 75MG BASE + @ SANOFI US + @ ZANTAC 75 EQ 150MG BASE EQ 150MG BASE + @ SANOFI US EQ 75MG BASE TRIAMCINOLONE ACETONIDE SPRAY, METERED;NASAL TRIAMCINOLONE ACETONIDE PERRIGO 0.055MG/SPRAY A 076350 001 Sep 10, 2002 Sep CAHN A 207579 001 Nov 13, 2017 A 207578 001 Nov 13, 2017 A 076760 001 Feb 24, 2006 Jun DISC Jun DISC Jan DISC N 021698 001 Aug 31, 2004 Apr DISC N 021698 002 Mar 13, 2007 Apr DISC N 020520 001 Dec 19, 1995 Apr DISC A 078104 002 Nov 14, 2014 Jul CAHN 3-1 DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST CUMULATIVE SUPPLEMENT NUMBER 10 OCTOBER 2021 NO OCTOBER 2021 APPROVALS 4-1 ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST The list of Orphan Designations and Approvals is available at: https://www.fda.gov/industry/developing-products-rare-diseasesconditions/designating-orphan-product-drugs-and-biological-products. 5-1 DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION NO OCTOBER 2021 ADDITIONS PRESCRIPTION AND OTC DRUG PRODUCT PATENT AND EXCLUSIVITY LIST - 41ST EDITION PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 1 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES ABALOPARATIDE - TYMLOS N 208743 001 10996208 Apr 30, 2038 DP ABEMACICLIB - VERZENIO N 208716 001 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 DS DP U-2132 DS DP U-2135 DS DP U-2251 DS DP U-3241 DS DP U-3242 DS DP U-3243 ABEMACICLIB - VERZENIO N 208716 002 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 DS DP U-2132 DS DP U-2135 DS DP U-2251 DS DP U-3241 DS DP U-3242 DS DP U-3243 ABEMACICLIB - VERZENIO N 208716 003 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 >A> 7855211 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 Dec 15, 2029 DS DP U-2132 DS DP U-2135 DS DP U-2251 DS DP U-3241 DS DP U-3242 DS DP U-3243 ACLIDINIUM BROMIDE - TUDORZA PRESSAIR N 202450 001 11000517 Mar 13, 2029 DP U-2513 ACLIDINIUM BROMIDE; FORMOTEROL FUMARATE - DUAKLIR PRESSAIR N 210595 001 11000517 Mar 13, 2029 DP U-2513 ALBUTEROL SULFATE - PROAIR DIGIHALER N 205636 002 10918816 Dec 14, 2035 DP 11000653 Dec 18, 2038 DP ALENDRONATE SODIUM - BINOSTO N 202344 001 9592195 Dec 05, 2031 DP AMANTADINE HYDROCHLORIDE - GOCOVRI N 208944 001 11065213 11077073 11077073 11077073 Aug 23, 2038 Aug 23, 2038 Aug 23, 2038 Aug 23, 2038 DP U-2106 U-2224 U-3180 AMANTADINE HYDROCHLORIDE - GOCOVRI N 208944 002 11065213 11077073 11077073 11077073 Aug 23, 2038 Aug 23, 2038 Aug 23, 2038 Aug 23, 2038 DP U-2106 U-2224 U-3180 AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 001 8389578 Jan 22, 2028 8389578 Jan 22, 2028 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8889740 Nov 23, 2025 8895614 Nov 23, 2025 8895615 Nov 23, 2025 8895615 Nov 23, 2025 8895616 Nov 23, 2025 8895616 Nov 23, 2025 U-219 U-3054 U-219 U-2497 U-3054 DP DP U-219 U-3054 U-219 U-3054 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE >A> M-270 Sep 20, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 2 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 001 8895617 Nov 23, 2025 8895617 Nov 23, 2025 8895618 Nov 23, 2025 8987333 Nov 23, 2025 9072697 Nov 23, 2025 9072697 Nov 23, 2025 AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 002 8389578 Jan 22, 2028 8389578 Jan 22, 2028 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8889740 Nov 23, 2025 8895614 Nov 23, 2025 8895615 Nov 23, 2025 8895615 Nov 23, 2025 8895616 Nov 23, 2025 8895616 Nov 23, 2025 8895617 Nov 23, 2025 8895617 Nov 23, 2025 8895618 Nov 23, 2025 8987333 Nov 23, 2025 9072697 Nov 23, 2025 9072697 Nov 23, 2025 AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 003 8389578 Jan 22, 2028 8389578 Jan 22, 2028 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8889740 Nov 23, 2025 8895614 Nov 23, 2025 8895615 Nov 23, 2025 8895615 Nov 23, 2025 8895616 Nov 23, 2025 8895616 Nov 23, 2025 8895617 Nov 23, 2025 8895617 Nov 23, 2025 8895618 Nov 23, 2025 8987333 Nov 23, 2025 9072697 Nov 23, 2025 9072697 Nov 23, 2025 AMANTADINE HYDROCHLORIDE - OSMOLEX ER N 209410 004 8389578 Jan 22, 2028 8389578 Jan 22, 2028 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8796337 Nov 23, 2025 8889740 Nov 23, 2025 8895614 Nov 23, 2025 8895615 Nov 23, 2025 8895615 Nov 23, 2025 8895616 Nov 23, 2025 8895616 Nov 23, 2025 8895617 Nov 23, 2025 8895617 Nov 23, 2025 8895618 Nov 23, 2025 8987333 Nov 23, 2025 9072697 Nov 23, 2025 9072697 Nov 23, 2025 PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE U-219 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-2497 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-2497 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-2497 U-3054 DP DP U-219 U-3054 U-219 U-3054 U-219 U-3054 DP DP U-219 U-3054 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 3 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES AMIFAMPRIDINE PHOSPHATE - FIRDAPSE N 208078 001 11060128 Jun 29, 2032 U-2956 AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN N 020965 001 10357567 Jan 12, 2038 11077192 Jan 12, 2038 >A> 11135293 Jan 12, 2038 U-3163 U-3163 U-3163 AMLODIPINE BENZOATE - KATERZIA N 211340 001 10894039 10894039 10952998 10959991 10959991 Oct 06, 2037 Oct 06, 2037 Oct 06, 2037 Oct 06, 2037 Oct 06, 2037 U-185 U-3 DP U-158 U-39 AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 001 10925835 Jun 14, 2038 10945960 Jun 14, 2038 U-2410 DP AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 002 10925835 Jun 14, 2038 10945960 Jun 14, 2038 U-2410 DP AMLODIPINE BESYLATE; CELECOXIB - CONSENSI N 210045 003 10925835 Jun 14, 2038 10945960 Jun 14, 2038 U-2410 DP AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN - TALICIA N 213004 001 >A> 11135172 Feb 12, 2034 DP U-2660 AMPHETAMINE SULFATE - EVEKEO ODT N 209905 005 10130580 Apr 19, 2024 DP 10441554 Mar 10, 2037 DP ANGIOTENSIN II ACETATE - GIAPREZA N 209360 001 11096983 11096983 Dec 18, 2034 Dec 18, 2034 U-3211 U-3212 ANGIOTENSIN II ACETATE - GIAPREZA N 209360 002 11096983 11096983 Dec 18, 2034 Dec 18, 2034 U-3211 U-3212 APALUTAMIDE - ERLEADA N 210951 001 >A> 9481663 Jun 04, 2033 DS APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 001 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 002 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 003 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 004 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 4 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 004 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP APOMORPHINE HYDROCHLORIDE - KYNMOBI N 210875 005 10888499 Feb 14, 2022 10959943 Apr 19, 2036 11077068 Feb 14, 2022 DP U-2825 DP APREPITANT - CINVANTI N 209296 001 10953018 Sep 18, 2035 U-2161 ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 001 10980803 Sep 24, 2033 10980803 Sep 24, 2033 U-1632 U-543 ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 002 10980803 Sep 24, 2033 10980803 Sep 24, 2033 U-1632 U-543 ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 003 10980803 Sep 24, 2033 10980803 Sep 24, 2033 U-1632 U-543 ARIPIPRAZOLE - ABILIFY MAINTENA KIT N 202971 004 10980803 Sep 24, 2033 10980803 Sep 24, 2033 U-1632 U-543 ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 001 >A> 11097006 Oct 24, 2033 DP U-764 ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 002 >A> 11097006 Oct 24, 2033 DP U-764 ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 003 >A> 11097006 Oct 24, 2033 DP U-764 ARIPIPRAZOLE LAUROXIL - ARISTADA N 207533 004 >A> 11097006 Oct 24, 2033 DP U-764 ARIPIPRAZOLE LAUROXIL - ARISTADA INITIO KIT N 209830 001 >A> 11154552 Aug 17, 2035 DP ASCORBIC ACID; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM ASCORBATE; SODIUM CHLORIDE; SODIUM SULFATE - PLENVU N 209381 001 10918723 Sep 10, 2033 U-2310 ASENAPINE - SECUADO N 212268 001 >A> 11123305 Jul 25, 2033 DP ASENAPINE - SECUADO N 212268 002 >A> 11123305 Jul 25, 2033 DP ASENAPINE - SECUADO N 212268 003 >A> 11123305 Jul 25, 2033 DP ASENAPINE MALEATE - ASENAPINE MALEATE A 206098 002 PC Jun 08, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 5 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES ATOGEPANT - QULIPTA N 215206 001 >A> 10117836 >A> 8754096 >A> 9499545 >A> 9850246 Jan 30, 2035 Jul 19, 2032 Nov 10, 2031 Mar 13, 2033 ATOGEPANT - QULIPTA N 215206 002 >A> 10117836 >A> 8754096 >A> 9499545 >A> 9850246 Jan 30, 2035 Jul 19, 2032 Nov 10, 2031 Mar 13, 2033 ATOGEPANT - QULIPTA N 215206 003 >A> 10117836 >A> 8754096 >A> 9499545 >A> 9850246 Jan 30, 2035 Jul 19, 2032 Nov 10, 2031 Mar 13, 2033 ATROPINE SULFATE - ATROPINE SULFATE A 212868 001 ATROPINE SULFATE - ATROPINE SULFATE A 212868 002 ATROPINE SULFATE - ATROPINE SULFATE A 212868 003 ATROPINE SULFATE - ATROPINE SULFATE A 213424 001 AVACOPAN - TAVNEOS N 214487 001 >A> 8445515 >A> 8906938 Feb 03, 2031 Dec 21, 2029 AVAPRITINIB - AYVAKIT N 212608 001 9200002 9200002 9944651 9944651 9994575 9994575 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 AVAPRITINIB - AYVAKIT N 212608 002 9200002 9200002 9944651 9944651 9994575 9994575 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 AVAPRITINIB - AYVAKIT N 212608 003 AVAPRITINIB - AYVAKIT N 212608 004 9200002 9944651 9994575 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 DP DS DP U-3142 DS DP U-3142 DS DP DS DP U-3142 DS DP U-3142 DS DP DS DP U-3142 DS DP U-3142 DS DS DP DS DP DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-2726 DS DP U-3168 DS DP U-3168 DS DP U-3168 DS DP U-3168 AVAPRITINIB - AYVAKIT N 212608 005 9200002 9944651 9994575 Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 DS DP U-3168 DS DP U-3168 DS DP U-3168 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE >A> NCE Sep 28, 2026 >A> NCE Sep 28, 2026 >A> NCE Sep 28, 2026 >A> CGT >A> CGT >A> CGT CGT >A> NCE Jan 26, 2022 Jan 26, 2022 Jan 26, 2022 Sep 21, 2021 Oct 07, 2026 I-863 I-864 ODE-356 Jun 16, 2024 Jun 16, 2024 Jun 16, 2028 I-863 I-864 ODE-356 Jun 16, 2024 Jun 16, 2024 Jun 16, 2028 ODE-356 Jun 16, 2028 I-863 I-864 NCE ODE-356 Jun 16, 2024 Jun 16, 2024 Jan 09, 2025 Jun 16, 2028 I-863 I-864 NCE ODE-356 Jun 16, 2024 Jun 16, 2024 Jan 09, 2025 Jun 16, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 6 APPL/PROD NO PATENT NO AVAPRITINIB - AYVAKIT N 212608 005 9200002 9944651 9994575 PATENT EXPIRATION DATE PATENT CODES Oct 15, 2034 Oct 15, 2034 Oct 15, 2034 DS DP U-3168 DS DP U-3168 DS DP U-3168 AXITINIB - INLYTA N 202324 001 10869924 Nov 05, 2036 U-3044 AXITINIB - INLYTA N 202324 002 10869924 Nov 05, 2036 U-3044 AZACITIDINE - ONUREG N 214120 001 AZACITIDINE - ONUREG N 214120 002 AZELASTINE HYDROCHLORIDE - ASTEPRO ALLERGY N 213872 001 8071073 Jun 04, 2028 8518919 Nov 22, 2025 9919050 Nov 22, 2025 DP U-3166 DP AZELASTINE HYDROCHLORIDE - CHILDREN'S ASTEPRO ALLERGY N 213872 002 8071073 Jun 04, 2028 8518919 Nov 22, 2025 9919050 Nov 22, 2025 DP U-3166 DP BALOXAVIR MARBOXIL - XOFLUZA N 210854 003 10392406 10633397 10633397 10759814 8927710 8987441 9815835 Apr 27, 2036 Apr 27, 2036 Apr 27, 2036 Aug 09, 2037 May 05, 2031 Sep 21, 2031 Jun 14, 2030 DS U-2816 U-3000 DS DP DP DS DP DP BALOXAVIR MARBOXIL - XOFLUZA N 214410 001 BELINOSTAT - BELEODAQ N 206256 001 6888027 Aug 10, 2026 DS DP U-1544 BELUMOSUDIL MESYLATE - REZUROCK N 214783 001 BELZUTIFAN - WELIREG N 215383 001 9908845 9969689 Sep 05, 2034 Sep 05, 2034 BEMPEDOIC ACID - NEXLETOL N 211616 001 10941095 Dec 23, 2023 BEMPEDOIC ACID; EZETIMIBE - NEXLIZET N 211617 001 >A> 10912751 Mar 14, 2036 10941095 Dec 23, 2023 BENDAMUSTINE HYDROCHLORIDE - BELRAPZO N 205580 001 11103483 Jan 28, 2031 11103483 Jan 28, 2031 DS DP U-3201 DS DP U-3201 U-2747 U-3224 U-2746 DP U-1971 DP U-1972 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-863 I-864 NCE ODE-356 Jun 16, 2024 Jun 16, 2024 Jan 09, 2025 Jun 16, 2028 ODE-320 Sep 01, 2027 ODE-320 Sep 01, 2027 I-811 NCE Oct 16, 2022 Oct 24, 2023 NCE Oct 24, 2023 NCE ODE-362 Jul 16, 2026 Jul 16, 2028 NCE ODE-364 Aug 13, 2026 Aug 13, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 7 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE BENDAMUSTINE HYDROCHLORIDE - BENDEKA N 208194 001 11103483 Jan 28, 2031 11103483 Jan 28, 2031 DP U-1971 DP U-1972 BENZOYL PEROXIDE; TRETINOIN - TWYNEO N 214902 001 11071878 Dec 30, 2030 9868103 Aug 08, 2028 DP DP U-3194 BEROTRALSTAT HYDROCHLORIDE - ORLADEYO N 214094 001 10125102 Apr 07, 2035 >A> 11117867 Nov 01, 2039 DS U-3010 DP U-3010 BEROTRALSTAT HYDROCHLORIDE - ORLADEYO N 214094 002 10125102 Apr 07, 2035 >A> 11117867 Nov 01, 2039 DS U-3010 DP U-3010 BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY N 210251 001 >A> 7390791 Apr 17, 2025 DS DP >A> 7390791*PED Oct 17, 2025 >A> 8754065 Aug 15, 2032 DS DP U-257 >A> 8754065*PED Feb 15, 2033 >A> 9296769 Aug 15, 2032 DS DP U-257 >A> 9296769*PED Feb 15, 2033 BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - BIKTARVY N 210251 002 >A> 10385067 Jun 19, 2035 U-257 >A> 7390791 Apr 17, 2025 DS DP >A> 7803788 Feb 02, 2022 U-257 >A> 8754065 Aug 15, 2032 DS DP U-257 >A> 9216996 Dec 19, 2033 DS DP >A> 9296769 Aug 15, 2032 DS DP U-257 >A> 9708342 Jun 19, 2035 DS DP >A> 9732092 Dec 19, 2033 DS DP BOSENTAN - TRACLEER N 021290 001 BOSENTAN - TRACLEER N 021290 002 BOSUTINIB MONOHYDRATE - BOSULIF N 203341 001 11103497 11103497 Feb 28, 2034 Feb 28, 2034 U-3216 U-3217 BOSUTINIB MONOHYDRATE - BOSULIF N 203341 002 11103497 11103497 Feb 28, 2034 Feb 28, 2034 U-3216 U-3217 BOSUTINIB MONOHYDRATE - BOSULIF N 203341 003 11103497 11103497 Feb 28, 2034 Feb 28, 2034 U-3216 U-3217 BREMELANOTIDE ACETATE - VYLEESI (AUTOINJECTOR) N 210557 001 6794489 Jun 28, 2025 DS DP BREXANOLONE - ZULRESSO N 211371 001 10940156 Mar 08, 2037 U-2552 BREXPIPRAZOLE - REXULTI N 205422 001 RE48059 Dec 23, 2028 DS NC Jul 26, 2024 NCE ODE-333 Dec 03, 2025 Dec 03, 2027 NCE ODE-333 Dec 03, 2025 Dec 03, 2027 M-82 Feb 24, 2024 ODE* ODE* Sep 05, 2024 Sep 05, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 8 APPL/PROD NO PATENT NO BREXPIPRAZOLE - REXULTI N 205422 002 RE48059 BREXPIPRAZOLE - REXULTI N 205422 003 RE48059 BREXPIPRAZOLE - REXULTI N 205422 004 RE48059 BREXPIPRAZOLE - REXULTI N 205422 005 RE48059 BREXPIPRAZOLE - REXULTI N 205422 006 RE48059 BRIMONIDINE TARTRATE - LUMIFY N 208144 001 9259425 BRINCIDOFOVIR - TEMBEXA N 214460 001 9303051 PATENT EXPIRATION DATE PATENT CODES Dec 23, 2028 DS Dec 23, 2028 DS Dec 23, 2028 DS Dec 23, 2028 DS Dec 23, 2028 DS Jul 14, 2030 U-2222 Aug 31, 2031 DS DP U-3165 BRINCIDOFOVIR - TEMBEXA N 214461 001 10112909 10487061 8962829 9303051 9371344 BRIVARACETAM - BRIVIACT N 205836 001 Oct 10, 2034 Oct 10, 2034 Oct 10, 2034 Aug 31, 2031 Oct 10, 2034 U-3165 DP U-3165 DS DP DS DP U-3165 DP BRIVARACETAM - BRIVIACT N 205836 002 BRIVARACETAM - BRIVIACT N 205836 003 BRIVARACETAM - BRIVIACT N 205836 004 BRIVARACETAM - BRIVIACT N 205836 005 BRIVARACETAM - BRIVIACT N 205837 001 BRIVARACETAM - BRIVIACT N 205838 001 BROMOCRIPTINE MESYLATE - CYCLOSET N 020866 001 11000522 11000522 11000522 11000522 Apr 30, 2032 Apr 30, 2032 Apr 30, 2032 Apr 30, 2032 U-3119 U-3120 U-3121 U-3122 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NP ODE-354 Jun 04, 2024 Jun 04, 2028 NP ODE-354 Jun 04, 2024 Jun 04, 2028 NPP >A> NPP NPP >A> NPP NPP >A> NPP NPP >A> NPP NPP >A> NPP >A> NPP NPP >A> NPP May 10, 2021 Aug 27, 2024 May 10, 2021 Aug 27, 2024 May 10, 2021 Aug 27, 2024 May 10, 2021 Aug 27, 2024 May 10, 2021 Aug 27, 2024 Aug 27, 2024 May 10, 2021 Aug 27, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 9 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE BUPIVACAINE - EXPAREL N 022496 001 11033495 Jan 22, 2041 BUPIVACAINE - EXPAREL N 022496 002 11033495 Jan 22, 2041 BUPIVACAINE - POSIMIR N 204803 001 8153149 8153661 8753665 8846072 Sep 15, 2025 Sep 15, 2025 Sep 15, 2025 Sep 15, 2025 BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 001 10098957 Apr 20, 2035 10213510 Apr 20, 2035 10398686 Mar 13, 2034 10632199 Apr 20, 2035 10898575 Apr 20, 2035 10980886 Apr 20, 2035 11083730 Apr 20, 2035 11083797 Apr 20, 2035 9592227 Mar 13, 2034 9694079 Apr 20, 2035 9744163 Mar 13, 2034 9801945 Apr 20, 2035 9913909 Mar 13, 2034 BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 002 10098957 Apr 20, 2035 10213510 Apr 20, 2035 10398686 Mar 13, 2034 10632199 Apr 20, 2035 10898575 Apr 20, 2035 10980886 Apr 20, 2035 11083730 Apr 20, 2035 11083797 Apr 20, 2035 9592227 Mar 13, 2034 9694079 Apr 20, 2035 9744163 Mar 13, 2034 9801945 Apr 20, 2035 9913909 Mar 13, 2034 BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 003 10098957 Apr 20, 2035 10213510 Apr 20, 2035 10398686 Mar 13, 2034 10632199 Apr 20, 2035 10898575 Apr 20, 2035 10980886 Apr 20, 2035 11083730 Apr 20, 2035 11083797 Apr 20, 2035 9592227 Mar 13, 2034 9694079 Apr 20, 2035 9744163 Mar 13, 2034 9801945 Apr 20, 2035 9913909 Mar 13, 2034 BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 004 10098957 Apr 20, 2035 10213510 Apr 20, 2035 10398686 Mar 13, 2034 10632199 Apr 20, 2035 10898575 Apr 20, 2035 10980886 Apr 20, 2035 11083730 Apr 20, 2035 11083797 Apr 20, 2035 9592227 Mar 13, 2034 PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE DP U-3182 DP U-3182 DP U-3074 DP U-3074 DP U-3074 U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP U-3118 DP U-3118 DP DP U-3118 U-3118 U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP U-3118 DP U-3118 DP DP U-3118 U-3118 U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP U-3118 DP U-3118 DP DP U-3118 U-3118 U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP DP U-3118 DP U-3118 DP U-3118 NPP Mar 22, 2024 NPP Mar 22, 2024 NP Feb 01, 2024 NP May 12, 2024 NP May 12, 2024 NP May 12, 2024 NP May 12, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 10 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES BUPIVACAINE; MELOXICAM - ZYNRELEF KIT N 211988 004 9694079 Apr 20, 2035 9744163 Mar 13, 2034 9801945 Apr 20, 2035 9913909 Mar 13, 2034 DP U-3118 DP DP U-3118 U-3118 BUPRENORPHINE - SUBLOCADE N 209819 001 11000520 Nov 06, 2035 U-3111 BUPRENORPHINE - SUBLOCADE N 209819 002 11000520 Nov 06, 2035 U-3111 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 001 >A> 11135216 Aug 07, 2029 DP U-3111 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 002 >A> 11135216 Aug 07, 2029 DP U-3111 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 003 >A> 11135216 Aug 07, 2029 DP U-3111 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - SUBOXONE N 022410 004 >A> 11135216 Aug 07, 2029 DP U-3111 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 001 10946010 Sep 18, 2032 DP 11020388 Sep 18, 2032 DP U-3131 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 002 10874661 Sep 18, 2032 DP 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 003 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 004 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 005 10946010 Sep 18, 2032 DP 11020387 Sep 18, 2032 DP U-3131 11020388 Sep 18, 2032 DP U-3131 BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV N 204242 006 10946010 Sep 18, 2032 DP 11020388 Sep 18, 2032 DP U-3131 BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE N 200063 001 >A> 10403170 Jun 05, 2033 U-1583 11033543 Jan 10, 2031 U-1583 >A> 11139056 Jun 05, 2033 U-1583 >A> 9633575 Jun 25, 2033 U-1583 CABAZITAXEL - JEVTANA KIT N 201023 001 8927592 8927592*PED Oct 27, 2030 Apr 27, 2031 U-3200 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-128 Dec 18, 2023 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 11 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES CABOTEGRAVIR SODIUM - VOCABRIA N 212887 001 10927129 8410103 Apr 28, 2026 Apr 28, 2026 DS DP DS DP U-3061 CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT N 212888 001 10927129 Apr 28, 2026 6838464 Feb 26, 2021 7125879 Apr 21, 2025 8080551 Apr 11, 2023 8410103 Apr 28, 2026 DS DP DS DP DS DP U-3059 DS DP DS DP U-3060 CABOTEGRAVIR; RILPIVIRINE - CABENUVA KIT N 212888 002 10927129 Apr 28, 2026 6838464 Feb 26, 2021 7125879 Apr 21, 2025 8080551 Apr 11, 2023 8410103 Apr 28, 2026 DS DP DS DP DS DP U-3059 DS DP DS DP U-3060 CABOZANTINIB S-MALATE - COMETRIQ N 203756 001 11091439 11091440 11098015 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 DS DP U-1617 CABOZANTINIB S-MALATE - COMETRIQ N 203756 002 11091439 11091440 11098015 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 DS DP U-1617 CABOZANTINIB S-MALATE - CABOMETYX N 208692 001 11091439 11091440 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11141413 >A> 8877776 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Apr 17, 2037 Oct 08, 2030 DS DP U-1220 U-1480 U-2488 U-3225 U-3239 DS DP U-3225 CABOZANTINIB S-MALATE - CABOMETYX N 208692 002 11091439 11091440 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11141413 >A> 8877776 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Apr 17, 2037 Oct 08, 2030 DS DP U-1220 U-1480 U-2488 U-3225 U-3239 DS DP U-3225 CABOZANTINIB S-MALATE - CABOMETYX N 208692 003 11091439 11091440 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11098015 >A> 11141413 >A> 8877776 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Jan 15, 2030 Apr 17, 2037 Oct 08, 2030 DS DP U-1220 U-1480 U-2488 U-3225 U-3239 DS DP U-3225 CALCITONIN SALMON - CALCITONIN-SALMON A 212416 001 CALCIUM GLUCONATE - CALCIUM GLUCONATE IN SODIUM CHLORIDE N 210906 003 >A> 10130646 Jul 25, 2037 DP >A> 10342813 Jul 25, 2037 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Jan 21, 2026 NCE Jan 21, 2026 NCE Jan 21, 2026 I-854 >A> I-873 Jan 22, 2024 Sep 17, 2024 I-854 >A> I-873 Jan 22, 2024 Sep 17, 2024 I-854 >A> I-873 Jan 22, 2024 Sep 17, 2024 CGT Nov 10, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 12 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CALCIUM OXYBATE; MAGNESIUM OXYBATE; POTASSIUM OXYBATE; SODIUM OXYBATE - XYWAV N 212690 001 10864181 Mar 15, 2033 U-3017 8772306 Mar 15, 2033 U-1532 8772306 Mar 15, 2033 U-3198 CANGRELOR - KENGREAL N 204958 001 8680052 Mar 09, 2033 U-2979 CANNABIDIOL - EPIDIOLEX N 210365 001 10918608 10918608 10918608 10966939 10966939 11065209 11096905 11096905 >A> 11154516 >A> 11154516 >A> 11160795 Oct 14, 2035 Oct 14, 2035 Oct 14, 2035 Jun 17, 2035 Jun 17, 2035 Oct 14, 2035 Oct 14, 2035 Oct 14, 2035 Jun 17, 2034 Jun 17, 2034 Mar 01, 2041 U-3071 U-3072 U-3073 DP U-2780 DP U-2781 U-3071 DS DP U-2780 DS DP U-2781 U-3235 U-3236 U-3233 CAPSAICIN - QUTENZA N 022395 001 >A> 10869827 Sep 05, 2023 DP CARGLUMIC ACID - CARBAGLU N 022562 001 CASIMERSEN - AMONDYS 45 N 213026 001 10287586 10533174 10781450 8524880 8524880 9228187 9416361 9447415 9758783 9758783 Nov 12, 2030 May 04, 2021 Nov 12, 2030 Apr 02, 2026 Apr 02, 2026 Nov 12, 2030 May 04, 2021 Jun 28, 2025 Nov 12, 2030 Nov 12, 2030 DS DP DP U-3089 DS DP U-3087 DS DP U-3088 DS DP DS DS DP U-3088 U-3089 CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA N 206829 001 10933053 Sep 09, 2034 10933053 Sep 09, 2034 U-3090 U-3091 CERITINIB - ZYKADIA N 211225 001 CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 001 CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 002 CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 003 CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 004 CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 212144 005 I-870 ODE-361 Aug 12, 2024 Jul 21, 2027 ODE-326 ODE-332 Jul 31, 2027 Jul 31, 2027 ODE-345 Jan 22, 2028 NCE ODE-347 Feb 25, 2026 Feb 25, 2028 ODE* ODE* CGT CGT CGT CGT CGT Apr 29, 2021 May 26, 2024 Sep 20, 2021 Sep 20, 2021 Sep 20, 2021 Sep 20, 2021 Sep 20, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 13 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 214542 001 CGT CHLORPROMAZINE HYDROCHLORIDE - CHLORPROMAZINE HYDROCHLORIDE A 214542 002 CGT CHLORZOXAZONE - CHLORZOXAZONE A 215158 001 >A> CGT CILASTATIN SODIUM; IMIPENEM; RELEBACTAM - RECARBRIO N 212819 001 NCE GAIN CIPROFLOXACIN - OTIPRIO N 207986 001 11040004 Nov 12, 2037 U-2252 CITRIC ACID; LACTIC ACID; POTASSIUM BITARTRATE - PHEXXI N 208352 001 6706276 Mar 06, 2022 DP CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE - CLENPIQ N 209589 001 NPP CLEVIDIPINE - CLEVIPREX N 022156 001 11103490 Oct 10, 2031 DP CLEVIDIPINE - CLEVIPREX N 022156 002 11103490 Oct 10, 2031 DP CLEVIDIPINE - CLEVIPREX N 022156 003 11103490 Oct 10, 2031 DP COBICISTAT - TYBOST N 203094 001 >A> 10039718 >A> 10039718*PED >A> 8148374 >A> 8148374*PED Oct 06, 2032 Apr 06, 2033 Sep 03, 2029 Mar 03, 2030 DP DS DP U-1279 COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - SYMTUZA N 210455 001 10786518 Jul 19, 2038 U-2978 COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA N 207561 001 10039718 Oct 06, 2032 DP 10039718*PED Apr 06, 2033 7176220 Aug 27, 2026 DS DP U-257 7176220*PED Feb 27, 2027 7390791 Apr 17, 2025 DS DP 7390791*PED Oct 17, 2025 7635704 Oct 26, 2026 DS DP U-257 7635704*PED Apr 26, 2027 8148374 Sep 03, 2029 DS DP U-1279 8148374*PED Mar 03, 2030 8633219 Apr 24, 2030 DP U-257 8633219*PED Oct 24, 2030 8754065 Aug 15, 2032 DS DP U-257 8754065*PED Feb 15, 2033 8981103 Oct 26, 2026 DS DP 8981103*PED Apr 26, 2027 9296769 Aug 15, 2032 DS DP U-257 9296769*PED Feb 15, 2033 9891239 Sep 03, 2029 DP U-257 9891239*PED Mar 03, 2030 Jan 29, 2022 Jan 29, 2022 Mar 29, 2022 Jul 16, 2024 Jul 16, 2029 Aug 15, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 14 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD N 203100 001 >A> 10039718 Oct 06, 2032 DP >A> 10039718*PED Apr 06, 2033 >A> 7176220 Aug 27, 2026 DS DP U-257 >A> 7176220*PED Feb 27, 2027 7635704 Oct 26, 2026 DS DP U-257 7635704*PED Apr 26, 2027 >A> 8633219 Apr 24, 2030 DP U-257 >A> 8633219*PED Oct 24, 2030 >A> 8981103 Oct 26, 2026 DS DP >A> 8981103*PED Apr 26, 2027 >A> 9891239 Sep 03, 2029 DP U-257 >A> 9891239*PED Mar 03, 2030 COBIMETINIB FUMARATE - COTELLIC N 206192 001 11087354 Jun 22, 2034 U-1776 COCAINE HYDROCHLORIDE - NUMBRINO N 209575 001 COCAINE HYDROCHLORIDE - GOPRELTO N 209963 001 10894012 10933060 10973811 10987347 CRIZOTINIB - XALKORI N 202570 001 Feb 07, 2037 Feb 07, 2037 Feb 07, 2037 Feb 07, 2037 U-3014 U-3014 U-2226 U-2225 CRIZOTINIB - XALKORI N 202570 002 CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - TRALEMENT N 209376 002 CUPRIC SULFATE; MANGANESE SULFATE; SELENIOUS ACID; ZINC SULFATE - MULTRYS N 209376 003 CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 210735 001 9662342 Jun 26, 2035 DP CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 210735 002 9662342 Jun 26, 2035 DP CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 212501 001 10993952 Feb 15, 2036 DP CYCLOPHOSPHAMIDE - CYCLOPHOSPHAMIDE N 212501 002 10993952 Feb 15, 2036 DP CYCLOSPORINE - CEQUA N 210913 001 10918694 Feb 28, 2037 DP CYCLOSPORINE - VERKAZIA N 214965 001 7973081 8298568 8524779 9132071 9220694 9956289 Jan 27, 2026 DP Nov 03, 2027 DP Jan 27, 2026 DP Jun 02, 2029 DP Jan 27, 2026 DP Jan 27, 2026 DP NCE Dec 14, 2022 NP Jan 10, 2023 I-852 ODE-328 Jan 14, 2024 Jan 14, 2028 I-852 ODE-328 Jan 14, 2024 Jan 14, 2028 NCE Apr 30, 2024 NCE Apr 30, 2024 NP ODE-358 Jun 23, 2023 Jun 23, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 15 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES CYSTEAMINE BITARTRATE - PROCYSBI N 203389 001 10905662 Aug 16, 2036 CYSTEAMINE BITARTRATE - PROCYSBI N 203389 002 10905662 Aug 16, 2036 CYSTEAMINE BITARTRATE - PROCYSBI N 213491 001 10905662 8026284 8026284*PED 9173851 9173851*PED 9192590 9192590*PED 9198882 9198882*PED 9233077 9233077*PED Aug 16, 2036 Sep 22, 2027 Mar 22, 2028 Jun 17, 2034 Dec 17, 2034 Jan 26, 2027 Jul 26, 2027 Jan 26, 2027 Jul 26, 2027 Jun 17, 2034 Dec 17, 2034 CYSTEAMINE BITARTRATE - PROCYSBI N 213491 002 10905662 8026284 8026284*PED 9173851 9173851*PED 9192590 9192590*PED 9198882 9198882*PED 9233077 9233077*PED Aug 16, 2036 Sep 22, 2027 Mar 22, 2028 Jun 17, 2034 Dec 17, 2034 Jan 26, 2027 Jul 26, 2027 Jan 26, 2027 Jul 26, 2027 Jun 17, 2034 Dec 17, 2034 CYSTEINE HYDROCHLORIDE - ELCYS N 210660 001 10905713 10905714 10912795 10918662 10933089 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 CYSTEINE HYDROCHLORIDE - NOURESS N 212535 001 10905713 10905714 10912795 10918662 10933089 11045438 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Jan 15, 2039 Mar 15, 2039 CYTARABINE; DAUNORUBICIN - VYXEOS N 209401 001 10028912 10028912 10166184 10835492 7850990 8022279 8092828 8431806 Sep 29, 2034 Sep 29, 2034 Oct 15, 2032 Oct 15, 2032 Jan 23, 2027 Sep 14, 2027 Apr 01, 2029 Apr 22, 2025 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 001 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 9034822 Jan 20, 2031 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 U-1399 U-1399 U-1399 U-1399 DP U-1399 U-1399 DP U-1399 U-1399 DP U-1399 U-1399 DP DP DP DP DP DP DP DP DP DP DP DP DP U-3149 DP U-3150 DP U-3149 U-3150 DP U-3147 DP U-3147 U-3147 DP U-3147 DS DP U-1931 U-1759 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE ODE* ODE* PED Aug 14, 2022 Dec 22, 2024 Feb 14, 2023 ODE* ODE* PED Aug 14, 2022 Dec 22, 2024 Feb 14, 2023 NPP ODE-350 Mar 30, 2024 Mar 30, 2028 I-862 PED Jun 21, 2024 Dec 21, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 16 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 002 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 9034822 Jan 20, 2031 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 022512 003 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7866474 Aug 31, 2027 7866474*PED Mar 02, 2028 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9034822 Jan 20, 2031 9034822*PED Jul 20, 2031 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 001 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 002 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 003 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 004 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 005 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DS DP U-1931 U-1759 DP DS DP U-1931 DP DS DP U-1759 DP DS DP U-3177 DS DP U-3178 DS DP DP DS DP U-3177 DS DP U-3178 DS DP DP DS DP U-3177 DS DP U-3178 DS DP DP DS DP U-3177 DS DP U-3178 DS DP DP DS DP U-3177 DS DP U-3178 DS DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-862 PED Jun 21, 2024 Dec 21, 2024 I-862 Jun 21, 2024 PED Dec 21, 2024 Y NP Jun 21, 2024 PED Dec 21, 2024 NP Jun 21, 2024 PED Dec 21, 2024 NP Jun 21, 2024 PED Dec 21, 2024 NP Jun 21, 2024 PED Dec 21, 2024 NP Jun 21, 2024 PED Dec 21, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 17 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES DABIGATRAN ETEXILATE MESYLATE - PRADAXA N 214358 006 6087380 Dec 28, 2021 6087380 Dec 28, 2021 6087380*PED Jun 28, 2022 7932273 Sep 07, 2025 7932273*PED Mar 07, 2026 9925174 Jun 14, 2023 9925174*PED Dec 14, 2023 DS DP U-3177 DS DP U-3178 DS DP DP DABRAFENIB MESYLATE - TAFINLAR N 202806 001 10869869 8703781 8703781 8703781 8703781 9233956 9233956 9233956 9233956 Aug 30, 2033 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 May 04, 2029 May 04, 2029 May 04, 2029 May 04, 2029 U-3185 DS DP U-1713 DS DP U-2032 DS DP U-2296 DS DP U-2298 U-1811 U-2031 U-2032 U-2296 DABRAFENIB MESYLATE - TAFINLAR N 202806 002 10869869 8703781 8703781 8703781 8703781 9233956 9233956 9233956 9233956 Aug 30, 2033 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 Oct 15, 2030 May 04, 2029 May 04, 2029 May 04, 2029 May 04, 2029 U-3185 DS DP U-1713 DS DP U-2032 DS DP U-2296 DS DP U-2298 U-1811 U-2031 U-2032 U-2296 DALBAVANCIN HYDROCHLORIDE - DALVANCE N 021883 001 DAPAGLIFLOZIN - FARXIGA N 202293 001 DAPAGLIFLOZIN - FARXIGA N 202293 002 10973836 Mar 09, 2040 U-3127 DAPTOMYCIN - DAPTOMYCIN N 210282 001 10357535 9655946 Sep 11, 2033 Sep 11, 2033 DP U-3176 DP U-3175 DAPTOMYCIN - DAPTOMYCIN N 210282 002 10357535 9655946 Sep 11, 2033 Sep 11, 2033 DP U-3176 DP U-3175 DAROLUTAMIDE - NUBEQA N 212099 001 11046713 Oct 27, 2030 DS DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE N 214231 001 10442847 Feb 03, 2035 DS DP DASIGLUCAGON HYDROCHLORIDE - ZEGALOGUE (AUTOINJECTOR) N 214231 002 10442847 Feb 03, 2035 DS DP DEFERIPRONE - DEFERIPRONE A 208800 001 DEFERIPRONE - FERRIPROX N 021825 001 7049328 Jun 28, 2021 U-3083 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NP Jun 21, 2024 PED Dec 21, 2024 NPP I-857 I-857 Jul 22, 2024 Apr 30, 2024 Apr 30, 2024 NCE NCE PC I-859 Mar 22, 2026 Mar 22, 2026 Mar 27, 2021 Apr 30, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 18 APPL/PROD NO PATENT NO DEFERIPRONE - FERRIPROX N 021825 002 7049328 DEFERIPRONE - FERRIPROX N 208030 001 7049328 8703156 DEFERIPRONE - FERRIPROX N 208030 002 7049328 8703156 DEFERIPRONE - FERRIPROX N 212269 001 10780055 10940115 10940116 7049328 DEFIBROTIDE SODIUM - DEFITELIO N 208114 001 11085043 DEGARELIX ACETATE - FIRMAGON N 022201 001 10973870 DEGARELIX ACETATE - FIRMAGON N 022201 002 10973870 DESMOPRESSIN ACETATE - NOCDURNA N 022517 001 11020448 DEUTETRABENAZINE - AUSTEDO N 208082 001 10959996 10959996*PED 8524733 8524733*PED 9233959 9233959*PED 9296739 9296739*PED 9550780 9550780 9550780*PED 9814708 9814708*PED DEUTETRABENAZINE - AUSTEDO N 208082 002 10959996 10959996*PED 8524733 8524733*PED 9233959 9233959*PED 9296739 9296739*PED 9550780 9550780 9550780*PED 9814708 9814708*PED DEUTETRABENAZINE - AUSTEDO N 208082 003 10959996 10959996*PED 8524733 8524733*PED 9233959 9233959*PED PATENT EXPIRATION DATE PATENT CODES Jun 28, 2021 U-3083 Jun 28, 2021 Oct 26, 2029 U-3083 DP U-3083 Jun 28, 2021 Oct 26, 2029 U-3083 DP U-3083 Oct 25, 2038 Oct 25, 2038 Oct 25, 2038 Jun 28, 2021 DP U-3083 DP U-3083 DP U-3083 Jun 22, 2032 DP Feb 10, 2029 U-1978 Feb 10, 2029 U-1978 May 21, 2029 U-2327 Mar 07, 2036 Sep 07, 2036 Apr 03, 2031 Oct 03, 2031 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 U-3055 DS DP DP DP DS DP U-1995 DS DP U-3055 DP Mar 07, 2036 Sep 07, 2036 Apr 03, 2031 Oct 03, 2031 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 U-3055 DS DP DP DP DS DP U-1995 DS DP U-3055 DP Mar 07, 2036 Sep 07, 2036 Apr 03, 2031 Oct 03, 2031 Sep 18, 2033 Mar 18, 2034 U-3055 DS DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-859 I-859 Apr 30, 2024 Apr 30, 2024 I-859 Apr 30, 2024 I-859 Apr 30, 2024 M-54 NCE ODE-134 PED PED PED Jun 24, 2024 Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024 Dec 24, 2024 M-54 NCE ODE-134 PED PED PED Jun 24, 2024 Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024 Dec 24, 2024 M-54 NCE ODE-134 PED PED PED Jun 24, 2024 Apr 03, 2022 Apr 03, 2024 Oct 03, 2022 Oct 03, 2024 Dec 24, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 19 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE DEUTETRABENAZINE - AUSTEDO N 208082 003 9296739 9296739*PED 9550780 9550780 9550780*PED 9814708 9814708*PED Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Sep 18, 2033 Mar 18, 2034 Sep 18, 2033 Mar 18, 2034 DP DS DP U-1995 DS DP U-3055 DP DEXAMETHASONE - DEXAMETHASONE A 215106 001 DEXAMETHASONE - DEXAMETHASONE A 215106 002 DEXAMETHASONE - DEXYCU KIT N 208912 001 10799642 May 11, 2032 DP DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 001 10584112 Dec 09, 2037 DS DP 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 002 10584112 Dec 09, 2037 DS DP 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP DEXMETHYLPHENIDATE HYDROCHLORIDE; SERDEXMETHYLPHENIDATE CHLORIDE - AZSTARYS N 212994 003 10584112 Dec 09, 2037 DS DP 10584113 Dec 09, 2037 DP 10759778 Dec 09, 2037 DP 10858341 Dec 09, 2037 U-3094 10954213 Dec 09, 2037 U-3094 9079928 Jul 27, 2032 DP DICLOFENAC POTASSIUM - ZIPSOR N 022202 001 DIFELIKEFALIN ACETATE - KORSUVA N 214916 001 10017536 10138270 10793596 7402564 7713937 7727963 8217007 8236766 8486894 8536131 9334305 9359399 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 Nov 12, 2027 DS U-3204 U-3204 DS DP U-3204 DS DP U-3204 DS DP U-3204 DS DP U-3204 U-3204 U-3204 U-3204 DS DP U-3204 U-3204 U-3204 DIHYDROERGOTAMINE MESYLATE - TRUDHESA N 213436 001 10507295 Dec 25, 2032 10940278 Jan 23, 2033 9550036 Sep 05, 2032 9919117 Mar 17, 2033 DP DP DP DP U-3218 >A> CGT >A> CGT NCE NCE NCE NPP NCE >A> NP Apr 20, 2022 Apr 19, 2022 May 07, 2026 May 07, 2026 May 07, 2026 May 25, 2024 Aug 23, 2026 Sep 02, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 20 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 001 DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 002 DILTIAZEM HYDROCHLORIDE - DILTIAZEM HYDROCHLORIDE A 212317 003 DIMETHYL FUMARATE - TECFIDERA N 204063 001 10391160 10555993 10959972 10994003 11007166 11007167 >A> 11129806 Mar 13, 2035 Mar 13, 2035 Nov 16, 2035 Mar 13, 2035 Nov 16, 2035 Nov 16, 2035 Nov 16, 2035 DIMETHYL FUMARATE - TECFIDERA N 204063 002 10391160 10555993 10959972 10994003 11007166 11007167 >A> 11129806 Mar 13, 2035 Mar 13, 2035 Nov 16, 2035 Mar 13, 2035 Nov 16, 2035 Nov 16, 2035 Nov 16, 2035 DOCETAXEL - DOCETAXEL N 205934 001 10842770 Aug 07, 2031 DOCETAXEL - DOCETAXEL N 205934 002 10842770 Aug 07, 2031 DOCETAXEL - DOCETAXEL N 205934 003 10842770 Aug 07, 2031 DOXEPIN HYDROCHLORIDE - SILENOR N 022036 001 11096920 11110074 Apr 11, 2028 Jul 20, 2027 DOXEPIN HYDROCHLORIDE - SILENOR N 022036 002 11096920 11110074 Apr 11, 2028 Jul 20, 2027 DROSPIRENONE - SLYND N 211367 001 10603281 10849857 10987364 11123299 Jun 28, 2031 Jun 28, 2031 Jun 28, 2031 Jun 28, 2031 DROSPIRENONE; ESTETROL - NEXTSTELLIS N 214154 001 7732430 Mar 02, 2025 DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 001 10959982 Apr 13, 2037 DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 002 10959982 Apr 13, 2037 DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 003 10959982 Apr 13, 2037 PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE U-3148 U-3148 U-1384 U-3148 U-1384 U-1384 U-1384 U-3148 U-3148 U-1384 U-3148 U-1384 U-1384 U-1384 DP U-2998 DP U-2998 DP U-2998 U-620 U-620 U-620 U-620 U-2553 DP U-2553 DP DP DP U-3152 DP DP DP CGT Sep 26, 2021 CGT Sep 26, 2021 CGT Sep 26, 2021 NCE Apr 15, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 21 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE DULOXETINE HYDROCHLORIDE - DRIZALMA SPRINKLE N 212516 004 10959982 Apr 13, 2037 DP EDARAVONE - RADICAVA N 209176 002 ODE* EDOXABAN TOSYLATE - SAVAYSA N 206316 001 7365205 Apr 18, 2027 DS EDOXABAN TOSYLATE - SAVAYSA N 206316 002 7365205 Apr 18, 2027 DS EDOXABAN TOSYLATE - SAVAYSA N 206316 003 7365205 Apr 18, 2027 DS EFINACONAZOLE - JUBLIA N 203567 001 10864274 7214506 Oct 02, 2034 Feb 22, 2026 U-2720 U-281 ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM - ORIAHNN (COPACKAGED) N 213388 001 10881659 Mar 14, 2034 U-2842 11045470 Mar 14, 2034 U-2842 ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) N 212273 001 10022352 Apr 09, 2027 DP U-2651 10022352 Apr 09, 2027 DP U-3156 10081621 Mar 25, 2031 DP U-2652 10081621 Mar 25, 2031 DP U-3032 10081621 Mar 25, 2031 DP U-3157 10239867 Apr 09, 2027 DS DP U-2653 10239867 Apr 09, 2027 DS DP U-3033 10239867 Apr 09, 2027 DS DP U-3158 10758534 Oct 06, 2035 DS DP U-2645 10758534 Oct 06, 2035 DS DP U-3028 10758534 Oct 06, 2035 DS DP U-3144 10793547 Dec 08, 2037 DS DP U-2645 10793547 Dec 08, 2037 DS DP U-3028 10793547 Dec 08, 2037 DS DP U-3144 8324242 Aug 05, 2027 U-2645 8324242 Aug 05, 2027 U-3028 8324242 Aug 05, 2027 U-3144 8354427 Jul 06, 2026 U-2646 8354427 Jul 06, 2026 U-3029 8354427 Jul 06, 2026 U-3145 8415387 Nov 12, 2027 U-2645 8415387 Nov 12, 2027 U-3028 8415387 Nov 12, 2027 U-3144 8598181 May 01, 2027 U-2645 8598181 May 01, 2027 U-3028 8598181 May 01, 2027 U-3144 8629162 Jun 24, 2025 U-2648 8629162 Jun 24, 2025 U-3030 8629162 Jun 24, 2025 U-3146 9012496 Jul 15, 2033 U-2649 9012496 Jul 15, 2033 U-3154 9670163 Dec 28, 2026 DP U-2650 9670163 Dec 28, 2026 DP U-3031 9670163 Dec 28, 2026 DP U-3155 9931334 Dec 28, 2026 DP U-2650 9931334 Dec 28, 2026 DP U-3031 9931334 Dec 28, 2026 DP U-3155 9974781 Apr 09, 2027 DP U-2645 9974781 Apr 09, 2027 DP U-3028 9974781 Apr 09, 2027 DP U-3144 NPP ODE-323 ODE-357 May 05, 2024 Jun 08, 2024 Dec 21, 2027 Jun 08, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 22 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR - TRIKAFTA (COPACKAGED) N 212273 002 10022352 Apr 09, 2027 DP U-3156 10081621 Mar 25, 2031 DP U-3157 10239867 Apr 09, 2027 DS DP U-3158 10646481 Aug 13, 2029 DP 10758534 Oct 06, 2035 DS DP U-3144 10793547 Dec 08, 2037 DS DP U-3144 7495103 May 20, 2027 DS DP 7645789 May 01, 2027 DS DP 7776905 Jun 03, 2027 DS DP 8324242 Aug 05, 2027 U-3144 8354427 Jul 06, 2026 U-3145 8410274 Dec 28, 2026 DP 8415387 Nov 12, 2027 U-3144 8598181 May 01, 2027 U-3144 8623905 May 01, 2027 DS DP 8629162 Jun 24, 2025 U-3146 8754224 Dec 28, 2026 DS DP 9012496 Jul 15, 2033 U-3154 9670163 Dec 28, 2026 DP U-3155 9931334 Dec 28, 2026 DP U-3155 9974781 Apr 09, 2027 DP U-3144 ELIGLUSTAT TARTRATE - CERDELGA N 205494 001 10888544 10888544 10888547 10888547 Dec 13, 2038 Dec 13, 2038 Jan 31, 2031 Jan 31, 2031 U-3040 U-3041 U-3042 U-3043 ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 001 ELTROMBOPAG OLAMINE - PROMACTA KIT N 207027 002 ELUXADOLINE - VIBERZI N 206940 001 11007179 11090291 ELUXADOLINE - VIBERZI N 206940 002 11007179 11090291 ELVITEGRAVIR - VITEKTA N 203093 001 >A> 7176220 >A> 7176220*PED >A> 7635704 >A> 7635704*PED >A> 8981103 >A> 8981103*PED ELVITEGRAVIR - VITEKTA N 203093 002 >A> 7176220 >A> 7176220*PED >A> 7635704 >A> 7635704*PED >A> 8981103 >A> 8981103*PED EMPAGLIFLOZIN - JARDIANCE N 204629 001 11090323 9949997 9949997 Mar 14, 2033 DP Mar 14, 2033 DP Mar 14, 2033 DP Mar 14, 2033 DP Aug 27, 2026 Feb 27, 2027 Oct 26, 2026 Apr 26, 2027 Oct 26, 2026 Apr 26, 2027 DS DP U-257 DS DP U-257 DS DP Aug 27, 2026 Feb 27, 2027 Oct 26, 2026 Apr 26, 2027 Oct 26, 2026 Apr 26, 2027 DS DP U-257 DS DP U-257 DS DP Apr 03, 2034 May 17, 2034 May 17, 2034 U-3191 U-2292 U-3199 NCE NCE NPP ODE-357 Feb 12, 2023 Oct 21, 2024 Jun 08, 2024 Jun 08, 2028 ODE* ODE* ODE* PED Nov 16, 2025 Aug 26, 2021 Nov 16, 2025 Feb 26, 2022 I-869 Aug 18, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 23 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EMPAGLIFLOZIN - JARDIANCE N 204629 002 11090323 Apr 03, 2034 U-3191 EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 001 11033552 May 04, 2027 11090323 Apr 03, 2034 DP U-3191 EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI N 206073 002 11033552 May 04, 2027 11090323 Apr 03, 2034 DP U-3191 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 001 11090323 Apr 03, 2034 U-3192 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 002 11090323 Apr 03, 2034 U-3192 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 003 11090323 Apr 03, 2034 U-3192 EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE - TRIJARDY XR N 212614 004 11090323 Apr 03, 2034 U-3192 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 001 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 002 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 003 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY N 206111 004 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 001 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 002 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 003 11090323 Apr 03, 2034 U-3193 EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - SYNJARDY XR N 208658 004 11090323 Apr 03, 2034 U-3193 EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY N 208351 001 >A> 7390791 Apr 17, 2025 DS DP >A> 7390791*PED Oct 17, 2025 >A> 8754065 Aug 15, 2032 DS DP U-257 >A> 8754065*PED Feb 15, 2033 >A> 9296769 Aug 15, 2032 DS DP U-257 >A> 9296769*PED Feb 15, 2033 EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY N 208215 001 >A> 7390791 Apr 17, 2025 DS DP >A> 7390791*PED Oct 17, 2025 >A> 8754065 Aug 15, 2032 DS DP U-1259 >A> 8754065 Aug 15, 2032 DS DP U-1663 >A> 8754065 Aug 15, 2032 DS DP U-257 >A> 8754065*PED Feb 15, 2033 >A> 9296769 Aug 15, 2032 DS DP U-1259 EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 24 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY N 208215 001 >A> 9296769 Aug 15, 2032 DS DP U-1663 >A> 9296769 Aug 15, 2032 DS DP U-257 >A> 9296769*PED Feb 15, 2033 EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 001 PC Mar 09, 2021 EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 002 PC Mar 09, 2021 EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE A 209721 003 PC Mar 09, 2021 ENALAPRIL MALEATE - ENALAPRIL MALEATE A 212408 001 PC Feb 13, 2022 ENALAPRIL MALEATE - EPANED N 208686 001 11040023 >A> 11141405 Mar 25, 2036 DP Mar 25, 2036 DP ENTRECTINIB - ROZLYTREK N 212725 001 11091469 11091469 May 18, 2037 May 18, 2037 U-2617 U-2618 ENTRECTINIB - ROZLYTREK N 212725 002 11091469 11091469 May 18, 2037 May 18, 2037 U-2617 U-2618 EPHEDRINE SULFATE - EMERPHED N 213407 001 11090278 May 16, 2040 U-3183 EPINEPHRINE - AUVI-Q N 201739 001 10960155 Jun 25, 2026 DP EPINEPHRINE - AUVI-Q N 201739 002 10842938 10960155 Dec 21, 2037 Jun 25, 2026 DP U-2980 DP EPINEPHRINE - AUVI-Q N 201739 003 10842938 10960155 Dec 21, 2037 Jun 25, 2026 DP U-2980 DP ERDAFITINIB - BALVERSA N 212018 001 10898482 10898482 10898482 10898482 11077106 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 02, 2038 DP U-2518 DP U-3065 DP U-3066 DP U-3067 U-3196 ERDAFITINIB - BALVERSA N 212018 002 10898482 10898482 10898482 10898482 11077106 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 02, 2038 DP U-2518 DP U-3065 DP U-3066 DP U-3067 U-3196 ERDAFITINIB - BALVERSA N 212018 003 10898482 10898482 10898482 10898482 11077106 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 09, 2036 Feb 02, 2038 DP U-2518 DP U-3065 DP U-3066 DP U-3067 U-3196 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 25 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE ERYTHROMYCIN - ERYTHROMYCIN A 211975 001 ERYTHROMYCIN - ERYTHROMYCIN A 211975 002 ESKETAMINE HYDROCHLORIDE - SPRAVATO N 211243 001 10869844 Sep 10, 2035 10869844 Sep 10, 2035 10869844 Sep 10, 2035 U-3034 U-3035 U-3036 ESLICARBAZEPINE ACETATE - APTIOM N 022416 001 10912781 Oct 23, 2028 DP ESLICARBAZEPINE ACETATE - APTIOM N 022416 002 10912781 Oct 23, 2028 DP ESLICARBAZEPINE ACETATE - APTIOM N 022416 003 10912781 Oct 23, 2028 DP ESLICARBAZEPINE ACETATE - APTIOM N 022416 004 10912781 Oct 23, 2028 DP ESTRADIOL - IMVEXXY N 208564 001 10888516 10888516 11065197 11116717 11123283 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 U-2316 U-2317 DP DP DP ESTRADIOL - IMVEXXY N 208564 002 10888516 10888516 11065197 11116717 11123283 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 Jun 18, 2033 U-2316 U-2317 DP DP DP ESTRADIOL; NORETHINDRONE ACETATE; RELUGOLIX - MYFEMBREE N 214846 001 11033551 Sep 29, 2037 U-3129 7300935 Jan 28, 2024 DS 8058280 Jan 28, 2024 DS DP 9346822 Feb 17, 2024 U-3129 ESTRADIOL; PROGESTERONE - BIJUVA N 210132 001 11033626 11103513 11103516 11110099 Nov 21, 2032 Nov 21, 2032 Nov 21, 2032 Nov 21, 2032 DP U-2439 U-2439 DP DP ETEPLIRSEN - EXONDYS 51 N 206488 001 RE47769 RE48468 Feb 02, 2029 Oct 27, 2028 DP U-2097 ETEPLIRSEN - EXONDYS 51 N 206488 002 RE47769 RE48468 Feb 02, 2029 Oct 27, 2028 DP U-2097 ETHINYL ESTRADIOL; LEVONORGESTREL - TYBLUME N 209405 001 ETHINYL ESTRADIOL; NORELGESTROMIN - ETHINYL ESTRADIOL AND NORELGESTROMIN A 213950 001 >A> CGT >A> CGT Apr 02, 2022 Apr 02, 2022 NCE Dec 18, 2025 NP May 26, 2024 NDF Mar 30, 2023 CGT Aug 25, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 26 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MERZEE A 212706 001 ETHINYL ESTRADIOL; SEGESTERONE ACETATE - ANNOVERA N 209627 001 10918649 Jun 21, 2039 DP 10925882 Jun 21, 2039 DP 10940157 Jun 21, 2039 DP EXENATIDE SYNTHETIC - BYDUREON N 022200 001 6515117 6515117*PED 7456254 7456254 7456254 7456254 7456254 7456254 7456254*PED 7612176 7612176 7612176 7612176 7612176 7612176 7612176*PED 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648*PED 8361972 8361972*PED 8431685 8431685 8431685 8431685 8431685 8431685 8431685*PED 8461105 8461105 8461105 8461105 8461105 8461105 8461105*PED 8501698 8501698*PED 8906851 8906851 8906851 8906851 8906851 8906851 8906851 8906851*PED 9238076 9238076 9238076 9238076 9238076 9238076 9238076 Oct 04, 2025 Apr 04, 2026 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Dec 30, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 Mar 21, 2028 Sep 21, 2028 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Jun 20, 2027 Dec 20, 2027 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 DS DP U-2588 DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 U-2588 U-2589 U-2590 U-2593 U-2594 U-2595 U-2596 U-3188 U-3189 U-3190 U-2588 DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP U-2588 U-2588 U-2589 U-2590 U-2593 U-3188 U-3189 U-3190 DP U-2588 DP U-2589 DP U-2590 DP U-2599 DP U-3188 DP U-3189 DP U-3190 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT Jul 17, 2021 M-240 NPP PED PED Feb 15, 2022 Jul 22, 2024 Aug 15, 2023 Jan 22, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 27 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES EXENATIDE SYNTHETIC - BYDUREON N 022200 001 9238076*PED 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092*PED Oct 15, 2024 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 EXENATIDE SYNTHETIC - BYDUREON PEN N 022200 002 6515117 6515117*PED 6824822 6824822*PED 7223440 7223440*PED 7456254 7456254 7456254 7456254 7456254 7456254 7456254*PED 7563871 7563871*PED 7612176 7612176 7612176 7612176 7612176 7612176 7612176*PED 8216180 8216180*PED 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648 8329648*PED 8361972 8361972*PED 8431685 8431685 8431685 8431685 8431685 8431685 8431685*PED 8439864 8439864*PED 8461105 8461105 8461105 8461105 8461105 8461105 8461105*PED 8501698 Oct 04, 2025 Apr 04, 2026 Oct 09, 2022 Apr 09, 2023 Aug 31, 2021 Mar 03, 2022 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Jun 30, 2025 Dec 30, 2025 Apr 15, 2024 Oct 15, 2024 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Jan 12, 2028 Jul 12, 2028 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 Mar 21, 2028 Sep 21, 2028 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Mar 25, 2028 Sep 25, 2028 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Apr 13, 2025 Oct 13, 2025 Jun 20, 2027 U-2588 U-2589 U-2590 U-2593 U-2594 U-2595 U-2596 U-3188 U-3189 U-3190 DS DP U-2588 DP DP DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP U-2588 U-2589 U-2590 U-2593 U-2594 U-2595 U-2596 U-3188 U-3189 U-3190 U-2588 DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP U-2588 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-240 NPP PED PED Feb 15, 2022 Jul 22, 2024 Aug 15, 2023 Jan 22, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 28 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES EXENATIDE SYNTHETIC - BYDUREON PEN N 022200 002 8501698*PED 8690837 8690837*PED 8721615 8721615*PED 8758292 8758292*PED 8827963 8827963*PED 8906851 8906851 8906851 8906851 8906851 8906851 8906851 8906851*PED 8998876 8998876*PED 9238076 9238076 9238076 9238076 9238076 9238076 9238076 9238076*PED 9320853 9320853*PED 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092 9884092*PED Dec 20, 2027 May 19, 2029 Nov 19, 2029 Jan 18, 2030 Jul 18, 2030 Nov 12, 2027 May 12, 2028 Feb 04, 2029 Aug 04, 2029 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 Jan 07, 2030 Jul 07, 2030 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Apr 15, 2024 Oct 15, 2024 Mar 25, 2028 Sep 25, 2028 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Aug 18, 2026 Feb 18, 2027 EXENATIDE SYNTHETIC - BYDUREON BCISE N 209210 001 6515117 Oct 04, 2025 6515117*PED Apr 04, 2026 6824822 Oct 09, 2022 6824822*PED Apr 09, 2023 7223440 Aug 31, 2021 7223440*PED Mar 03, 2022 7456254 Jun 30, 2025 7456254 Jun 30, 2025 7456254 Jun 30, 2025 7456254 Jun 30, 2025 7456254 Jun 30, 2025 7456254 Jun 30, 2025 7456254*PED Dec 30, 2025 7563871 Apr 15, 2024 7563871*PED Oct 15, 2024 7612176 Apr 13, 2025 7612176 Apr 13, 2025 7612176 Apr 13, 2025 7612176 Apr 13, 2025 7612176 Apr 13, 2025 7612176*PED Oct 13, 2025 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 DP DP DP DP U-2588 U-2589 U-2590 U-2593 U-3188 U-3189 U-3190 DP DP U-2588 DP U-2589 DP U-2590 DP U-2599 DP U-3188 DP U-3189 DP U-3190 DP U-2588 U-2589 U-2590 U-2593 U-2594 U-2595 U-2596 U-3188 U-3189 U-3190 DS DP U-2588 DP DP DP U-2588 DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 DP DP U-2589 DP U-2590 DP U-3188 DP U-3189 DP U-3190 U-2588 U-2589 U-2590 U-2593 U-2594 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-240 NPP PED PED Feb 15, 2022 Jul 22, 2024 Aug 15, 2023 Jan 22, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 29 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE EXENATIDE SYNTHETIC - BYDUREON BCISE N 209210 001 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648 Aug 18, 2026 8329648*PED Feb 18, 2027 8361972 Mar 21, 2028 8361972*PED Sep 21, 2028 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685 Apr 13, 2025 8431685*PED Oct 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105 Apr 13, 2025 8461105*PED Oct 13, 2025 8501698 Jun 20, 2027 8501698*PED Dec 20, 2027 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033 Oct 04, 2030 8895033*PED Apr 04, 2031 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851 Aug 18, 2026 8906851*PED Feb 18, 2027 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076 Apr 15, 2024 9238076*PED Oct 15, 2024 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092 Aug 18, 2026 9884092*PED Feb 18, 2027 PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE U-2595 U-2596 U-3188 U-3189 U-3190 U-2588 DP U-2588 DP U-2589 DP U-2590 DP U-2597 DP U-3188 DP U-3189 DP U-3190 DP U-2588 DP U-2589 DP U-2590 DP U-2597 DP U-3188 DP U-3189 DP U-3190 U-2588 DP U-2589 DP U-2590 DP U-2597 DP U-2601 DP U-2602 DP U-3188 DP U-3189 DP U-3190 U-2588 U-2589 U-2590 U-2593 U-2597 U-3188 U-3189 U-3190 DP U-2588 DP U-2589 DP U-2590 DP U-2597 DP U-2599 DP U-3188 DP U-3189 DP U-3190 U-2588 U-2589 U-2590 U-2593 U-2594 U-2595 U-2596 U-2597 U-3188 U-3189 U-3190 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 30 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 001 10376470 May 01, 2033 9763885 May 01, 2033 EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 002 10376470 May 01, 2033 9763885 May 01, 2033 EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 003 10376470 May 01, 2033 9763885 May 01, 2033 EZETIMIBE; ROSUVASTATIN CALCIUM - ROSZET N 213072 004 10376470 May 01, 2033 9763885 May 01, 2033 FENFLURAMINE HYDROCHLORIDE - FINTEPLA N 212102 001 10452815 Jun 29, 2038 10947183 Dec 20, 2036 10950331 Sep 28, 2035 11040018 Aug 02, 2037 FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 001 >A> 11123321 >A> 11123321 7754702 7754702 7754702 7754702 8895612 8895612 8895612 8895612 8895612 Oct 20, 2023 Oct 20, 2023 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 002 >A> 11123321 >A> 11123321 7612109 7754702 7754702 7754702 8895612 8895612 8895612 8895612 8895612 9376505 Oct 20, 2023 Oct 20, 2023 Feb 05, 2024 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Oct 20, 2023 FERRIC CARBOXYMALTOSE - INJECTAFER N 203565 003 >A> 11123321 >A> 11123321 7612109 7754702 7754702 7754702 8895612 8895612 8895612 8895612 8895612 9376505 Oct 20, 2023 Oct 20, 2023 Feb 05, 2024 Feb 15, 2028 Feb 15, 2028 Feb 15, 2028 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Jan 08, 2027 Oct 20, 2023 FERRIC OXYHYDROXIDE - VELPHORO N 205109 001 10624855 10624855*PED Nov 26, 2034 May 26, 2035 DP U-3095 DP U-3095 DP U-3095 DP U-3095 DP U-3095 DP U-3095 DP U-3095 DP U-3095 U-2859 DS DP U-3098 U-2861 DS DP U-2555 DS DP U-2557 U-1432 U-2555 U-2556 U-2557 U-1620 U-3050 U-3051 U-3115 U-3116 DS DP U-2555 DS DP U-2557 DS DP U-2555 U-2556 U-2557 U-1620 U-3050 U-3051 U-3115 U-3116 DS DP DS DP U-2555 DS DP U-2557 DS DP U-2555 U-2556 U-2557 U-1620 U-3050 U-3051 U-3115 U-3116 DS DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NS Apr 28, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 31 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE FERRIC OXYHYDROXIDE - VELPHORO N 205109 001 10682376 10682376*PED 10695367 10695367*PED 10925896 10925896*PED 10925897 10925897*PED 10933090 10933090*PED 11013761 11013761*PED 11013762 11013762*PED 9561251 9561251*PED Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Nov 13, 2028 May 13, 2029 Jan 23, 2030 Jul 23, 2030 DP DP DP DP DP DP DP DP U-1468 FESOTERODINE FUMARATE - TOVIAZ N 022030 001 8501723 Jun 07, 2027 DP 8501723*PED Dec 07, 2027 I-861 PED FESOTERODINE FUMARATE - TOVIAZ N 022030 002 8501723 Jun 07, 2027 DP 8501723*PED Dec 07, 2027 I-861 PED FEXINIDAZOLE - FEXINIDAZOLE N 214429 001 NCE ODE-359 FINERENONE - KERENDIA N 215341 001 8436180 Apr 12, 2029 DS DP NCE FINERENONE - KERENDIA N 215341 002 8436180 Apr 12, 2029 DS DP NCE FLUCICLOVINE F-18 - AXUMIN N 208054 001 10933147 10953112 10967077 Dec 30, 2035 Nov 28, 2026 Dec 30, 2035 U-2450 U-1879 U-2450 FLUTICASONE FUROATE; UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - TRELEGY ELLIPTA N 209482 001 11090294 Nov 29, 2030 U-3202 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 001 >A> 11116721 Feb 26, 2029 DP U-1401 >A> 11116721 Feb 26, 2029 DP U-1691 FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA N 204275 002 >A> 11116721 Feb 26, 2029 DP U-1691 FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 Jun 17, 2024 Dec 17, 2024 Jun 17, 2024 Dec 17, 2024 Jul 16, 2026 Jul 16, 2028 Jul 09, 2026 Jul 09, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 32 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 001 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 002 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10765820 May 19, 2025 10765820*PED Nov 19, 2025 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10765820 May 19, 2025 10765820*PED Nov 19, 2025 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 PATENT CODES DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 33 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 003 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10765820 May 19, 2025 10765820*PED Nov 19, 2025 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 004 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 10569034*PED Feb 16, 2037 10765820 May 19, 2025 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 11000653*PED Jun 18, 2039 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 9782551*PED Feb 28, 2036 PATENT CODES DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NPP Jul 09, 2024 PED Jan 09, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 34 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 005 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 10569034*PED Feb 16, 2037 10765820 May 19, 2025 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 11000653*PED Jun 18, 2039 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 9731087 May 18, 2031 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 9782551*PED Feb 28, 2036 FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 006 10022510 May 18, 2031 10022510*PED Nov 18, 2031 10124131 May 18, 2031 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 10569034*PED Feb 16, 2037 10765820 May 19, 2025 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 11000653*PED Jun 18, 2039 7540282 May 06, 2023 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 8978966*PED Jul 13, 2032 9216260 Jun 28, 2031 9216260*PED Dec 28, 2031 9463288 May 19, 2025 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 9616024*PED Mar 01, 2025 PATENT CODES DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 35 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES FLUTICASONE PROPIONATE - ARMONAIR DIGIHALER N 208798 006 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 FLUTICASONE PROPIONATE - ARMONAIR RESPICLICK N 208798 007 10022510 May 18, 2031 DP 10124131 May 18, 2031 DP 10195375 Feb 14, 2031 DP 10561808 Jan 01, 2032 DP 10765820 May 19, 2025 DP 7540282 May 06, 2023 DP 8651103 Mar 26, 2028 DP 8714149 Feb 25, 2032 DP 8978966 Jan 13, 2032 DP 9216260 Jun 28, 2031 DP 9463288 May 19, 2025 DP 9616024 Sep 01, 2024 DP 9731087 May 18, 2031 DP FLUTICASONE PROPIONATE - XHANCE N 209022 001 11033696 May 20, 2033 DP FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 001 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9415008 Oct 06, 2034 DP U-645 9415008*PED Apr 06, 2035 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NS Jul 09, 2024 PED Jan 09, 2025 M-61 PED Jul 09, 2024 Jan 09, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 36 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 002 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO RESPICLICK N 208799 003 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 004 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE >A> M-61 >A> PED Jul 09, 2024 Jan 09, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 37 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 004 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9415008 Oct 06, 2034 DP U-645 9415008*PED Apr 06, 2035 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 005 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 38 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 005 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - AIRDUO DIGIHALER N 208799 006 10022510 May 18, 2031 DP 10022510*PED Nov 18, 2031 10124131 May 18, 2031 DP 10124131*PED Nov 18, 2031 10195375 Feb 14, 2031 DP 10195375*PED Aug 14, 2031 10561808 Jan 01, 2032 DP 10561808*PED Jul 01, 2032 10569034 Aug 16, 2036 DP 10569034*PED Feb 16, 2037 10765820 May 19, 2025 DP 10765820*PED Nov 19, 2025 10918816 Dec 14, 2035 DP 10918816*PED Jun 14, 2036 11000653 Dec 18, 2038 DP 11000653*PED Jun 18, 2039 7540282 May 06, 2023 DP 7540282*PED Nov 06, 2023 8651103 Mar 26, 2028 DP 8651103*PED Sep 26, 2028 8714149 Feb 25, 2032 DP 8714149*PED Aug 25, 2032 8978966 Jan 13, 2032 DP 8978966*PED Jul 13, 2032 9066957 Oct 06, 2034 DP U-645 9066957*PED Apr 06, 2035 9216260 Jun 28, 2031 DP 9216260*PED Dec 28, 2031 9463288 May 19, 2025 DP 9463288*PED Nov 19, 2025 9616024 Sep 01, 2024 DP 9616024*PED Mar 01, 2025 9731087 May 18, 2031 DP 9731087*PED Nov 18, 2031 9782550 Aug 28, 2035 DP 9782550*PED Feb 28, 2036 9782551 Aug 28, 2035 DP 9782551*PED Feb 28, 2036 9987229 Sep 01, 2024 DP 9987229*PED Mar 01, 2025 FOSCARNET SODIUM - FOSCARNET SODIUM A 213001 001 FOSDENOPTERIN HYDROBROMIDE - NULIBRY N 214018 001 7504095 Jan 31, 2025 DP U-3092 GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11 N 212642 001 GALLIUM GA-68 PSMA-11 - GALLIUM GA 68 PSMA-11 N 212643 001 GLECAPREVIR; PIBRENTASVIR - MAVYRET N 209394 001 10028937 Jun 10, 2030 10028937 Jun 10, 2030 U-2141 U-2532 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT Dec 28, 2021 NCE ODE-342 Feb 26, 2026 Feb 26, 2028 NCE Dec 01, 2025 W Dec 01, 2025 NCE Dec 01, 2025 W Dec 01, 2025 D-175 M-259 Sep 26, 2022 Apr 10, 2023 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 39 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES GLECAPREVIR; PIBRENTASVIR - MAVYRET N 209394 001 10028937*PED Dec 10, 2030 10039754 Jun 10, 2030 10039754 Jun 10, 2030 10039754*PED Dec 10, 2030 10286029 Mar 14, 2034 10286029*PED Sep 14, 2034 8648037 Jan 19, 2032 8648037 Jan 19, 2032 8648037*PED Jul 19, 2032 8937150 May 18, 2032 8937150*PED Nov 18, 2032 9321807 Jun 05, 2035 9321807*PED Dec 05, 2035 >A> 9586978 Nov 06, 2030 >A> 9586978 Nov 06, 2030 >A> 9586978 Nov 06, 2030 >A> 9586978*PED May 06, 2031 GLECAPREVIR; PIBRENTASVIR - MAVYRET N 215110 001 10028937 Jun 10, 2030 10028937*PED Dec 10, 2030 10039754 Jun 10, 2030 10039754*PED Dec 10, 2030 10286029 Mar 14, 2034 10286029*PED Sep 14, 2034 8648037 Jan 19, 2032 8648037*PED Jul 19, 2032 8937150 May 18, 2032 8937150*PED Nov 18, 2032 9321807 Jun 05, 2035 9321807*PED Dec 05, 2035 >A> 9586978 Nov 06, 2030 >A> 9586978 Nov 06, 2030 >A> 9586978*PED May 06, 2031 GLUCAGON - BAQSIMI N 210134 001 10894133 Jan 03, 2038 GLYCEROL PHENYLBUTYRATE - RAVICTI N 203284 001 GLYCOPYRROLATE - LONHALA MAGNAIR KIT N 208437 001 10940110 Feb 26, 2029 GOLODIRSEN - VYONDYS 53 N 211970 001 10968450 10995337 Jun 28, 2025 Jun 28, 2025 HALOBETASOL PROPIONATE - LEXETTE N 210566 001 10857159 10857159*PED 11020407 Nov 30, 2036 May 30, 2037 Nov 30, 2036 HYDROCORTISONE - ALKINDI SPRINKLE N 213876 001 9649280 9675559 9717740 May 12, 2034 Jan 10, 2033 Nov 19, 2032 HYDROCORTISONE - ALKINDI SPRINKLE N 213876 002 9649280 9675559 9717740 May 12, 2034 Jan 10, 2033 Nov 19, 2032 U-2141 U-2532 U-2532 DS DP U-2141 DS DP U-2532 DS DP DS U-2141 U-2532 U-3237 U-3167 U-3167 U-3167 DS DP U-3167 DS DP DS DP U-3167 U-3238 DP DP U-1773 DS DP DP U-2675 DP DP U-3143 DP U-3075 U-3075 U-3075 DP U-3075 U-3075 U-3075 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE NPP ODE-232 ODE-233 PED PED PED PED PED PED Aug 03, 2022 Apr 30, 2022 Apr 30, 2026 Apr 30, 2026 Oct 30, 2022 Feb 03, 2023 Mar 26, 2023 Oct 10, 2023 Oct 30, 2026 Oct 30, 2026 NPP Dec 21, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 40 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES HYDROCORTISONE - ALKINDI SPRINKLE N 213876 003 9649280 9675559 9717740 May 12, 2034 Jan 10, 2033 Nov 19, 2032 HYDROCORTISONE - ALKINDI SPRINKLE N 213876 004 9649280 9675559 9717740 May 12, 2034 Jan 10, 2033 Nov 19, 2032 IBREXAFUNGERP CITRATE - BREXAFEMME N 214900 001 10174074 10370406 10927142 8188085 Jan 19, 2035 Jan 19, 2035 Jan 19, 2035 Aug 28, 2030 IBRUTINIB - IMBRUVICA N 205552 001 10961251 Jun 03, 2033 IBRUTINIB - IMBRUVICA N 205552 002 10961251 Jun 03, 2033 IBRUTINIB - IMBRUVICA N 210563 001 10961251 Jun 03, 2033 IBRUTINIB - IMBRUVICA N 210563 002 10961251 Jun 03, 2033 IBRUTINIB - IMBRUVICA N 210563 003 10961251 Jun 03, 2033 IBRUTINIB - IMBRUVICA N 210563 004 10961251 Jun 03, 2033 ICOSAPENT ETHYL - VASCEPA N 202057 001 10881632 10894028 11000499 11103477 >A> 11116742 >A> 11154526 Apr 29, 2030 Jun 28, 2033 Jun 28, 2033 Apr 29, 2030 Jun 28, 2033 Apr 29, 2030 ICOSAPENT ETHYL - VASCEPA N 202057 002 10881632 10894028 11000499 11103477 >A> 11116742 >A> 11154526 Apr 29, 2030 Jun 28, 2033 Jun 28, 2033 Apr 29, 2030 Jun 28, 2033 Apr 29, 2030 IMIQUIMOD - ZYCLARA N 022483 001 10918635 10918635 Apr 30, 2030 Apr 30, 2030 INFIGRATINIB PHOSPHATE - TRUSELTIQ N 214622 001 10278969 8552002 9067896 Dec 11, 2034 Aug 25, 2029 Aug 06, 2028 INFIGRATINIB PHOSPHATE - TRUSELTIQ N 214622 002 10278969 8552002 9067896 Dec 11, 2034 Aug 25, 2029 Aug 06, 2028 DP U-3075 U-3075 U-3075 DP U-3075 U-3075 U-3075 DS DP U-3159 DS DS DP U-3159 DP DP DP DP DP DP U-3052 U-3053 U-3126 U-3209 U-3221 U-3240 U-3052 U-3053 U-3126 U-3209 U-3221 U-3240 U-1455 U-172 DP DS DP DS DP DS DP DS PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE GAIN Jun 01, 2026 Jun 01, 2031 NCE ODE-353 May 28, 2026 May 28, 2028 NCE ODE-353 May 28, 2026 May 28, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 41 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES IRINOTECAN HYDROCHLORIDE - ONIVYDE N 207793 001 10980795 10993914 8329213 Jun 12, 2033 Oct 15, 2036 Jan 06, 2027 U-1848 DP DS DP ISOPROPYL ALCOHOL - ZURAGARD N 210872 001 10688291 8226971 8389583 8703828 9011897 9629368 9844654 Dec 20, 2034 May 06, 2025 Aug 09, 2029 May 23, 2028 Feb 08, 2025 May 23, 2028 Apr 24, 2036 DP U-1397 DP U-1397 DP DP U-1397 DP U-1397 IVACAFTOR - KALYDECO N 203188 001 IVACAFTOR - KALYDECO N 207925 001 IVACAFTOR - KALYDECO N 207925 002 IVACAFTOR - KALYDECO N 207925 003 IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED) N 210491 001 10058546 Jul 15, 2033 U-2399 10058546 Jul 15, 2033 U-2572 10058546 Jul 15, 2033 U-3022 10058546 Jul 15, 2033 U-3023 10081621 Mar 25, 2031 DP U-2420 10081621 Mar 25, 2031 DP U-2571 10081621 Mar 25, 2031 DP U-3024 10081621 Mar 25, 2031 DP U-3025 10206877 Apr 14, 2035 DP U-2498 10206877 Apr 14, 2035 DP U-2570 10206877 Apr 14, 2035 DP U-3026 10206877 Apr 14, 2035 DP U-3027 8354427 Jul 06, 2026 U-3021 IVACAFTOR; IVACAFTOR, TEZACAFTOR - SYMDEKO (COPACKAGED) N 210491 002 10058546 Jul 15, 2033 U-2399 10058546 Jul 15, 2033 U-2572 10058546 Jul 15, 2033 U-3022 10058546 Jul 15, 2033 U-3023 10081621 Mar 25, 2031 DP U-2420 10081621 Mar 25, 2031 DP U-2571 10081621 Mar 25, 2031 DP U-3024 10081621 Mar 25, 2031 DP U-3025 10206877 Apr 14, 2035 DP U-2498 10206877 Apr 14, 2035 DP U-2570 10206877 Apr 14, 2035 DP U-3026 10206877 Apr 14, 2035 DP U-3027 8354427 Jul 06, 2026 U-3021 IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 001 11052075 Dec 04, 2028 DP U-3181 IVACAFTOR; LUMACAFTOR - ORKAMBI N 206038 002 11052075 Dec 04, 2028 DP U-3181 IVERMECTIN - IVERMECTIN A 210720 001 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-268 Jun 24, 2024 ODE-338 Dec 21, 2027 ODE-338 Dec 21, 2027 ODE-338 Dec 21, 2027 ODE-338 Dec 21, 2027 ODE-335 Dec 21, 2027 ODE-335 Dec 21, 2027 PC May 29, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 42 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES IVERMECTIN - SOOLANTRA N 206255 001 11033565 Apr 22, 2024 IVOSIDENIB - TIBSOVO N 211192 001 10717764 10980788 10980788 10980788 9474779 9474779 9474779 9474779 9850277 9850277 9850277 9850277 Jan 18, 2033 Jun 07, 2039 Jun 07, 2039 Jun 07, 2039 Aug 19, 2033 Aug 19, 2033 Aug 19, 2033 Aug 19, 2033 Jan 18, 2033 Jan 18, 2033 Jan 18, 2033 Jan 18, 2033 LANSOPRAZOLE - LANSOPRAZOLE N 208025 001 11077055 Apr 21, 2036 LAROTRECTINIB SULFATE - VITRAKVI N 210861 001 10799505 Aug 15, 2036 LAROTRECTINIB SULFATE - VITRAKVI N 210861 002 10799505 Aug 15, 2036 LAROTRECTINIB SULFATE - VITRAKVI N 211710 001 10799505 Aug 15, 2036 LASMIDITAN SUCCINATE - REYVOW N 211280 001 11053214 Dec 05, 2037 LASMIDITAN SUCCINATE - REYVOW N 211280 002 11053214 Dec 05, 2037 LASMIDITAN SUCCINATE - REYVOW N 211280 003 11053214 7423050 8748459 Dec 05, 2037 Apr 06, 2025 Mar 27, 2023 LATANOPROST; NETARSUDIL DIMESYLATE - ROCKLATAN N 208259 001 10882840 Jul 11, 2026 11021456 Jul 11, 2026 11028081 Jan 27, 2030 LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 001 DP U-3215 U-3112 U-3113 U-3214 DS DP U-2350 DS DP U-2533 DS DP U-2534 DS DP U-3213 DS DP U-2350 DS DP U-2533 DS DP U-2534 DS DP U-3213 DP DS DP DS DP DS DS DP U-1719 DS DP U-1719 DS DP U-1719 DS DP U-1719 U-1719 U-1524 U-1524 U-1524 LEDIPASVIR; SOFOSBUVIR - HARVONI N 205834 002 LENVATINIB MESYLATE - LENVIMA N 206947 001 7253286 LENVATINIB MESYLATE - LENVIMA N 206947 002 7253286 Oct 24, 2025 DS DP Oct 24, 2025 DS DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE >A> I-875 Aug 25, 2024 NCE Jan 31, 2025 ODE* ODE* ODE* ODE* ODE* ODE* ODE* PED I-868 M-269 I-868 M-269 Aug 28, 2026 Aug 28, 2026 Aug 28, 2026 Apr 07, 2024 Aug 28, 2026 Aug 28, 2026 Aug 28, 2026 Oct 07, 2024 Aug 10, 2024 Jul 21, 2024 Aug 10, 2024 Jul 21, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 43 APPL/PROD NO PATENT NO LENVATINIB MESYLATE - LENVIMA N 206947 002 7253286 PATENT EXPIRATION DATE PATENT CODES Oct 24, 2025 DS DP LEUPROLIDE MESYLATE - CAMCEVI KIT N 211488 001 10646572 9572857 9744207 Jan 16, 2027 Jan 16, 2027 Jan 16, 2027 LEVONORGESTREL - MIRENA N 021225 001 10987244 Apr 01, 2031 LEVONORGESTREL - SKYLA N 203159 001 10987244 Apr 01, 2031 LEVONORGESTREL - LILETTA N 206229 001 11090186 Oct 24, 2033 LEVONORGESTREL - KYLEENA N 208224 001 10987244 Apr 01, 2031 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 001 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 002 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 003 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 004 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 005 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 006 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 007 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 008 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 009 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 010 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 011 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 012 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 013 11096913 Feb 28, 2037 DP DP DP DP DP U-2348 DP DP DP DP DP DP DP DP DP DP DP DP DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-868 M-269 NP Aug 10, 2024 Jul 21, 2024 May 25, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 44 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 014 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - TIROSINT-SOL N 206977 015 11096913 Feb 28, 2037 LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 001 >A> 11135190 Dec 01, 2036 LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 002 >A> 11135190 Dec 01, 2036 LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 210632 003 >A> 11135190 Dec 01, 2036 LEVOTHYROXINE SODIUM - LEVOTHYROXINE SODIUM N 214253 001 >A> 11154498 Jul 20, 2036 LIFITEGRAST - XIIDRA N 208073 001 11058677 Dec 18, 2033 LINAGLIPTIN - TRADJENTA N 201280 001 11033552 May 04, 2027 LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 001 10973827 Apr 02, 2029 LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 002 10973827 Apr 02, 2029 LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO N 201281 003 10973827 Apr 02, 2029 LIRAGLUTIDE RECOMBINANT - SAXENDA N 206321 001 11097063 Jul 17, 2026 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 001 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 002 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 PATENT CODES DP DP DP DP DP DP DP DP DP DP DP DP U-727 DP U-727 DP U-842 U-842 DP U-842 DP U-842 DP U-727 DP U-727 DP U-842 U-842 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NPP Dec 04, 2023 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 45 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 002 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 003 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 004 7105486 Feb 24, 2023 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 005 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 006 7105486 Feb 24, 2023 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 PATENT CODES DP U-842 DP U-842 DP U-727 DP U-727 DP U-842 U-842 DP U-842 DP U-842 DP U-727 U-842 DP U-727 DP U-842 U-842 DP U-842 DP U-842 DP U-842 U-727 DP U-842 U-842 DP U-842 DP U-842 DP U-727 U-842 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 46 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 006 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 021977 007 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7700561 Feb 24, 2023 7700561*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 001 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 U-727 DP U-842 U-842 DP U-842 DP U-842 DP DP DS DS DP U-727 U-1034 DS U-727 DP U-727 U-727 DP U-842 U-842 DP DP DP U-842 DP U-727 DP U-842 U-727 DP DS DP DS DP U-727 U-727 DS U-727 DP U-727 U-727 DP U-727 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 47 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 001 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 002 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 003 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 U-727 DP DS DP DS DP U-727 U-727 DS U-727 DP U-727 U-727 DP U-727 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 U-727 DP DS DP DS DP U-727 U-727 DS U-727 DP U-727 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 48 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 003 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 004 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 005 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 U-727 DP U-727 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 U-727 DP DS DP DS DP U-727 U-727 DS U-727 DP U-727 U-727 DP U-727 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 U-727 DP DS DP DS DP U-727 U-727 DS PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 49 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 005 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISDEXAMFETAMINE DIMESYLATE - VYVANSE N 208510 006 7105486 Feb 24, 2023 7105486*PED Aug 24, 2023 7223735 Feb 24, 2023 7223735*PED Aug 24, 2023 7655630 Feb 24, 2023 7655630*PED Aug 24, 2023 7659253 Feb 24, 2023 7659253*PED Aug 24, 2023 7659254 Feb 24, 2023 7659254*PED Aug 24, 2023 7662787 Feb 24, 2023 7662787*PED Aug 24, 2023 7662788 Feb 24, 2023 7662788*PED Aug 24, 2023 7671030 Feb 24, 2023 7671030*PED Aug 24, 2023 7671031 Feb 24, 2023 7671031*PED Aug 24, 2023 7674774 Feb 24, 2023 7674774*PED Aug 24, 2023 7678770 Feb 24, 2023 7678770*PED Aug 24, 2023 7678771 Feb 24, 2023 7678771*PED Aug 24, 2023 7687466 Feb 24, 2023 7687466*PED Aug 24, 2023 7687467 Feb 24, 2023 7687467*PED Aug 24, 2023 7713936 Feb 24, 2023 7713936*PED Aug 24, 2023 7718619 Feb 24, 2023 7718619*PED Aug 24, 2023 7723305 Feb 24, 2023 7723305*PED Aug 24, 2023 LISINOPRIL - QBRELIS N 208401 001 10940177 Nov 06, 2035 LONAFARNIB - ZOKINVY N 213969 001 7838531 8828356 Jul 26, 2024 Oct 17, 2023 U-727 DP U-727 U-727 DP U-727 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 U-727 DP DS DP DS DP U-727 U-727 DS U-727 DP U-727 U-727 DP U-727 U-727 DP U-727 DP DP U-727 U-727 DP U-727 DP U-727 DP U-3070 U-3070 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE ODE-324 Nov 20, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 50 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE LONAFARNIB - ZOKINVY N 213969 002 7838531 8828356 Jul 26, 2024 Oct 17, 2023 U-3070 U-3070 LOPERAMIDE HYDROCHLORIDE - LOPERAMIDE HYDROCHLORIDE A 213070 001 LORAZEPAM - LOREEV XR N 214826 001 8999393 Jan 08, 2034 DP U-3210 LORAZEPAM - LOREEV XR N 214826 002 8999393 Jan 08, 2034 DP U-3210 LORAZEPAM - LOREEV XR N 214826 003 8999393 Jan 08, 2034 DP U-3210 LORLATINIB - LORBRENA N 210868 001 10420749 10420749 11020376 Jul 27, 2036 Jul 27, 2036 Jul 27, 2036 DS DP U-2633 DS DP U-3096 DP LORLATINIB - LORBRENA N 210868 002 10420749 10420749 11020376 Jul 27, 2036 Jul 27, 2036 Jul 27, 2036 DS DP U-2633 DS DP U-3096 DP LOTEPREDNOL ETABONATE - LOTEPREDNOL ETABONATE A 212450 001 LOTEPREDNOL ETABONATE - EYSUVIS N 210933 001 10940108 10945948 10993908 May 03, 2033 May 03, 2033 May 03, 2033 U-2985 U-2985 U-3117 LUMASIRAN SODIUM - OXLUMO N 214103 001 11060093 Dec 26, 2034 DS DP U-2995 LUMATEPERONE TOSYLATE - CAPLYTA N 209500 001 10960009 Dec 03, 2034 U-814 MACITENTAN - OPSUMIT N 204410 001 10946015 Sep 11, 2026 DP U-1445 MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM SULFATE - SUTAB (COPACKAGED) N 213135 001 11033498 Aug 04, 2037 U-3164 MANNITOL - BRONCHITOL N 202049 001 MARALIXIBAT CHLORIDE - LIVMARLI N 214662 001 MELOXICAM - ANJESO N 210583 001 10881663 Mar 08, 2039 MELPHALAN FLUFENAMIDE HYDROCHLORIDE - PEPAXTO N 214383 001 10285946 Apr 25, 2032 10322182 Apr 25, 2032 10543274 Apr 25, 2032 10869928 Apr 25, 2032 6992207 Jun 25, 2022 U-3038 DP DP U-3093 DP DS DP U-3093 ODE-324 Nov 20, 2027 >A> CGT Apr 20, 2022 I-847 ODE-349 Mar 03, 2024 Mar 03, 2028 I-847 ODE-349 Mar 03, 2024 Mar 03, 2028 CGT Nov 02, 2021 ODE-339 Nov 23, 2027 NP ODE-327 Oct 30, 2023 Oct 30, 2027 >A> NCE Sep 29, 2026 NCE ODE-348 Feb 26, 2026 Feb 26, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 51 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES MELPHALAN HYDROCHLORIDE - EVOMELA N 207155 001 10940128 11020363 Jun 14, 2030 May 28, 2030 DP U-3086 DP MEROPENEM; VABORBACTAM - VABOMERE N 209776 001 11007206 8680136 Aug 08, 2031 Aug 29, 2031 U-3128 DS DP METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 001 METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET N 022044 002 METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 001 METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR N 202270 002 METHYLENE BLUE - PROVAYBLUE N 204630 002 METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 001 11103494 Aug 14, 2033 11103495 Aug 14, 2033 METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 002 11103494 Aug 14, 2033 11103495 Aug 14, 2033 METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER N 207960 003 11103494 Aug 14, 2033 11103495 Aug 14, 2033 METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 001 10881618 Mar 23, 2032 10905652 Mar 23, 2032 METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 002 10881618 Mar 23, 2032 10905652 Mar 23, 2032 METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 003 10881618 Mar 23, 2032 10905652 Mar 23, 2032 METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 004 10881618 Mar 23, 2032 10905652 Mar 23, 2032 METHYLPHENIDATE HYDROCHLORIDE - JORNAY PM N 209311 005 10881618 Mar 23, 2032 10905652 Mar 23, 2032 METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 001 DP DP U-2993 DP DP U-2993 DP DP U-2993 U-2357 DP U-2357 DP U-2357 DP U-2357 DP U-2357 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE GAIN M-187 PED M-187 PED M-187 PED M-187 PED ODE* Aug 29, 2022 Aug 29, 2027 Dec 04, 2023 Jun 04, 2024 Dec 04, 2023 Jun 04, 2024 Dec 04, 2023 Jun 04, 2024 Dec 04, 2023 Jun 04, 2024 Apr 08, 2023 M-82 Jun 28, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 52 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 002 METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 003 METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 004 METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 005 METHYLPHENIDATE HYDROCHLORIDE - ADHANSIA XR N 212038 006 METOCLOPRAMIDE HYDROCHLORIDE - GIMOTI N 209388 001 11020361 Dec 22, 2029 MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE N 211844 001 10966990 Jun 20, 2038 MIDAZOLAM - MIDAZOLAM IN 0.9% SODIUM CHLORIDE N 211844 002 10966990 Jun 20, 2038 MIGALASTAT HYDROCHLORIDE - GALAFOLD N 208623 001 10874655 May 30, 2038 10874656 May 30, 2038 10874657 May 30, 2038 10925866 Apr 28, 2028 11033538 Apr 28, 2028 RE48608 Feb 12, 2029 MINOCYCLINE HYDROCHLORIDE - MINOLIRA N 209269 001 11103517 Apr 07, 2036 MINOCYCLINE HYDROCHLORIDE - MINOLIRA N 209269 002 11103517 Apr 07, 2036 MINOCYCLINE HYDROCHLORIDE - ZILXI N 213690 001 10946101 Oct 01, 2030 MIRABEGRON - MYRBETRIQ N 202611 001 10842780 10842780*PED 6346532 6346532*PED 8772315 8772315*PED 8835474 8835474*PED RE44872 RE44872*PED Sep 28, 2029 Mar 28, 2030 Mar 27, 2022 Sep 27, 2022 Oct 30, 2028 Apr 30, 2029 Nov 04, 2023 May 04, 2024 Nov 04, 2023 May 04, 2024 MIRABEGRON - MYRBETRIQ N 202611 002 10842780 10842780*PED 6346532 6346532*PED 8772315 8772315*PED 8835474 8835474*PED RE44872 RE44872*PED Sep 28, 2029 Mar 28, 2030 Mar 27, 2022 Sep 27, 2022 Oct 30, 2028 Apr 30, 2029 Nov 04, 2023 May 04, 2024 Nov 04, 2023 May 04, 2024 U-2843 DP DP U-2371 U-2371 U-2371 U-2371 U-2371 U-2371 DP DP U-1631 DP U-2996 DS DP U-2300 U-1527 U-1527 DP U-2996 DS DP U-2300 U-1527 U-1527 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-82 M-82 M-82 M-82 M-82 Jun 28, 2024 Jun 28, 2024 Jun 28, 2024 Jun 28, 2024 Jun 28, 2024 I-777 I-855 PED Apr 27, 2021 Mar 25, 2024 Sep 25, 2024 I-777 I-855 PED Apr 27, 2021 Mar 25, 2024 Sep 25, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 53 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES MIRABEGRON - MYRBETRIQ N 202611 002 10842780 10842780*PED 6346532 6346532*PED 8772315 8772315*PED 8835474 8835474*PED RE44872 RE44872*PED Sep 28, 2029 Mar 28, 2030 Mar 27, 2022 Sep 27, 2022 Oct 30, 2028 Apr 30, 2029 Nov 04, 2023 May 04, 2024 Nov 04, 2023 May 04, 2024 MIRABEGRON - MYRBETRIQ GRANULES N 213801 001 10058536 10058536*PED 6346532 6346532*PED 7342117 7342117*PED 7982049 7982049*PED Mar 31, 2036 Oct 01, 2036 Mar 27, 2022 Sep 27, 2022 Nov 04, 2023 May 04, 2024 Nov 04, 2023 May 04, 2024 MOBOCERTINIB SUCCINATE - EXKIVITY N 215310 001 10227342 9796712 May 13, 2035 May 13, 2035 MONOMETHYL FUMARATE - BAFIERTAM N 210296 001 10918615 10918616 10918617 10945985 Aug 12, 2035 Jun 03, 2035 Aug 10, 2035 Aug 14, 2035 MORPHINE SULFATE - MORPHINE SULFATE A 212451 001 MORPHINE SULFATE - MORPHINE SULFATE A 212451 002 MORPHINE SULFATE - MORPHINE SULFATE N 022195 001 MORPHINE SULFATE - MORPHINE SULFATE N 022195 002 MORPHINE SULFATE - MORPHINE SULFATE N 022207 001 MORPHINE SULFATE - MORPHINE SULFATE N 022207 002 NALDEMEDINE TOSYLATE - SYMPROIC N 208854 001 10952968 May 13, 2033 NALOXONE HYDROCHLORIDE - EVZIO N 205787 001 10960155 Jun 25, 2026 NALOXONE HYDROCHLORIDE - EVZIO (AUTOINJECTOR) N 209862 001 10960155 Jun 25, 2026 NALOXONE HYDROCHLORIDE - KLOXXADO N 212045 001 10722510 10973814 Aug 26, 2034 Aug 26, 2034 DP U-2996 DS DP U-2300 U-1527 U-1527 DP U-3108 DS DS DP DS DP U-3220 DS DP DP U-1384 U-1384 DP DP DS DP DP DP DP U-3110 DP U-3110 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-777 I-855 PED Apr 27, 2021 Mar 25, 2024 Sep 25, 2024 NP Mar 25, 2024 PED Sep 25, 2024 NCE Sep 15, 2026 CGT Aug 10, 2021 CGT Aug 10, 2021 NPP Jun 02, 2024 NPP Jun 02, 2024 NPP Jun 02, 2024 NPP Jun 02, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 54 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES NAPROXEN SODIUM - NAPROXEN SODIUM N 021920 001 11090280 11090280 11090280 Mar 03, 2026 Mar 03, 2026 Mar 03, 2026 DP U-1731 DP U-1732 DP U-3195 NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE A 203659 001 NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE A 203659 002 NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE A 203659 003 NEBIVOLOL HYDROCHLORIDE - NEBIVOLOL HYDROCHLORIDE A 203659 004 NERATINIB MALEATE - NERLYNX N 208051 001 10035788 10035788 10035788 7982043 7982043 7982043 8518446 8518446 8518446 8669273 8790708 8790708 8790708 9139558 9139558 9139558 9211291 9211291 9265784 9630946 9630946 9630946 Oct 15, 2028 Oct 15, 2028 Oct 15, 2028 Oct 08, 2025 Oct 08, 2025 Oct 08, 2025 Nov 20, 2030 Nov 20, 2030 Nov 20, 2030 Jul 18, 2031 Nov 05, 2030 Nov 05, 2030 Nov 05, 2030 Oct 15, 2028 Oct 15, 2028 Oct 15, 2028 Mar 24, 2030 Mar 24, 2030 Aug 04, 2029 Oct 15, 2028 Oct 15, 2028 Oct 15, 2028 U-2043 U-3047 U-3097 U-2043 U-3047 U-3097 DP U-2043 DP U-3047 DP U-3097 U-3047 DP U-2043 DP U-3047 DP U-3097 U-2043 U-3047 U-3097 U-2043 U-3097 U-3047 U-2043 U-3047 U-3097 NETARSUDIL MESYLATE - RHOPRESSA N 208254 001 10882840 11021456 11028081 Jul 11, 2026 Jul 11, 2026 Jan 27, 2030 U-1524 U-1524 U-1524 NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO N 205718 001 10961195 Sep 25, 2035 DS DP NIFURTIMOX - LAMPIT N 213464 001 NIFURTIMOX - LAMPIT N 213464 002 NILOTINIB HYDROCHLORIDE - TASIGNA N 022068 001 >A> 8389537 >A> 8389537*PED >A> 8415363 >A> 8415363 >A> 8415363*PED >A> 8501760 >A> 8501760*PED >A> 9061029 >A> 9061029 >A> 9061029*PED Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jan 18, 2027 Apr 07, 2032 Apr 07, 2032 Oct 07, 2032 U-1374 DS DP U-1374 DS DP U-1407 DP DS U-1374 DS U-3231 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PC PC PC PC >A> D-182 Dec 17, 2021 Dec 17, 2021 Dec 17, 2021 Dec 17, 2021 Jun 28, 2024 ODE-319 Aug 06, 2027 ODE-319 Aug 06, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 55 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES NILOTINIB HYDROCHLORIDE - TASIGNA N 022068 001 >A> 8389537 >A> 8389537*PED >A> 8415363 >A> 8415363 >A> 8415363*PED >A> 8501760 >A> 8501760*PED >A> 9061029 >A> 9061029 >A> 9061029*PED Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jan 18, 2027 Apr 07, 2032 Apr 07, 2032 Oct 07, 2032 NILOTINIB HYDROCHLORIDE - TASIGNA N 022068 002 >A> 8389537 >A> 8389537*PED >A> 8415363 >A> 8415363 >A> 8415363*PED >A> 8501760 >A> 8501760*PED >A> 9061029 >A> 9061029 >A> 9061029*PED Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jan 18, 2027 Apr 07, 2032 Apr 07, 2032 Oct 07, 2032 NILOTINIB HYDROCHLORIDE - TASIGNA N 022068 003 >A> 8389537 >A> 8389537*PED >A> 8415363 >A> 8415363 >A> 8415363*PED >A> 8501760 >A> 8501760*PED >A> 9061029 >A> 9061029 >A> 9061029*PED Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jul 18, 2026 Jan 18, 2027 Jul 18, 2026 Jan 18, 2027 Apr 07, 2032 Apr 07, 2032 Oct 07, 2032 NIRAPARIB TOSYLATE - ZEJULA N 208447 001 11091459 8071623 Mar 27, 2038 Mar 27, 2031 NITAZOXANIDE - NITAZOXANIDE A 213820 001 NITRIC OXIDE - GENOSYL N 202860 001 10124142 10814092 10926054 11103669 7947227 8057742 8226916 8607785 8609028 8821801 8944049 9522249 9701538 9956373 Aug 18, 2025 Oct 17, 2025 Aug 13, 2029 Jun 21, 2030 Oct 17, 2026 Jan 18, 2026 Aug 18, 2025 Jul 14, 2030 Aug 18, 2025 Aug 18, 2025 Aug 13, 2029 Aug 18, 2025 Jan 28, 2029 Aug 18, 2025 OBETICHOLIC ACID - OCALIVA N 207999 001 RE48286 Nov 16, 2027 OBETICHOLIC ACID - OCALIVA N 207999 002 RE48286 Nov 16, 2027 U-1374 DS DP U-1374 DS DP U-1407 DP DS U-1374 DS U-3231 U-1374 DS DP U-1374 DS DP U-1407 DP DS U-1374 DS U-3231 U-1374 DS DP U-1374 DS DP U-1407 DP DS U-1374 DS U-3231 DP DS DP U-3037 U-3037 DP DP U-3037 U-3037 U-3037 DP U-3037 DP DP DP DP U-3037 DS DP DS DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT Jun 05, 2021 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 56 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES OCTREOTIDE ACETATE - MYCAPSSA N 208232 001 11052126 >A> 11141457 Feb 03, 2036 Dec 28, 2040 ODEVIXIBAT - BYLVAY N 215498 001 10011633 10093697 10487111 10487111 10975046 10981952 10981952 7132416 9694018 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031 ODEVIXIBAT - BYLVAY N 215498 002 10011633 10093697 10487111 10487111 10975046 10981952 10981952 7132416 9694018 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031 ODEVIXIBAT - BYLVAY N 215498 003 10011633 10093697 10487111 10487111 10975046 10981952 10981952 7132416 9694018 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031 ODEVIXIBAT - BYLVAY N 215498 004 10011633 10093697 10487111 10487111 10975046 10981952 10981952 7132416 9694018 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Nov 08, 2031 Jun 20, 2039 Nov 08, 2031 Nov 08, 2031 Sep 05, 2022 Nov 08, 2031 OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 001 10300054 Aug 23, 2031 10300054 Aug 23, 2031 10716785 Aug 23, 2031 10716785 Aug 23, 2031 7262298 Nov 23, 2025 7956187 Oct 31, 2021 8252929 Oct 31, 2021 8778960 Feb 13, 2032 8778960 Feb 13, 2032 9119848 Aug 30, 2031 9126977 Aug 23, 2031 9126977 Aug 23, 2031 9517235 Aug 23, 2031 9517235 Aug 23, 2031 OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 002 10300054 Aug 23, 2031 10300054 Aug 23, 2031 U-2857 U-3232 U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186 U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186 U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186 U-3186 U-3186 U-3186 U-3187 DS U-3186 U-3187 DS DP U-3186 DP U-3140 DP U-3141 U-3136 U-3137 DS DS DS U-3136 U-3137 DS DP U-3136 DP U-3137 U-3138 U-3139 DP U-3140 DP U-3141 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE ODE-363 Jul 20, 2026 Jul 20, 2028 NCE ODE-363 Jul 20, 2026 Jul 20, 2028 NCE ODE-363 Jul 20, 2026 Jul 20, 2028 NCE ODE-363 Jul 20, 2026 Jul 20, 2028 NCE May 28, 2026 NCE May 28, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 57 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 002 10716785 Aug 23, 2031 10716785 Aug 23, 2031 7262298 Nov 23, 2025 7956187 Oct 31, 2021 8252929 Oct 31, 2021 8778960 Feb 13, 2032 8778960 Feb 13, 2032 9119848 Aug 30, 2031 9126977 Aug 23, 2031 9126977 Aug 23, 2031 9517235 Aug 23, 2031 9517235 Aug 23, 2031 OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 003 10300054 Aug 23, 2031 10300054 Aug 23, 2031 10716785 Aug 23, 2031 10716785 Aug 23, 2031 7262298 Nov 23, 2025 7956187 Oct 31, 2021 8252929 Oct 31, 2021 8778960 Feb 13, 2032 8778960 Feb 13, 2032 9119848 Aug 30, 2031 9126977 Aug 23, 2031 9126977 Aug 23, 2031 9517235 Aug 23, 2031 9517235 Aug 23, 2031 OLANZAPINE; SAMIDORPHAN L-MALATE - LYBALVI N 213378 004 10300054 Aug 23, 2031 10300054 Aug 23, 2031 10716785 Aug 23, 2031 10716785 Aug 23, 2031 7262298 Nov 23, 2025 7956187 Oct 31, 2021 8252929 Oct 31, 2021 8778960 Feb 13, 2032 8778960 Feb 13, 2032 9119848 Aug 30, 2031 9126977 Aug 23, 2031 9126977 Aug 23, 2031 9517235 Aug 23, 2031 9517235 Aug 23, 2031 OLAPARIB - LYNPARZA N 208558 001 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8859562 8859562 8859562 8859562 8859562 8859562 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 U-3136 U-3137 DS DS DS U-3136 U-3137 DS DP U-3136 DP U-3137 U-3138 U-3139 DP U-3140 DP U-3141 U-3136 U-3137 DS DS DS U-3136 U-3137 DS DP U-3136 DP U-3137 U-3138 U-3139 DP U-3140 DP U-3141 U-3136 U-3137 DS DS DS U-3136 U-3137 DS DP U-3136 DP U-3137 U-3138 U-3139 U-2101 U-2103 U-2480 U-2481 U-2482 U-2483 U-2716 U-2819 U-2820 U-2821 U-2822 U-2823 U-2824 U-2832 U-2833 U-2101 U-2103 U-2480 U-2481 U-2482 U-2483 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE May 28, 2026 NCE May 28, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 58 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES OLAPARIB - LYNPARZA N 208558 001 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 OLAPARIB - LYNPARZA N 208558 002 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8071579 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 8859562 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 12, 2027 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 Aug 04, 2031 OLICERIDINE - OLINVYK N 210730 001 11077098 Mar 23, 2032 OLICERIDINE - OLINVYK N 210730 002 11077098 Mar 23, 2032 OLICERIDINE - OLINVYK N 210730 003 11077098 Mar 23, 2032 ORITAVANCIN DIPHOSPHATE - KIMYRSA N 214155 001 8420592 9649352 9682061 Aug 29, 2029 Jul 16, 2035 Apr 26, 2030 OSIMERTINIB MESYLATE - TAGRISSO N 208065 001 10183020 10183020 10183020 8946235 8946235 8946235 9732058 9732058 9732058 Jan 02, 2035 Jan 02, 2035 Jan 02, 2035 Aug 08, 2032 Aug 08, 2032 Aug 08, 2032 Jul 25, 2032 Jul 25, 2032 Jul 25, 2032 U-2716 U-2819 U-2820 U-2821 U-2822 U-2823 U-2824 U-2832 U-2833 U-2101 U-2103 U-2480 U-2481 U-2482 U-2483 U-2716 U-2819 U-2820 U-2821 U-2822 U-2823 U-2824 U-2832 U-2833 U-2101 U-2103 U-2480 U-2481 U-2482 U-2483 U-2716 U-2819 U-2820 U-2821 U-2822 U-2823 U-2824 U-2832 U-2833 DS DP U-2986 DS DP U-2986 DS DP U-2986 U-3101 DS DP U-3101 DP U-1777 DP U-2289 DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Oct 30, 2025 NCE Oct 30, 2025 NCE Oct 30, 2025 NCE NP GAIN Aug 06, 2019 Mar 12, 2024 Aug 06, 2024 I-853 ODE-337 Dec 18, 2023 Dec 18, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 59 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES OSIMERTINIB MESYLATE - TAGRISSO N 208065 001 10183020 10183020 10183020 8946235 8946235 8946235 9732058 9732058 9732058 Jan 02, 2035 Jan 02, 2035 Jan 02, 2035 Aug 08, 2032 Aug 08, 2032 Aug 08, 2032 Jul 25, 2032 Jul 25, 2032 Jul 25, 2032 OSIMERTINIB MESYLATE - TAGRISSO N 208065 002 10183020 10183020 10183020 8946235 8946235 8946235 9732058 9732058 9732058 Jan 02, 2035 Jan 02, 2035 Jan 02, 2035 Aug 08, 2032 Aug 08, 2032 Aug 08, 2032 Jul 25, 2032 Jul 25, 2032 Jul 25, 2032 OSPEMIFENE - OSPHENA N 203505 001 9566252 Nov 02, 2022 OXYMETAZOLINE HYDROCHLORIDE - UPNEEQ N 212520 001 10898573 Dec 16, 2039 10912765 Aug 26, 2031 10940138 Dec 16, 2039 11103482 Dec 16, 2039 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 001 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 002 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 003 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 004 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 005 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 006 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 DP U-1777 DP U-2289 DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 DP U-1777 DP U-2289 DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 DS DP U-1777 DS DP U-2289 DS DP U-3016 U-1370 DP U-2849 U-2849 DP DP DP U-3085 DS DP DP U-3085 DS DP DP U-3085 DS DP DP U-3085 DS DP DP U-3085 DS DP DP U-3085 DS PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-853 ODE-337 Dec 18, 2023 Dec 18, 2027 I-853 ODE-337 Dec 18, 2023 Dec 18, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 60 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 006 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OXYMORPHONE HYDROCHLORIDE - OPANA ER N 021610 007 8309112 Feb 04, 2023 8329216 Feb 04, 2023 8808737 Jun 21, 2027 8871779 Nov 22, 2029 OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 001 10239846 Nov 15, 2030 OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 002 10239846 Nov 15, 2030 OZANIMOD HYDROCHLORIDE - ZEPOSIA N 209899 003 10239846 Nov 15, 2030 OZENOXACIN - XEPI N 208945 001 6335447 Nov 09, 2023 PALBOCICLIB - IBRANCE N 207103 001 RE47739 Mar 05, 2027 PALBOCICLIB - IBRANCE N 207103 002 RE47739 Mar 05, 2027 PALBOCICLIB - IBRANCE N 207103 003 RE47739 Mar 05, 2027 PALBOCICLIB - IBRANCE N 212436 001 11065250 RE47739 May 24, 2036 Mar 05, 2027 PALBOCICLIB - IBRANCE N 212436 002 11065250 RE47739 May 24, 2036 Mar 05, 2027 PALBOCICLIB - IBRANCE N 212436 003 11065250 RE47739 May 24, 2036 Mar 05, 2027 PALIPERIDONE PALMITATE - INVEGA HAFYERA N 207946 005 PALIPERIDONE PALMITATE - INVEGA HAFYERA N 207946 006 PARICALCITOL - ZEMPLAR N 020819 001 PARICALCITOL - ZEMPLAR N 020819 002 PARICALCITOL - ZEMPLAR N 020819 003 DP DP U-3085 DS DP DP U-3085 DS U-3132 U-3132 U-3132 DS DS DP DS DP DS DP DP DS DP DP DS DP DP DS DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-860 I-860 I-860 May 27, 2024 May 27, 2024 May 27, 2024 NS NS ODE* ODE* ODE* Aug 30, 2024 Aug 30, 2024 Oct 18, 2023 Oct 18, 2023 Oct 18, 2023 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 61 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PAROXETINE HYDROCHLORIDE - PAROXETINE HYDROCHLORIDE A 215003 001 PATIROMER SORBITEX CALCIUM - VELTASSA N 205739 001 11123363 Oct 08, 2033 U-1766 PATIROMER SORBITEX CALCIUM - VELTASSA N 205739 002 11123363 Oct 08, 2033 U-1766 PATIROMER SORBITEX CALCIUM - VELTASSA N 205739 003 11123363 Oct 08, 2033 U-1766 PATISIRAN SODIUM - ONPATTRO N 210922 001 10240152 11079379 >A> 11141378 Oct 20, 2029 Aug 27, 2035 Apr 15, 2029 DS DP U-2378 DS DP U-2378 DP PEGCETACOPLAN - EMPAVELI N 215014 001 10035822 10125171 10875893 11040107 11040107 11040107 7888323 7989589 9169307 Nov 15, 2033 Aug 02, 2033 Nov 15, 2033 Apr 09, 2038 Apr 09, 2038 Apr 09, 2038 Dec 04, 2027 Dec 04, 2027 Nov 18, 2027 DS DS DS U-3124 DP U-3172 DP U-3173 DP U-3174 DS DS DS U-3123 PERAMIVIR - RAPIVAB N 206426 001 10391075 10391075 8778997 8778997 8778997 Feb 12, 2027 Feb 12, 2027 May 07, 2027 May 07, 2027 May 07, 2027 U-2622 U-3069 U-1627 U-2622 U-3069 PERAMPANEL - FYCOMPA N 202834 001 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 PERAMPANEL - FYCOMPA N 202834 002 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 PERAMPANEL - FYCOMPA N 202834 003 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 PERAMPANEL - FYCOMPA N 202834 004 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT Mar 12, 2022 NCE ODE-351 May 14, 2026 May 14, 2028 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 62 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PERAMPANEL - FYCOMPA N 202834 005 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 PERAMPANEL - FYCOMPA N 202834 006 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 PERAMPANEL - FYCOMPA N 208277 001 6949571 6949571 6949571 6949571 6949571 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 Jun 08, 2022 PEXIDARTINIB HYDROCHLORIDE - TURALIO N 211810 001 10941142 Jul 24, 2038 10961240 Jul 24, 2038 PIFLUFOLASTAT F-18 - PYLARIFY N 214793 001 10947197 8487129 8778305 9861713 Jun 09, 2037 Nov 07, 2027 Sep 21, 2030 Jul 31, 2029 PIMAVANSERIN TARTRATE - NUPLAZID N 207318 002 10953000 Mar 23, 2037 PITOLISANT HYDROCHLORIDE - WAKIX N 211150 001 PITOLISANT HYDROCHLORIDE - WAKIX N 211150 002 PLECANATIDE - TRULANCE N 208745 001 >A> 11142549 Jun 05, 2034 POMALIDOMIDE - POMALYST N 204026 001 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 DS DP U-106 DS DP U-2088 DS DP U-2089 DS DP U-2428 DS DP U-2429 DP U-2606 DS DP U-3130 DS DP DS DP U-3130 DS DP U-3130 U-1974 DP POMALIDOMIDE - POMALYST N 204026 002 POMALIDOMIDE - POMALYST N 204026 003 POMALIDOMIDE - POMALYST N 204026 004 PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 001 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE May 26, 2026 ODE-331 Oct 13, 2027 ODE-331 Oct 13, 2027 M-14 PED M-14 PED M-14 PED M-14 PED I-849 Nov 20, 2023 May 20, 2024 Nov 20, 2023 May 20, 2024 Nov 20, 2023 May 20, 2024 Nov 20, 2023 May 20, 2024 Dec 18, 2023 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 63 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 002 PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 003 8114874 Jan 24, 2027 DS DP PONATINIB HYDROCHLORIDE - ICLUSIG N 203469 004 8114874 9029533 9029533 9029533 9029533 9029533 9493470 9493470 Jan 24, 2027 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 22, 2026 Dec 12, 2033 Dec 12, 2033 DS DP U-1283 U-1699 U-1700 U-1701 U-836 DS DP U-1700 DS DP U-1948 PONESIMOD - PONVORY N 213498 001 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 002 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 003 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 004 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 005 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 006 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PONESIMOD - PONVORY N 213498 007 10220023 8273779 9000018 9062014 RE43728 Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-849 I-849 I-849 Dec 18, 2023 Dec 18, 2023 Dec 18, 2023 NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 64 APPL/PROD NO PATENT NO PONESIMOD - PONVORY N 213498 008 10220023 8273779 9000018 9062014 RE43728 PONESIMOD - PONVORY N 213498 009 10220023 8273779 9000018 9062014 RE43728 PONESIMOD - PONVORY N 213498 010 10220023 8273779 9000018 9062014 RE43728 POSACONAZOLE - NOXAFIL N 205053 001 PATENT EXPIRATION DATE PATENT CODES Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP Dec 10, 2035 Dec 17, 2025 Nov 16, 2024 May 06, 2032 Nov 16, 2024 U-3103 U-2774 U-3102 DS DP U-2774 DS DP POSACONAZOLE - NOXAFIL N 205596 001 9023790 9023790 9023790 9358297 9358297 Jul 04, 2031 Jul 04, 2031 Jul 04, 2031 Jun 24, 2031 Jun 24, 2031 POSACONAZOLE - NOXAFIL POWDERMIX KIT N 214770 001 PRALSETINIB - GAVRETO N 213721 001 DP U-1698 DP U-3160 DP U-3171 DP U-3160 DP U-3171 PYRIMETHAMINE - PYRIMETHAMINE A 211271 001 RELUGOLIX - ORGOVYX N 214621 001 10350170 10449191 10786501 7300935 8058280 8735401 REMDESIVIR - VEKLURY N 214787 001 11007208 REMDESIVIR - VEKLURY N 214787 002 11007208 REMIMAZOLAM BESYLATE - BYFAVO N 212295 001 REVEFENACIN - YUPELRI N 210598 001 11008289 Feb 25, 2036 Sep 29, 2037 Sep 29, 2037 Jan 28, 2024 Jan 28, 2024 Feb 04, 2024 DP U-3020 U-3020 DS DS DP U-3019 Sep 16, 2036 U-2984 Sep 16, 2036 U-2984 Jul 14, 2030 U-2440 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Mar 18, 2026 NCE Mar 18, 2026 NCE Mar 18, 2026 NPP ODE-355 May 31, 2024 Jun 17, 2028 NPP ODE-355 May 31, 2024 Jun 17, 2028 NP May 31, 2024 ODE-340 ODE-341 Dec 01, 2027 Dec 01, 2027 CGT Apr 02, 2022 NCE Dec 18, 2025 NCE Oct 06, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 65 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES RIFAXIMIN - XIFAXAN N 021361 002 10314828 10335397 10456384 10456384 10703763 10703763 10703763 10709694 10765667 10765667 7045620 7612199 7902206 7906542 7915275 7915275 8158644 8158781 8193196 8193196 8309569 8309569 8518949 8642573 8741904 8741904 8741904 8829017 8835452 8853231 8946252 8969398 9271968 9421195 9629828 Jul 24, 2029 Jul 24, 2029 Feb 26, 2029 Feb 26, 2029 Feb 27, 2026 Feb 27, 2026 Feb 27, 2026 Jul 24, 2029 Feb 26, 2029 Feb 26, 2029 Jun 19, 2024 Jun 19, 2024 Jun 19, 2024 Jun 01, 2025 Feb 23, 2025 Feb 23, 2025 Jun 19, 2024 Jun 19, 2024 Sep 02, 2027 Sep 02, 2027 Jul 18, 2029 Jul 18, 2029 Feb 27, 2026 Oct 02, 2029 Feb 27, 2026 Feb 27, 2026 Feb 27, 2026 Jul 24, 2029 Jun 19, 2024 Jun 19, 2024 Jul 24, 2029 Oct 02, 2029 Feb 27, 2026 Jul 24, 2029 Jul 24, 2029 RILPIVIRINE HYDROCHLORIDE - EDURANT N 202022 001 7125879 Apr 21, 2025 7125879 Apr 21, 2025 7125879 Apr 21, 2025 7125879 Apr 21, 2025 RIMEGEPANT SULFATE - NURTEC ODT N 212728 001 11083724 11083724 8314117 8314117 Mar 25, 2039 Mar 25, 2039 Feb 22, 2031 Feb 22, 2031 RIPRETINIB - QINLOCK N 213973 001 10966966 RE48731 Aug 12, 2040 Jun 07, 2032 RISDIPLAM - EVRYSDI N 213535 001 RISPERIDONE - PERSERIS KIT N 210655 001 11013809 11110093 Feb 13, 2028 Nov 05, 2026 RISPERIDONE - PERSERIS KIT N 210655 002 11013809 11110093 Feb 13, 2028 Nov 05, 2026 U-1481 U-2579 U-2643 U-2644 U-1708 U-2847 U-2848 U-2579 U-2643 U-2644 DS DS DP DS DP DS DP U-1707 U-1708 DP DS DS DP U-1707 DS DP U-1708 U-1707 U-1708 DP U-1481 DS U-1526 DS U-1707 DS U-1708 U-1562 DS DP DP U-1481 U-1481 DP U-1481 U-1994 DS DP U-1153 DS DP U-1307 DS DP U-1740 DS DP U-3068 DP U-2718 DP U-3142 DS DP U-2718 DS DP U-3142 U-3153 U-3219 DP U-3135 DP U-3135 DP U-3135 DP U-3135 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-865 May 27, 2024 ODE-334 Aug 07, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 66 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES RIVAROXABAN - XARELTO N 022406 001 RIVAROXABAN - XARELTO N 022406 002 RIVAROXABAN - XARELTO N 022406 003 RIVAROXABAN - XARELTO N 022406 004 10828310 10828310 9415053 9415053 9415053 Jan 31, 2039 Jan 31, 2039 Nov 13, 2024 Nov 13, 2024 Nov 13, 2024 ROLAPITANT HYDROCHLORIDE - VARUBI N 206500 001 7049320 Aug 19, 2028 ROLAPITANT HYDROCHLORIDE - VARUBI N 208399 001 7049320 Aug 19, 2028 RUFINAMIDE - RUFINAMIDE A 204988 001 RUFINAMIDE - RUFINAMIDE A 204988 002 RUXOLITINIB PHOSPHATE - JAKAFI N 202192 001 >A> 10016429 >A> 10016429 >A> 7598257 >A> 7598257 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8829013 >A> 8829013 >A> 8829013 >A> 8829013 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9814722 >A> 9814722 Jun 12, 2028 Jun 12, 2028 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 RUXOLITINIB PHOSPHATE - JAKAFI N 202192 002 >A> 10016429 >A> 10016429 >A> 7598257 >A> 7598257 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8829013 >A> 8829013 >A> 8829013 >A> 8829013 >A> 9079912 Jun 12, 2028 Jun 12, 2028 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Dec 12, 2026 U-3207 U-3208 DP U-2435 DP U-3205 DP U-3206 DS DP U-1741 DS DP U-1741 U-3226 U-3230 DS DP U-3227 DS DP U-3228 U-1573 U-3226 U-3227 U-3228 U-3230 U-1201 U-1622 U-3227 U-3228 U-1573 U-1721 U-3226 U-3227 U-3228 U-3230 U-3226 U-3230 U-3226 U-3230 DS DP U-3227 DS DP U-3228 U-1573 U-3226 U-3227 U-3228 U-3230 U-1201 U-1622 U-3227 U-3228 U-1573 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-867 I-867 I-867 I-867 Aug 23, 2024 Aug 23, 2024 Aug 23, 2024 Aug 23, 2024 PC PC >A> I-872 Nov 28, 2021 Nov 28, 2021 Sep 22, 2024 >A> I-872 Sep 22, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 67 APPL/PROD NO PATENT NO RUXOLITINIB PHOSPHATE - JAKAFI N 202192 002 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9814722 >A> 9814722 RUXOLITINIB PHOSPHATE - JAKAFI N 202192 003 >A> 10016429 >A> 10016429 >A> 7598257 >A> 7598257 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8829013 >A> 8829013 >A> 8829013 >A> 8829013 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9814722 >A> 9814722 RUXOLITINIB PHOSPHATE - JAKAFI N 202192 004 >A> 10016429 >A> 10016429 >A> 7598257 >A> 7598257 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8829013 >A> 8829013 >A> 8829013 >A> 8829013 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9814722 >A> 9814722 RUXOLITINIB PHOSPHATE - JAKAFI N 202192 005 >A> 10016429 >A> 10016429 >A> 7598257 >A> 7598257 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8822481 >A> 8829013 >A> 8829013 >A> 8829013 PATENT EXPIRATION DATE PATENT CODES Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 U-1721 U-3226 U-3227 U-3228 U-3230 U-3226 U-3230 Jun 12, 2028 Jun 12, 2028 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 U-3226 U-3230 DS DP U-3227 DS DP U-3228 U-1573 U-3226 U-3227 U-3228 U-3230 U-1201 U-1622 U-3227 U-3228 U-1573 U-1721 U-3226 U-3227 U-3228 U-3230 U-3226 U-3230 Jun 12, 2028 Jun 12, 2028 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 U-3226 U-3230 DS DP U-3227 DS DP U-3228 U-1573 U-3226 U-3227 U-3228 U-3230 U-1201 U-1622 U-3227 U-3228 U-1573 U-1721 U-3226 U-3227 U-3228 U-3230 U-3226 U-3230 Jun 12, 2028 Jun 12, 2028 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 Jun 12, 2028 U-3226 U-3230 DS DP U-3227 DS DP U-3228 U-1573 U-3226 U-3227 U-3228 U-3230 U-1201 U-1622 U-3227 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 68 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES RUXOLITINIB PHOSPHATE - JAKAFI N 202192 005 >A> 8829013 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9079912 >A> 9814722 >A> 9814722 Jun 12, 2028 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 Dec 12, 2026 RUXOLITINIB PHOSPHATE - OPZELURA N 215309 001 >A> 10610530 >A> 10639310 >A> 10758543 >A> 10869870 >A> 7598257 >A> 8415362 >A> 8722693 >A> 8822481 >A> 9079912 >A> 9974790 Jun 12, 2028 Dec 12, 2026 May 20, 2031 May 20, 2031 Dec 24, 2027 Dec 24, 2027 Jun 12, 2028 Jun 12, 2028 Dec 12, 2026 Dec 12, 2026 SACUBITRIL; VALSARTAN - ENTRESTO N 207620 001 11058667 >A> 11135192 >A> 8101659 >A> 8101659*PED 9517226 9937143 May 09, 2036 Aug 22, 2033 Jan 15, 2025 Jul 15, 2025 Aug 22, 2033 Aug 22, 2033 SACUBITRIL; VALSARTAN - ENTRESTO N 207620 002 11058667 >A> 11135192 >A> 8101659 >A> 8101659*PED 9517226 9937143 May 09, 2036 Aug 22, 2033 Jan 15, 2025 Jul 15, 2025 Aug 22, 2033 Aug 22, 2033 SACUBITRIL; VALSARTAN - ENTRESTO N 207620 003 11058667 >A> 11135192 >A> 8101659 >A> 8101659*PED 9517226 9937143 May 09, 2036 Aug 22, 2033 Jan 15, 2025 Jul 15, 2025 Aug 22, 2033 Aug 22, 2033 SAFINAMIDE MESYLATE - XADAGO N 207145 001 8283380 Mar 21, 2031 SAFINAMIDE MESYLATE - XADAGO N 207145 002 8283380 Mar 21, 2031 SECNIDAZOLE - SOLOSEC N 209363 001 10849884 10849884 11000507 11000507 11000508 11000508 11020377 11020377 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 Sep 04, 2035 SELENIOUS ACID - SELENIOUS ACID N 209379 002 U-3228 U-1573 U-1721 U-3226 U-3227 U-3228 U-3230 U-3226 U-3230 U-3229 U-3229 DP U-3229 DS DP DS DP DS DP U-3229 U-3229 U-3229 U-3170 U-3084 DP U-3084 U-3084 U-3170 U-3084 DP U-3084 U-3084 U-3170 U-3084 DP U-3084 U-3084 U-1993 U-1993 DP U-2583 DP U-3169 DP U-2583 DP U-3169 DP U-2583 DP U-3169 DP U-2583 DP U-3169 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-82 Feb 16, 2024 M-82 Feb 16, 2024 M-82 Feb 16, 2024 I-866 Jun 30, 2024 NCE Apr 30, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 69 APPL/PROD NO PATENT NO SELENIOUS ACID - SELENIOUS ACID N 209379 003 SELEXIPAG - UPTRAVI N 214275 001 7205302 8791122 9173881 9284280 SELINEXOR - XPOVIO N 212306 001 10519139 10519139 10519139 10544108 10544108 11034660 11034660 9079865 9079865 9079865 SELINEXOR - XPOVIO N 212306 002 10519139 10519139 10519139 10544108 10544108 11034660 11034660 8999996 9079865 9079865 9079865 9714226 SELINEXOR - XPOVIO N 212306 003 10519139 10519139 10519139 10544108 10544108 11034660 11034660 8999996 9079865 9079865 9079865 9714226 SELINEXOR - XPOVIO N 212306 004 10519139 10519139 10519139 10544108 10544108 11034660 11034660 8999996 9079865 9079865 9079865 9714226 SEMAGLUTIDE - OZEMPIC N 209637 001 11097063 PATENT EXPIRATION DATE PATENT CODES Apr 04, 2023 Aug 01, 2030 Aug 12, 2029 Jun 25, 2030 DS DP U-1797 DS DP U-1798 U-1831 Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-3018 U-2584 U-2855 U-3018 Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Sep 15, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-3018 DS DP U-2584 U-2855 U-3018 DS DP Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Sep 15, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-3018 DS DP U-2584 U-2855 U-3018 DS DP Aug 14, 2035 Aug 14, 2035 Aug 14, 2035 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Sep 15, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 Jul 26, 2032 DS DP U-2584 DS DP U-2855 DS DP U-3018 U-2584 U-3018 U-2584 U-3018 DS DP U-2584 U-2855 U-3018 DS DP Jul 17, 2026 DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Apr 30, 2024 ODE-346 Dec 18, 2027 >A> ODE* >A> ODE* >A> ODE* Jul 03, 2026 Jun 22, 2027 Dec 18, 2027 >A> ODE* >A> ODE* >A> ODE* Jul 03, 2026 Jun 22, 2027 Dec 18, 2027 >A> ODE* >A> ODE* >A> ODE* Jul 03, 2026 Jun 22, 2027 Dec 18, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 70 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES SEMAGLUTIDE - OZEMPIC N 209637 002 11097063 SEMAGLUTIDE - RYBELSUS N 213051 001 10933120 10960052 SEMAGLUTIDE - RYBELSUS N 213051 002 10933120 10960052 SEMAGLUTIDE - RYBELSUS N 213051 003 10933120 10960052 SEMAGLUTIDE - WEGOVY N 215256 001 10888605 8129343 8536122 9764003 SEMAGLUTIDE - WEGOVY N 215256 002 10888605 8129343 8536122 9764003 SEMAGLUTIDE - WEGOVY N 215256 003 10888605 8129343 8536122 9764003 SEMAGLUTIDE - WEGOVY N 215256 004 10888605 8129343 8536122 9764003 SEMAGLUTIDE - WEGOVY N 215256 005 10888605 8129343 8536122 9764003 SETMELANOTIDE ACETATE - IMCIVREE N 213793 001 >A> 11129869 SIPONIMOD FUMARIC ACID - MAYZENT N 209884 003 7939519 8492441 SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 001 Jul 17, 2026 Mar 15, 2033 Dec 16, 2031 Mar 15, 2033 Dec 16, 2031 Mar 15, 2033 Dec 16, 2031 Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033 Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033 Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033 Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033 Aug 24, 2038 Jan 29, 2029 Mar 20, 2026 Jun 21, 2033 Jul 04, 2034 May 19, 2024 Nov 30, 2030 DP DP DP DP DP DP DP DP U-3162 DS DP DS DP U-3161 DP U-3162 DS DP DS DP U-3161 DP U-3162 DS DP DS DP U-3161 DP U-3162 DS DP DS DP U-3161 DP U-3162 DS DP DS DP U-3161 DP DS DP U-2511 SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 002 SITAGLIPTIN PHOSPHATE - JANUVIA N 021995 003 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Dec 05, 2022 NP Jun 04, 2024 NCE Dec 05, 2022 NP Jun 04, 2024 NCE Dec 05, 2022 NP Jun 04, 2024 NCE Dec 05, 2022 NP Jun 04, 2024 NCE Dec 05, 2022 NP Jun 04, 2024 ODE-336 Nov 25, 2027 NCE Mar 26, 2024 M-187 PED M-187 PED M-187 PED Dec 04, 2023 Jun 04, 2024 Dec 04, 2023 Jun 04, 2024 Dec 04, 2023 Jun 04, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 71 APPL/PROD NO PATENT NO SODIUM ACETATE - SODIUM ACETATE A 214805 001 SODIUM OXYBATE - XYREM N 021196 001 10864181 SOFOSBUVIR - SOVALDI N 204671 001 SOFOSBUVIR - SOVALDI N 204671 002 PATENT EXPIRATION DATE Mar 15, 2033 PATENT CODES U-1532 SOFOSBUVIR; VELPATASVIR - EPCLUSA N 208341 001 10086011 10086011*PED >A> 11116783 >A> 11116783*PED 8575135 8575135*PED 8735372 8735372*PED 8921341 8921341*PED 8940718 8940718*PED 9757406 9757406*PED Jan 30, 2034 Jul 30, 2034 Jan 30, 2034 Jul 30, 2034 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Nov 16, 2032 May 16, 2033 Nov 16, 2032 May 16, 2033 Jan 30, 2034 Jul 30, 2034 SOFOSBUVIR; VELPATASVIR - EPCLUSA N 208341 002 10086011 10086011*PED >A> 11116783 >A> 11116783*PED 7964580 7964580*PED 8334270 8334270*PED 8575135 8575135*PED 8580765 8580765*PED 8618076 8618076*PED 8633309 8633309*PED 8735372 8735372*PED 8889159 8889159*PED 8921341 8921341*PED 8940718 8940718*PED 9085573 9085573*PED 9284342 9284342*PED 9757406 9757406*PED Jan 30, 2034 Jul 30, 2034 Jan 30, 2034 Jul 30, 2034 Mar 26, 2029 Sep 26, 2029 Mar 21, 2028 Sep 21, 2028 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Dec 11, 2030 Jun 11, 2031 Mar 26, 2029 Sep 26, 2029 Mar 21, 2028 Sep 21, 2028 Mar 26, 2029 Sep 26, 2029 Nov 16, 2032 May 16, 2033 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Sep 13, 2030 Mar 13, 2031 Jan 30, 2034 Jul 30, 2034 SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 001 11116783 11116783*PED 7964580 7964580*PED Jan 30, 2034 Jul 30, 2034 Mar 26, 2029 Sep 26, 2029 U-1470 DP U-1470 DS DP U-1470 U-1470 DS DP U-1470 DS DP U-1470 DP U-1470 DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 U-1470 DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DP DP U-1470 DS DP U-1470 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT Jan 03, 2022 ODE* ODE* ODE* PED D-177 M-264 NPP PED PED PED Aug 28, 2026 Apr 07, 2024 Aug 28, 2026 Oct 07, 2024 Nov 15, 2022 Jul 14, 2023 Mar 19, 2023 May 15, 2023 Sep 19, 2023 Jan 14, 2024 M-264 NS PED PED Jul 14, 2023 Mar 19, 2023 Sep 19, 2023 Jan 14, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 72 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 001 8334270 8334270*PED 8575135 8575135*PED 8580765 8580765*PED 8618076 8618076*PED 8633309 8633309*PED 8735372 8735372*PED 8889159 8889159*PED 8921341 8921341*PED 8940718 8940718*PED 9085573 9085573*PED 9284342 9284342*PED Mar 21, 2028 Sep 21, 2028 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Dec 11, 2030 Jun 11, 2031 Mar 26, 2029 Sep 26, 2029 Mar 21, 2028 Sep 21, 2028 Mar 26, 2029 Sep 26, 2029 Nov 16, 2032 May 16, 2033 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Sep 13, 2030 Mar 13, 2031 SOFOSBUVIR; VELPATASVIR - EPCLUSA N 214187 002 11116783 11116783*PED 7964580 7964580*PED 8334270 8334270*PED 8575135 8575135*PED 8580765 8580765*PED 8618076 8618076*PED 8633309 8633309*PED 8735372 8735372*PED 8889159 8889159*PED 8921341 8921341*PED 8940718 8940718*PED 9085573 9085573*PED 9284342 9284342*PED Jan 30, 2034 Jul 30, 2034 Mar 26, 2029 Sep 26, 2029 Mar 21, 2028 Sep 21, 2028 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Dec 11, 2030 Jun 11, 2031 Mar 26, 2029 Sep 26, 2029 Mar 21, 2028 Sep 21, 2028 Mar 26, 2029 Sep 26, 2029 Nov 16, 2032 May 16, 2033 Nov 16, 2032 May 16, 2033 Mar 21, 2028 Sep 21, 2028 Sep 13, 2030 Mar 13, 2031 SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI N 209195 001 10912814 Jun 01, 2037 11116783 Jan 30, 2034 11116783 Jan 30, 2034 11116783*PED Jul 30, 2034 8575135 Nov 16, 2032 8575135 Nov 16, 2032 8575135*PED May 16, 2033 8735372 Mar 21, 2028 8735372 Mar 21, 2028 8735372*PED Sep 21, 2028 8921341 Nov 16, 2032 8921341 Nov 16, 2032 8921341*PED May 16, 2033 8940718 Nov 16, 2032 8940718 Nov 16, 2032 8940718*PED May 16, 2033 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 U-1470 DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 U-1470 DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DS DP U-1470 DP DP U-2039 DP U-2040 DS DP U-2039 DS DP U-2040 DS DP U-2039 DS DP U-2040 DS DP U-2039 DS DP U-2040 DS DP U-2039 DS DP U-2040 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 73 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR - VOSEVI N 209195 001 8957046 Mar 21, 2028 8957046 Mar 21, 2028 SOLIFENACIN SUCCINATE - VESICARE LS N 209529 001 9918970 May 18, 2031 SOLRIAMFETOL HYDROCHLORIDE - SUNOSI N 211230 001 10912754 Jun 01, 2038 10940133 Mar 19, 2040 10959976 Jun 01, 2038 SOLRIAMFETOL HYDROCHLORIDE - SUNOSI N 211230 002 10912754 Jun 01, 2038 10959976 Jun 01, 2038 SOTALOL HYDROCHLORIDE - SOTALOL HYDROCHLORIDE N 022306 001 10799138 Apr 05, 2039 SOTALOL HYDROCHLORIDE - SOTYLIZE N 205108 001 11013703 Apr 01, 2034 SOTORASIB - LUMAKRAS N 214665 001 SPINOSAD - NATROBA N 022408 001 SPIRONOLACTONE - CAROSPIR N 209478 001 10888570 SUFENTANIL CITRATE - DSUVIA N 209128 001 10896751 SUGAMMADEX SODIUM - BRIDION N 022225 001 SUGAMMADEX SODIUM - BRIDION N 022225 002 TACROLIMUS - PROGRAF N 050708 001 TACROLIMUS - PROGRAF N 050708 002 TACROLIMUS - PROGRAF N 050708 003 TACROLIMUS - PROGRAF N 050709 001 TACROLIMUS - ASTAGRAF XL N 204096 001 TACROLIMUS - ASTAGRAF XL N 204096 002 TACROLIMUS - ASTAGRAF XL N 204096 003 Oct 28, 2036 Mar 16, 2030 PATENT CODES PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE U-2039 U-2040 DP U-3082 U-3099 U-3151 U-3082 U-3151 U-3125 DP DP DP NCE ODE-352 May 28, 2026 May 28, 2028 I-858 Apr 28, 2024 NPP Jun 25, 2024 NPP Jun 25, 2024 ODE-360 Jul 16, 2028 ODE-360 Jul 16, 2028 ODE-360 Jul 16, 2028 ODE-360 Jul 16, 2028 ODE* May 24, 2025 ODE* May 24, 2025 ODE* May 24, 2025 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 74 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES TACROLIMUS - ENVARSUS XR N 206406 001 11110081 11123331 May 30, 2028 May 30, 2028 TACROLIMUS - ENVARSUS XR N 206406 002 11110081 11123331 May 30, 2028 May 30, 2028 TACROLIMUS - ENVARSUS XR N 206406 003 11110081 11123331 May 30, 2028 May 30, 2028 TACROLIMUS - PROGRAF N 210115 001 TACROLIMUS - PROGRAF N 210115 002 TAFENOQUINE SUCCINATE - ARAKODA N 210607 001 10888558 Dec 02, 2035 TAFLUPROST - ZIOPTAN N 202514 001 10864159 May 28, 2029 TALAZOPARIB TOSYLATE - TALZENNA N 211651 003 >A> 10189837 >A> 8012976 >A> 8420650 >A> 8735392 >A> 9820985 Oct 20, 2031 Oct 19, 2029 Jul 27, 2029 Oct 20, 2031 Jul 27, 2029 TALAZOPARIB TOSYLATE - TALZENNA N 211651 004 >A> 10189837 >A> 8012976 >A> 8420650 >A> 8735392 >A> 9820985 Oct 20, 2031 Oct 19, 2029 Jul 27, 2029 Oct 20, 2031 Jul 27, 2029 TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 001 11007156 Oct 22, 2022 11007156 Oct 22, 2022 TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 002 11007156 Oct 22, 2022 11007156 Oct 22, 2022 TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 003 11007156 Oct 22, 2022 11007156 Oct 22, 2022 TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 004 11007156 Oct 22, 2022 11007156 Oct 22, 2022 TAPENTADOL HYDROCHLORIDE - NUCYNTA ER N 200533 005 11007156 Oct 22, 2022 11007156 Oct 22, 2022 TASIMELTEON - HETLIOZ N 205677 001 10610511 10610511 10945988 10980770 10980770 Oct 10, 2034 Oct 10, 2034 Jan 25, 2033 Jan 25, 2033 Jan 25, 2033 U-2678 U-2677 U-2678 U-2677 U-2678 U-2677 U-2582 DP U-778 DS DP DS DP DS DP DS DP U-2437 DS DP DS DP DS DP DS DP U-2437 DP U-1178 DP U-1276 DP U-1178 DP U-1276 DP U-1178 DP U-1276 DP U-1178 DP U-1276 DP U-1178 DP U-1276 U-2615 U-3007 U-2149 U-3106 U-3107 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE ODE-360 Jul 16, 2028 ODE-360 Jul 16, 2028 >A> NCE Oct 16, 2023 >A> NCE Oct 16, 2023 I-850 ODE-330 Dec 01, 2023 Dec 01, 2027 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 75 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES TASIMELTEON - HETLIOZ N 205677 001 >A> 11141400 >A> 11141400 Oct 10, 2034 Oct 10, 2034 TASIMELTEON - HETLIOZ LQ N 214517 001 10980770 >A> 11141400 Jan 25, 2033 Oct 10, 2034 TAVABOROLE - TAVABOROLE A 211963 001 TAZEMETOSTAT HYDROBROMIDE - TAZVERIK N 211723 001 10786511 Dec 19, 2035 11052093 Apr 13, 2032 11052093 Apr 13, 2032 TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT N 202207 001 TENOFOVIR ALAFENAMIDE FUMARATE - VEMLIDY N 208464 001 >A> 7390791 Apr 17, 2025 >A> 7390791*PED Oct 17, 2025 >A> 8754065 Aug 15, 2032 >A> 8754065*PED Feb 15, 2033 >A> 9296769 Aug 15, 2032 >A> 9296769*PED Feb 15, 2033 TEPOTINIB HYDROCHLORIDE - TEPMETKO N 214096 001 8329692 8580781 8658643 8921357 8927540 9062029 9284300 9403799 Oct 30, 2029 Mar 19, 2030 Jul 04, 2028 May 30, 2028 Jul 21, 2028 Jul 04, 2028 Apr 29, 2028 Jul 04, 2028 TERIFLUNOMIDE - AUBAGIO N 202992 001 6794410 6794410*PED 8802735 8802735*PED 9186346 9186346*PED Sep 12, 2026 Mar 12, 2027 Sep 14, 2030 Mar 14, 2031 Feb 04, 2034 Aug 04, 2034 TERIFLUNOMIDE - AUBAGIO N 202992 002 6794410 6794410*PED 8802735 8802735*PED 9186346 9186346*PED Sep 12, 2026 Mar 12, 2027 Sep 14, 2030 Mar 14, 2031 Feb 04, 2034 Aug 04, 2034 TESTOSTERONE - NATESTO N 205488 001 11090312 Mar 17, 2034 TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 001 10881798 Feb 11, 2034 10905827 Aug 21, 2031 10912782 Feb 19, 2035 TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 002 10881798 Feb 11, 2034 10905827 Aug 21, 2031 10912782 Feb 19, 2035 U-2615 U-3007 U-3106 U-3007 DP DS DP U-2736 DS DP U-3179 DS DP DS DP U-999 DS DP U-999 DS DP DS DP U-3077 DS DP U-3078 DP DP U-3077 U-1285 DP U-1786 U-1285 DP U-1786 U-1616 DP DP DP U-2418 DP DP DP U-2418 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NP ODE-329 Dec 01, 2023 Dec 01, 2027 PC Apr 17, 2021 NPP May 19, 2024 NCE ODE-325 Feb 03, 2026 Feb 03, 2028 M-61 PED Apr 30, 2024 Oct 30, 2024 M-61 PED Apr 30, 2024 Oct 30, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 76 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 002 10881798 Feb 11, 2034 10905827 Aug 21, 2031 10912782 Feb 19, 2035 TESTOSTERONE ENANTHATE - XYOSTED (AUTOINJECTOR) N 209863 003 10881798 Feb 11, 2034 10905827 Aug 21, 2031 10912782 Feb 19, 2035 THEOPHYLLINE - THEOPHYLLINE A 212184 002 TICAGRELOR - BRILINTA N 022433 001 TICAGRELOR - BRILINTA N 022433 002 TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 001 10960004 Feb 03, 2037 RE46284 Sep 22, 2029 RE46284 Sep 22, 2029 TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE - LONSURF N 207981 002 10960004 Feb 03, 2037 RE46284 Sep 22, 2029 RE46284 Sep 22, 2029 TIRBANIBULIN - KLISYRI N 213189 001 10323001 10617693 10669236 7300931 7851470 8236799 8980890 Dec 28, 2027 Mar 12, 2038 Sep 07, 2038 Feb 06, 2026 Feb 02, 2029 Dec 28, 2025 Dec 28, 2025 TIVOZANIB HYDROCHLORIDE - FOTIVDA N 212904 001 6821987 7166722 Apr 26, 2022 Nov 16, 2023 TIVOZANIB HYDROCHLORIDE - FOTIVDA N 212904 002 6821987 7166722 Apr 26, 2022 Nov 16, 2023 TOLVAPTAN - SAMSCA N 022275 001 10905694 Apr 07, 2030 TOLVAPTAN - SAMSCA N 022275 002 10905694 Apr 07, 2030 TOLVAPTAN - SAMSCA N 022275 003 10905694 Apr 07, 2030 TOLVAPTAN - JYNARQUE N 204441 001 10905694 Apr 07, 2030 TOLVAPTAN - JYNARQUE N 204441 002 10905694 Apr 07, 2030 DP DP DP U-2418 DP DP DP U-2418 U-2642 U-1751 U-2503 U-2642 U-1751 U-2503 DP U-3015 DS DP DS DP DS DP U-3015 DS DP DS DP DS DP U-3100 DS DS DP U-3100 DS DP DP DP DP DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE CGT I-851 I-851 Dec 08, 2021 May 28, 2023 May 28, 2023 NCE Dec 14, 2025 NCE Mar 10, 2026 NCE Mar 10, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 77 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES TOLVAPTAN - JYNARQUE N 204441 003 10905694 Apr 07, 2030 TOLVAPTAN - JYNARQUE N 204441 004 10905694 Apr 07, 2030 TOLVAPTAN - JYNARQUE N 204441 005 10905694 Apr 07, 2030 TORSEMIDE - SOAANZ N 213218 001 10154963 Oct 06, 2033 TORSEMIDE - SOAANZ N 213218 002 10154963 Oct 06, 2033 TRAMADOL HYDROCHLORIDE - QDOLO N 214044 001 11103452 Sep 01, 2040 TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 001 10869869 Aug 30, 2033 TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 002 10869869 Aug 30, 2033 TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST N 204114 003 10869869 Aug 30, 2033 TREPROSTINIL - REMODULIN N 021272 005 10076505 10695308 7999007 8653137 8658694 9199908 9593066 9604901 9713599 Dec 16, 2024 Dec 16, 2024 Mar 29, 2029 Sep 05, 2028 Sep 05, 2028 May 24, 2024 Dec 15, 2028 Dec 15, 2028 Dec 16, 2024 TREPROSTINIL - TYVASO N 022387 001 TRIAMCINOLONE ACETONIDE - XIPERE N 211950 001 >A> 8636713 >A> 9636332 >A> 9937075 May 02, 2027 Nov 08, 2033 May 02, 2034 TRIFAROTENE - AKLIEF N 211527 001 9498465 May 30, 2033 TRILACICLIB DIHYDROCHLORIDE - COSELA N 214200 001 10085992 Mar 14, 2034 10189849 Oct 25, 2031 10189850 Oct 25, 2031 10927120 Oct 25, 2031 10966984 Mar 14, 2034 10966984 Mar 14, 2034 11040042 Mar 14, 2034 8598186 Oct 25, 2031 8598197 Oct 25, 2031 9487530 Mar 14, 2034 9487530 Mar 14, 2034 9957276 Oct 25, 2031 DP DP DP DP DP DP U-3197 U-3184 U-3184 U-3184 DP U-2845 DP U-1437 U-1437 U-1437 U-1771 DS DS U-2036 U-3234 U-3234 DP DP U-1033 U-3081 DS DP DP U-3079 U-3080 DP DS DP DS DP U-3079 U-3080 DS PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE I-856 Mar 31, 2024 NCE Feb 12, 2026 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 78 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES UMBRALISIB TOSYLATE - UKONIQ N 213176 001 10072013 10072013 10414773 10414773 10570142 10570142 10947244 10947244 9150579 9669033 9669033 9969740 9969740 Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035 Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035 Jul 02, 2033 Jul 02, 2033 Jul 02, 2033 May 26, 2035 May 26, 2035 U-3063 U-3064 DS DP U-3063 DS DP U-3064 DS DP U-3063 DS DP U-3064 U-3063 U-3064 DS DP U-3063 U-3064 DS DP U-3063 DS DP U-3064 UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA N 203975 001 11090294 Nov 29, 2030 U-3203 UPADACITINIB - RINVOQ N 211675 001 10981923 10981924 Oct 17, 2036 Oct 17, 2036 DS DP VALBENAZINE TOSYLATE - INGREZZA N 209241 001 10874648 10874648 10906902 10906903 10912771 10912771 10919892 10940141 10952997 10993941 11026931 11026939 11040029 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 Oct 10, 2037 Aug 14, 2039 Sep 18, 2038 Oct 10, 2037 U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 U-1995 U-1995 DP U-1995 U-1995 VALBENAZINE TOSYLATE - INGREZZA N 209241 002 10874648 10874648 10906902 10906903 10912771 10912771 10919892 10940141 10952997 10993941 11026931 11026939 11040029 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 Oct 10, 2037 Aug 14, 2039 Sep 18, 2038 Oct 10, 2037 U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 U-1995 U-1995 DP U-1995 U-1995 VALBENAZINE TOSYLATE - INGREZZA N 209241 003 10065952 10844058 10851103 10851104 10857137 10857148 10874648 10874648 10906902 10906903 10912771 10912771 10919892 10940141 10952997 Oct 28, 2036 Oct 28, 2036 Oct 28, 2036 Oct 28, 2036 Oct 10, 2037 Oct 10, 2037 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Dec 22, 2036 Oct 10, 2037 Oct 10, 2037 Dec 22, 2036 Aug 10, 2040 Oct 10, 2037 DS DP U-1995 DS DP U-1995 DS DP U-1995 DS U-1995 U-1995 U-1995 U-1995 U-3046 DS DP DS DP U-1995 U-3076 DS DP U-1995 U-1995 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE ODE-343 ODE-344 Feb 05, 2026 Feb 05, 2028 Feb 05, 2028 NCE Apr 11, 2022 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 79 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES VALBENAZINE TOSYLATE - INGREZZA N 209241 003 10993941 11026931 11026939 11040029 8039627 8357697 Oct 10, 2037 Aug 14, 2039 Sep 18, 2038 Oct 10, 2037 Oct 06, 2029 Nov 08, 2027 VALSARTAN - DIOVAN N 021283 001 VALSARTAN - DIOVAN N 021283 002 VALSARTAN - DIOVAN N 021283 004 VANCOMYCIN - VANCOMYCIN N 213895 001 10039804 10188697 10849956 11000567 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 Nov 06, 2035 VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT N 208910 001 10959946 Mar 13, 2035 10959947 Mar 13, 2035 10959947 Mar 13, 2035 10959948 Mar 13, 2035 10959948 Mar 13, 2035 10959949 Mar 13, 2035 10959949 Mar 13, 2035 VANCOMYCIN HYDROCHLORIDE - FIRVANQ KIT N 208910 002 10959946 Mar 13, 2035 10959947 Mar 13, 2035 10959947 Mar 13, 2035 10959948 Mar 13, 2035 10959948 Mar 13, 2035 10959949 Mar 13, 2035 10959949 Mar 13, 2035 VARENICLINE TARTRATE - TYRVAYA N 213978 001 >A> 10456396 >A> 9504644 >A> 9504645 >A> 9532944 >A> 9597284 Oct 19, 2035 Oct 19, 2035 Oct 19, 2035 Oct 19, 2035 Oct 19, 2035 VENETOCLAX - VENCLEXTA N 208573 001 10993942 >A> 11110087 >A> 11110087 Sep 06, 2033 Sep 06, 2033 Sep 06, 2033 VENETOCLAX - VENCLEXTA N 208573 002 10993942 >A> 11110087 >A> 11110087 Sep 06, 2033 Sep 06, 2033 Sep 06, 2033 VENETOCLAX - VENCLEXTA N 208573 003 10993942 >A> 11110087 >A> 11110087 Sep 06, 2033 Sep 06, 2033 Sep 06, 2033 U-1995 U-1995 DP U-1995 U-1995 DS DP U-1995 DP U-282 DP U-282 DP DP DP DP U-3104 DP U-3105 DP U-3104 DP U-3105 DP U-3104 DP U-3105 DP DP U-3104 DP U-3105 DP U-3104 DP U-3105 DP U-3104 DP U-3105 DP U-1900 U-1900 DP U-1900 U-1900 U-3114 U-3222 U-3223 U-3114 U-3222 U-3223 U-3114 U-3222 U-3223 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NPP Apr 19, 2024 NPP Apr 19, 2024 NPP Apr 19, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 80 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES VERICIGUAT - VERQUVO N 214377 001 10736896 8420656 8921377 9604948 9993476 May 19, 2031 May 19, 2031 May 19, 2031 Nov 26, 2032 May 19, 2031 VERICIGUAT - VERQUVO N 214377 002 10736896 8420656 8921377 9604948 9993476 May 19, 2031 May 19, 2031 May 19, 2031 Nov 26, 2032 May 19, 2031 VERICIGUAT - VERQUVO N 214377 003 10736896 8420656 8921377 9604948 9993476 May 19, 2031 May 19, 2031 May 19, 2031 Nov 26, 2032 May 19, 2031 VIBEGRON - GEMTESA N 213006 001 8247415 8653260 Dec 01, 2030 Apr 02, 2029 VIGABATRIN - VIGABATRIN A 211539 001 VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 001 9358204 9603853 9662338 Feb 07, 2033 Feb 07, 2033 Feb 07, 2033 VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 002 9358204 9603853 9662338 Feb 07, 2033 Feb 07, 2033 Feb 07, 2033 VILOXAZINE HYDROCHLORIDE - QELBREE N 211964 003 9358204 9603853 9662338 Feb 07, 2033 Feb 07, 2033 Feb 07, 2033 VILTOLARSEN - VILTEPSO N 212154 001 10870676 Aug 31, 2031 VISMODEGIB - ERIVEDGE N 203388 001 9790183 Sep 02, 2025 VOCLOSPORIN - LUPKYNIS N 213716 001 10286036 7332472 Dec 07, 2037 Oct 17, 2022 VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 001 VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 002 VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 003 DS DP DS DP U-3062 DS DP U-3062 U-3062 DS DP DS DP U-3062 DS DP U-3062 U-3062 DS DP DS DP U-3062 DS DP U-3062 U-3062 DS DP U-3045 DS DP U-727 DP DP U-727 DP DP U-727 DP DS DP U-3039 U-3109 U-3056 DS DP U-3056 PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE NCE Jan 19, 2026 NCE Jan 19, 2026 NCE Jan 19, 2026 NCE Dec 23, 2025 CGT Jul 31, 2021 NCE Apr 02, 2026 NCE Apr 02, 2026 NCE Apr 02, 2026 ODE-280 Aug 12, 2027 NCE Jan 22, 2026 M-187 M-187 M-187 Jan 22, 2024 Jan 22, 2024 Jan 22, 2024 PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 10 - October 2021 A - 81 APPL/PROD NO PATENT NO PATENT EXPIRATION DATE PATENT CODES VORTIOXETINE HYDROBROMIDE - TRINTELLIX N 204447 004 VOXELOTOR - OXBRYTA N 213137 001 11020382 11020382 Dec 02, 2036 Dec 02, 2036 ZANUBRUTINIB - BRUKINSA N 213217 001 10570139 10927117 Apr 22, 2034 Aug 15, 2037 U-3133 U-3134 DS DP U-2145 DS DP PATENT DELIST REQUESTED EXCLUSIVITY CODE(S) EXCLUSIVITY EXPIRATION DATE M-187 Jan 22, 2024 >A> I-871 >A> I-874 Aug 31, 2024 Sep 14, 2024 B-1 PATENT AND EXCLUSIVITY TERMS Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 41ST Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes). The current complete list of patent terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_patent.cfm The current complete list of exclusivity terms is available at http://www.accessdata.fda.gov/scripts/cder/ob/results_exclusivity.cfmAdobe Acrobat Pro 11.0.20